1 00:00:04,437 --> 00:00:05,905 THANK YOU SO MUCH FOR 2 00:00:05,972 --> 00:00:07,307 PARTICIPATING IN OUR 35th 3 00:00:07,374 --> 00:00:10,410 MEETING OF THE NATIONAL CENTER 4 00:00:10,477 --> 00:00:12,178 FOR ADVANCING TRANSLATIONAL 5 00:00:12,245 --> 00:00:13,580 SCIENCES, OUR ADVISORY COUNCIL 6 00:00:13,646 --> 00:00:14,447 TODAY. 7 00:00:14,514 --> 00:00:16,449 IT'S A WINTER WONDERLAND HERE IN 8 00:00:16,516 --> 00:00:16,916 MARYLAND. 9 00:00:16,983 --> 00:00:18,952 AND WE HAVE MOST OF OUR STAFF 10 00:00:19,018 --> 00:00:20,286 WORKING FROM HOME AND SOME OF US 11 00:00:20,353 --> 00:00:21,187 ARE HERE. 12 00:00:21,254 --> 00:00:23,656 I WANT TO THANK THE COUNCIL 13 00:00:23,723 --> 00:00:25,425 MEMBERS WHO HAVE ALSO BEEN 14 00:00:25,492 --> 00:00:26,793 EXPERIENCING WEATHER AS WELL AND 15 00:00:26,860 --> 00:00:29,562 APPRECIATE YOUR ATTENDANCE TO 16 00:00:29,629 --> 00:00:30,630 THE MEETING TOO. 17 00:00:30,697 --> 00:00:32,132 HOPEFULLY THINGS WILL GO RATHER 18 00:00:32,198 --> 00:00:32,499 SMOOTHLY TODAY. 19 00:00:32,565 --> 00:00:35,034 THIS IS WHY WE DO OUR MEETINGS 20 00:00:35,101 --> 00:00:36,836 VIRTUALLY IN JANUARY SO WE CAN 21 00:00:36,903 --> 00:00:37,904 ACTUALLY ACCOMMODATE THIS SORT 22 00:00:37,971 --> 00:00:40,006 OF THING, SO I'M HOPING IT WILL 23 00:00:40,073 --> 00:00:40,407 GO ALONG WELL. 24 00:00:40,473 --> 00:00:42,208 IF YOU HAVE ANY TROUBLE ALONG 25 00:00:42,275 --> 00:00:44,644 THE WAY PLEASE DO LET US KNOW, 26 00:00:44,711 --> 00:00:46,413 AND WE'LL TRY TO HELP YOU OUT 27 00:00:46,479 --> 00:00:47,113 ALONG THE WAY. 28 00:00:47,180 --> 00:00:50,316 I WANTED TO MAKE A QUICK 29 00:00:50,383 --> 00:00:50,650 ANNOUNCEMENT. 30 00:00:50,717 --> 00:00:53,486 MANY OF YOU KNOW ANNA 31 00:00:53,553 --> 00:00:55,121 RAMSEY-EWING, SHE'S REALLY THE 32 00:00:55,188 --> 00:00:56,956 PERSON WHO RUNS THESE COUNCILS 33 00:00:57,023 --> 00:00:59,592 AS OUR EXECUTIVE OFFICERS FOR 34 00:00:59,659 --> 00:01:00,894 THE COUNCIL MEETINGS, OUR 35 00:01:00,960 --> 00:01:03,430 DIRECTOR OF THE DIVISION OF 36 00:01:03,496 --> 00:01:04,330 EXTRAMURAL AFFAIRS AT NCATS. 37 00:01:04,397 --> 00:01:06,499 SHE'S FEELING A LITTLE BIT UNDER 38 00:01:06,566 --> 00:01:08,701 THE WEATHER, AND SHE'S FEELING 39 00:01:08,768 --> 00:01:10,003 FINE BUT FEELS LIKE SHE MAY NOT 40 00:01:10,069 --> 00:01:12,839 BE ABLE TO GET THROUGH SOME 41 00:01:12,906 --> 00:01:15,375 TALKING SO SHE HAS ASKED HER 42 00:01:15,442 --> 00:01:19,212 DEPUTY TO ALSO SORT OF MANAGE 43 00:01:19,279 --> 00:01:22,415 AND MODERATE THE MEETING, SO HE 44 00:01:22,482 --> 00:01:23,349 WILL TAKE THE REINS. 45 00:01:23,416 --> 00:01:24,250 ANNA WILL BE ON FOLLOWING 46 00:01:24,317 --> 00:01:25,985 THROUGH BUT WANTED TO GIVE HER A 47 00:01:26,052 --> 00:01:27,854 BREAK AND I'M SURE GREG DID TOO 48 00:01:27,921 --> 00:01:29,622 AND MAKE SURE SHE'S GOING TO 49 00:01:29,689 --> 00:01:31,658 FEEL WELL AS WE GO FORWARD. 50 00:01:31,724 --> 00:01:33,226 ANNA, WE'RE HERE FOR YOU, AND 51 00:01:33,293 --> 00:01:35,595 WE'VE GOT YOUR BACK FOR THIS. 52 00:01:35,662 --> 00:01:38,264 GREG, I WILL TURN IT OVER TO YOU 53 00:01:38,331 --> 00:01:40,099 TO TAKE THE ROLL CALL AFTER I 54 00:01:40,166 --> 00:01:42,068 GAVEL US IN. 55 00:01:42,135 --> 00:01:43,136 WELCOME TO THE MEETING, 56 00:01:43,203 --> 00:01:43,837 EVERYONE. 57 00:01:43,903 --> 00:01:44,270 GREG, OVER TO YOU. 58 00:01:44,337 --> 00:01:45,772 >> OKAY. 59 00:01:45,839 --> 00:01:54,414 THANK YOU, JONI. 60 00:01:54,481 --> 00:01:54,981 NEXT SLIDE. 61 00:01:55,048 --> 00:01:56,950 WE'LL START WITH THE ROLL CALL 62 00:01:57,016 --> 00:02:06,493 BEFORE WE GO INTO THE AGENDA. 63 00:02:06,559 --> 00:02:10,830 FIRST UP, SERGIO GAXIOLA. 64 00:02:10,897 --> 00:02:13,032 >> HERE; IT'S AGUILAR. 65 00:02:13,099 --> 00:02:17,103 >> THANK YOU. 66 00:02:17,170 --> 00:02:18,972 PAUL HARRIS. 67 00:02:19,038 --> 00:02:22,408 >> HERE. 68 00:02:22,475 --> 00:02:24,110 >> GREAT. 69 00:02:24,177 --> 00:02:26,012 MATIAS PRESS LEER. 70 00:02:26,079 --> 00:02:26,412 >> YES. 71 00:02:26,479 --> 00:02:28,348 >> KELLY McVEERY. 72 00:02:28,414 --> 00:02:29,582 >> ROBIN NORMALSTEIN. 73 00:02:29,649 --> 00:02:32,085 >> HERE. 74 00:02:32,151 --> 00:02:32,986 >> KEITH MULLER. 75 00:02:33,052 --> 00:02:34,420 >> HERE. 76 00:02:34,487 --> 00:02:35,421 >> PAULA SHERMAN. 77 00:02:35,488 --> 00:02:38,424 >> HERE. 78 00:02:38,491 --> 00:02:40,927 >> MARSHAL SUMMER. 79 00:02:40,994 --> 00:02:41,427 >> HERE. 80 00:02:41,494 --> 00:02:41,794 >> ANIKA WAYMAN. 81 00:02:41,861 --> 00:02:42,428 >> HERE. 82 00:02:42,495 --> 00:02:42,795 >> GREAT. 83 00:02:42,862 --> 00:02:48,635 WE DO NOT HAVE ANY COUNCIL 84 00:02:48,701 --> 00:02:50,770 NOMINEES ATTENDING AS AD HOCS, 85 00:02:50,837 --> 00:02:52,438 ANNIE KENNEDY IS NOT PRESENT. 86 00:02:52,505 --> 00:02:56,042 LET'S GO OVER THE AGENDA WITH 87 00:02:56,109 --> 00:02:57,443 SOME ANNOUNCEMENTS AND REMINDERS 88 00:02:57,510 --> 00:03:00,847 FOLLOWED BY JONI PROVIDING THE 89 00:03:00,914 --> 00:03:01,648 NCATS DIRECTOR'S REPORT, THEN 90 00:03:01,714 --> 00:03:03,449 SPECIAL PRESENTATION BY OUR 91 00:03:03,516 --> 00:03:07,220 GUEST SPEAKER DR. MONICA 92 00:03:07,287 --> 00:03:10,423 BERTAGNOLLI, DIRECTOR OF NIH, A 93 00:03:10,490 --> 00:03:12,358 SHORT 15-MINUTE BREAK. 94 00:03:12,425 --> 00:03:13,793 AFTER THE BREAK TWO PROGRAM 95 00:03:13,860 --> 00:03:16,996 UPDATES, FIRST FROM OFFICE OF 96 00:03:17,063 --> 00:03:18,264 SPECIAL INITIATIVES, PRESENTED 97 00:03:18,331 --> 00:03:21,200 BY DAN TAGLE AND HIS TEAM, AND 98 00:03:21,267 --> 00:03:24,170 AFTER THAT THE OFFICE OF 99 00:03:24,237 --> 00:03:26,406 STRATEGIC ALLIANCES WILL PRESENT 100 00:03:26,472 --> 00:03:28,741 THEIR PROGRAM UPDATE PRESENTED 101 00:03:28,808 --> 00:03:39,352 BY KRISHNA BALAKRISHNAN AND HIS 102 00:03:46,726 --> 00:03:47,260 TEAM. 103 00:03:47,327 --> 00:03:47,827 PLEASE USE THE "RAISE HAND" 104 00:03:47,894 --> 00:03:50,430 FEATURE AND WAIT UNTIL CALLED ON 105 00:03:50,496 --> 00:03:51,864 TO PROVIDE INPUT. 106 00:03:51,931 --> 00:03:53,399 THIS IS A PUBLIC MEETING. 107 00:03:53,466 --> 00:03:54,400 ANYTHING IN THE CHAT BECOMES 108 00:03:54,467 --> 00:03:55,868 PART OF THE PUBLIC RECORD, 109 00:03:55,935 --> 00:03:56,769 INCORPORATED INTO THE MINUTES. 110 00:03:56,836 --> 00:03:58,638 A TRANSCRIPT OF THE CHAT IS KEPT 111 00:03:58,705 --> 00:03:59,539 FOR THE RECORD. 112 00:03:59,606 --> 00:04:02,542 SO PLEASE KEEP THE USE OF THE 113 00:04:02,609 --> 00:04:04,444 CHAT TO A MINIMUM. 114 00:04:04,510 --> 00:04:06,412 PLEASE ALSO ALLOW SPEAKERS TO 115 00:04:06,479 --> 00:04:07,880 MOVE THROUGH PRESENTATIONS, 116 00:04:07,947 --> 00:04:11,484 NOTING YOUR COMMENTS AND 117 00:04:11,551 --> 00:04:13,252 PRESENTING THEM WHEN CALLED 118 00:04:13,319 --> 00:04:13,453 UPON. 119 00:04:13,519 --> 00:04:16,489 WE'RE USING THE VIDEOCAST 120 00:04:16,556 --> 00:04:19,158 FEATURE SO AUDIENCE MEMBERS MAY 121 00:04:19,225 --> 00:04:22,328 SUBMIT COMMENTS UNTIL FEBRUARY 2 122 00:04:22,395 --> 00:04:23,396 BY USING THE "SEND LIVE 123 00:04:23,463 --> 00:04:25,064 FEEDBACK" BUTTON OR BY SENDING 124 00:04:25,131 --> 00:04:28,101 AN E-MAIL TO THE E-MAIL ADDRESS 125 00:04:28,167 --> 00:04:28,434 SHOWN. 126 00:04:28,501 --> 00:04:29,669 PLEASE BE SURE WHEN YOU ARE 127 00:04:29,736 --> 00:04:31,938 SPEAKING YOUR CAMERA IS ON SO 128 00:04:32,005 --> 00:04:33,506 YOU ARE SPOTLIGHTED FOR VIEWERS 129 00:04:33,573 --> 00:04:34,407 OF THE VIDEOCAST. 130 00:04:34,474 --> 00:04:39,979 IF NOT ON CAMERA THE PREVIOUS 131 00:04:40,046 --> 00:04:40,546 SPEAKER REMAINS SPOTLIGHTED. 132 00:04:40,613 --> 00:04:41,280 NEXT SLIDE PLEASE. 133 00:04:41,347 --> 00:04:44,684 HERE'S A LIST OF THE FUTURE 134 00:04:44,751 --> 00:04:48,388 NCATS ADVISORY COUNCIL MEETINGS 135 00:04:48,454 --> 00:04:51,658 IN 2024, MAY 23 AND SEPTEMBER 19 136 00:04:51,724 --> 00:04:56,796 ARE IN-PERSON MEETINGS, IN 2025 137 00:04:56,863 --> 00:04:59,532 JANUARY MEETING IS VIRTUAL 138 00:04:59,599 --> 00:05:01,334 JANUARY 30-31, TWO IN-PERSON 139 00:05:01,401 --> 00:05:05,638 MEETINGS ON MAY 22 AND SEPTEMBER 140 00:05:05,705 --> 00:05:07,140 18. 141 00:05:07,206 --> 00:05:08,141 NEXT SLIDE PLEASE. 142 00:05:08,207 --> 00:05:09,642 IN JANUARY WE'RE SEEKING 143 00:05:09,709 --> 00:05:11,544 APPROVAL OF NCATS ADVISORY 144 00:05:11,611 --> 00:05:13,713 COUNCIL 2024 GENERAL OPERATING 145 00:05:13,780 --> 00:05:15,048 PROCEDURES, PROVIDED AHEAD OF 146 00:05:15,114 --> 00:05:17,750 TIME FOR YOUR REVIEW AND ARE 147 00:05:17,817 --> 00:05:19,886 AVAILABLE IN THE ECB, ELECTRONIC 148 00:05:19,952 --> 00:05:20,219 COUNCIL BOOK. 149 00:05:20,286 --> 00:05:25,058 SO COULD WE HAVE A MOTION TO 150 00:05:25,124 --> 00:05:31,864 APPROVE THE 2024 GENERAL 151 00:05:31,931 --> 00:05:34,434 OPERATING PROCEDURES. 152 00:05:34,500 --> 00:05:35,668 >> SO MOVED. 153 00:05:35,735 --> 00:05:35,935 >> SECOND. 154 00:05:36,002 --> 00:05:37,203 >> IN FAVOR. 155 00:05:37,270 --> 00:05:37,437 >> AYE. 156 00:05:37,503 --> 00:05:39,872 >> ANY OPPOSED, ANY ABSTENTIONS 157 00:05:39,939 --> 00:05:40,540 IN GREAT. 158 00:05:40,606 --> 00:05:42,175 THE 2024 GENERAL COUNCIL 159 00:05:42,241 --> 00:05:43,042 OPERATING PROCEDURES ARE 160 00:05:43,109 --> 00:05:43,543 APPROVED. 161 00:05:43,609 --> 00:05:51,984 NOW I'LL TURN IT BACK TO JONI 162 00:05:52,051 --> 00:05:53,419 FOR THE DIRECTOR'S REPORT. 163 00:05:53,486 --> 00:05:53,586 >> . 164 00:05:53,653 --> 00:05:53,953 >> THANKS, GREG. 165 00:05:54,020 --> 00:05:55,421 I HAVE A VARIETY OF THINGS TO 166 00:05:55,488 --> 00:05:57,690 RELATE AND I WILL JUMP RIGHT IN. 167 00:05:57,757 --> 00:06:00,960 AS I HAVE BEEN DOING IN THE 168 00:06:01,027 --> 00:06:04,263 PAST, I PULL OUT THE SUMMARY 169 00:06:04,330 --> 00:06:06,499 FROM MY PREVIOUS COUNCIL 170 00:06:06,566 --> 00:06:07,767 PRESENTATION TO REMIND ME AND 171 00:06:07,834 --> 00:06:11,304 ALL OF YOU WHAT WAS PRESENTED 172 00:06:11,370 --> 00:06:14,540 LAST TIME, AND SO AT THE LAST 173 00:06:14,607 --> 00:06:16,075 MEETING PRESIDENT BIDEN HAD 174 00:06:16,142 --> 00:06:19,112 NOMINATED DR. BERTAGNOLLI AS NIH 175 00:06:19,178 --> 00:06:20,513 DIRECTOR, AND I'LL TALK MORE 176 00:06:20,580 --> 00:06:20,813 ABOUT THAT. 177 00:06:20,880 --> 00:06:22,448 WE'RE REALLY LUCKY TO HAVE HER 178 00:06:22,515 --> 00:06:25,051 HERE TODAY TO SPEAK AFTER MY 179 00:06:25,118 --> 00:06:25,384 PRESENTATION. 180 00:06:25,451 --> 00:06:28,020 I HAD ASKED HER ACTUALLY TO 181 00:06:28,087 --> 00:06:29,422 PRESENT WHEN SHE WAS NCI 182 00:06:29,489 --> 00:06:31,290 DIRECTOR, AND KIND OF JUST 183 00:06:31,357 --> 00:06:33,126 WORKED OUT, SO REALLY HAPPY TO 184 00:06:33,192 --> 00:06:34,660 HAVE HER HERE LATER TODAY. 185 00:06:34,727 --> 00:06:37,063 I ALSO TALKED ABOUT HOW NCATS 186 00:06:37,130 --> 00:06:38,397 LEADERSHIP IS GROWING, I'LL TALK 187 00:06:38,464 --> 00:06:41,000 MORE ABOUT THAT AGAIN BECAUSE IT 188 00:06:41,067 --> 00:06:41,567 CONTINUES. 189 00:06:41,634 --> 00:06:44,270 AND A VARIETY OF IMPACTFUL 190 00:06:44,337 --> 00:06:45,605 ADVANCES THAT I'LL PICK UP WHERE 191 00:06:45,671 --> 00:06:47,940 WE LEFT OFF LAST TIME. 192 00:06:48,007 --> 00:06:50,777 SO, THAT'S WHERE WE WERE. 193 00:06:50,843 --> 00:06:53,679 HERE'S SOME OF THESE ACTIVITIES 194 00:06:53,746 --> 00:06:58,050 THAT HAVE HAPPENED TO DATE. 195 00:06:58,117 --> 00:07:00,052 MONICA BERTAGNOLLI IS NOW THE 196 00:07:00,119 --> 00:07:02,588 NIH DIRECTOR, SHE'S HAD A COUPLE 197 00:07:02,655 --> 00:07:03,089 INTERVIEWS. 198 00:07:03,156 --> 00:07:03,890 SO I'VE HIGHLIGHTED THE ONE SHE 199 00:07:03,956 --> 00:07:06,659 DID IN THE NIH RECORD HERE TO 200 00:07:06,726 --> 00:07:09,262 TALK ABOUT HER PRIORITIES, 201 00:07:09,328 --> 00:07:10,029 LARGELY RELATED TO ENSURING 202 00:07:10,096 --> 00:07:12,532 CLINICAL TRIALS YIELD THE BEST 203 00:07:12,598 --> 00:07:15,067 RESULTS, INCREASING DIVERSITY OF 204 00:07:15,134 --> 00:07:17,703 PARTICIPANTS IN CLINICAL 205 00:07:17,770 --> 00:07:19,272 RESEARCH, USING LEARNING-BASED 206 00:07:19,338 --> 00:07:20,339 ANALYTICAL TOOLS, AND ENSURING 207 00:07:20,406 --> 00:07:25,211 THEIR USE IMPROVES CARE FOR ALL, 208 00:07:25,278 --> 00:07:25,912 RESTORING TRUST IN SCIENCE, 209 00:07:25,978 --> 00:07:28,314 INSPIRING THE NEXT GENERATION OF 210 00:07:28,381 --> 00:07:33,386 DOCTORS AND SCIENTISTS, 211 00:07:33,452 --> 00:07:35,054 LEVERAGING COMMONALITIES ACROSS 212 00:07:35,121 --> 00:07:36,222 DISEASES. 213 00:07:36,289 --> 00:07:38,324 I PULLED OUT HIGHLIGHTS, NEAR 214 00:07:38,391 --> 00:07:40,092 AND DEAR TO OUR HEARTS AS WELL 215 00:07:40,159 --> 00:07:41,194 AT NCATS. 216 00:07:41,260 --> 00:07:42,261 THERE'S A LOT OF ALIGNMENT IN 217 00:07:42,328 --> 00:07:46,566 THE VISION AND I'M EXCITED TO 218 00:07:46,632 --> 00:07:48,067 HELP THIS TAKE SHAPE. 219 00:07:48,134 --> 00:07:49,702 AND AS I MENTIONED, SHE WILL BE 220 00:07:49,769 --> 00:07:51,904 HERE LATER TODAY AT 1:45 TO GIVE 221 00:07:51,971 --> 00:07:52,972 HER OWN VISION AND PRIORITIES 222 00:07:53,039 --> 00:07:54,941 AND TALK TO YOU MORE ABOUT 223 00:07:55,007 --> 00:07:55,274 THOSE. 224 00:07:55,341 --> 00:07:57,376 SO WE'RE EXCITED FOR THAT. 225 00:07:57,443 --> 00:08:02,315 IN ADDITION TO SOME OTHER 226 00:08:02,381 --> 00:08:08,754 LEADERSHIP ACTIVITIES, THE NEW 227 00:08:08,821 --> 00:08:13,926 NCI DIRECTOR, AS DR. BERTAGNOLLI 228 00:08:13,993 --> 00:08:15,661 LEFT, IT WAS PRETTY QUICK TURN 229 00:08:15,728 --> 00:08:22,235 AROUND IN TERMS GESTING THE NEXT 230 00:08:22,301 --> 00:08:25,404 NCI DIRECTOR, DR. KIMRYM 231 00:08:25,471 --> 00:08:27,473 RATHMELL, ANOTHER REAL STAR HERE 232 00:08:27,540 --> 00:08:37,683 AT NCI TO LEAD THAT INSTITUTE. 233 00:08:37,750 --> 00:08:38,584 WE HAVE AN OPENING AT NATIONAL 234 00:08:38,651 --> 00:08:43,289 LIBRARY OF MEDICINE TO REPLACE 235 00:08:43,356 --> 00:08:45,491 DR. PATTI BRENNAN AND FOGARTY 236 00:08:45,558 --> 00:08:45,958 INTERNATIONAL CENTER. 237 00:08:46,025 --> 00:08:47,994 BOTH THESE POSITIONS ARE IN 238 00:08:48,060 --> 00:08:49,495 VARIOUS STAGES OF THEIR 239 00:08:49,562 --> 00:08:51,063 ACTIVITIES, SO WE'RE HOPING TO 240 00:08:51,130 --> 00:08:54,133 HEAR SOON ON ONE, BUT THE THINK 241 00:08:54,200 --> 00:08:57,937 THE NLM IS FURTHER BEHIND. 242 00:08:58,004 --> 00:08:59,839 NOW, IN ADDITION TO SOME COMINGS 243 00:08:59,906 --> 00:09:03,009 AND GOINGS, AS YOU KNOW THERE'S 244 00:09:03,075 --> 00:09:05,511 A TERM LIMIT ON YOUR 245 00:09:05,578 --> 00:09:07,046 PARTICIPATION IN COUNCIL. 246 00:09:07,113 --> 00:09:08,814 THIS TIME WE'RE -- FOR THIS 247 00:09:08,881 --> 00:09:14,520 COUNCIL WE'RE SAYING FAREWELL TO 248 00:09:14,587 --> 00:09:16,589 TWO COUNCIL MEMBERS, THESE 249 00:09:16,656 --> 00:09:18,457 THINGS AREN'T EASY WHEN WE HAVE 250 00:09:18,524 --> 00:09:20,126 GROWN ACCUSTOMED TO ONE ANOTHER 251 00:09:20,192 --> 00:09:25,031 BUT I WANT TO RECOGNIZE DR. 252 00:09:25,097 --> 00:09:25,831 MATTIAS KRETZLER, A FANTASTIC 253 00:09:25,898 --> 00:09:27,967 MEMBER ON COUNCIL FROM THE 254 00:09:28,034 --> 00:09:29,702 UNIVERSITY OF MICHIGAN AT ANN 255 00:09:29,769 --> 00:09:33,773 ARBOR, HAS WORKED IN THE RDCRN 256 00:09:33,839 --> 00:09:36,208 PROGRAM AND JUST GENERAL 257 00:09:36,275 --> 00:09:38,945 EXCITEMENT AROUND TRANSLATIONAL 258 00:09:39,011 --> 00:09:39,178 SCIENCE. 259 00:09:39,245 --> 00:09:40,212 THEN THE OTHER COUNCIL MEMBER 260 00:09:40,279 --> 00:09:49,055 WHO IS LEAVING US IS DR. 261 00:09:49,121 --> 00:09:51,090 MARSHALL SUMMER, NOW CHIEF 262 00:09:51,157 --> 00:09:55,428 OFFICER IN WASHINGTON, D.C. AND 263 00:09:55,494 --> 00:09:59,131 HAS BEEN SUCH A CHAMPION OF THE 264 00:09:59,198 --> 00:10:08,240 RARE DISEASE WORK SAD TO SEE 265 00:10:08,307 --> 00:10:09,775 THEM GO, IT'S ALWAYS DIFFICULT 266 00:10:09,842 --> 00:10:11,544 TO SAY FAREWELL. 267 00:10:11,610 --> 00:10:13,145 DURING THEIR TENURE, THEY HAVE 268 00:10:13,212 --> 00:10:15,481 NOT JUST BEEN SORT OF THE 269 00:10:15,548 --> 00:10:17,283 ADVISORS THAT YOU ALL ARE, BUT 270 00:10:17,350 --> 00:10:19,852 ALSO THE BEST CRITICS AND 271 00:10:19,919 --> 00:10:22,021 DEEPEST ALLIES THAT WE CAN HAVE. 272 00:10:22,088 --> 00:10:23,689 THAT'S SUPER IMPORTANT FOR WHAT 273 00:10:23,756 --> 00:10:24,423 WE'RE TRYING TO DO. 274 00:10:24,490 --> 00:10:29,595 THE WORK WE DO TOGETHER IS 275 00:10:29,662 --> 00:10:31,964 REALLY MADE BETTER BY OUR 276 00:10:32,031 --> 00:10:32,331 CONVERSATIONS. 277 00:10:32,398 --> 00:10:34,734 SO YOUR INSIGHTS, DEDICATION AND 278 00:10:34,800 --> 00:10:36,535 UNWAVERING SUPPORT HAVE BEEN 279 00:10:36,602 --> 00:10:38,237 INSTRUMENTAL IN GUIDING OUR 280 00:10:38,304 --> 00:10:38,871 INITIATIVES AND DECISIONS 281 00:10:38,938 --> 00:10:41,674 ESPECIALLY IN THE SPACE OF RARE 282 00:10:41,741 --> 00:10:43,175 DISEASES AND THERAPEUTIC 283 00:10:43,242 --> 00:10:46,679 DEVELOPMENT, AND NEW PREDICTIVE 284 00:10:46,746 --> 00:10:47,980 MODELS. 285 00:10:48,047 --> 00:10:51,617 SO MATTIAS AND MARSHALL, YOUR 286 00:10:51,684 --> 00:10:53,652 CONTRIBUTIONS SHAPED OUR WORK, 287 00:10:53,719 --> 00:10:55,721 THIS IS NOT A GOOD-BYE BUT MORE 288 00:10:55,788 --> 00:11:00,059 OF A "WE'LL BE IN TOUCH SOON" 289 00:11:00,126 --> 00:11:01,494 AND I WANT TO EXTEND MY 290 00:11:01,560 --> 00:11:03,629 GRATITUDE FOR YOUR SERVICE AND 291 00:11:03,696 --> 00:11:04,864 DEDICATION. 292 00:11:04,930 --> 00:11:05,731 THANK YOU FOR BEING INTEGRAL 293 00:11:05,798 --> 00:11:09,668 MEMBERS OF OUR NCATS TEAM. 294 00:11:09,735 --> 00:11:11,103 OUR VIRTUAL ENVIRONMENT MAKES 295 00:11:11,170 --> 00:11:12,505 THIS LESS TANGIBLE BUT PLEASE, A 296 00:11:12,571 --> 00:11:15,474 ROUND OF APPLAUSE FOR THE TWO 297 00:11:15,541 --> 00:11:18,077 MEMBERS AND THE SERVICE. 298 00:11:18,144 --> 00:11:19,311 SO THANK YOU. 299 00:11:19,378 --> 00:11:20,379 >> JONI, IT'S BEEN TREMENDOUS 300 00:11:20,446 --> 00:11:23,049 FUN TO DO THIS. 301 00:11:23,115 --> 00:11:23,749 REALLY APPRECIATE, DEEPLY 302 00:11:23,816 --> 00:11:24,450 APPRECIATE, THE OPPORTUNITY TO 303 00:11:24,517 --> 00:11:26,152 DO THIS. 304 00:11:26,218 --> 00:11:27,620 I'VE LEARNED SO MUCH. 305 00:11:27,686 --> 00:11:29,688 I LEAVE KNOWING THE PLACE IS IN 306 00:11:29,755 --> 00:11:31,690 GREAT HANDS UNDER YOUR 307 00:11:31,757 --> 00:11:33,025 LEADERSHIP, AND SO EXCITED TO 308 00:11:33,092 --> 00:11:35,327 HAVE NEW LEADERSHIP WITH THE 309 00:11:35,394 --> 00:11:36,962 RARE DISEASE GROUP WITH 310 00:11:37,029 --> 00:11:37,430 DOMINIQUE. 311 00:11:37,496 --> 00:11:39,031 SO JUST SUCH A GOOD JOB YOU'RE 312 00:11:39,098 --> 00:11:41,801 DOING. 313 00:11:41,867 --> 00:11:43,169 >> THANK YOU. 314 00:11:43,235 --> 00:11:44,837 THANK YOU, MARSHALL. 315 00:11:44,904 --> 00:11:45,604 >> CONGRATULATIONS FOR AN 316 00:11:45,671 --> 00:11:46,705 OUTSTANDING TRANSITION AND 317 00:11:46,772 --> 00:11:49,175 EXCITING TIME FOR NCATS. 318 00:11:49,241 --> 00:11:50,309 YES, PLEASE CALL UP ON US WHEN 319 00:11:50,376 --> 00:11:52,678 WE CAN BE IN ANY WAY, SHAPE, OR 320 00:11:52,745 --> 00:11:54,046 FORM HELPING YOU ON WHAT HAS 321 00:11:54,113 --> 00:11:56,315 BEEN AN OUTSTANDING START. 322 00:11:56,382 --> 00:11:57,483 THANKS SO MUCH. 323 00:11:57,550 --> 00:11:57,817 >> FANTASTIC. 324 00:11:57,883 --> 00:11:58,150 >> ABSOLUTELY. 325 00:11:58,217 --> 00:11:58,484 >> THANK YOU. 326 00:11:58,551 --> 00:12:00,152 THANK YOU FOR THAT. 327 00:12:00,219 --> 00:12:01,720 YES, OUR VIRTUAL ENVIRONMENT 328 00:12:01,787 --> 00:12:07,827 MAKES THIS LESS TANGIBLE BUT IT 329 00:12:07,893 --> 00:12:08,694 IS NO LESS FELT. 330 00:12:08,761 --> 00:12:11,530 THANK YOU FOR THE ROUND OF 331 00:12:11,597 --> 00:12:11,997 APPLAUSE TOO. 332 00:12:12,064 --> 00:12:15,901 ON A SAD NOTE WE'VE LEARNED THAT 333 00:12:15,968 --> 00:12:19,205 AN NCATS COUNCIL MEMBER HAS 334 00:12:19,271 --> 00:12:22,541 PASSED AWAY LAST YEAR. 335 00:12:22,608 --> 00:12:25,678 I MET RAJESH MANY YEARS AGO WHEN 336 00:12:25,744 --> 00:12:27,646 HEADING TRANSLATIONAL EFFORTS AT 337 00:12:27,713 --> 00:12:32,685 NINDS, AND HE HELPED LAUNCH THE 338 00:12:32,751 --> 00:12:33,285 BLUEPRINT NEUROTHERAPEUTICS 339 00:12:33,352 --> 00:12:34,854 PROGRAM OUT OF THE -- SOME 340 00:12:34,920 --> 00:12:35,688 INSTITUTES AND CENTERS ACROSS 341 00:12:35,754 --> 00:12:38,324 THE NIH, AND HE WAS ALSO PART OF 342 00:12:38,390 --> 00:12:42,428 A CORE GROUP AT THE NIH THAT WAS 343 00:12:42,495 --> 00:12:44,597 INSTRUMENTAL IN SUPPORTING THIS 344 00:12:44,663 --> 00:12:47,933 NEW I.C. FOCUSED ON 345 00:12:48,000 --> 00:12:49,768 TRANSLATIONAL SCIENCE NOW KNOWN 346 00:12:49,835 --> 00:12:52,404 AS NCATS. 347 00:12:52,471 --> 00:12:53,973 HE PLAYED A PIVOTAL ROLE AND 348 00:12:54,039 --> 00:12:54,974 INITIATED TRANSLATIONAL SCIENCE 349 00:12:55,040 --> 00:12:56,675 PROGRAM OUT OF THE OFFICE OF 350 00:12:56,742 --> 00:12:57,343 INTRAMURAL TRAINING AND 351 00:12:57,409 --> 00:12:59,011 EDUCATION, AND HE AND I SHARED 352 00:12:59,078 --> 00:13:02,915 THE HONOR OF KICKING OFF THAT 353 00:13:02,982 --> 00:13:03,482 TWO-DAY IMMERSIVE TRAINING 354 00:13:03,549 --> 00:13:03,883 PROGRAM. 355 00:13:03,949 --> 00:13:05,784 HE REALLY HAD THIS PASSION FOR 356 00:13:05,851 --> 00:13:08,954 TRAINING AND HE HAD THIS ALSO 357 00:13:09,021 --> 00:13:10,789 NO-NONSENSE WAY OF DELIVERY THAT 358 00:13:10,856 --> 00:13:13,125 I REALLY GREW TO APPRECIATE. 359 00:13:13,192 --> 00:13:14,226 AND HE JOINED THE NCATS COUNCIL 360 00:13:14,293 --> 00:13:16,695 WHEN I WAS ACTING DIRECTOR, AND 361 00:13:16,762 --> 00:13:18,898 AM TRULY SADDENED BY HIS LOSS 362 00:13:18,964 --> 00:13:24,837 AND WANTED TO SHARE THAT WITH 363 00:13:24,904 --> 00:13:26,238 YOU AS WELL. 364 00:13:26,305 --> 00:13:27,773 IN TERMS OF THE NCATS 365 00:13:27,840 --> 00:13:30,843 LEADERSHIP, THERE HAVE BEEN A 366 00:13:30,910 --> 00:13:31,610 VARIETY OF DIFFERENT TRANSITIONS 367 00:13:31,677 --> 00:13:33,045 AS YOU'VE HEARD ABOUT AT OUR 368 00:13:33,112 --> 00:13:33,946 LAST MEETING. 369 00:13:34,013 --> 00:13:35,748 I WANTED TO LET YOU KNOW STATUS 370 00:13:35,814 --> 00:13:37,783 OF WHERE WE ARE NOW. 371 00:13:37,850 --> 00:13:41,587 WE ARE VERY CLOSE TO ANNOUNCING 372 00:13:41,654 --> 00:13:43,556 OUR SCIENTIFIC DIRECTOR AND OUR 373 00:13:43,622 --> 00:13:45,958 OFFICE OF TRANSLATIONAL MEDICINE 374 00:13:46,025 --> 00:13:46,425 POSITIONS. 375 00:13:46,492 --> 00:13:48,060 WE HAVE -- WE'RE SORT OF IN THE 376 00:13:48,127 --> 00:13:50,262 MIDST OF THE PROCESS FOR THE 377 00:13:50,329 --> 00:13:50,996 DEPUTY DIRECTOR POSITION. 378 00:13:51,063 --> 00:13:52,398 AND THE CHIEF OF STAFF POSITION. 379 00:13:52,464 --> 00:13:55,601 SO I HOPE THAT BY OUR NEXT 380 00:13:55,668 --> 00:13:58,537 MEETING YOU WILL HEAR THE FULLY 381 00:13:58,604 --> 00:13:59,939 FORMED LEADERSHIP AT NCATS. 382 00:14:00,005 --> 00:14:01,941 SO, IT'S TAKEN US A WHILE TO GET 383 00:14:02,007 --> 00:14:03,242 HERE BUT I FEEL LIKE WE'RE 384 00:14:03,309 --> 00:14:08,380 REALLY IN VERY GOOD SHAPE IN 385 00:14:08,447 --> 00:14:09,815 THAT REGARD. 386 00:14:09,882 --> 00:14:12,818 SO, THAT SAID, IT IS ALSO THE 387 00:14:12,885 --> 00:14:17,690 LAST COUNCIL FOR OUR DEPUTY 388 00:14:17,756 --> 00:14:18,490 DIRECTOR, CLARE SCHMITT. 389 00:14:18,557 --> 00:14:20,826 WE'VE GONE THROUGH THE PROCESS 390 00:14:20,893 --> 00:14:22,861 OF SEARCHING FOR A NEW DEPUTY, 391 00:14:22,928 --> 00:14:26,498 SO I WANTED TO SAY A THANK YOU 392 00:14:26,565 --> 00:14:29,969 TO CLARE FOR THREE YEARS, HAS 393 00:14:30,035 --> 00:14:32,605 SERVED AS ACTING DEPUTY 394 00:14:32,671 --> 00:14:34,106 DIRECTOR, GRACIOUSLY EXTENDING 395 00:14:34,173 --> 00:14:34,807 HER COMMITMENT FOR ANOTHER YEAR 396 00:14:34,873 --> 00:14:35,908 TO THIS YEAR. 397 00:14:35,975 --> 00:14:38,077 SHE WAS HOPING TO RETIRE LAST 398 00:14:38,143 --> 00:14:41,013 YEAR BUT EXTENDED THAT A LITTLE 399 00:14:41,080 --> 00:14:42,481 BIT. 400 00:14:42,548 --> 00:14:43,983 AND HER PARTNERSHIP, LEADERSHIP, 401 00:14:44,049 --> 00:14:45,317 HAVE BEEN INVALUABLE. 402 00:14:45,384 --> 00:14:47,052 SHE HAS THIS MASTERY OF 403 00:14:47,119 --> 00:14:50,022 EMOTIONAL INTELLIGENCE THAT HAS 404 00:14:50,089 --> 00:14:51,323 BEEN INCREDIBLY VALUABLE TO ME 405 00:14:51,390 --> 00:14:53,692 AND A GUIDING LIGHT FOR A LOT OF 406 00:14:53,759 --> 00:14:54,260 US HERE. 407 00:14:54,326 --> 00:14:57,997 HER JOURNEY WITH NIH BEGAN IN 408 00:14:58,063 --> 00:14:59,064 2000, SINCE THEN SHE'S BEEN 409 00:14:59,131 --> 00:15:03,769 WORKING IN THE FIELD OF 410 00:15:03,836 --> 00:15:05,571 MICROBIOLOGY WITH VERY KEEN 411 00:15:05,638 --> 00:15:09,141 FOCUS I THINK ON MICROBIAL 412 00:15:09,208 --> 00:15:11,243 PATHOGENESIS, FOOD AND 413 00:15:11,310 --> 00:15:13,512 WATER-BORNE ILLNESSES, 414 00:15:13,579 --> 00:15:15,080 TRANSLATION OF BASIC SCIENCE 415 00:15:15,147 --> 00:15:16,248 INTO LIFE SAVING SOLUTIONS, 416 00:15:16,315 --> 00:15:18,017 DURING THE COURSE OF THE 417 00:15:18,083 --> 00:15:20,853 PANDEMIC SHE WAS INSTRUMENTAL IN 418 00:15:20,919 --> 00:15:22,688 HELPING US NAVIGATE THAT. 419 00:15:22,755 --> 00:15:25,924 AS SHE PREPARES TO EMBARK ON 420 00:15:25,991 --> 00:15:28,093 WELL-DESERVED ENVIRONMENT I FEEL 421 00:15:28,160 --> 00:15:32,831 PROFOUND GRATITUDE FOR HER 422 00:15:32,898 --> 00:15:35,167 WISDOM AND THE WARMTH SHE 423 00:15:35,234 --> 00:15:38,170 BROUGHT, THIS SENTIMENT IS 424 00:15:38,237 --> 00:15:38,704 SHARED ACROSS NCATS. 425 00:15:38,771 --> 00:15:40,005 CLARE, YOU'VE BEEN MORE THAN A 426 00:15:40,072 --> 00:15:41,140 DEPUTY DIRECTOR. 427 00:15:41,206 --> 00:15:42,241 YOU'VE BEEN A MENTOR, LEADER, 428 00:15:42,308 --> 00:15:43,409 AND A FRIEND. 429 00:15:43,475 --> 00:15:44,343 ON BEHALF OF EVERYONE HERE I 430 00:15:44,410 --> 00:15:46,412 THANK YOU SO MUCH FOR YOUR 431 00:15:46,478 --> 00:15:47,446 EXTRAORDINARY SERVICE AND I WISH 432 00:15:47,513 --> 00:15:50,416 YOU ALL THE BEST IN YOUR 433 00:15:50,482 --> 00:15:51,850 RETIREMENT. 434 00:15:51,917 --> 00:15:55,554 SO THANK YOU, CLARE. 435 00:15:55,621 --> 00:15:59,692 AGAIN, NOT TANGIBLE BUT VERY 436 00:15:59,758 --> 00:16:02,127 HEARTFELT, SO THANK YOU. 437 00:16:02,194 --> 00:16:06,065 AND THEN ON TO SORT OF THE 438 00:16:06,131 --> 00:16:07,166 MATTERS MORE BUSINESS-LIKE 439 00:16:07,232 --> 00:16:10,202 MATTERS, FILLING YOU IN ON THE 440 00:16:10,269 --> 00:16:12,538 APPROPRIATIONS NEWS AND BUDGET 441 00:16:12,604 --> 00:16:13,839 ACTIVITIES THAT ARE ONGOING. 442 00:16:13,906 --> 00:16:17,443 AT OUR LAST COUNCIL I MENTIONED 443 00:16:17,509 --> 00:16:18,610 WE HAD NOT HAD CLARITY ON THE 444 00:16:18,677 --> 00:16:19,545 BUDGET AS YET. 445 00:16:19,611 --> 00:16:22,815 THAT REMAINS TO BE THE CASE AS 446 00:16:22,881 --> 00:16:24,717 WE STAND NOW. 447 00:16:24,783 --> 00:16:27,186 BUT THERE HAS BEEN RECENT 448 00:16:27,252 --> 00:16:27,453 ACTIVITY. 449 00:16:27,519 --> 00:16:30,389 NCATS IS OPERATING UNDER A 450 00:16:30,456 --> 00:16:31,590 CONTINUING RESOLUTION THROUGH 451 00:16:31,657 --> 00:16:34,993 MARCH 8 THAT WAS JUST DONE 452 00:16:35,060 --> 00:16:35,327 YESTERDAY. 453 00:16:35,394 --> 00:16:38,397 SO WE HAVE THE ABILITY TO MOVE 454 00:16:38,464 --> 00:16:39,798 FORWARD THROUGH MARCH 8. 455 00:16:39,865 --> 00:16:42,434 AND I BELIEVE IT'S STILL PENDING 456 00:16:42,501 --> 00:16:43,335 THE PRESIDENT'S SIGNATURE BUT 457 00:16:43,402 --> 00:16:46,805 THAT'S MEANT TO BE IMMINENT, FIT 458 00:16:46,872 --> 00:16:48,774 HASN'T ALREADY HAPPENED. 459 00:16:48,841 --> 00:16:51,310 THE HOUSE AND SENATE BILLS FOR 460 00:16:51,377 --> 00:16:53,679 OUR BUDGET REMAIN AS THEY ARE. 461 00:16:53,746 --> 00:16:56,348 THEY WERE PROPOSED TO BE A FLAT 462 00:16:56,415 --> 00:16:58,617 BUDGET FOR NCATS. 463 00:16:58,684 --> 00:17:02,221 AND, AGAIN, DEPENDING HOW 464 00:17:02,287 --> 00:17:04,390 SCENARIOS UNFOLD WILL DETERMINE 465 00:17:04,456 --> 00:17:05,424 WHAT BUDGET ULTIMATELY GETS 466 00:17:05,491 --> 00:17:06,325 APPROVED FOR NCATS. 467 00:17:06,392 --> 00:17:07,326 SO, PLEASE STAY TUNED. 468 00:17:07,393 --> 00:17:12,297 I HOPE TO HAVE A BROADER UPDATE 469 00:17:12,364 --> 00:17:13,866 FOR YOU IN MAY. 470 00:17:13,932 --> 00:17:14,166 OKAY. 471 00:17:14,233 --> 00:17:19,938 SO NOW ON TO SOME SORT OF OTHER 472 00:17:20,005 --> 00:17:20,806 NEWS AND ACTIVITIES. 473 00:17:20,873 --> 00:17:24,376 AT OUR LAST MEETING TOO I 474 00:17:24,443 --> 00:17:26,078 MENTIONED THERE WERE A FEW 475 00:17:26,145 --> 00:17:28,680 TOPICS THAT THE ADVISORY 476 00:17:28,747 --> 00:17:30,883 COMMITTEE TO THE DIRECTOR HAD 477 00:17:30,949 --> 00:17:33,118 BEEN TAKEN UP AND EVALUATING. 478 00:17:33,185 --> 00:17:34,920 IN DECEMBER OF LAST YEAR THEY 479 00:17:34,987 --> 00:17:36,455 BOTH HAVE PUT FORWARD THEIR 480 00:17:36,522 --> 00:17:38,924 RECOMMENDATIONS ON THESE TWO 481 00:17:38,991 --> 00:17:39,158 TOPICS. 482 00:17:39,224 --> 00:17:42,428 SO ONE WAS REENVISIONING THE 483 00:17:42,494 --> 00:17:43,662 NIH-SUPPORTED POSTDOCTORAL 484 00:17:43,729 --> 00:17:44,396 TRAINING PROGRAM. 485 00:17:44,463 --> 00:17:47,599 AND THEIR CHARGE WAS TO 486 00:17:47,666 --> 00:17:48,700 EVALUATE, ASSESS, REVIEW, AND 487 00:17:48,767 --> 00:17:51,970 CONSIDER A VARIETY OF THE WAYS 488 00:17:52,037 --> 00:17:54,506 WE COULD EXPLORE TO, NUMBER ONE, 489 00:17:54,573 --> 00:17:56,942 LOOK AT SHORTAGE OF PhDs, 490 00:17:57,009 --> 00:18:01,079 AND NUMBER TWO, THINK ABOUT 491 00:18:01,146 --> 00:18:03,015 SCOPE AND PERSISTENCE OF THE 492 00:18:03,081 --> 00:18:04,650 ISSUE OF GETTING MORE Ph.D.s 493 00:18:04,716 --> 00:18:07,653 INTO THE FOLD AND TRAINING THAT 494 00:18:07,719 --> 00:18:09,421 MAY GO BEYOND ACADEMIA, 495 00:18:09,488 --> 00:18:12,491 CONSIDERS THE FULL BREADTH OF 496 00:18:12,558 --> 00:18:16,962 TRAINING ACTIVITIES, TO SUPPORT 497 00:18:17,029 --> 00:18:18,897 MORE OF A WORK/LIFE BALANCE, 498 00:18:18,964 --> 00:18:21,467 SOME THINGS THAT WERE DISCUSSED. 499 00:18:21,533 --> 00:18:23,702 THE QR CODE ON THE RIGHT IS THE 500 00:18:23,769 --> 00:18:24,636 REPORT OF RECOMMENDATIONS BUT I 501 00:18:24,703 --> 00:18:27,172 WANTED TO HIGHLIGHT THOSE HERE. 502 00:18:27,239 --> 00:18:28,674 SIX RECOMMENDATIONS WERE PUT 503 00:18:28,740 --> 00:18:29,107 FORWARD. 504 00:18:29,174 --> 00:18:31,977 ONE WAS TO INCREASE PAY AND 505 00:18:32,044 --> 00:18:32,678 BENEFITS FOR NIH-SUPPORTED 506 00:18:32,744 --> 00:18:33,745 POSTDOCTORAL SCHOLARS. 507 00:18:33,812 --> 00:18:36,014 TWO WAS TO CREATE AND EXPAND 508 00:18:36,081 --> 00:18:38,650 MECHANISMS TO SUPPORT FULL 509 00:18:38,717 --> 00:18:40,853 TALENT POOL OF POSTDOCTORAL 510 00:18:40,919 --> 00:18:41,687 SCHOLARS. 511 00:18:41,753 --> 00:18:44,256 THIRD WAS TO FACILITATE 512 00:18:44,323 --> 00:18:44,923 TRANSITION OF POSTDOCTORAL 513 00:18:44,990 --> 00:18:47,526 SCHOLARS INTO THEIR NEXT CAREER 514 00:18:47,593 --> 00:18:49,061 STAGE, HERE AGAIN THINKING ABOUT 515 00:18:49,127 --> 00:18:51,063 ROLES BEYOND ACADEMIA. 516 00:18:51,129 --> 00:18:52,931 AND THEN THE THIRD WHICH I THINK 517 00:18:52,998 --> 00:18:55,033 IS REALLY IMPORTANT IS TO 518 00:18:55,100 --> 00:18:57,336 PROMOTE TRAINING AND 519 00:18:57,402 --> 00:18:57,936 PROFESSIONAL DEVELOPMENT OF 520 00:18:58,003 --> 00:18:59,638 POSTDOCTORAL SCHOLARS AND THEIR 521 00:18:59,705 --> 00:19:00,205 MENTORS. 522 00:19:00,272 --> 00:19:01,907 I REALLY LIKE THE CONCEPT HERE 523 00:19:01,974 --> 00:19:03,909 OF NOT JUST THINKING ABOUT 524 00:19:03,976 --> 00:19:07,079 POSTDOCTORAL SCHOLARS BUT ALSO 525 00:19:07,145 --> 00:19:07,813 MENTORS. 526 00:19:07,880 --> 00:19:09,515 IT'S THAT DYNAMIC THAT'S SUPER 527 00:19:09,581 --> 00:19:10,782 IMPORTANT AS WELL. 528 00:19:10,849 --> 00:19:12,684 NUMBER FIVE, SUPPORT SAFE AND 529 00:19:12,751 --> 00:19:14,186 DIVERSE PERSPECTIVES AND 530 00:19:14,253 --> 00:19:15,487 RESEARCH ENVIRONMENTS WITHIN 531 00:19:15,554 --> 00:19:15,821 INSTITUTIONS. 532 00:19:15,888 --> 00:19:18,423 AND SIX, TO IMPROVE MEANS TO 533 00:19:18,490 --> 00:19:21,093 MEASURE AND SHARE CAREER 534 00:19:21,159 --> 00:19:23,695 PROGRESSION FOR POSTDOCS. 535 00:19:23,762 --> 00:19:24,830 THESE ARE THE SIX 536 00:19:24,897 --> 00:19:25,797 RECOMMENDATIONS THAT WE'RE NOW 537 00:19:25,864 --> 00:19:27,232 CONSIDERING AT THE NIH TO 538 00:19:27,299 --> 00:19:29,501 UNDERSTAND HOW WE CAN THEN 539 00:19:29,568 --> 00:19:30,502 IMPLEMENT THEM AND MOVE FORWARD. 540 00:19:30,569 --> 00:19:32,070 STAY TUNED ON THESE. 541 00:19:32,137 --> 00:19:35,407 I'M SURE IF YOU HAVE POSTDOCS 542 00:19:35,474 --> 00:19:36,808 WITHIN YOUR INSTITUTIONS THAT 543 00:19:36,875 --> 00:19:38,176 YOU'RE ALREADY PAYING ATTENTION 544 00:19:38,243 --> 00:19:40,212 TO THESE BUT HOPE THIS WILL ADD 545 00:19:40,279 --> 00:19:42,414 SOME VALUE TO THAT. 546 00:19:42,481 --> 00:19:45,150 THE NEXT TOPIC THAT WAS 547 00:19:45,217 --> 00:19:47,319 DISCUSSED LAST YEAR FOR THE 548 00:19:47,386 --> 00:19:48,921 ADVISORY COMMITTEE TO DIRECTOR 549 00:19:48,987 --> 00:19:50,289 WAS ON CATALYZING DEVELOPMENT 550 00:19:50,355 --> 00:19:52,925 AND USE OF ALTERNATIVE METHODS 551 00:19:52,991 --> 00:19:55,761 TO ADVANCE BIOMEDICAL RESEARCH, 552 00:19:55,827 --> 00:19:58,830 SO-CALLED NAMs, NEW APPROACH 553 00:19:58,897 --> 00:20:00,465 METHODS, NOVEL APPROACH 554 00:20:00,532 --> 00:20:02,434 METHODOLOGIES, A COUPLE ACRONYMS 555 00:20:02,501 --> 00:20:03,502 ARE USED FOR THIS. 556 00:20:03,569 --> 00:20:05,804 AND CHARGE FOR THIS GROUP WAS TO 557 00:20:05,871 --> 00:20:07,839 IDENTIFY THESE METHODS, TO 558 00:20:07,906 --> 00:20:08,640 ASSESS STRENGTHS AND WEAKNESSES 559 00:20:08,707 --> 00:20:10,309 FOR A VARIETY OF ACTIVITIES THAT 560 00:20:10,375 --> 00:20:14,012 WE DO IN THE BIOMEDICAL 561 00:20:14,079 --> 00:20:14,880 ECOSYSTEM, CHARACTERIZE AND 562 00:20:14,947 --> 00:20:15,547 UNDERSTAND WHAT CONDITIONS THEY 563 00:20:15,614 --> 00:20:18,016 CAN BE USED FOR RECOGNIZING IT'S 564 00:20:18,083 --> 00:20:19,952 NOT ABOUT NECESSARILY REPLACING 565 00:20:20,018 --> 00:20:22,220 BUT ACTUALLY PROVIDING OTHER 566 00:20:22,287 --> 00:20:25,190 MEANS BY WHICH TO STUDY DISEASE 567 00:20:25,257 --> 00:20:27,626 PROCESSES THAT MAY REDUCE THE 568 00:20:27,693 --> 00:20:28,961 ABILITY -- REDUCE OUR USE OF 569 00:20:29,027 --> 00:20:30,128 ANIMAL MODELS AS WELL, 570 00:20:30,195 --> 00:20:31,296 RECOGNIZING WE'RE PROBABLY NOT 571 00:20:31,363 --> 00:20:35,367 GOING TO BE ABLE TO REPLACE THEM 572 00:20:35,434 --> 00:20:35,601 WHOLLY. 573 00:20:35,667 --> 00:20:36,602 THAT'S NOT REALLY THE GOAL. 574 00:20:36,668 --> 00:20:38,570 THE GOAL IS TO UNDERSTAND HOW WE 575 00:20:38,637 --> 00:20:40,305 CAN COMPLEMENT THEM. 576 00:20:40,372 --> 00:20:41,974 SO, THIS GROUP CAME TOGETHER TO 577 00:20:42,040 --> 00:20:43,508 THINK ABOUT THESE DIFFERENT 578 00:20:43,575 --> 00:20:45,677 IDEAS AND QR CODE IS SHOWN HERE 579 00:20:45,744 --> 00:20:47,713 FOR THEIR REPORT. 580 00:20:47,779 --> 00:20:49,381 AND I WILL GIVE YOU JUST A 581 00:20:49,448 --> 00:20:51,650 LITTLE BIT OF OVERVIEW OF THOSE 582 00:20:51,717 --> 00:20:52,117 RECOMMENDATIONS. 583 00:20:52,184 --> 00:20:54,219 I ALSO WANTED TO LET YOU KNOW 584 00:20:54,286 --> 00:20:56,288 THAT FOR THIS PARTICULAR 585 00:20:56,355 --> 00:20:58,857 ACTIVITY WE HAD SPECIFIC PEOPLE 586 00:20:58,924 --> 00:21:01,760 FROM THE FDA, EPA, ALSO FROM 587 00:21:01,827 --> 00:21:03,228 NCATS, BECAUSE NCATS HAS BEEN A 588 00:21:03,295 --> 00:21:06,264 STRONG LEADER IN THIS SPACE AND 589 00:21:06,331 --> 00:21:07,666 WE WILL CONTINUE TO DO SO. 590 00:21:07,733 --> 00:21:10,402 I WANTED TO LET YOU KNOW WHO WAS 591 00:21:10,469 --> 00:21:12,371 ON THIS PARTICULAR PROGRAM AND A 592 00:21:12,437 --> 00:21:14,239 VARIETY OF EXTRAMURAL MEMBERS 593 00:21:14,306 --> 00:21:16,308 FROM THE COMMUNITY WITH A 594 00:21:16,375 --> 00:21:17,576 VARIETY OF DIFFERENT EXPERIENCE 595 00:21:17,643 --> 00:21:18,877 AND EXPERTISE THAT WERE BROUGHT 596 00:21:18,944 --> 00:21:20,545 TO THE TABLE. 597 00:21:20,612 --> 00:21:22,514 SO THIS WAS A FANTASTIC GROUP 598 00:21:22,581 --> 00:21:25,217 THAT REALLY PULLED TOGETHER, 599 00:21:25,283 --> 00:21:27,853 THREE DIFFERENT KIND OF NAMs 600 00:21:27,919 --> 00:21:30,155 THEY ARE CONSIDERING. 601 00:21:30,222 --> 00:21:33,225 THESE ARE CELL-FREE METHODS AND 602 00:21:33,291 --> 00:21:34,526 CHEMICAL GENETICS, FOR EXAMPLE. 603 00:21:34,593 --> 00:21:37,929 IN VITRO METHODS ARE CULTURED 604 00:21:37,996 --> 00:21:39,364 CELLS, iPS AND 605 00:21:39,431 --> 00:21:45,570 MICROPHYSIOLOGICAL SYSTEMS OR 606 00:21:45,637 --> 00:21:55,947 3D CHIPS AND BIO. 607 00:21:59,484 --> 00:22:01,953 AND IN SILICO. 608 00:22:02,020 --> 00:22:04,523 HOW WE CAN USE THESE IN BASIC 609 00:22:04,589 --> 00:22:05,724 RESEARCH, TRANSLATE INTO 610 00:22:05,791 --> 00:22:05,991 PRACTICE. 611 00:22:06,058 --> 00:22:08,260 THESE ARE RECOMMENDATIONS THEY 612 00:22:08,326 --> 00:22:11,163 PUT FORWARD TO PRIORITIZE 613 00:22:11,229 --> 00:22:14,399 DEVELOPMENT OF USE, ESTABLISH 614 00:22:14,466 --> 00:22:15,300 RESOURCES AND INFRASTRUCTURE, 615 00:22:15,367 --> 00:22:17,002 PROMOTE DISSEMINATION, INVEST IN 616 00:22:17,069 --> 00:22:19,738 TRAINING TO BOLSTER THE NEXT 617 00:22:19,805 --> 00:22:22,607 CADRE OF SCIENTISTS, AND TO 618 00:22:22,674 --> 00:22:24,676 DEVELOP INTERDISCIPLINARY TEAMS 619 00:22:24,743 --> 00:22:25,777 AND PROMOTE SOCIAL 620 00:22:25,844 --> 00:22:27,879 RESPONSIBILITY IN THE CREATION 621 00:22:27,946 --> 00:22:29,247 AND DEPLOYMENT OF NAMs ACROSS 622 00:22:29,314 --> 00:22:30,182 THE RESEARCH LIFE CYCLE. 623 00:22:30,248 --> 00:22:32,084 I THINK THIS IS A REALLY 624 00:22:32,150 --> 00:22:33,118 IMPORTANT ONE AS WELL. 625 00:22:33,185 --> 00:22:36,521 AND THEN TO SUPPORT AND MAINTAIN 626 00:22:36,588 --> 00:22:38,390 COORDINATED INFRASTRUCTURE TO 627 00:22:38,457 --> 00:22:40,125 THEN MAKE THESE NAMs BEING 628 00:22:40,192 --> 00:22:46,498 USED IN A RESPONSIBLE WAY, TO 629 00:22:46,565 --> 00:22:48,200 CONTINUE FURTHER DEVELOPMENT. 630 00:22:48,266 --> 00:22:50,068 ONE OF THE UNIQUE ASPECTS OF 631 00:22:50,135 --> 00:22:51,069 THIS WORKING GROUP WE WERE 632 00:22:51,136 --> 00:22:53,705 CONSIDERING AND STILL ARE 633 00:22:53,772 --> 00:22:54,439 CONSIDERING A COMMON FUND 634 00:22:54,506 --> 00:22:57,776 APPROACH TO LOOK AT WHAT WE'RE 635 00:22:57,843 --> 00:23:01,279 CALLING COMPLEMENTARY, WHICH IS 636 00:23:01,346 --> 00:23:04,182 ESSENTIALLY COMPLEMENT ANIMAL 637 00:23:04,249 --> 00:23:04,916 RESEARCH IN EXPERIMENTATION, A 638 00:23:04,983 --> 00:23:07,586 TORTURED ACRONYM. 639 00:23:07,652 --> 00:23:09,721 IF YOU GOOGLE IT, YOU CAN FIND 640 00:23:09,788 --> 00:23:11,456 IT WELL IN THE GOOGLE SPACE. 641 00:23:11,523 --> 00:23:12,324 THAT'S ALWAYS GOOD. 642 00:23:12,390 --> 00:23:14,059 WE WERE WORKING ON THIS WHEN THE 643 00:23:14,126 --> 00:23:16,561 ACD WAS TALKING ABOUT THESE 644 00:23:16,628 --> 00:23:17,662 ISSUES, THAT HELPED US I THINK 645 00:23:17,729 --> 00:23:19,097 SOLIDIFY SOME AREAS WE MIGHT BE 646 00:23:19,164 --> 00:23:20,599 ABLE TO GO INTO. 647 00:23:20,665 --> 00:23:23,668 AS WE'RE THINKING ABOUT PLANNING 648 00:23:23,735 --> 00:23:26,304 FOR THIS ACTIVITY, IF IT DOES 649 00:23:26,371 --> 00:23:28,907 CONTINUE TO MOVE FORWARD, WE 650 00:23:28,974 --> 00:23:29,808 PULLED TOGETHER ROUNDTABLES 651 00:23:29,875 --> 00:23:32,644 ASKING INDUSTRY AND ACADEMIC 652 00:23:32,711 --> 00:23:33,478 PARTNERS, NON-GOVERNMENT AND 653 00:23:33,545 --> 00:23:34,179 ORGANIZATIONAL REPRESENTATIVES 654 00:23:34,246 --> 00:23:35,847 AS WELL AS FDA PARTNERS TO COME 655 00:23:35,914 --> 00:23:36,915 TOGETHER AND TELL US WHAT THEY 656 00:23:36,982 --> 00:23:38,583 WERE SEEING IN THE SPACE AND HOW 657 00:23:38,650 --> 00:23:40,852 WE MIGHT BE ABLE TO HELP MOVE 658 00:23:40,919 --> 00:23:41,720 THIS FORWARD. 659 00:23:41,787 --> 00:23:44,656 IN ADDITION TO PART OF THIS 660 00:23:44,723 --> 00:23:46,892 LANDSCAPE IS DOING SORT OF A 661 00:23:46,958 --> 00:23:48,193 LANDSCAPE ANALYSIS BUT ALSO 662 00:23:48,260 --> 00:23:49,361 IDEATION PRIZES. 663 00:23:49,427 --> 00:23:52,030 SO WE HAD A CHALLENGE OR PRIZE 664 00:23:52,097 --> 00:23:53,565 COMPETITION TO ASK PEOPLE TO 665 00:23:53,632 --> 00:23:56,701 SUBMIT THEIR IDEAS FOR HOW WE 666 00:23:56,768 --> 00:23:58,403 COULD USE COMPLEMENTARY IN A WAY 667 00:23:58,470 --> 00:24:01,406 THAT COULD PUSH THE FIELD 668 00:24:01,473 --> 00:24:01,840 FORWARD. 669 00:24:01,907 --> 00:24:02,974 AND SO I'M EXCITED TO SEE WHERE 670 00:24:03,041 --> 00:24:05,343 THIS GOES BUT I THINK ULTIMATELY 671 00:24:05,410 --> 00:24:08,446 IT'S HOW WE PULL TOGETHER THOSE 672 00:24:08,513 --> 00:24:10,215 THREE DIFFERENT KINDS OF 673 00:24:10,282 --> 00:24:11,416 COMPLEMENTARY APPROACHES IN 674 00:24:11,483 --> 00:24:13,919 THOSE NAMs, AND INTEGRATE THEM 675 00:24:13,985 --> 00:24:15,420 TOGETHER TO MAKE THEM EVEN 676 00:24:15,487 --> 00:24:17,055 GREATER THAN THE -- THE WHOLE 677 00:24:17,122 --> 00:24:18,523 GREATER THAN THE SUM OF THEIR 678 00:24:18,590 --> 00:24:20,058 PARTS, AND I THINK THAT WOULD BE 679 00:24:20,125 --> 00:24:21,693 A REALLY GOOD ADVANCE FOR THE 680 00:24:21,760 --> 00:24:22,160 BIOMEDICAL COMMUNITY. 681 00:24:22,227 --> 00:24:24,996 SO PLEASE STAY TUNED ON THAT. 682 00:24:25,063 --> 00:24:26,531 NOW I MENTIONED TOO THE DEEP 683 00:24:26,598 --> 00:24:27,833 INTERACTIONS WITH THE FDA AS 684 00:24:27,899 --> 00:24:31,870 WE'VE BEEN TALKING ABOUT THAT 685 00:24:31,937 --> 00:24:32,537 IDEA. 686 00:24:32,604 --> 00:24:33,705 BUT IN PARALLEL, NCATS 687 00:24:33,772 --> 00:24:34,306 SPECIFICALLY, I SPECIFICALLY 688 00:24:34,372 --> 00:24:37,142 REALLY WANTED TO MAKE SURE WE'RE 689 00:24:37,209 --> 00:24:38,410 STRENGTHENING OUR PARTNERSHIPS 690 00:24:38,476 --> 00:24:43,515 WITH FDA TOO BECAUSE OF OUR 691 00:24:43,582 --> 00:24:47,185 PLACE IN THE TRANSLATIONAL 692 00:24:47,252 --> 00:24:50,121 SCIENCE PIPELINE, SPECTRUM, 693 00:24:50,188 --> 00:24:50,922 PRE-CLINICAL AND CLINICAL 694 00:24:50,989 --> 00:24:53,024 ACTIVITY IS -- FDA ARE REALLY 695 00:24:53,091 --> 00:24:53,358 OUR PARTNERS. 696 00:24:53,425 --> 00:24:54,659 SO WE'VE WORKED WITH THEM ON A 697 00:24:54,726 --> 00:24:56,761 VARIETY OF TOPICS AND WE WANT TO 698 00:24:56,828 --> 00:24:58,930 CONTINUE TO DO SO. 699 00:24:58,997 --> 00:25:00,465 ONE TOPIC WAS AROUND REALLY 700 00:25:00,532 --> 00:25:03,134 TALKING ABOUT IDEAS IN GENERAL 701 00:25:03,201 --> 00:25:05,437 BUT THE OVERARCHING THEME FOR 702 00:25:05,503 --> 00:25:10,408 THIS WAS GENE THERAPY AND GENE 703 00:25:10,475 --> 00:25:11,743 EDITING, WORKING WITH CBER 704 00:25:11,810 --> 00:25:13,245 COLLEAGUES, INCLUDING RELEVANT 705 00:25:13,311 --> 00:25:14,145 AREAS OF INFORMATICS IN THIS 706 00:25:14,212 --> 00:25:16,081 SPACE, EVEN THE NAMs AS WELL. 707 00:25:16,147 --> 00:25:20,485 SO THIS IS ONE AREA WE'VE BEEN 708 00:25:20,552 --> 00:25:21,887 WORKING ON. 709 00:25:21,953 --> 00:25:23,655 ANOTHER TOPIC OF INTERACTION, 710 00:25:23,722 --> 00:25:26,091 CONTINUING ON THE NAM THEME IS 711 00:25:26,157 --> 00:25:27,058 THINKING ABOUT THE TOXICOLOGICAL 712 00:25:27,125 --> 00:25:29,227 RESEARCH THAT WE ALSO THINK IS 713 00:25:29,294 --> 00:25:30,195 VERY IMPORTANT. 714 00:25:30,262 --> 00:25:34,399 SO WE -- A FEW OF US WENT OUT TO 715 00:25:34,466 --> 00:25:37,469 AR-KANSAS, I SAY THAT BECAUSE 716 00:25:37,535 --> 00:25:39,337 I'M FROM KANSAS, SORRY, BUT I 717 00:25:39,404 --> 00:25:42,941 GUESS I SHOULD SAY ARKANSAS. 718 00:25:43,008 --> 00:25:46,411 AND WE HAD A GREAT MEETING WITH 719 00:25:46,478 --> 00:25:50,348 TUCKER PATTERSON AND HIS TEAM 720 00:25:50,415 --> 00:25:52,017 FROM NCTR, OPPORTUNITIES TO 721 00:25:52,083 --> 00:25:53,952 ADVANCE HUMAN CELL-BASED MODELS 722 00:25:54,019 --> 00:25:56,354 FOR SAFETY AND EFFICACY AND 723 00:25:56,421 --> 00:25:58,256 REALLY WHAT THEY MIGHT NEED TO 724 00:25:58,323 --> 00:26:00,425 HELP US THINK THIS THROUGH. 725 00:26:00,492 --> 00:26:02,193 NCTR IS SUCH A VALUABLE PARTNER 726 00:26:02,260 --> 00:26:03,395 HERE BECAUSE A LOT OF THE WORK 727 00:26:03,461 --> 00:26:05,764 THEY DO IS IN ANIMAL MODELS, SO 728 00:26:05,830 --> 00:26:08,166 IT WILL BE CRITICAL TO BE ABLE 729 00:26:08,233 --> 00:26:09,200 TO UNDERSTAND, YOU KNOW, WHAT 730 00:26:09,267 --> 00:26:10,702 THEY ARE SEEING FROM THEIR END 731 00:26:10,769 --> 00:26:13,271 ON THE ANIMAL MODEL SPACE AND 732 00:26:13,338 --> 00:26:16,408 INCORPORATING THEN THESE NOVEL 733 00:26:16,474 --> 00:26:16,942 APPROACH METHODOLOGIES TO 734 00:26:17,008 --> 00:26:17,375 COMPARE. 735 00:26:17,442 --> 00:26:21,880 SO THIS IS A REALLY IMPORTANT 736 00:26:21,947 --> 00:26:23,281 PARTNERSHIP THAT WE HAVE. 737 00:26:23,348 --> 00:26:24,582 COMING SOON, IN MAY, WE'RE 738 00:26:24,649 --> 00:26:26,318 HOLDING ANOTHER MEETING TO TALK 739 00:26:26,384 --> 00:26:31,289 ABOUT NATURAL HISTORY STUDIES. 740 00:26:31,356 --> 00:26:33,024 AND ALSO HE DISEASE REGISTRIES 741 00:26:33,091 --> 00:26:34,359 IN RARE DISEASE TREATMENTS. 742 00:26:34,426 --> 00:26:36,561 THE IDEA HERE IS TO THINK ABOUT 743 00:26:36,628 --> 00:26:38,630 THE ROLE AND DESIGN OF THESE 744 00:26:38,697 --> 00:26:41,466 REGISTRIES AND HOW THEY COULD BE 745 00:26:41,533 --> 00:26:46,204 USED VERY SPECIFICALLY IN SORT 746 00:26:46,271 --> 00:26:46,938 OF CLINICAL ASSESSMENTS, 747 00:26:47,005 --> 00:26:47,472 ENDPOINTS, BIOMARKERS, ET 748 00:26:47,539 --> 00:26:47,839 CETERA. 749 00:26:47,906 --> 00:26:49,441 THIS WILL BE AN IMPORTANT 750 00:26:49,507 --> 00:26:50,875 MEETING I THINK, ESPECIALLY FOR 751 00:26:50,942 --> 00:26:52,610 OUR RARE DISEASE COMMUNITY. 752 00:26:52,677 --> 00:26:54,512 SO STAY TUNED FOR THAT. 753 00:26:54,579 --> 00:26:56,781 AND REGISTRATION IS NOT YET 754 00:26:56,848 --> 00:26:58,416 OPEN, BUT HOPEFULLY WE CAN FIND 755 00:26:58,483 --> 00:27:02,354 THAT ON THE WEBSITE AND MAKE YOU 756 00:27:02,420 --> 00:27:02,687 AWARE OF THAT. 757 00:27:02,754 --> 00:27:03,021 ALL RIGHT. 758 00:27:03,088 --> 00:27:05,757 I WANT TO ALSO TALK ABOUT SOME 759 00:27:05,824 --> 00:27:07,959 OF THE INNOVATIONS AND IMPACTS 760 00:27:08,026 --> 00:27:11,229 THAT NCATS HAS HAD SINCE WE LAST 761 00:27:11,296 --> 00:27:11,429 SPOKE. 762 00:27:11,496 --> 00:27:13,498 AND SORT OF ON A CONTINUOUS 763 00:27:13,565 --> 00:27:15,867 THEME HERE ABOUT THESE NOVEL 764 00:27:15,934 --> 00:27:18,570 APPROACH METHODOLOGIES, WE HAD A 765 00:27:18,636 --> 00:27:25,343 MEETING ON WHAT WE CALL I3D RARE 766 00:27:25,410 --> 00:27:27,512 WORKSHOP TO DEVELOP 3D 767 00:27:27,579 --> 00:27:28,279 BIOPRINTED TISSUES, TO CONTINUE 768 00:27:28,346 --> 00:27:30,715 A PRECISION MEDICINE PLATFORM OF 769 00:27:30,782 --> 00:27:32,217 STEM CELL-DERIVED TISSUES FROM 770 00:27:32,283 --> 00:27:33,418 PARTICULAR RARE DISEASE 771 00:27:33,485 --> 00:27:33,685 PATIENTS. 772 00:27:33,752 --> 00:27:36,588 AND THINK ABOUT HOW WE CAN USE 773 00:27:36,654 --> 00:27:37,722 THESE TO ACCELERATE DEVELOPMENT 774 00:27:37,789 --> 00:27:39,657 OF THERAPEUTICS FOR RARE 775 00:27:39,724 --> 00:27:42,093 DISEASES IN THIS WAY, SO THE 776 00:27:42,160 --> 00:27:44,829 WORKSHOP BROUGHT TOGETHER A 777 00:27:44,896 --> 00:27:48,733 VARIED OF STAKEHOLDERS WHO COME 778 00:27:48,800 --> 00:27:53,204 FROM DIFFERENT AREAS OF THE 779 00:27:53,271 --> 00:27:54,406 BIOMEDICAL COMMUNITY, AND 780 00:27:54,472 --> 00:27:55,640 DISCUSSED GAPS, BOTTLENECKS, 781 00:27:55,707 --> 00:27:57,609 CHALLENGES WE SEE AT THE FORE OF 782 00:27:57,675 --> 00:28:01,446 HOW WE CAN MOVE FORWARD IN THIS 783 00:28:01,513 --> 00:28:02,480 SPACE ESPECIALLY WHEN THERE 784 00:28:02,547 --> 00:28:04,549 AREN'T MANY ANIMAL MODELS FOR 785 00:28:04,616 --> 00:28:05,750 RARE DISEASES. 786 00:28:05,817 --> 00:28:07,786 SO THIS BECOMES PARTICULARLY 787 00:28:07,852 --> 00:28:09,354 IMPACTFUL IF WE'RE ABLE TO THINK 788 00:28:09,421 --> 00:28:11,222 MORE GENERALLY ABOUT THIS TO 789 00:28:11,289 --> 00:28:12,924 APPLY THEM TO AS MANY OF THESE 790 00:28:12,991 --> 00:28:14,893 TYPES OF MODELS THAT WE CAN DO 791 00:28:14,959 --> 00:28:18,129 PERHAPS IN THE FUTURE. 792 00:28:18,196 --> 00:28:19,864 THIS WAS A RECORDED EVENT, SO 793 00:28:19,931 --> 00:28:22,133 I'M COPIED THE QR CODE FOR THE 794 00:28:22,200 --> 00:28:24,636 YouTube IF YOU'RE INTERESTED 795 00:28:24,702 --> 00:28:25,370 IN VIEWING THAT. 796 00:28:25,437 --> 00:28:27,672 I WANTED TO SHOW YOU TOO JUST 797 00:28:27,739 --> 00:28:29,207 SORT OF POWER THAT WE'RE 798 00:28:29,274 --> 00:28:35,380 THINKING ABOUT IN TERMS OF 3D 799 00:28:35,447 --> 00:28:40,085 MODELS THAT HAVE BEEN EVALUATED 800 00:28:40,151 --> 00:28:40,351 AT NCATS. 801 00:28:40,418 --> 00:28:42,387 THEY HAVE DEVELOPED TISSUE 802 00:28:42,454 --> 00:28:45,990 MODELS FOR GENE THERAPY THROUGH 803 00:28:46,057 --> 00:28:47,826 OUR PAVE-GT PROGRAM, WE'RE 804 00:28:47,892 --> 00:28:50,128 USING -- WE'RE LOOKING AT TWO -- 805 00:28:50,195 --> 00:28:52,097 WELL, I SHOULD SAY FOUR REAL 806 00:28:52,163 --> 00:28:55,834 DISEASES FOR GENE THERAPY HERE 807 00:28:55,900 --> 00:28:58,403 FOR THE PAVE-GT PROGRAM AS A 808 00:28:58,470 --> 00:29:03,241 PILOT FOR THIS, TWO DISEASES ARE 809 00:29:03,308 --> 00:29:06,678 IN ORGANIC ACIDEMIA, AND TWO ARE 810 00:29:06,744 --> 00:29:07,245 NEUROMUSCULAR JUNCTION, AAV 811 00:29:07,312 --> 00:29:08,680 VECTORS WILL BE MADE FOR THOSE 812 00:29:08,746 --> 00:29:11,616 GENES THAT WILL SERVE AS SORT OF 813 00:29:11,683 --> 00:29:12,617 GENE REPLACEMENT. 814 00:29:12,684 --> 00:29:19,124 SO WE WANTED TO CREATE LIVER 815 00:29:19,190 --> 00:29:20,792 SPHEROIDS FOR ACIDEMIA GENE 816 00:29:20,859 --> 00:29:22,894 THERAPY AND WE RECEIVED CELLS 817 00:29:22,961 --> 00:29:26,397 FROM A PATIENT FROM PITTSBURGH 818 00:29:26,464 --> 00:29:27,465 AND CREATED ORGANOIDS FOR THIS 819 00:29:27,532 --> 00:29:31,536 PARTICULAR ACTIVITY, LOOKING AT 820 00:29:31,603 --> 00:29:38,209 HOW TO INFUSE VECTORS TO LOOK 821 00:29:38,276 --> 00:29:39,010 AT FUNCTIONAL READOUTS STARTING 822 00:29:39,077 --> 00:29:41,179 WITH ONE TISSUE BUT ULTIMATELY, 823 00:29:41,246 --> 00:29:42,480 YOU KNOW, THE IMPACT OF WHAT IT 824 00:29:42,547 --> 00:29:46,551 MIGHT HAVE ON OTHER SYSTEMS CAN 825 00:29:46,618 --> 00:29:48,386 BE EVALUATED IN THE FUTURE. 826 00:29:48,453 --> 00:29:49,954 WE LOOKED AT NEUROMUSCULAR 827 00:29:50,021 --> 00:29:50,321 JUNCTIONS. 828 00:29:50,388 --> 00:29:53,124 IF YOU LOOK CLOSELY YOU CAN SEE 829 00:29:53,191 --> 00:29:55,093 THAT MUSCLE FIBER TWITCHING, AND 830 00:29:55,160 --> 00:30:00,665 HERE AGAIN WE USE iPS CELLS TO 831 00:30:00,732 --> 00:30:08,139 CREATE CELL TYPE THAT WOULD LOOK 832 00:30:08,206 --> 00:30:13,611 AT CONGENITAL MYASTHENIC 833 00:30:13,678 --> 00:30:14,913 SYNDROMES, TO ASSESS HOW THEY 834 00:30:14,979 --> 00:30:16,314 COULD BE USEFUL FOR LOOKING AT 835 00:30:16,381 --> 00:30:24,155 SAFETY AND TOXICITY AND EFFICACY 836 00:30:24,222 --> 00:30:25,456 FOR THESE DISEASES IN THE 837 00:30:25,523 --> 00:30:25,823 FUTURE. 838 00:30:25,890 --> 00:30:26,858 IN ANOTHER SORT OF ACTIVITY 839 00:30:26,925 --> 00:30:30,795 WE'RE ALSO LOOKING AT THE SPACE 840 00:30:30,862 --> 00:30:32,764 OF LARGE LANGUAGE MODELS, AND WE 841 00:30:32,830 --> 00:30:38,102 HAD SORT OF A HYBRID MEETING IN 842 00:30:38,169 --> 00:30:40,838 NOVEMBER THAT BROUGHT ERIC TOPOL 843 00:30:40,905 --> 00:30:43,041 AS A KEYNOTE SPEAKER TO TALK 844 00:30:43,107 --> 00:30:45,443 ABOUT UNITS OF USING LLMs. 845 00:30:45,510 --> 00:30:49,047 THIS IS A BIG TOOL. 846 00:30:49,113 --> 00:30:50,248 EVEN IN ITS EARLY PHASES IT'S 847 00:30:50,315 --> 00:30:51,149 QUITE POWERFUL. 848 00:30:51,216 --> 00:30:52,650 WE WANTED TO MAKE SURE WE'RE 849 00:30:52,717 --> 00:30:54,219 APPROACHING IT IN A WAY THAT 850 00:30:54,285 --> 00:30:55,753 MAKES SENSE FOR US IN THE 851 00:30:55,820 --> 00:30:56,688 RESEARCH WE WANT TO DO. 852 00:30:56,754 --> 00:31:00,558 SO THE FOLKS ON THE LEFT, MIKE, 853 00:31:00,625 --> 00:31:04,762 JOSH, SAM AND DAVID, PULLED A 854 00:31:04,829 --> 00:31:05,196 GROUP TOGETHER. 855 00:31:05,263 --> 00:31:09,801 THE QR CODE IS THE VIDEO CAST. 856 00:31:09,867 --> 00:31:10,802 WHAT CAME OUT WAS EVOLVING NEEDS 857 00:31:10,868 --> 00:31:13,404 WE WANT TO PAY ATTENTION TO AS 858 00:31:13,471 --> 00:31:16,040 WE GO FORWARD, COMPUTATIONAL 859 00:31:16,107 --> 00:31:16,674 RESOURCES, DATA SOURCES, 860 00:31:16,741 --> 00:31:18,943 TRUSTWORTHINESS OF THE DATA, CAN 861 00:31:19,010 --> 00:31:22,413 WE TRUST THESE LOMs, HOW DO WE 862 00:31:22,480 --> 00:31:24,816 NAVIGATE THAT AND AND EVALUATE 863 00:31:24,882 --> 00:31:25,516 THAT. 864 00:31:25,583 --> 00:31:26,084 WHAT ARE BEST PRACTICES, 865 00:31:26,150 --> 00:31:33,191 ESPECIALLY WHEN IT COMES TO 866 00:31:33,258 --> 00:31:39,430 REGULATORY POLICY 867 00:31:39,497 --> 00:31:39,797 CONSIDERATIONS. 868 00:31:39,864 --> 00:31:40,965 IMPORTANT IS ETHICS, DIVERSITY 869 00:31:41,032 --> 00:31:41,599 AND INCLUSION, MAKING FOLKS 870 00:31:41,666 --> 00:31:42,834 AWARE OF THE VALUE OF THESE 871 00:31:42,900 --> 00:31:45,370 SORTS OF TYPES OF DATA THAT CAN 872 00:31:45,436 --> 00:31:47,105 BE USED. 873 00:31:47,171 --> 00:31:47,772 SO, WE'RE EXCITED ABOUT THIS, 874 00:31:47,839 --> 00:31:50,408 YOU KNOW, CONTINUING TO HAVE 875 00:31:50,475 --> 00:31:51,809 THESE CONVERSATIONS, AND THIS IS 876 00:31:51,876 --> 00:31:56,614 ALSO TRANSLATED INTO SOME OF THE 877 00:31:56,681 --> 00:31:58,516 WORK THAT LITCOIN HAS BEEN 878 00:31:58,583 --> 00:32:02,053 DOING, THIS EXCITING NCATS 879 00:32:02,120 --> 00:32:04,289 PROGRAM OUT OF CHRISTINE COLVIS' 880 00:32:04,355 --> 00:32:08,926 OFFICE, TYLER BECK IS ONE OF THE 881 00:32:08,993 --> 00:32:09,160 LEADERS. 882 00:32:09,227 --> 00:32:10,695 ONE TO INCENTIVIZE DATA AND 883 00:32:10,762 --> 00:32:11,562 KNOWLEDGE SHARING GIVING AUTHORS 884 00:32:11,629 --> 00:32:13,865 A WAY TO PUBLISH VALUABLE 885 00:32:13,931 --> 00:32:16,834 RESEARCH THAT FALLS OUTSIDE THE 886 00:32:16,901 --> 00:32:18,403 CURRENT PUBLISHING PARADIGM. 887 00:32:18,469 --> 00:32:21,306 SO THAT MEANS NEGATIVE RESULTS, 888 00:32:21,372 --> 00:32:23,341 FOR EXAMPLE, REPLICATION 889 00:32:23,408 --> 00:32:24,575 STUDIES, OR OTHER MISCELLANEOUS 890 00:32:24,642 --> 00:32:26,644 FINDINGS YOU MAY NOT THINK ABOUT 891 00:32:26,711 --> 00:32:28,513 A PUBLICATION BUT THIS OFFERS A 892 00:32:28,579 --> 00:32:30,415 WAY TO PERHAPS PUBLISH THOSE 893 00:32:30,481 --> 00:32:32,817 DATA AND MAKE THEM AVAILABLE. 894 00:32:32,884 --> 00:32:35,119 SO, IT ALLOWS US TO BUILD 895 00:32:35,186 --> 00:32:39,223 MACHINE READABLE OR A.I.-READY 896 00:32:39,290 --> 00:32:40,925 KNOWLEDGE BASE TO CONSIDER OUT 897 00:32:40,992 --> 00:32:42,393 OF THE TEXT THAT COULD COME 898 00:32:42,460 --> 00:32:42,593 FROM. 899 00:32:42,660 --> 00:32:44,829 AND I WANTED TO GIVE AN UPDATE 900 00:32:44,896 --> 00:32:47,665 ON SORT OF WHAT I MEAN BY THAT 901 00:32:47,732 --> 00:32:50,501 SECOND BULLET HERE. 902 00:32:50,568 --> 00:32:52,470 SO, IN BUILDING THIS 903 00:32:52,537 --> 00:32:54,872 MACHINE-READABLE A.I.-READY 904 00:32:54,939 --> 00:32:56,240 KNOWLEDGE BASE THESE LARGE 905 00:32:56,307 --> 00:32:59,377 LANGUAGE MODELS CAN HAVE ABILITY 906 00:32:59,444 --> 00:33:01,479 TO IDENTIFY AND SORT OF GRAB 907 00:33:01,546 --> 00:33:02,880 THESE KEY FINDINGS IN THE 908 00:33:02,947 --> 00:33:03,514 SUBMITTED MATERIALS. 909 00:33:03,581 --> 00:33:06,584 SO IT CAN BE PRETTY QUICK AND 910 00:33:06,651 --> 00:33:08,186 ACCURATE, AND FAIRLY CONSISTENT 911 00:33:08,252 --> 00:33:10,388 TOO IN TERMS OF THE 912 00:33:10,455 --> 00:33:11,089 IDENTIFICATION OF SCIENTIFIC 913 00:33:11,155 --> 00:33:12,957 RESEARCH, FINDINGS WITHIN THE 914 00:33:13,024 --> 00:33:15,426 LITERATURE, BUT REALLY AT SCALE. 915 00:33:15,493 --> 00:33:17,662 AND THESE FINDINGS ARE BROKEN 916 00:33:17,729 --> 00:33:19,197 DOWN INTO SUBJECT, OBJECT, AND 917 00:33:19,263 --> 00:33:19,464 RELATION. 918 00:33:19,530 --> 00:33:23,034 AND ASSEMBLED IN THAT WAY INTO 919 00:33:23,101 --> 00:33:24,135 THE MACHINE-READABLE SORT OF 920 00:33:24,202 --> 00:33:24,869 FIELD LEVEL. 921 00:33:24,936 --> 00:33:27,705 BEFORE YOU CAN INCORPORATE THAT 922 00:33:27,772 --> 00:33:30,408 INTO ANY LITCOIN CORPUS WE'RE 923 00:33:30,475 --> 00:33:31,943 THINKING ABOUT, THESE KNOWLEDGE 924 00:33:32,009 --> 00:33:38,316 GRAPHS ARE VALIDATED TO ENSURE 925 00:33:38,383 --> 00:33:41,252 THEIR ACCURATE, TRUSTING THESE 926 00:33:41,319 --> 00:33:42,320 SORTS OF MODELS. 927 00:33:42,387 --> 00:33:45,923 IT ALSO IS BUILT ON TOP -- THIS 928 00:33:45,990 --> 00:33:52,163 ISN'T NEW, BUILT ON TOP OF META. 929 00:33:52,230 --> 00:33:54,499 META CREATED THIS PLATFORM 930 00:33:54,565 --> 00:33:56,968 THAT'S DESIGNED TO FACILITATE 931 00:33:57,034 --> 00:33:58,069 COLLABORATION, INFORMATION 932 00:33:58,136 --> 00:33:59,737 SHARING, IN THE BIOMEDICAL 933 00:33:59,804 --> 00:34:00,605 RESEARCH COMMUNITY. 934 00:34:00,671 --> 00:34:03,608 SO LAVA 2 IS PARTICULARLY 935 00:34:03,674 --> 00:34:04,909 HELPFUL FOR TRANSLATIONAL 936 00:34:04,976 --> 00:34:07,178 SCIENCE AND RARE DISEASES AND 937 00:34:07,245 --> 00:34:08,513 RELATED FIELDS, SO LITCOIN HAS 938 00:34:08,579 --> 00:34:17,755 TAKEN A PAGE FROM THE LLAMA 2 939 00:34:17,822 --> 00:34:22,393 PROGRAM, CREATED A PROGRAM 940 00:34:22,460 --> 00:34:25,563 CALLED HEAL-PACA, FOR THE 941 00:34:25,630 --> 00:34:29,300 HELPING END ADICTION LONG TERM 942 00:34:29,367 --> 00:34:34,639 STUDY, TRANSLATING TO CREATING 943 00:34:34,705 --> 00:34:44,715 THIS LLM HEALPACA FOR ALGORITHMS 944 00:34:44,782 --> 00:34:46,884 AROUND THE HEAL-RELATED WORK. 945 00:34:46,951 --> 00:34:50,888 TO DEVELOP THIS PART OF THE 946 00:34:50,955 --> 00:34:55,059 LITCOIN ALGORITHM FOR HEALPAC, 947 00:34:55,126 --> 00:34:56,994 SUGGESTING HEALPACA MAY 948 00:34:57,061 --> 00:34:59,197 OUTPERFORM CHATGPT IN HUMAN 949 00:34:59,263 --> 00:35:02,800 COMPARISON MODELS AND OUTPUTS. 950 00:35:02,867 --> 00:35:12,310 WE HAD A LOT OF FUN PUTTING THIS 951 00:35:12,376 --> 00:35:13,511 LITCOIN TOGETHER, ALPACA-PUNCH 952 00:35:13,578 --> 00:35:22,820 WITH THIS VISUAL, VISUALS ARE SO 953 00:35:22,887 --> 00:35:23,020 GOOD. 954 00:35:23,087 --> 00:35:25,456 IN ANOTHER AREA TALKING ABOUT 955 00:35:25,523 --> 00:35:27,525 TRANSLATIONAL SCIENCE AND 956 00:35:27,592 --> 00:35:30,161 EDUCATION, AND TRAINING 957 00:35:30,228 --> 00:35:31,262 PROGRAMS, WE HAVE CREATED THESE 958 00:35:31,329 --> 00:35:33,297 EIGHT KEY PRINCIPLES OF 959 00:35:33,364 --> 00:35:34,966 TRANSLATIONAL SCIENCE. 960 00:35:35,032 --> 00:35:37,602 I HAVE EVEN A VISUAL HERE OF 961 00:35:37,668 --> 00:35:39,170 SOME STICKERS AND MAGNETS WE 962 00:35:39,237 --> 00:35:39,437 HAVE. 963 00:35:39,504 --> 00:35:40,872 I'LL MAKE SURE TO GIVE THOSE TO 964 00:35:40,938 --> 00:35:44,709 YOU NEXT TIME WE'RE IN PERSON. 965 00:35:44,775 --> 00:35:46,410 BUT THESE HAVE BECOME REALLY 966 00:35:46,477 --> 00:35:49,413 FANTASTIC TOOLS FOR PEOPLE WHO 967 00:35:49,480 --> 00:35:54,552 ARE THINKING ABOUT TRAINING IN 968 00:35:54,619 --> 00:35:55,553 EDUCATION FOR TRANSLATION 969 00:35:55,620 --> 00:35:57,622 ALSCIENCE, RESONATING WITH EIGHT 970 00:35:57,688 --> 00:36:01,225 KEY PRINCIPLES OF WHAT IT MIPS 971 00:36:01,292 --> 00:36:06,230 MEANS TO BE A TRANSLATIONAL 972 00:36:06,297 --> 00:36:07,064 SCIENTIST. 973 00:36:07,131 --> 00:36:10,368 I'VE BEEN HIGHLIGHTING THESE, 974 00:36:10,434 --> 00:36:11,669 KEY THEMES THROUGHOUT CTSA 975 00:36:11,736 --> 00:36:13,404 MEETING LAST FALL, ADOPTED THIS 976 00:36:13,471 --> 00:36:14,505 AS A WAY OF COMMUNICATING WHAT 977 00:36:14,572 --> 00:36:16,574 THE WORK THAT WE'RE TRYING TO 978 00:36:16,641 --> 00:36:19,677 DO, HOW IT FITS IN THE BROADER 979 00:36:19,744 --> 00:36:21,178 LANDSCAPE OF THESE KEY 980 00:36:21,245 --> 00:36:21,479 PRINCIPLES. 981 00:36:21,546 --> 00:36:23,814 WE'VE ALSO PUBLISHED A 982 00:36:23,881 --> 00:36:25,349 LITERATURE REVIEW ON 983 00:36:25,416 --> 00:36:27,118 TRANSLATIONAL SCIENCE EDUCATION 984 00:36:27,184 --> 00:36:28,986 AND TRAINING ALIGNED WITH THESE 985 00:36:29,053 --> 00:36:29,287 PRINCIPLES. 986 00:36:29,353 --> 00:36:31,722 I PUT THAT QR CODE HERE. 987 00:36:31,789 --> 00:36:33,257 NEXT YEAR WE'LL CONTINUE TO DO 988 00:36:33,324 --> 00:36:37,395 THIS WORK, DEVELOP MORE CASE 989 00:36:37,461 --> 00:36:38,729 STUDIES OF NCATS' SUCCESSES AND 990 00:36:38,796 --> 00:36:40,131 DEVELOP RESOURCES FOR OUR 991 00:36:40,197 --> 00:36:40,565 COMMUNITY. 992 00:36:40,631 --> 00:36:42,033 SO WE'RE PRETTY EXCITED ABOUT 993 00:36:42,099 --> 00:36:42,900 THIS PART TOO. 994 00:36:42,967 --> 00:36:44,535 ALL RIGHT. 995 00:36:44,602 --> 00:36:48,940 I WANT TO MOVE INTO THE AREA OF 996 00:36:49,006 --> 00:36:51,576 WHAT WE'VE CONTINUED TO DO IN 997 00:36:51,642 --> 00:36:53,544 THIS SPACE OF COVID-19. 998 00:36:53,611 --> 00:36:56,781 YOU KNOW, ALTHOUGH WE'RE KIND OF 999 00:36:56,847 --> 00:36:58,950 MOVING ON OUT OF THE COVID-19 1000 00:36:59,016 --> 00:37:01,018 REALM, BUT NCATS IS STILL VERY 1001 00:37:01,085 --> 00:37:02,520 MUCH LEARNING A LOT FROM THE 1002 00:37:02,587 --> 00:37:04,889 WORK THAT WE'VE BEEN DOING IN 1003 00:37:04,956 --> 00:37:05,890 COVID. 1004 00:37:05,957 --> 00:37:11,128 AND SEE A LOT OF VALUE IN 1005 00:37:11,195 --> 00:37:11,495 CONTINUING THAT. 1006 00:37:11,562 --> 00:37:15,399 TWO COUNCILS AGO I SHOWED YOU A 1007 00:37:15,466 --> 00:37:19,704 PAPER THAT WAS PENNED BY SEVERAL 1008 00:37:19,770 --> 00:37:26,077 NCATS AUTHORS HERE, SHOWN HERE 1009 00:37:26,143 --> 00:37:27,678 ON PAXLOVID EFFECTIVENESS, USING 1010 00:37:27,745 --> 00:37:30,982 N3C DATA, A PAPER REQUESTED FROM 1011 00:37:31,048 --> 00:37:34,051 THE COVID-19 RESPONSE TEAM AT 1012 00:37:34,118 --> 00:37:36,887 THE WHITE HOUSE, AND HE SAID, 1013 00:37:36,954 --> 00:37:40,257 HEY, CAN YOU TAKE A LOOK AT 1014 00:37:40,324 --> 00:37:42,693 WHETHER OR NOT -- HOW MANY 1015 00:37:42,760 --> 00:37:44,495 PEOPLE HAVE GOTTEN PAXLOVID WHO 1016 00:37:44,562 --> 00:37:46,464 WERE ELIGIBLE, HOW MANY HAVEN'T 1017 00:37:46,530 --> 00:37:52,003 GOTTEN BUT WERE ELIGIBLE. 1018 00:37:52,069 --> 00:37:55,606 WHAT WOULD THE IMPACT HAVE BEEN 1019 00:37:55,673 --> 00:37:56,273 HAD THEY RECEIVED PAXLOVID, THAT 1020 00:37:56,340 --> 00:37:57,508 WAS THE QUESTION. 1021 00:37:57,575 --> 00:38:03,247 THE QR CODE IS ON THE UPPER 1022 00:38:03,314 --> 00:38:03,447 RIGHT. 1023 00:38:03,514 --> 00:38:06,117 BASICALLY THE FIGURE SHOWN HERE 1024 00:38:06,183 --> 00:38:09,987 SHOWS THE UPTAKE OF COVID FROM 1025 00:38:10,054 --> 00:38:13,858 VERY RED ZERO TO BLUE VERY HIGH, 1026 00:38:13,924 --> 00:38:15,493 AND YOU CAN SEE IN 2021 PAXLOVID 1027 00:38:15,559 --> 00:38:18,262 FIRST CAME OUT, IT WASN'T USED 1028 00:38:18,329 --> 00:38:18,696 VERY MUCH. 1029 00:38:18,763 --> 00:38:21,732 2022 STARTING TO BE EVEN MORE. 1030 00:38:21,799 --> 00:38:28,205 2023 AND EVEN NOW, IT'S PROBABLY 1031 00:38:28,272 --> 00:38:29,807 NOT USED AT MAXIMAL POTENTIAL. 1032 00:38:29,874 --> 00:38:32,009 THIS PAPER IS STARTING TO GET 1033 00:38:32,076 --> 00:38:34,412 ATTENTION IN THE PRESS, COVERED 1034 00:38:34,478 --> 00:38:35,880 NOW, IT'S A PRE-PRINT STILL BUT 1035 00:38:35,946 --> 00:38:38,516 COVERED IN THE "NEW YORK TIMES," 1036 00:38:38,582 --> 00:38:40,451 WASHINGTON POST, USA TODAY, SO A 1037 00:38:40,518 --> 00:38:43,721 SHOUT OUT TO JOSH FESSEL WHO 1038 00:38:43,788 --> 00:38:46,357 COORDINATED THIS EFFORT, HE SAID 1039 00:38:46,424 --> 00:38:48,125 IF YOU CAN TAKE PAXLOVID AND YOU 1040 00:38:48,192 --> 00:38:50,394 DO, WITHIN THE RECOMMENDED TIME 1041 00:38:50,461 --> 00:38:54,632 FRAME, LIKELIHOOD OF DEATH OR 1042 00:38:54,699 --> 00:38:55,066 HOSPITALIZATION ARE 1043 00:38:55,132 --> 00:38:57,768 SIGNIFICANTLY REDUCED, THAT'S A 1044 00:38:57,835 --> 00:38:58,736 BIG DEAL. 1045 00:38:58,803 --> 00:39:01,472 THIS PAPER SHOWED APPROXIMATELY 1046 00:39:01,539 --> 00:39:02,907 48,000 DEATHS AND 135,000 1047 00:39:02,973 --> 00:39:05,643 HOSPITALIZATIONS AT THE TIME OF 1048 00:39:05,710 --> 00:39:07,712 THIS PUBLICATION COULD 1049 00:39:07,778 --> 00:39:13,317 POTENTIALLY HAVE BEEN PREVENTED 1050 00:39:13,384 --> 00:39:16,554 HAD THE ELIGIBLE PEOPLE TAKEN 1051 00:39:16,620 --> 00:39:18,189 THE PAXLOVID. 1052 00:39:18,255 --> 00:39:20,057 WE'RE STILL WANTING TO LEARN 1053 00:39:20,124 --> 00:39:22,393 ABOUT THE ENTHUSE OF THESE 1054 00:39:22,460 --> 00:39:23,561 THERAPEUTIC TOOLS FOR FIGHTING 1055 00:39:23,627 --> 00:39:24,995 AND COMBATING COVID-19 BECAUSE 1056 00:39:25,062 --> 00:39:26,530 IT'S STILL OUT THERE, THIS IS 1057 00:39:26,597 --> 00:39:28,733 IMPORTANT PUBLIC HEALTH KIND OF 1058 00:39:28,799 --> 00:39:29,967 WORK. 1059 00:39:30,034 --> 00:39:30,868 WE'RE NOW TRANSITIONING TO 1060 00:39:30,935 --> 00:39:32,703 LOOKING AT AND CONTINUING EVEN 1061 00:39:32,770 --> 00:39:37,041 SOME OF THE ACTIVE SIX STUDIES 1062 00:39:37,108 --> 00:39:37,641 THAT WE'RE DOING. 1063 00:39:37,708 --> 00:39:39,276 ACTIVE SIX IS ONE OF THE 1064 00:39:39,343 --> 00:39:41,312 PROGRAMS THROUGH THE COVID-19 1065 00:39:41,378 --> 00:39:43,414 WORK THAT WE'VE BEEN DOING. 1066 00:39:43,481 --> 00:39:47,952 AND IT IS A COMPLETELY VIRTUAL 1067 00:39:48,018 --> 00:39:49,687 CLINICAL TRIAL, DECENTRALIZED 1068 00:39:49,754 --> 00:39:53,023 CLINICAL TRIAL, AND METFORMIN IS 1069 00:39:53,090 --> 00:39:56,527 NOW OUR LAST THERAPEUTIC THAT 1070 00:39:56,594 --> 00:39:58,095 WE'RE EVALUATING. 1071 00:39:58,162 --> 00:40:00,798 WE SAW FROM A COVID OUT CLINICAL 1072 00:40:00,865 --> 00:40:02,099 TRIAL CONDUCTED PRIOR TO THIS, 1073 00:40:02,166 --> 00:40:06,036 PRIOR TO OUR TAKING IT ON, THAT 1074 00:40:06,103 --> 00:40:08,672 THEY SAW BENEFIT OF USE OF 1075 00:40:08,739 --> 00:40:09,573 METFORMIN FOR COVID-19. 1076 00:40:09,640 --> 00:40:12,209 AND SO IT WAS A SMALL STUDY, WE 1077 00:40:12,276 --> 00:40:14,011 WANTED TO EVALUATE THAT IN THE 1078 00:40:14,078 --> 00:40:14,578 ACTIVE SIX PLATFORM. 1079 00:40:14,645 --> 00:40:20,084 SO SARAH DUNSMORE IS LEADING 1080 00:40:20,151 --> 00:40:23,420 THIS SPACE, LOOKING AT PRIMARY 1081 00:40:23,487 --> 00:40:24,755 ENDPOINT, TIME TO RECOVERY FOR 1082 00:40:24,822 --> 00:40:27,691 THESE ACUTE COVID SYMPTOMS BUT 1083 00:40:27,758 --> 00:40:29,894 WE'RE ALSO ABLE TO EVALUATE THE 1084 00:40:29,960 --> 00:40:31,228 LONG COVID SYMPTOMS AS WELL 1085 00:40:31,295 --> 00:40:35,800 BECAUSE WE WILL HAVE A LONGER 1086 00:40:35,866 --> 00:40:38,135 TERM FOLLOW-UP, EXPANDING THIS 1087 00:40:38,202 --> 00:40:43,007 PARTICULAR METFORMIN ARM OF THE 1088 00:40:43,073 --> 00:40:43,741 ACTIV 6-PLATFORM. 1089 00:40:43,808 --> 00:40:53,250 WE'LL BE ABLE TO DO THIS 1090 00:40:53,317 --> 00:40:54,151 RANDOMIZED CLINICAL TRIAL. 1091 00:40:54,218 --> 00:40:56,420 WE HOPE TO GET TO 3,000 1092 00:40:56,487 --> 00:40:58,956 PARTICIPANTS AND BE ABLE TO 1093 00:40:59,023 --> 00:41:00,457 EVALUATE THESE PRIMARY ENDPOINTS 1094 00:41:00,524 --> 00:41:11,068 AS WELL AS LONG COVID ENDPOINTS. 1095 00:41:13,971 --> 00:41:17,474 WE HAVE THE FASTER PROGRAM, N3C 1096 00:41:17,541 --> 00:41:20,878 PUBLIC HEALTH ANSWERS TO SPEED 1097 00:41:20,945 --> 00:41:22,413 TRACTABLE RESULTS, AN ACRONYM, 1098 00:41:22,479 --> 00:41:27,952 HELPS US GET TO ANSWERS FASTER, 1099 00:41:28,018 --> 00:41:29,253 WE'RE LOOKING AT DATABASE FROM 1100 00:41:29,320 --> 00:41:30,454 ELECTRONIC HEALTH RECORD FROM 1101 00:41:30,521 --> 00:41:32,756 PEOPLE WHO STARTED TAKING 1102 00:41:32,823 --> 00:41:34,425 METFORMIN AFTER A COVID-POSITIVE 1103 00:41:34,491 --> 00:41:36,360 TEST, THAT COMBINED WITH THE 1104 00:41:36,427 --> 00:41:39,296 RANDOMIZED CLINICAL TRIAL AS 1105 00:41:39,363 --> 00:41:41,098 WELL, TRIAL EMULATION, REAL 1106 00:41:41,165 --> 00:41:43,067 TRIAL, WE'LL BE ABLE TO ASSESS 1107 00:41:43,133 --> 00:41:46,637 THE VALUE OF THE TRIAL EMULATION 1108 00:41:46,704 --> 00:41:47,705 METHODOLOGY USING ELECTRONIC 1109 00:41:47,771 --> 00:41:48,739 HEALTH RECORDS TO HELP INFORM 1110 00:41:48,806 --> 00:41:52,042 MAYBE HOW WE WANT TO DESIGN AND 1111 00:41:52,109 --> 00:41:53,744 SET UP FUTURE CLINICAL TRIALS. 1112 00:41:53,811 --> 00:41:56,146 WE'RE EXCITED ABOUT DOING THIS 1113 00:41:56,213 --> 00:42:00,885 AND THIS UNIQUE WAY THROUGH 1114 00:42:00,951 --> 00:42:02,453 ACTIV-6 AND N3C PLATFORM. 1115 00:42:02,519 --> 00:42:06,223 YOU CAN SEE MORE ON THE QR CODE 1116 00:42:06,290 --> 00:42:06,690 SHOWN HERE. 1117 00:42:06,757 --> 00:42:09,727 METFORMIN, WE HAVE A DATABASE ON 1118 00:42:09,793 --> 00:42:12,229 METFORMIN, IF YOU'RE INTERESTED 1119 00:42:12,296 --> 00:42:15,466 IN LOOKING AT THAT, HERE IS 1120 00:42:15,532 --> 00:42:19,270 WHERE WE HAVE NUMBERS OF PEOPLE 1121 00:42:19,336 --> 00:42:20,471 WITHIN N3C, RECORDS THAT ARE 1122 00:42:20,537 --> 00:42:22,439 AVAILABLE FOR THIS TYPE OF 1123 00:42:22,506 --> 00:42:22,740 ANALYSIS. 1124 00:42:22,806 --> 00:42:26,443 AGAIN, THIS WILL BE VERY HELPFUL 1125 00:42:26,510 --> 00:42:28,779 FOR US MOVING FORWARD. 1126 00:42:28,846 --> 00:42:30,981 I ALSO JUST WANTED TO SAY A NOTE 1127 00:42:31,048 --> 00:42:33,717 ON N3C IN AND OF ITSELF. 1128 00:42:33,784 --> 00:42:35,786 THIS IS SORT OF LIKE OUR 1129 00:42:35,853 --> 00:42:40,391 SNOWSTORM TODAY. 1130 00:42:40,457 --> 00:42:40,824 IT'S OVERPERFORMING. 1131 00:42:40,891 --> 00:42:43,227 IT HAS REALLY BEEN SUCH A HUGE 1132 00:42:43,294 --> 00:42:44,795 SUCCESS, AND REALLY THANK ALL OF 1133 00:42:44,862 --> 00:42:46,530 THE NCATS TEAMS WHO HAVE BEEN 1134 00:42:46,597 --> 00:42:47,298 WORKING ON THIS. 1135 00:42:47,364 --> 00:42:49,366 THERE ARE TOO MANY TO NAME. 1136 00:42:49,433 --> 00:42:52,002 SO MANY PEOPLE ON THE EXTRAMURAL 1137 00:42:52,069 --> 00:42:55,172 COMMUNITY AS WELL. 1138 00:42:55,239 --> 00:42:57,574 BUT CTSA PROGRAM, YOU KNOW, HAD 1139 00:42:57,641 --> 00:43:01,078 THIS VISION AS WELL. 1140 00:43:01,145 --> 00:43:03,347 BUT IT WAS ALSO RDCRN GROUPS WHO 1141 00:43:03,414 --> 00:43:06,450 LAID THE FRAMEWORK FOR PULL 1142 00:43:06,517 --> 00:43:08,986 DISPARATE DATA TYPES TOGETHER IN 1143 00:43:09,053 --> 00:43:13,257 A WAY, VIRTUAL RESEARCH 1144 00:43:13,324 --> 00:43:14,558 RESEARCH INFRASTRUCTURE. 1145 00:43:14,625 --> 00:43:16,226 THE RDCRN HAD THE SEEDS TO HAVE 1146 00:43:16,293 --> 00:43:17,795 THE TOOLS IN PLACE TO BUILD AND 1147 00:43:17,861 --> 00:43:20,431 BE READY FOR THE PANDEMIC, AND 1148 00:43:20,497 --> 00:43:23,267 THEN THE CTSA PROGRAM WAS REALLY 1149 00:43:23,334 --> 00:43:24,601 READY TO JUMP IN AND EVEN ADD 1150 00:43:24,668 --> 00:43:26,770 MORE VALUE TO THAT. 1151 00:43:26,837 --> 00:43:32,176 SO THIS HAS REALLY BEEN ACROSS 1152 00:43:32,242 --> 00:43:33,010 THE BOARD NCATS APPROACH, I 1153 00:43:33,077 --> 00:43:35,079 WANTED TO SAY HOW PROUD I AM OF 1154 00:43:35,145 --> 00:43:37,848 EVERYONE WHO HAS WORKED ON THIS 1155 00:43:37,915 --> 00:43:41,185 TO CREATE SUCH A NATIONAL 1156 00:43:41,251 --> 00:43:46,857 VIRTUAL RESEARCH INFRASTRUCTURE 1157 00:43:46,924 --> 00:43:48,492 WITH GOVERNANCE, WITH 1158 00:43:48,559 --> 00:43:49,259 INTEROPERABILITY, 1159 00:43:49,326 --> 00:43:50,561 DE-IDENTIFICATION, BEST 1160 00:43:50,627 --> 00:43:51,261 PRACTICES, IMPORTANT FOR 1161 00:43:51,328 --> 00:43:52,096 EVALUATING DATA. 1162 00:43:52,162 --> 00:43:53,897 I WANTED TO GIVE YOU A SENSE OF 1163 00:43:53,964 --> 00:43:56,600 WHERE WE'RE GOING. 1164 00:43:56,667 --> 00:43:58,435 WE STARTED WITH COVID-19 FOR 1165 00:43:58,502 --> 00:44:01,739 N3C, BUT NOW WE'RE THINKING 1166 00:44:01,805 --> 00:44:02,639 ABOUT IN ADDITION TO IF THERE 1167 00:44:02,706 --> 00:44:04,341 ARE WAYS TO CONTINUE THAT WE 1168 00:44:04,408 --> 00:44:05,776 WANT TO EXPLORE THAT. 1169 00:44:05,843 --> 00:44:07,378 BUT ALSO WE'RE THINKING ABOUT 1170 00:44:07,444 --> 00:44:09,813 WAYS TO EXPAND IT INTO NON-COVID 1171 00:44:09,880 --> 00:44:10,781 SPACES, AND WORKING WITH THE 1172 00:44:10,848 --> 00:44:12,916 COMMUNITY TO SEE BEST WAYS OF 1173 00:44:12,983 --> 00:44:14,318 DOING THAT. 1174 00:44:14,385 --> 00:44:16,587 WE'VE ESTABLISHED THIS IDEA OF 1175 00:44:16,653 --> 00:44:18,422 BEING ABLE TO COMPARE ONE EHR 1176 00:44:18,489 --> 00:44:20,424 FROM ONE HOSPITAL TO ANOTHER EHR 1177 00:44:20,491 --> 00:44:24,328 IN ANOTHER HOSPITAL, THAT ARE 1178 00:44:24,395 --> 00:44:25,396 COMPLETELY DISPARATE. 1179 00:44:25,462 --> 00:44:28,565 AND NOW WE CAN CONVERT THOSE 1180 00:44:28,632 --> 00:44:30,434 MODELS ONTO ONE ANOTHER THROUGH 1181 00:44:30,501 --> 00:44:32,269 WHAT WE CALL CODE MAPPING 1182 00:44:32,336 --> 00:44:32,536 SERVICES. 1183 00:44:32,603 --> 00:44:36,640 THIS IS REALLY KEN GERSING IS 1184 00:44:36,707 --> 00:44:38,008 MASTERFUL AT THIS IDEA, HAS 1185 00:44:38,075 --> 00:44:39,977 REALLY LED THIS WORK. 1186 00:44:40,044 --> 00:44:42,079 BUT WE CAN BASICALLY TAKE ANY OF 1187 00:44:42,146 --> 00:44:45,182 THESE MODELS AND CONVERT THEM TO 1188 00:44:45,249 --> 00:44:46,950 ANOTHER MODEL, WITHOUT ANY 1189 00:44:47,017 --> 00:44:50,454 TROUBLE, MAP THEM ONTO FHIR 1190 00:44:50,521 --> 00:44:51,722 RESOURCES TOO. 1191 00:44:51,789 --> 00:44:53,991 THIS IS COLLABORATION, DATA 1192 00:44:54,058 --> 00:44:57,628 LINKAGE, AND HELPING US 1193 00:44:57,694 --> 00:44:59,229 STREAMLINE FDA SUBMISSIONS AND 1194 00:44:59,296 --> 00:45:00,798 PHARMACOVIGILANCE, ENSURING WE 1195 00:45:00,864 --> 00:45:05,803 HAVE A CONTROLLED VOCABULARY 1196 00:45:05,869 --> 00:45:09,640 TRANSFORM FOR VERY DISPARATE EHR 1197 00:45:09,706 --> 00:45:10,774 DATA SOURCES. 1198 00:45:10,841 --> 00:45:12,276 EHR IS MESSY, THERE NEEDS A LOT 1199 00:45:12,342 --> 00:45:15,012 OF WORK IN THIS SPACE BUT I 1200 00:45:15,079 --> 00:45:17,314 THINK IF WE CAN ELEVATE AND 1201 00:45:17,381 --> 00:45:20,050 MATURE THE MESSINESS, SO TO 1202 00:45:20,117 --> 00:45:21,718 SPEAK, OF EHRs WE'RE VERY MUCH 1203 00:45:21,785 --> 00:45:23,120 READY TO CONTINUE TO WORK 1204 00:45:23,187 --> 00:45:25,556 THROUGH THOSE IN THESE CODE 1205 00:45:25,622 --> 00:45:28,692 MAPPING SERVICE WAYS SO WE CAN 1206 00:45:28,759 --> 00:45:29,693 COMPARE AND INTEROPERATE THE 1207 00:45:29,760 --> 00:45:32,529 SCIENTIFIC QUESTIONS THAT WE 1208 00:45:32,596 --> 00:45:33,230 HAVE. 1209 00:45:33,297 --> 00:45:36,733 SO, N3C IS A CENTRALIZED 1210 00:45:36,800 --> 00:45:37,835 RESOURCE, CENTRALIZED ANALYTICS. 1211 00:45:37,901 --> 00:45:39,203 WE'RE NOW THINKING ABOUT MOVING 1212 00:45:39,269 --> 00:45:42,272 INTO A TENANT MODEL TESTING FOR 1213 00:45:42,339 --> 00:45:42,940 FEASIBILITY. 1214 00:45:43,006 --> 00:45:47,478 ESSENTIALLY WHAT THIS MEANS IT 1215 00:45:47,544 --> 00:45:48,312 INCORPORATES A FEDERATED 1216 00:45:48,378 --> 00:45:50,848 APPROACH, DATA LIVE AT ACADEMIC 1217 00:45:50,914 --> 00:45:52,483 MEDICAL CENTER, AND THEN IF THEY 1218 00:45:52,549 --> 00:45:54,118 ARE INTERESTED IN RESEARCH 1219 00:45:54,184 --> 00:45:57,855 QUESTION THEY CAN THEN DELIVER 1220 00:45:57,921 --> 00:46:00,924 THEIR DATA TO AN ENCLAVE LIKE 1221 00:46:00,991 --> 00:46:02,993 N3C AND HAVE A RESEARCH 1222 00:46:03,060 --> 00:46:04,495 QUESTIONS OTHERS MIGHT WANT TO 1223 00:46:04,561 --> 00:46:07,164 ADD THEIR DATA TO AS WELL SO WE 1224 00:46:07,231 --> 00:46:09,133 CAN CREATE THEN THESE TENANT 1225 00:46:09,199 --> 00:46:10,200 MODELS OF A PARTICULAR RESEARCH 1226 00:46:10,267 --> 00:46:11,969 QUESTION THAT PEOPLE CAN USE AND 1227 00:46:12,035 --> 00:46:12,302 EVALUATE. 1228 00:46:12,369 --> 00:46:13,837 SO THAT'S THE KIND OF MODEL 1229 00:46:13,904 --> 00:46:14,872 WE'RE THINKING ABOUT AND 1230 00:46:14,938 --> 00:46:18,876 PILOTING AS WE SPEAK TO 1231 00:46:18,942 --> 00:46:19,543 DETERMINE FEASIBILITY, SECURITY, 1232 00:46:19,610 --> 00:46:20,244 ET CETERA. 1233 00:46:20,310 --> 00:46:21,211 SO STAY TUNED ON THIS. 1234 00:46:21,278 --> 00:46:24,181 WE'RE TRYING TO TEST THE WATERS 1235 00:46:24,248 --> 00:46:25,215 ON IT. 1236 00:46:25,282 --> 00:46:25,482 ALL RIGHT. 1237 00:46:25,549 --> 00:46:30,187 I'M GOING TO MOVE INTO THE RARE 1238 00:46:30,254 --> 00:46:31,588 DISEASE SPACE NOW. 1239 00:46:31,655 --> 00:46:36,360 AND, YOU KNOW, JANUARY IS A 1240 00:46:36,426 --> 00:46:37,594 PRECURSOR TO THE FEBRUARY RARE 1241 00:46:37,661 --> 00:46:43,867 DISEASE DAY SO THIS IS ALWAYS A 1242 00:46:43,934 --> 00:46:46,870 FUN TIME TO BE PREPARING FOR ONE 1243 00:46:46,937 --> 00:46:47,771 OF MY FAVORITE MEETINGS. 1244 00:46:47,838 --> 00:46:48,972 WE HAVE ARTIFICIAL INTELLIGENCE 1245 00:46:49,039 --> 00:46:51,375 THIS YEAR, ITS ROLE IN RARE 1246 00:46:51,441 --> 00:46:54,678 DISEASES, SO BUILDING OFF 1247 00:46:54,745 --> 00:46:56,847 DISCUSSIONS WE HAD EARLIER. 1248 00:46:56,914 --> 00:46:57,848 RECENT APPROVALS IN GENE 1249 00:46:57,915 --> 00:46:58,982 THERAPY, ENGAGING THE RARE 1250 00:46:59,049 --> 00:47:02,452 DISEASE COMMUNITY TO HEAR FROM 1251 00:47:02,519 --> 00:47:03,854 THEIR STORIES. 1252 00:47:03,921 --> 00:47:08,125 I CAN'T THANK ALICE, MEERA AND 1253 00:47:08,192 --> 00:47:10,127 AINSLIE ENOUGH, AND OF COURSE 1254 00:47:10,194 --> 00:47:13,764 NOW THE DIRECTOR OF DRDRI. 1255 00:47:13,830 --> 00:47:15,265 REGISTER IF YOU HAVEN'T. 1256 00:47:15,332 --> 00:47:16,767 THE QR CODE IS THERE. 1257 00:47:16,833 --> 00:47:18,435 I HOPE TO SEE YOU. 1258 00:47:18,502 --> 00:47:22,839 IN OTHER RARE DISEASE NEWS, WE 1259 00:47:22,906 --> 00:47:24,308 HAVE TWO BASKET TRIALS OF SORT 1260 00:47:24,374 --> 00:47:30,514 OF OUR SHARED MOLECULAR 1261 00:47:30,581 --> 00:47:32,282 ETIOLOGY GROUP, TREATING MORE 1262 00:47:32,349 --> 00:47:34,084 THAN ONE DISEASE AT A TIME 1263 00:47:34,151 --> 00:47:34,284 GROUP. 1264 00:47:34,351 --> 00:47:35,719 TWO STUDIES HAVE A SAFE TO 1265 00:47:35,786 --> 00:47:36,720 PROCEED LETTER FROM THE FDA, 1266 00:47:36,787 --> 00:47:39,223 WE'RE EXCITED ABOUT THAT. 1267 00:47:39,289 --> 00:47:42,192 AND THEN A QR CODE TO AN SBIR 1268 00:47:42,259 --> 00:47:44,294 PROGRAM OF THE SAME VEIN, WANTED 1269 00:47:44,361 --> 00:47:50,167 TO MAKE YOU ARE AWARE OF THE 1270 00:47:50,234 --> 00:47:53,003 SBIR DUE MARCH 15. 1271 00:47:53,070 --> 00:47:53,804 WE'RE TRANSITIONING SOMATIC GENE 1272 00:47:53,870 --> 00:47:55,672 CELL PROGRAM IN THE COMMON FUND, 1273 00:47:55,739 --> 00:47:58,208 P.J. BROOKS IS OUR LEAD FOR THIS 1274 00:47:58,275 --> 00:47:59,509 PROGRAM, ACROSS THE NIH. 1275 00:47:59,576 --> 00:48:01,578 AND WE MOVED FROM PHASE 1 TO 1276 00:48:01,645 --> 00:48:05,115 PHASE 2, NOW HOPING TO START TO 1277 00:48:05,182 --> 00:48:07,618 DRIVE SOME GENE EDITING 1278 00:48:07,684 --> 00:48:08,819 ACTIVITIES MORE TOWARDS CLINICAL 1279 00:48:08,885 --> 00:48:09,720 DEVELOPMENT, WE'RE VERY EXCITED 1280 00:48:09,786 --> 00:48:16,159 ABOUT KICK OFF THIS PARTICULAR 1281 00:48:16,226 --> 00:48:19,663 PART OF THE PROGRAM. 1282 00:48:19,730 --> 00:48:22,799 ONE OF THE CHALLENGES FOR THE 1283 00:48:22,866 --> 00:48:27,237 FIRST PHASE TRANSITION INTO THE 1284 00:48:27,304 --> 00:48:28,572 SECOND IS HERE, PROGRAMMABLE 1285 00:48:28,639 --> 00:48:29,940 DELIVERY SYSTEMS, WHAT ARE 1286 00:48:30,007 --> 00:48:32,376 EFFICIENT WAYS TO DELIVER GENE 1287 00:48:32,442 --> 00:48:35,445 THERAPIES, THEN ALSO LOOKING AT 1288 00:48:35,512 --> 00:48:36,046 NON-VIRAL DELIVERY ACROSS THE 1289 00:48:36,113 --> 00:48:36,980 BLOOD-BRAIN BARRIER, VERY HARD 1290 00:48:37,047 --> 00:48:38,749 TO GET TO TISSUES. 1291 00:48:38,815 --> 00:48:41,818 WE HAD 30 WINNERS FOR PHASE 1 1292 00:48:41,885 --> 00:48:47,057 CHALLENGE, NOW PHASE 2 IS 1293 00:48:47,124 --> 00:48:47,324 UNDERWAY. 1294 00:48:47,391 --> 00:48:53,196 THE INFORMATION WEBINAR IS THE 1295 00:48:53,263 --> 00:48:54,298 25th OF JANUARY, EVERYTHING 1296 00:48:54,364 --> 00:48:55,832 ELSE WILL FOLLOW SUIT. 1297 00:48:55,899 --> 00:48:58,769 QUICKLY, SOME UPDATES FROM THE 1298 00:48:58,835 --> 00:48:59,436 DPI PERSPECTIVE. 1299 00:48:59,503 --> 00:49:06,109 WE HAVE A VARIETY OF REGULATORY 1300 00:49:06,176 --> 00:49:06,576 MILESTONES FROM OUR 1301 00:49:06,643 --> 00:49:09,980 TRANSLATIONAL DEVELOPMENT 1302 00:49:10,047 --> 00:49:10,414 BRANCH. 1303 00:49:10,480 --> 00:49:14,418 A DRUG APPROVAL TO TREAT 1304 00:49:14,484 --> 00:49:14,985 DUCHENNE MUSCULAR DYSTROPHY. 1305 00:49:15,052 --> 00:49:15,852 WE'RE NOT THE SOLE GROUPS 1306 00:49:15,919 --> 00:49:18,422 WORKING IN THIS SPACE BUT HAVE 1307 00:49:18,488 --> 00:49:19,990 CONTRIBUTED IN SIGNIFICANT WAYS 1308 00:49:20,057 --> 00:49:24,261 TO THESE ACTIVITIES. 1309 00:49:24,328 --> 00:49:25,362 WE HAVE SAFE-TO-PROCEED 1310 00:49:25,429 --> 00:49:29,733 TREATMENTS FROM THE FDA, WE'VE 1311 00:49:29,800 --> 00:49:31,068 HELD PRE-IND MEETINGS WITH FDA, 1312 00:49:31,134 --> 00:49:32,602 HAVE OTHER APPROVED DESIGNATIONS 1313 00:49:32,669 --> 00:49:34,171 FROM THE FDA FOR A VARIETY OF 1314 00:49:34,237 --> 00:49:36,873 THESE RARE DISEASE TREATMENTS. 1315 00:49:36,940 --> 00:49:39,743 SO JUST A LITTLE SORT OF 1316 00:49:39,810 --> 00:49:42,112 AT-A-GLANCE SHOT AT THAT. 1317 00:49:42,179 --> 00:49:43,680 ALSO FOR OUR INTRAMURAL 1318 00:49:43,747 --> 00:49:44,915 TRAINING, I MENTIONED SOME WORK 1319 00:49:44,981 --> 00:49:47,651 GOING ON IN OUR TRAINING 1320 00:49:47,718 --> 00:49:48,552 PROGRAMS, BUT CERTAINLY WE'VE I 1321 00:49:48,618 --> 00:49:54,424 THINK VERY MUCH MATURED IN OUR 1322 00:49:54,491 --> 00:49:59,196 INTRAMURAL TRAINING SPACE TOO. 1323 00:49:59,262 --> 00:50:03,500 BELEN HURLE IS FANTASTIC, AND 1324 00:50:03,567 --> 00:50:05,435 MARCUS HODGES IS LEAD, BOTH 1325 00:50:05,502 --> 00:50:07,304 INCREDIBLE ASSETS AT NCATS AND 1326 00:50:07,371 --> 00:50:09,473 OUR TRAINEES. 1327 00:50:09,539 --> 00:50:12,576 THEY WORK ON COURSES, WORKSHOPS, 1328 00:50:12,642 --> 00:50:13,310 GRANT WRITING, GETTING THEM 1329 00:50:13,377 --> 00:50:15,946 EXPOSED TO A VARIETY OF CAREERS, 1330 00:50:16,012 --> 00:50:16,513 ET CETERA. 1331 00:50:16,580 --> 00:50:18,415 HOLD RETREATS, THINGS OF THAT 1332 00:50:18,482 --> 00:50:18,648 NATURE. 1333 00:50:18,715 --> 00:50:21,118 AND ALSO MAKING SURE THAT THEY 1334 00:50:21,184 --> 00:50:25,722 ARE EXPOSED TO MEETINGS, TO 1335 00:50:25,789 --> 00:50:27,224 PROFESSIONAL SOCIETIES TO FOSTER 1336 00:50:27,290 --> 00:50:28,158 A DIVERSE SCIENTIFIC WORK FORCE, 1337 00:50:28,225 --> 00:50:30,427 SO EXCITED ABOUT THE DIRECTIONS 1338 00:50:30,494 --> 00:50:31,461 OUR INTRAMURAL TRAINING PROGRAMS 1339 00:50:31,528 --> 00:50:36,433 ARE GOING IN AS WELL. 1340 00:50:36,500 --> 00:50:39,403 I WANT TO END, MY LAST TWO 1341 00:50:39,469 --> 00:50:41,772 SLIDES, ON STRATEGIC PLANNING 1342 00:50:41,838 --> 00:50:42,005 PROCESS. 1343 00:50:42,072 --> 00:50:43,974 WE TALKED ABOUT THIS AT OUR LAST 1344 00:50:44,040 --> 00:50:44,975 MEETING. 1345 00:50:45,041 --> 00:50:47,811 WE'RE NOW IN SORT OF THIS 1346 00:50:47,878 --> 00:50:48,812 IN-BETWEEN PHASE. 1347 00:50:48,879 --> 00:50:50,881 WE'VE DONE A LOT OF THE 1348 00:50:50,947 --> 00:50:51,515 ROUNDTABLES, GATHERED FEEDBACK, 1349 00:50:51,581 --> 00:50:52,883 LAST TIME WE SPOKE WE WERE AT 1350 00:50:52,949 --> 00:50:54,818 THE STAGE OF REQUEST FOR 1351 00:50:54,885 --> 00:50:57,821 INFORMATION THAT WE WERE WANTING 1352 00:50:57,888 --> 00:50:59,122 YOUR FEEDBACK ON. 1353 00:50:59,189 --> 00:51:00,891 SO WE'VE GATHERED ALL OF THAT 1354 00:51:00,957 --> 00:51:04,161 INPUT FROM ALL THE ROUNDTABLES, 1355 00:51:04,227 --> 00:51:05,796 FROM ALL THE RESPONSES TO THE 1356 00:51:05,862 --> 00:51:05,996 RFI. 1357 00:51:06,062 --> 00:51:09,232 AND SO WE'RE NOW AT THIS POINT 1358 00:51:09,299 --> 00:51:11,601 OF DRAFTING THE STRATEGIC PLAN, 1359 00:51:11,668 --> 00:51:14,004 AND WE PLAN TO DISCUSS THIS MORE 1360 00:51:14,070 --> 00:51:15,739 DEEPLY IN OUR MAY COUNCIL BUT I 1361 00:51:15,806 --> 00:51:17,808 DIDN'T WANT YOU TO THINK I 1362 00:51:17,874 --> 00:51:19,910 FORGOT ABOUT THIS STRATEGIC 1363 00:51:19,976 --> 00:51:20,343 PLAN. 1364 00:51:20,410 --> 00:51:21,678 AND OBVIOUSLY, IF THERE'S 1365 00:51:21,745 --> 00:51:23,947 ANYTHING THAT YOU ARE CURIOUS 1366 00:51:24,014 --> 00:51:29,119 ABOUT OR MAYBE FORGOT TO SAY WE 1367 00:51:29,186 --> 00:51:30,086 SHOULD INCLUDE WE'D LOVE TO HEAR 1368 00:51:30,153 --> 00:51:31,521 FROM YOU CERTAINLY AS WELL. 1369 00:51:31,588 --> 00:51:34,558 SO WE LOOK TO GET THIS, YOU 1370 00:51:34,624 --> 00:51:35,959 KNOW, DISCUSSED REALLY MORE OF A 1371 00:51:36,026 --> 00:51:40,897 DRAFT STAGE IN MAY, AND WE'LL 1372 00:51:40,964 --> 00:51:41,665 FINALIZE THAT, ROLLOUT FOR THE 1373 00:51:41,731 --> 00:51:45,535 STRATEGIC PLAN . 1374 00:51:45,602 --> 00:51:46,937 WE'RE ALMOST TOUCHING THIRD 1375 00:51:47,003 --> 00:51:49,239 BASE, WE'RE ON THE HOME STRETCH, 1376 00:51:49,306 --> 00:51:50,874 ROUNDING TOWARDS HOME. 1377 00:51:50,941 --> 00:51:51,241 OKAY. 1378 00:51:51,308 --> 00:51:56,346 THIS IS JUST A VISUAL OF WHERE 1379 00:51:56,413 --> 00:51:57,781 WE IN THE DRAFT STRATEGIC GOALS 1380 00:51:57,848 --> 00:51:58,648 WE'RE WORKING TOWARDS. 1381 00:51:58,715 --> 00:52:00,183 YOU'VE SEEN THIS SLIDE BEFORE SO 1382 00:52:00,250 --> 00:52:02,486 I WON'T DWELL ON IT BUT WANTED 1383 00:52:02,552 --> 00:52:04,120 TO REMIND YOU ABOUT THAT. 1384 00:52:04,187 --> 00:52:09,392 WITH THAT, YOU KNOW, JUST A 1385 00:52:09,459 --> 00:52:11,695 SUMMARY HERE IS WE'RE STILL 1386 00:52:11,761 --> 00:52:13,997 WAITING, HOW WE'RE GOING TO HAVE 1387 00:52:14,064 --> 00:52:15,899 A 2024 BUDGET, BUT WE'RE 1388 00:52:15,966 --> 00:52:17,534 OPERATING UNDER A C.R. 1389 00:52:17,601 --> 00:52:21,404 WE'VE HAD A VARIETY OF IMPACTFUL 1390 00:52:21,471 --> 00:52:23,206 ADVANCES, AND ESPECIALLY IN THE 1391 00:52:23,273 --> 00:52:25,408 DATA SCIENCE SPACE, AND GENE 1392 00:52:25,475 --> 00:52:28,912 THERAPY, GENE EDITING SPACE. 1393 00:52:28,979 --> 00:52:30,280 AND REALLY SOLIDIFYING AND 1394 00:52:30,347 --> 00:52:32,015 DEEPENING OUR INTERACTIONS WITH 1395 00:52:32,082 --> 00:52:33,316 THE FDA AS WELL. 1396 00:52:33,383 --> 00:52:35,919 OUR STRATEGIC PLAN IS ON TRACK 1397 00:52:35,986 --> 00:52:38,421 FOR EARLY 2024 DRAFT PLAN, MORE 1398 00:52:38,488 --> 00:52:39,489 ABOUT THAT LATER. 1399 00:52:39,556 --> 00:52:43,426 AND OF COURSE UPDATES TODAY, DR. 1400 00:52:43,493 --> 00:52:44,895 BERTAGNOLLI WILL SPEAK ABOUT HER 1401 00:52:44,961 --> 00:52:47,797 VISION AND, YOU KNOW, AS A NEW 1402 00:52:47,864 --> 00:52:49,799 DIRECTOR I'M REALLY EXCITED 1403 00:52:49,866 --> 00:52:50,967 YOU'RE ABLE TO HEAR FROM HER, 1404 00:52:51,034 --> 00:52:54,037 ONE OF THE FIRST TIMES. 1405 00:52:54,104 --> 00:53:03,246 I'M EXCITED TO HEAR FROM HER AS 1406 00:53:03,313 --> 00:53:03,713 WELL. 1407 00:53:03,780 --> 00:53:04,548 DR. BALAKRISHNAN WILL TALK ABOUT 1408 00:53:04,614 --> 00:53:11,922 THE OFFICE OF STRATEGIC 1409 00:53:11,988 --> 00:53:21,731 ALLIANCE, AND DR. TAGLE SPECIAL 1410 00:53:21,798 --> 00:53:22,365 INITIATIVES. 1411 00:53:22,432 --> 00:53:28,271 I OPEN IT UP FOR SUGGESTIONS. 1412 00:53:28,338 --> 00:53:30,307 >> WOW. 1413 00:53:30,373 --> 00:53:33,209 >> THANK YOU. 1414 00:53:33,276 --> 00:53:33,443 SERGIO? 1415 00:53:33,510 --> 00:53:35,745 >> WHAT A WONDERFUL PRESENTATION 1416 00:53:35,812 --> 00:53:37,948 AND REVIEW. 1417 00:53:38,014 --> 00:53:40,784 ONE COMMENT THAT I SO MUCH 1418 00:53:40,850 --> 00:53:41,651 APPRECIATE THAT YOU INCLUDE THE 1419 00:53:41,718 --> 00:53:44,621 QR CODES IN EACH OF THE SLIDES. 1420 00:53:44,688 --> 00:53:45,922 IT'S VERY WELL DONE. 1421 00:53:45,989 --> 00:53:51,027 AND I HAVE BEEN CURIOUS ENOUGH 1422 00:53:51,094 --> 00:53:53,029 TO CLICK. 1423 00:53:53,096 --> 00:53:59,836 LIKE IN THE PAPER THAT YOU 1424 00:53:59,903 --> 00:54:04,207 PUBLISHED ON EDUCATION, YOU 1425 00:54:04,274 --> 00:54:08,178 KNOW, WITH JCPS, SO IT IS A 1426 00:54:08,244 --> 00:54:08,845 WONDERFUL IDEA. 1427 00:54:08,912 --> 00:54:10,280 AND VERY HELPFUL AS WELL. 1428 00:54:10,347 --> 00:54:11,381 SO THANK YOU. 1429 00:54:11,448 --> 00:54:12,649 >> THANK YOU. 1430 00:54:12,716 --> 00:54:14,584 YOU KNOW, WHEN WE WENT INTO THE 1431 00:54:14,651 --> 00:54:16,920 PANDEMIC, I THINK WE GOT USED TO 1432 00:54:16,987 --> 00:54:18,955 PUTTING IN LINKS THEMSELVES. 1433 00:54:19,022 --> 00:54:20,290 I REALIZED IT DIDN'T MAKE SENSE. 1434 00:54:20,357 --> 00:54:21,791 PEOPLE COULDN'T CLICK ON THEM. 1435 00:54:21,858 --> 00:54:24,260 SO, THIS WAS A GOOD WAY TO GET 1436 00:54:24,327 --> 00:54:25,662 THAT INTERACTION AND MAKE SURE 1437 00:54:25,729 --> 00:54:28,865 THAT EVERYONE HAD THE MATERIALS 1438 00:54:28,932 --> 00:54:29,199 AT THE READY. 1439 00:54:29,265 --> 00:54:31,034 SO THANK YOU. 1440 00:54:31,101 --> 00:54:33,770 HAPPY FOR THE FEEDBACK. 1441 00:54:33,837 --> 00:54:36,840 >> YEAH, NO, VERY -- ACTUALLY I 1442 00:54:36,906 --> 00:54:38,308 WAS GOING TO ASK IF YOU CAN 1443 00:54:38,375 --> 00:54:39,609 SHARE THE SLIDES SO I CAN CLICK 1444 00:54:39,676 --> 00:54:41,611 ON SOME THAT I MISSED. 1445 00:54:41,678 --> 00:54:43,413 >> YES, ABSOLUTELY. 1446 00:54:43,480 --> 00:54:45,348 ABSOLUTELY. 1447 00:54:45,415 --> 00:54:46,383 HAPPY TO. 1448 00:54:46,449 --> 00:54:47,684 >> SECOND THING IS THAT -- AND 1449 00:54:47,751 --> 00:54:49,319 I'M GLAD THAT YOU TOUCHED BASED 1450 00:54:49,386 --> 00:54:52,622 A LITTLE BIT ON THE STRATEGIC 1451 00:54:52,689 --> 00:54:53,823 PLANNING AS TO WHERE YOU HAVE 1452 00:54:53,890 --> 00:54:56,660 BEEN AND WHERE YOU ARE CURRENTLY 1453 00:54:56,726 --> 00:54:59,829 AND WHAT ARE THE NEXT STEPS. 1454 00:54:59,896 --> 00:55:02,499 ARE YOU PLANNING TO ASK FOR 1455 00:55:02,565 --> 00:55:06,503 PUBLIC COMMENTS WHEN THE DRAFT, 1456 00:55:06,569 --> 00:55:09,806 STRATEGIC PLANNING IS AVAILABLE? 1457 00:55:09,873 --> 00:55:11,875 I WOULD ENCOURAGE THAT, AND I 1458 00:55:11,941 --> 00:55:17,814 WOULD ENCOURAGE, YOU KNOW, TO 1459 00:55:17,881 --> 00:55:20,450 REALLY GET IN PARTICULAR 1460 00:55:20,517 --> 00:55:22,352 COMMUNITIES, YOU KNOW, CBOs, 1461 00:55:22,419 --> 00:55:25,555 COMMUNITY MEMBERS, ADVISORY 1462 00:55:25,622 --> 00:55:29,893 BOARDS, ESPECIALLY ADVISORY 1463 00:55:29,959 --> 00:55:32,228 BOARDS, ACROSS CTSAs TO WEIGH 1464 00:55:32,295 --> 00:55:32,462 IN. 1465 00:55:32,529 --> 00:55:34,431 YOU'VE ALREADY DONE A FANTASTIC 1466 00:55:34,497 --> 00:55:40,503 JOB WITH LISTENING TOURS. 1467 00:55:40,570 --> 00:55:42,472 AND WHICH IS TERRIFIC. 1468 00:55:42,539 --> 00:55:46,309 I ENCOURAGE YOU, IF THAT CAN BE 1469 00:55:46,376 --> 00:55:46,543 FITTING. 1470 00:55:46,609 --> 00:55:49,713 >> THANK YOU FOR THAT, SERGIO. 1471 00:55:49,779 --> 00:55:52,048 MEREDITH IS THE ONE LEADING OUR 1472 00:55:52,115 --> 00:55:52,882 STRATEGIC PLANNING ACTIVITIES, I 1473 00:55:52,949 --> 00:55:56,219 COULD ANSWER THIS BUT I'M GOING 1474 00:55:56,286 --> 00:55:58,421 TO ALLOW MEREDITH TO DO THIS. 1475 00:55:58,488 --> 00:55:59,589 >> HELLO. 1476 00:55:59,656 --> 00:56:01,091 THANK YOU, JONI. 1477 00:56:01,157 --> 00:56:04,928 AND THANK YOU, DR. AGUILAR. 1478 00:56:04,994 --> 00:56:08,131 SO, YES, A COUPLE THINGS TO FILL 1479 00:56:08,198 --> 00:56:09,499 IN. 1480 00:56:09,566 --> 00:56:11,835 ONE, WE DID DO RFI ON THE DRAFT 1481 00:56:11,901 --> 00:56:12,102 FRAMEWORK. 1482 00:56:12,168 --> 00:56:15,805 SO, WE DID HAVE A REQUEST FOR 1483 00:56:15,872 --> 00:56:17,440 INFORMATION AND GOT OVER 50 1484 00:56:17,507 --> 00:56:19,743 COMMENTS BACK FROM FOLKS ABOUT 1485 00:56:19,809 --> 00:56:20,677 THE DRAFT GOALS AND, YOU KNOW, 1486 00:56:20,744 --> 00:56:23,146 KIND OF WHERE THE FRAMEWORK WAS 1487 00:56:23,213 --> 00:56:23,913 AT THAT POINT. 1488 00:56:23,980 --> 00:56:25,782 THAT WAS -- WE POSTED THAT I 1489 00:56:25,849 --> 00:56:29,586 BELIEVE BACK IN SEPTEMBER, IT 1490 00:56:29,652 --> 00:56:30,687 RAN THROUGH NOVEMBER. 1491 00:56:30,754 --> 00:56:33,690 AND THE OTHER PLAN WE HAVE, AS 1492 00:56:33,757 --> 00:56:35,525 YOU MAY HAVE SEEN IN JONI'S 1493 00:56:35,592 --> 00:56:37,360 TIMELINE, SHE'S GOING TO SHARE 1494 00:56:37,427 --> 00:56:40,096 THE SLIDES, WE'RE DRAFTING THE 1495 00:56:40,163 --> 00:56:42,532 PLAN AND THEN IN GENERAL WHAT 1496 00:56:42,599 --> 00:56:45,568 MOST NIH I.C.s DO IS POST A 1497 00:56:45,635 --> 00:56:47,904 DRAFT OF THE PLAN PUBLICLY ON 1498 00:56:47,971 --> 00:56:49,405 THEIR WEBSITE. 1499 00:56:49,472 --> 00:56:51,775 AND THEN THAT GIVES, YOU KNOW, 1500 00:56:51,841 --> 00:56:52,509 ALL CONSTITUENTS THE OPPORTUNITY 1501 00:56:52,575 --> 00:56:56,012 TO TAKE A LOOK AT IT AND GIVE US 1502 00:56:56,079 --> 00:56:57,781 ANY FEEDBACK RIGHT BEFORE WE 1503 00:56:57,847 --> 00:56:58,982 FINALIZE IT. 1504 00:56:59,048 --> 00:57:02,385 SO, AS JONI WAS INDICATING, OUR 1505 00:57:02,452 --> 00:57:04,020 PLAN IS TO -- WE'RE STILL IN THE 1506 00:57:04,087 --> 00:57:05,655 BUSY WRITING STAGES RIGHT NOW SO 1507 00:57:05,722 --> 00:57:06,790 WE'RE NOT EXACTLY SURE HOW ALL 1508 00:57:06,856 --> 00:57:08,725 OF THE DUCKS ARE GOING TO 1509 00:57:08,792 --> 00:57:12,128 TOTALLY LINE UP BUT OUR PLAN IS 1510 00:57:12,195 --> 00:57:13,429 TO HAVE SOMETHING VERY 1511 00:57:13,496 --> 00:57:17,600 SUBSTANTIVE TO DISCUSS WITH YOU 1512 00:57:17,667 --> 00:57:19,569 ALL IN MAY, AND THEN WE WILL 1513 00:57:19,636 --> 00:57:21,738 LIKELY POST IT RIGHT AFTER THAT, 1514 00:57:21,805 --> 00:57:22,972 DEPENDING ON THE FEEDBACK THAT 1515 00:57:23,039 --> 00:57:24,507 WE GET FROM YOU. 1516 00:57:24,574 --> 00:57:26,476 THAT'S OUR TENTATIVE GAME PLAN. 1517 00:57:26,543 --> 00:57:28,344 >> I THINK MAYBE, MEREDITH, WHAT 1518 00:57:28,411 --> 00:57:31,214 WE WOULD THINK ABOUT THEN IS 1519 00:57:31,281 --> 00:57:33,483 ONCE WE DO POST THAT WE COULD 1520 00:57:33,550 --> 00:57:35,351 CONSIDER SORT OF THE RFI BUT I 1521 00:57:35,418 --> 00:57:36,886 THINK WE MIGHT HAVE BETTER 1522 00:57:36,953 --> 00:57:38,988 OUTREACH IF WE DO A DIRECTOR'S 1523 00:57:39,055 --> 00:57:40,390 MESSAGE THAT SAYS -- 1524 00:57:40,456 --> 00:57:40,723 >> CORRECT. 1525 00:57:40,790 --> 00:57:42,892 >> AND THEN DO OUR SIMILAR 1526 00:57:42,959 --> 00:57:45,829 OUTREACH TO ALL OF THE PEOPLE 1527 00:57:45,895 --> 00:57:47,597 WHO JOINED OUR ROUNDTABLES, LIKE 1528 00:57:47,664 --> 00:57:48,932 THE ADVISORY BOARDS AT THE 1529 00:57:48,998 --> 00:57:50,400 CTSAs, AND MAKE SURE THAT 1530 00:57:50,466 --> 00:57:52,569 EVERYBODY HAS ACCESS TO THAT. 1531 00:57:52,635 --> 00:57:55,071 SO, I THINK WE'LL DO SOMEWHAT, 1532 00:57:55,138 --> 00:57:57,140 AGAIN, OF A WARM TOUCH, A 1533 00:57:57,207 --> 00:57:58,474 PERSONAL TOUCH TO THOSE GROUPS. 1534 00:57:58,541 --> 00:57:58,708 >> YEP. 1535 00:57:58,775 --> 00:58:00,777 >> TO LET THEM KNOW WHAT WE HAVE 1536 00:58:00,844 --> 00:58:02,478 ON OUR WEBSITE IS READY TO BE 1537 00:58:02,545 --> 00:58:06,149 REVIEWED AND WE WOULD LOVE TO 1538 00:58:06,216 --> 00:58:08,218 HEAR COMMENTS BEFORE FINALIZING 1539 00:58:08,284 --> 00:58:08,551 THAT DRAFT. 1540 00:58:08,618 --> 00:58:09,986 LONG ANSWER TO YOUR QUESTION, 1541 00:58:10,053 --> 00:58:13,289 BUT THE SHORT ANSWER IS YES. 1542 00:58:13,356 --> 00:58:13,623 >> ABSOLUTELY. 1543 00:58:13,690 --> 00:58:14,824 I WAS GOING TO SAY WE'LL BE VERY 1544 00:58:14,891 --> 00:58:16,226 MUCH WORKING WITH THE 1545 00:58:16,292 --> 00:58:18,394 COMMUNICATIONS TEAM ON OUR WAYS 1546 00:58:18,461 --> 00:58:20,063 TO -- EMILY HAS GREAT WAYS OF 1547 00:58:20,129 --> 00:58:23,032 REACHING OUT TO OUR DIFFERENT 1548 00:58:23,099 --> 00:58:24,634 CONSTITUENTS, SO WE WILL 1549 00:58:24,701 --> 00:58:26,736 DEFINITELY BE COMING UP WITH A 1550 00:58:26,803 --> 00:58:28,204 PLAN FOR THAT, FOR DISSEMINATING 1551 00:58:28,271 --> 00:58:31,341 AND MAKING SURE PEOPLE ARE AWARE 1552 00:58:31,407 --> 00:58:32,475 THAT IT'S OUT THERE. 1553 00:58:32,542 --> 00:58:33,309 >> YEAH, NO, THAT'S MUSIC TO MY 1554 00:58:33,376 --> 00:58:33,743 EARS. 1555 00:58:33,810 --> 00:58:38,248 THANK YOU SO MUCH FOR THAT. 1556 00:58:38,314 --> 00:58:39,916 THANK YOU, MEREDITH, FOR THE 1557 00:58:39,983 --> 00:58:40,717 DETAILS. 1558 00:58:40,783 --> 00:58:44,921 AND JONI, ONE LAST THING. 1559 00:58:44,988 --> 00:58:48,858 THERE IS A LOT OF ACTIVITY AND 1560 00:58:48,925 --> 00:58:50,393 ATTENTION BEING BROUGHT 1561 00:58:50,460 --> 00:58:52,395 NATIONWIDE, AT LEAST WITHIN THE 1562 00:58:52,462 --> 00:58:53,830 COMMUNITY ENGAGEMENT FIELD, 1563 00:58:53,897 --> 00:58:57,767 ABOUT THE IMPORTANCE OF 1564 00:58:57,834 --> 00:58:58,268 TRUSTWORTHINESS. 1565 00:58:58,334 --> 00:58:59,702 HOW CRITICALLY IMPORTANT IT IS 1566 00:58:59,769 --> 00:59:02,372 FOR OUR INSTITUTIONS AND 1567 00:59:02,438 --> 00:59:03,439 AGENCIES TO BE TRUSTWORTHY. 1568 00:59:03,506 --> 00:59:08,611 JUST TO GIVE YOU THE HEADS UP 1569 00:59:08,678 --> 00:59:11,814 THAT PRINCIPLES OF ENGAGEMENT, 1570 00:59:11,881 --> 00:59:13,316 THIRD EDITION, IS READY. 1571 00:59:13,383 --> 00:59:13,549 >> YES. 1572 00:59:13,616 --> 00:59:18,855 >> AND I'M SURE YOU KNOW ABOUT 1573 00:59:18,922 --> 00:59:20,623 IT. 1574 00:59:20,690 --> 00:59:20,857 >> YES. 1575 00:59:20,924 --> 00:59:24,160 >> THERE IS A PRINCIPAL THING 1576 00:59:24,227 --> 00:59:29,632 THAT WAS ADDED THIS NEW EDITION, 1577 00:59:29,699 --> 00:59:30,867 WHICH IS ON TRUSTWORTHINESS, AS 1578 00:59:30,934 --> 00:59:33,803 A FUNDAMENTAL ELEMENT FOR 1579 00:59:33,870 --> 00:59:35,238 ADVANCING HEALTH EQUITY. 1580 00:59:35,305 --> 00:59:39,242 AND JUST MY BRIEF COMMENT TO YOU 1581 00:59:39,309 --> 00:59:41,044 IS THAT -- AND YOU'RE THE FIRST 1582 00:59:41,110 --> 00:59:47,817 PERSON I HAVE HEARD THIS FROM. 1583 00:59:47,884 --> 00:59:51,421 YOU TALK ABOUT TRUSTWORTHINESS 1584 00:59:51,487 --> 00:59:53,423 OF DATA AS WELL. 1585 00:59:53,489 --> 00:59:54,490 THAT WAS FASCINATING FOR ME TO 1586 00:59:54,557 --> 00:59:54,924 HEAR. 1587 00:59:54,991 --> 00:59:56,793 BUT I WOULD BE VERY INTERESTED 1588 00:59:56,859 --> 01:00:00,063 IF IN THE LISTENING SESSIONS 1589 01:00:00,129 --> 01:00:05,101 THAT YOU HAVE, ESPECIALLY WITH 1590 01:00:05,168 --> 01:00:06,736 COMMUNITIES AND ADVISORY -- WITH 1591 01:00:06,803 --> 01:00:08,104 COMMUNITY ADVISORY BOARDS, IF 1592 01:00:08,171 --> 01:00:09,639 YOU HEARD ABOUT THAT, I THINK 1593 01:00:09,706 --> 01:00:11,307 THAT IS IMPORTANT TO KEEP A 1594 01:00:11,374 --> 01:00:14,410 FINGER ON THAT PULSE AS WELL. 1595 01:00:14,477 --> 01:00:19,015 >> YES, THANK YOU, SERGIO. 1596 01:00:19,082 --> 01:00:21,517 TRUST AND TRUSTWORTHINESS, I SEE 1597 01:00:21,584 --> 01:00:26,422 THOSE AS TWO DIFFERENT BUT 1598 01:00:26,489 --> 01:00:30,660 INTERTWINED TERMS. 1599 01:00:30,727 --> 01:00:33,563 BOTH WERE I THINK CLEAR IN MANY 1600 01:00:33,629 --> 01:00:35,531 OF THE ROUNDTABLE 1601 01:00:35,598 --> 01:00:37,400 COMMUNICATIONS, ESPECIALLY WITH 1602 01:00:37,467 --> 01:00:38,434 THE COMMUNITIES. 1603 01:00:38,501 --> 01:00:41,671 YOU KNOW, I THINK THAT IN TERMS 1604 01:00:41,738 --> 01:00:42,472 OF -- SO THAT'S WHY I THINK 1605 01:00:42,538 --> 01:00:44,440 WE'RE TRYING TO MAKE SURE THAT 1606 01:00:44,507 --> 01:00:45,708 IT IS FRONT AND CENTER. 1607 01:00:45,775 --> 01:00:47,043 I WILL GIVE YOU A LITTLE BIT OF 1608 01:00:47,110 --> 01:00:47,677 A GLIMPSE. 1609 01:00:47,744 --> 01:00:50,880 I TRY NOT TO THINK TOO FAR IN 1610 01:00:50,947 --> 01:00:51,214 ADVANCE. 1611 01:00:51,280 --> 01:00:52,515 IF YOU'RE A SPORTS TEAM YOU 1612 01:00:52,582 --> 01:00:53,716 DON'T WANT TO THINK ABOUT THE 1613 01:00:53,783 --> 01:00:55,485 TEAM YOU'RE GOING TO PLAY NEXT 1614 01:00:55,551 --> 01:00:55,685 WEEK. 1615 01:00:55,752 --> 01:00:58,221 YOU WANT TO THINK ABOUT THE ONE 1616 01:00:58,287 --> 01:00:58,421 TODAY. 1617 01:00:58,488 --> 01:01:01,391 BUT IN MAY, DURING THAT COUNCIL, 1618 01:01:01,457 --> 01:01:03,559 I DO PLAN ON GIVING A LITTLE BIT 1619 01:01:03,626 --> 01:01:06,062 MORE AROUND WHAT NCATS 1620 01:01:06,129 --> 01:01:07,497 SPECIFICALLY IS DOING, GIVING A 1621 01:01:07,563 --> 01:01:08,464 LITTLE BIT OF DEEPER DIVE, NOT 1622 01:01:08,531 --> 01:01:09,799 JUST IN TERMS OF THE WORK THAT 1623 01:01:09,866 --> 01:01:12,735 WE DO IN DATA SCIENCE BUT IN 1624 01:01:12,802 --> 01:01:17,273 THINKING ABOUT WHAT -- FROM THE 1625 01:01:17,340 --> 01:01:18,508 DATA SCIENCE PERSPECTIVE, IT'S 1626 01:01:18,574 --> 01:01:23,346 USING A.I.-ENABLED TOOLS AND 1627 01:01:23,413 --> 01:01:24,714 LARGE LANGUAGE MODELS, WE WANT 1628 01:01:24,781 --> 01:01:27,650 TO BE VERY CAREFUL WE'RE NOT 1629 01:01:27,717 --> 01:01:29,819 USING AND/OR PERPETUATING BIASED 1630 01:01:29,886 --> 01:01:30,553 DATA. 1631 01:01:30,620 --> 01:01:33,022 AND HOW CAN WE IDENTIFY WHERE 1632 01:01:33,089 --> 01:01:33,990 THAT MIGHT EXIST, THAT, YOU 1633 01:01:34,057 --> 01:01:35,825 KNOW, THAT MAY NOT BE SO EASY. 1634 01:01:35,892 --> 01:01:38,361 SO THINKING ABOUT WAYS IN WHICH 1635 01:01:38,428 --> 01:01:40,596 TO IDENTIFY AND ADDRESS THOSE 1636 01:01:40,663 --> 01:01:44,467 AREAS OF BIAS WILL BE ONE THING. 1637 01:01:44,534 --> 01:01:46,402 BUT THE OTHER THING IS TO, YOU 1638 01:01:46,469 --> 01:01:48,871 KNOW, WHAT THE WORK THAT HAS 1639 01:01:48,938 --> 01:01:53,443 BEEN DONE THROUGH THE LITCOIN 1640 01:01:53,509 --> 01:01:54,777 MODELS AND LLM IDEAS, THINKING 1641 01:01:54,844 --> 01:01:56,512 ABOUT REALLY ENGAGING THE 1642 01:01:56,579 --> 01:01:58,281 COMMUNITY TO SAY, YOU KNOW, 1643 01:01:58,347 --> 01:01:58,915 WE'VE DEVELOPED THESE 1644 01:01:58,981 --> 01:02:01,117 ALGORITHMS, THESE A.I.-ENABLED 1645 01:02:01,184 --> 01:02:03,219 ALGORITHMS, BUT WE NEED TO KNOW 1646 01:02:03,286 --> 01:02:05,488 FOR SURE THAT THEY ARE PRODUCING 1647 01:02:05,555 --> 01:02:07,223 WHAT WE EXPECT TO SEE. 1648 01:02:07,290 --> 01:02:09,725 AND SO ENGAGING THE COMMUNITY TO 1649 01:02:09,792 --> 01:02:11,594 HELP US, YOU KNOW, KICK THE 1650 01:02:11,661 --> 01:02:13,162 TIRES, SO TO SPEAK, ON THAT I 1651 01:02:13,229 --> 01:02:16,666 THINK WILL ALSO ADD TO THAT 1652 01:02:16,732 --> 01:02:19,936 TRUST AND TRUSTWORTHINESS OF THE 1653 01:02:20,002 --> 01:02:20,136 DATA. 1654 01:02:20,203 --> 01:02:22,672 BUT ALSO JUST AS A PRELUDE TO 1655 01:02:22,738 --> 01:02:24,540 WHAT I HOPE TO TALK ABOUT MORE 1656 01:02:24,607 --> 01:02:26,709 IN MAY IS SOME OF THE WORK THAT 1657 01:02:26,776 --> 01:02:29,812 PRE-CLINICAL MODELS THAT IES- 1658 01:02:29,879 --> 01:02:32,982 TALKED ABOUT, THE NEW APPROACH 1659 01:02:33,049 --> 01:02:33,316 METHODOLOGIES. 1660 01:02:33,382 --> 01:02:35,818 IT IS DATA IN SOME RESPECTS, BUT 1661 01:02:35,885 --> 01:02:38,688 IT'S ALSO THE ACTUAL CELLS AND 1662 01:02:38,754 --> 01:02:41,290 THE METHODS AND APPROACHES TO DO 1663 01:02:41,357 --> 01:02:43,025 MORE PREDICTIVE MODELING. 1664 01:02:43,092 --> 01:02:44,026 THERE AGAIN, YOU KNOW, WE'VE 1665 01:02:44,093 --> 01:02:46,562 SEEN IT OVER AND OVER AGAIN IN 1666 01:02:46,629 --> 01:02:48,331 THE LITERATURE THERE'S BIAS IN, 1667 01:02:48,397 --> 01:02:49,966 YOU KNOW, PERHAPS WHERE YOU GET 1668 01:02:50,032 --> 01:02:52,034 THE CELL TYPES, WHO YOU GET 1669 01:02:52,101 --> 01:02:52,969 THOSE FROM, EVEN IN CLINICAL 1670 01:02:53,035 --> 01:02:55,471 TRIALS WE KNOW THERE ARE GROUPS 1671 01:02:55,538 --> 01:02:56,372 THAT ARE UNDERREPRESENTED IN 1672 01:02:56,439 --> 01:02:57,173 CLINICAL TRIALS. 1673 01:02:57,240 --> 01:02:59,275 AND SO WE WANT TO MAKE SURE THAT 1674 01:02:59,342 --> 01:03:03,446 EVEN IN THE PRE-CLINICAL SPACE, 1675 01:03:03,513 --> 01:03:05,815 THE WORK THAT'S BEING DONE AT 1676 01:03:05,882 --> 01:03:07,917 THE CELLULAR LEVEL, THAT WE'RE 1677 01:03:07,984 --> 01:03:10,419 PAYING ATTENTION TO THOSE 1678 01:03:10,486 --> 01:03:11,721 FACTORS AS WELL. 1679 01:03:11,787 --> 01:03:13,689 SEX AS A BIOLOGICAL VARIABLE AND 1680 01:03:13,756 --> 01:03:15,358 THE ORIGINATION OF THE CELLS AND 1681 01:03:15,424 --> 01:03:18,528 SOURCES SO WE CAN MAKE SURE THAT 1682 01:03:18,594 --> 01:03:19,529 WE'RE BEING DIVERSE, INCLUSIVE 1683 01:03:19,595 --> 01:03:22,899 IN THOSE ACTIVITIES. 1684 01:03:22,965 --> 01:03:23,633 MORE SPECIFICALLY, EVALUATING 1685 01:03:23,699 --> 01:03:26,402 THAT AS A WAY IN WHICH WE CAN 1686 01:03:26,469 --> 01:03:27,170 UNDERSTAND THE EFFECTIVENESS OF 1687 01:03:27,236 --> 01:03:29,038 THAT MODEL IN AND OF ITSELF. 1688 01:03:29,105 --> 01:03:37,246 SO WE'RE TRYING TO MAKE THAT 1689 01:03:37,313 --> 01:03:38,181 INCLUSIVENESS, THAT DIVERSITY, 1690 01:03:38,247 --> 01:03:39,949 THAT TRUSTWORTHINESS AND INFUSE 1691 01:03:40,016 --> 01:03:41,184 THAT INTO MODELS WE'RE 1692 01:03:41,250 --> 01:03:42,218 DEVELOPING IN EARLIER PHASES SO 1693 01:03:42,285 --> 01:03:44,253 THEY CAN BE MORE SORT OF 1694 01:03:44,320 --> 01:03:46,455 INGRAINED AS WE GO FORWARD IN 1695 01:03:46,522 --> 01:03:48,858 THE DEVELOPMENT PROCESS. 1696 01:03:48,925 --> 01:03:54,964 >> THANK YOU. 1697 01:03:55,031 --> 01:03:55,231 >> ANIKA? 1698 01:03:55,298 --> 01:03:58,401 >> THANK YOU. 1699 01:03:58,467 --> 01:04:00,803 AGAIN, VERY IMPRESSIVE. 1700 01:04:00,870 --> 01:04:01,771 I ECHO SERGIO'S COMMENT. 1701 01:04:01,837 --> 01:04:04,974 YOU STARTED TO TOUCH ON ONE OF 1702 01:04:05,041 --> 01:04:07,143 THE COMMENTS I HAD, AS YOU'RE 1703 01:04:07,210 --> 01:04:11,113 BUILDING UP SO MUCH THE LINKAGES 1704 01:04:11,180 --> 01:04:13,049 BETWEEN WHAT YOU'RE DOING, AS 1705 01:04:13,115 --> 01:04:14,517 YOU SPOKE TO I THINK IT WOULD BE 1706 01:04:14,584 --> 01:04:15,051 REALLY INTERESTING. 1707 01:04:15,117 --> 01:04:17,820 SO, YOU KNOW, LIKE THE 1708 01:04:17,887 --> 01:04:19,755 PRE-CLINICAL RESEARCH YOU'RE 1709 01:04:19,822 --> 01:04:22,391 DOING, HOW LITCOIN -- HOW THAT 1710 01:04:22,458 --> 01:04:24,994 CAN BE LEVERAGED IN LITCOIN, AS 1711 01:04:25,061 --> 01:04:25,328 YOU MENTIONED. 1712 01:04:25,394 --> 01:04:30,466 THE SAME AS YOU'RE MOVING INTO 1713 01:04:30,533 --> 01:04:34,237 PHASE 2 WITH GENE EDITING, 1714 01:04:34,303 --> 01:04:36,172 MODELS FOR RARE DISEASE WITH 1715 01:04:36,239 --> 01:04:38,374 FACTOR IN, GLAD TO SEE THOSE 1716 01:04:38,441 --> 01:04:40,977 LINKAGES ARE STARTING TO BE 1717 01:04:41,043 --> 01:04:41,310 THOUGHT ABOUT. 1718 01:04:41,377 --> 01:04:43,913 THE OTHER COMMENT, TWO MORE 1719 01:04:43,980 --> 01:04:47,850 COMMENTS, I HAD, ONE WITH THE 1720 01:04:47,917 --> 01:04:48,884 TRANSLATIONAL SCIENCE PRINCIPLE 1721 01:04:48,951 --> 01:04:50,419 STICKERS, I'M WONDERING HOW WE 1722 01:04:50,486 --> 01:04:52,588 CAN GET THOSE OUT AS MUCH AS 1723 01:04:52,655 --> 01:04:52,855 POSSIBLE. 1724 01:04:52,922 --> 01:04:54,323 YOU KNOW, IT WOULD BE GREAT TO 1725 01:04:54,390 --> 01:04:56,859 SEE THAT LIKE EVEN IN PRIVATE 1726 01:04:56,926 --> 01:04:57,426 SECTOR INDUSTRIES, RIGHT? 1727 01:04:57,493 --> 01:05:01,230 BECAUSE THEY ARE STARTING TO 1728 01:05:01,297 --> 01:05:03,332 BUILD TRANSLATIONAL SCIENCE 1729 01:05:03,399 --> 01:05:03,799 TEAMS. 1730 01:05:03,866 --> 01:05:05,835 THESE ARE PRINCIPLES THEY MAY 1731 01:05:05,901 --> 01:05:07,236 PROMOTE FOR THEIR TEAMS. 1732 01:05:07,303 --> 01:05:09,472 SO I WOULD LOVE TO SEE HOW TO 1733 01:05:09,538 --> 01:05:10,740 DISSEMINATE THOSE STICKERS FAR 1734 01:05:10,806 --> 01:05:11,641 AND WIDE. 1735 01:05:11,707 --> 01:05:13,676 >> THAT'S A GREAT IDEA. 1736 01:05:13,743 --> 01:05:14,810 WE HAVEN'T THOUGHT ABOUT, YOU 1737 01:05:14,877 --> 01:05:21,484 KNOW, SORT OF SECONDHAND 1738 01:05:21,550 --> 01:05:22,151 DISSEMINATION BEYOND CTSAs AND 1739 01:05:22,218 --> 01:05:26,922 RARE DISEASE GROUPS BUT IT'S A 1740 01:05:26,989 --> 01:05:30,893 GREAT, AND I'LL START THINKING 1741 01:05:30,960 --> 01:05:32,161 ABOUT THAT. 1742 01:05:32,228 --> 01:05:33,829 >> AND COMMUNICATION, THE IND 1743 01:05:33,896 --> 01:05:34,764 SUBMISSIONS, THAT'S FANTASTIC, 1744 01:05:34,830 --> 01:05:35,965 WONDERING HOW THAT STORY IS 1745 01:05:36,032 --> 01:05:38,200 BEING TOLD AS WELL. 1746 01:05:38,267 --> 01:05:40,836 AND THAT DOVETAILS INTO MY LAST 1747 01:05:40,903 --> 01:05:42,905 COMMENT OF WITH THE STRATEGIC 1748 01:05:42,972 --> 01:05:44,006 PLAN AS YOU'RE DRAFTING IT, I 1749 01:05:44,073 --> 01:05:47,176 LOOKED AT THE OLD ONE AND DIDN'T 1750 01:05:47,243 --> 01:05:49,078 SEE LIKE AN IMPACT SECTION. 1751 01:05:49,145 --> 01:05:51,247 AND PERHAPS AT THE TIME IT MAY 1752 01:05:51,314 --> 01:05:53,649 BE TOO EARLY BUT I THINK TRYING 1753 01:05:53,716 --> 01:05:56,485 TO BUILD ON GETTING THE MESSAGE 1754 01:05:56,552 --> 01:05:59,322 OUT OF NCATS IMPACT AND THINKING 1755 01:05:59,388 --> 01:06:01,390 ABOUT WHO WILL BE SEEING THE 1756 01:06:01,457 --> 01:06:02,925 STRATEGIC PLAN I THINK HAVING 1757 01:06:02,992 --> 01:06:06,429 IT, YOU KNOW, CAPTURED IN THAT 1758 01:06:06,495 --> 01:06:08,964 STRATEGIC PLAN LIKE A GRAPHIC 1759 01:06:09,031 --> 01:06:10,032 OR, YOU KNOW, EVEN WRITTEN 1760 01:06:10,099 --> 01:06:13,669 SECTION THAT TALKS ABOUT THE BIG 1761 01:06:13,736 --> 01:06:15,171 WINS OF NCATS COULD BE HELP 1762 01:06:15,237 --> 01:06:18,174 FOLLOW HAVE AT THE BEGINNING OF 1763 01:06:18,240 --> 01:06:18,674 THE STRATEGIC PLAN. 1764 01:06:18,741 --> 01:06:21,811 >> ANIKA, YOU'RE READING OUR 1765 01:06:21,877 --> 01:06:23,612 MINDS FOR SURE. 1766 01:06:23,679 --> 01:06:26,916 ONE OF THE THINGS WE'VE DONE, TO 1767 01:06:26,982 --> 01:06:28,517 THAT END, ON NEWLY ROLLED OUT 1768 01:06:28,584 --> 01:06:29,752 WEBSITE WE HAVE AN IMPACT 1769 01:06:29,819 --> 01:06:31,387 SECTION EXACTLY FOR THAT REASON. 1770 01:06:31,454 --> 01:06:33,789 I THINK IT'S STILL NEW. 1771 01:06:33,856 --> 01:06:36,892 WE'RE EXPLORING HOW BEST TO USE 1772 01:06:36,959 --> 01:06:38,094 THAT. 1773 01:06:38,160 --> 01:06:40,463 BUT MEREDITH AND I TALKED ABOUT 1774 01:06:40,529 --> 01:06:42,098 THIS WITH TEAMS AS WELL, IMPACT 1775 01:06:42,164 --> 01:06:43,532 IS SO IMPORTANT FOR US AS WELL. 1776 01:06:43,599 --> 01:06:45,634 WE DON'T WANT TO HAVE A 1777 01:06:45,701 --> 01:06:46,302 STRATEGIC PLAN THAT'S WRITTEN 1778 01:06:46,369 --> 01:06:47,370 AND DONE. 1779 01:06:47,436 --> 01:06:50,339 WE WANT A STRATEGIC PLAN THAT'S 1780 01:06:50,406 --> 01:06:52,208 MEASURABLE, AND SHOWS THAT 1781 01:06:52,274 --> 01:06:52,441 IMPACT. 1782 01:06:52,508 --> 01:06:53,709 I REALLY RESONATE WITH YOUR 1783 01:06:53,776 --> 01:06:55,945 IDEAS HERE, AND WE DO PLAN TO 1784 01:06:56,011 --> 01:06:58,981 HAVE WAYS IN WHICH WE CAN TALK 1785 01:06:59,048 --> 01:06:59,749 ABOUT THAT MORE. 1786 01:06:59,815 --> 01:07:02,718 I WANT TO JUST TAKE A MOMENT TO 1787 01:07:02,785 --> 01:07:04,820 PAUSE BECAUSE I DO SEE DR. 1788 01:07:04,887 --> 01:07:08,090 BERTAGNOLLI ON THE SCREEN. 1789 01:07:08,157 --> 01:07:08,290 HELLO. 1790 01:07:08,357 --> 01:07:08,557 >> HELLO. 1791 01:07:08,624 --> 01:07:13,629 >> AND I WOULD LIKE TO JUST 1792 01:07:13,696 --> 01:07:15,564 OFFER THE IDEA OF -- MONICA, ARE 1793 01:07:15,631 --> 01:07:16,165 YOU READY TO GO? 1794 01:07:16,232 --> 01:07:18,033 WOULD YOU LIKE TO PROCEED? 1795 01:07:18,100 --> 01:07:19,368 >> WHATEVER YOU LIKE. 1796 01:07:19,435 --> 01:07:20,770 YOU CAN CERTAINLY GO FINISH WITH 1797 01:07:20,836 --> 01:07:22,405 THIS CONVERSATION IF YOU LIKE. 1798 01:07:22,471 --> 01:07:24,006 I DON'T NEED TO INTERRUPT IT. 1799 01:07:24,073 --> 01:07:24,840 >> OKAY. 1800 01:07:24,907 --> 01:07:29,011 WE'LL TAKE ONE MORE QUESTION AND 1801 01:07:29,078 --> 01:07:29,779 WE WILL TURN IT OVER TO YOU AND 1802 01:07:29,845 --> 01:07:32,047 PICK UP ON THE BACK END BEFORE 1803 01:07:32,114 --> 01:07:34,950 THE BREAK IF THAT SOUNDS OKAY. 1804 01:07:35,017 --> 01:07:39,188 SO, MARSHALL, PLEASE GO AHEAD. 1805 01:07:39,255 --> 01:07:40,389 >> SO, LIKE I SAID, GREAT 1806 01:07:40,456 --> 01:07:40,723 OVERVIEW. 1807 01:07:40,790 --> 01:07:44,760 ONE OF THE THINGS THAT WOULD BE 1808 01:07:44,827 --> 01:07:45,628 REALLY FASCINATING, SOMETHING 1809 01:07:45,694 --> 01:07:46,996 PAUL HARRIS AND I HAVE BEEN 1810 01:07:47,062 --> 01:07:50,232 BOUNCING OFF, HOW DO WE USE SOME 1811 01:07:50,299 --> 01:07:51,267 MACHINE LEARNING SYSTEMS, 1812 01:07:51,333 --> 01:07:53,836 CHATBOT TYPE SYSTEMS WHEN WE'RE 1813 01:07:53,903 --> 01:07:54,637 STARTING TO INCORPORATE THIS, A 1814 01:07:54,703 --> 01:07:56,472 LOT OF THESE NATURAL HISTORY 1815 01:07:56,539 --> 01:08:00,209 STUDIES WE'RE WORKING ON. 1816 01:08:00,276 --> 01:08:03,245 BECAUSE RIGHT KNOW WE 1817 01:08:03,312 --> 01:08:04,513 STRAITJACKET OURSELVES WITH 1818 01:08:04,580 --> 01:08:05,448 FORMALISTIC QUESTIONS, MISSING 1819 01:08:05,514 --> 01:08:06,682 INFORMATION ABOUT WHAT WE DON'T 1820 01:08:06,749 --> 01:08:08,117 KNOW WE DON'T KNOW. 1821 01:08:08,184 --> 01:08:09,985 ONE THING I'D LOVE TO SEE IN 1822 01:08:10,052 --> 01:08:11,587 THAT STRATEGIC PLAN IS -- AND 1823 01:08:11,654 --> 01:08:15,224 IT'S NOT -- YOU KNOW, IT'S NOT A 1824 01:08:15,291 --> 01:08:16,225 PANACEA FOR EVERYTHING BUT 1825 01:08:16,292 --> 01:08:18,260 THERE'S WAYS THOSE THINGS CAN 1826 01:08:18,327 --> 01:08:18,894 INTERACT WITH PATIENTS GIVING 1827 01:08:18,961 --> 01:08:21,263 INFORMATION THAT WILL BE MORE 1828 01:08:21,330 --> 01:08:23,699 EFFECTIVE AND PROBABLY ALLOW FOR 1829 01:08:23,766 --> 01:08:24,700 BROADER DATA COLLECTION ACROSS 1830 01:08:24,767 --> 01:08:27,670 SOME OFS THEY THINGS SO I'D LOVE 1831 01:08:27,736 --> 01:08:31,407 TO SEE THAT BUILT IN THERE. 1832 01:08:31,474 --> 01:08:32,608 >> A GREAT IDEA. 1833 01:08:32,675 --> 01:08:35,144 A GOOD USE OF THAT AS A TOOL. 1834 01:08:35,211 --> 01:08:37,213 YOU KNOW, IT COULD ALSO BE A WAY 1835 01:08:37,279 --> 01:08:39,315 IN WHICH -- YOU KNOW, IF YOU 1836 01:08:39,381 --> 01:08:44,453 LOOK EVEN BEYOND USING 1837 01:08:44,520 --> 01:08:47,857 A.I.-ENABLED OR MACHINE LEARNING 1838 01:08:47,923 --> 01:08:48,591 AND ALGORITHMS EVEN WITH MORE 1839 01:08:48,657 --> 01:08:50,759 CUTTING EDGE TOOLS YOU CAN START 1840 01:08:50,826 --> 01:08:54,396 TO FILL IN SOME BLANKS YOU MAY 1841 01:08:54,463 --> 01:08:56,365 NOT SEE IN NATURAL HISTORY 1842 01:08:56,432 --> 01:08:56,599 STUDIES. 1843 01:08:56,665 --> 01:08:56,966 >> RIGHT. 1844 01:08:57,032 --> 01:08:58,667 THAT'S WHAT I MEAN, WAYS TO PULL 1845 01:08:58,734 --> 01:08:59,535 THE DATA TOGETHER THAT SIMPLY 1846 01:08:59,602 --> 01:09:01,937 YOU CAN'T DO BECAUSE PEOPLE 1847 01:09:02,004 --> 01:09:03,305 DON'T HAVE THE TIME OR THE 1848 01:09:03,372 --> 01:09:04,507 BREADTH FOR THAT. 1849 01:09:04,573 --> 01:09:07,877 I THINK THAT WOULD BE INCREDIBLY 1850 01:09:07,943 --> 01:09:08,143 POWERFUL. 1851 01:09:08,210 --> 01:09:09,845 >> COMPLEX OF THOSE DATA ARE 1852 01:09:09,912 --> 01:09:11,413 PRETTY BIG SO HAVING THE MACHINE 1853 01:09:11,480 --> 01:09:13,382 HELP WITH THAT IS GOOD, AND THEN 1854 01:09:13,449 --> 01:09:19,255 HAVING THE HUMANS TEST IT. 1855 01:09:19,321 --> 01:09:21,090 SOUNDS LIKE AN IDEAL THING WE 1856 01:09:21,156 --> 01:09:22,858 CAN CONSIDER, MAYBE WHEN WE MEET 1857 01:09:22,925 --> 01:09:23,993 WITH THE FDA IN MAY THAT MIGHT 1858 01:09:24,059 --> 01:09:26,395 BE ONE THING WE CAN TALK A 1859 01:09:26,462 --> 01:09:29,131 LITTLE BIT ABOUT IN THINKING 1860 01:09:29,198 --> 01:09:29,665 MORE -- 1861 01:09:29,732 --> 01:09:33,068 >> THINKING ALONG THOSE LINES, 1862 01:09:33,135 --> 01:09:33,836 PARTICULARLY POST-MARKETING 1863 01:09:33,903 --> 01:09:34,069 STUDIES. 1864 01:09:34,136 --> 01:09:34,303 >> YEAH. 1865 01:09:34,370 --> 01:09:39,074 >> WHAT YOU DON'T KNOW IS WHAT 1866 01:09:39,141 --> 01:09:40,676 WILL ACTUALLY BITE YOU. 1867 01:09:40,743 --> 01:09:41,243 >> EXACTLY. 1868 01:09:41,310 --> 01:09:42,778 WE'RE TALKING ABOUT THE KIND OF 1869 01:09:42,845 --> 01:09:43,679 THINGS WE'RE THINKING. 1870 01:09:43,746 --> 01:09:45,748 AND WE WANT TO MAKE SURE THAT 1871 01:09:45,814 --> 01:09:48,150 WE'RE SETTING THE STAGE SO THAT 1872 01:09:48,217 --> 01:09:49,251 OUR COMMUNITIES CAN NAVIGATE 1873 01:09:49,318 --> 01:09:51,186 THAT AS WELL. 1874 01:09:51,253 --> 01:09:56,525 SO, I LOVE THE IDEA, MARSHALL. 1875 01:09:56,592 --> 01:09:56,959 LET'S KEEP TALKING. 1876 01:09:57,026 --> 01:09:57,226 >> ALWAYS. 1877 01:09:57,293 --> 01:09:57,893 >> ALL RIGHT. 1878 01:09:57,960 --> 01:09:59,461 WITH THAT, I THINK WE'RE 1879 01:09:59,528 --> 01:10:00,963 PROBABLY A LITTLE BIT EARLY. 1880 01:10:01,030 --> 01:10:04,033 GREG, ARE WE OKAY TO GO AHEAD 1881 01:10:04,099 --> 01:10:07,002 AND MOVE FORWARD WITH DR. 1882 01:10:07,069 --> 01:10:08,103 BERTAGNOLLI? 1883 01:10:08,170 --> 01:10:10,372 EVERYTHING OKAY ON YOUR END? 1884 01:10:10,439 --> 01:10:10,606 >> YEP. 1885 01:10:10,673 --> 01:10:11,874 THAT'S PERFECTLY FINE. 1886 01:10:11,941 --> 01:10:16,812 >> ALL RIGHT. 1887 01:10:16,879 --> 01:10:18,414 WELL, I'M SUPER, SUPER, SUPER, 1888 01:10:18,480 --> 01:10:20,449 EXCITEMENTED TO HAVE THE 17th 1889 01:10:20,516 --> 01:10:23,052 DIRECTOR OF THE NIH HERE TODAY, 1890 01:10:23,118 --> 01:10:25,220 DR. MONICA BERTAGNOLLI. 1891 01:10:25,287 --> 01:10:28,991 SHE'S THE FIRST SURGEON AND THE 1892 01:10:29,058 --> 01:10:30,826 FIRST -- ACTUALLY THE SECOND 1893 01:10:30,893 --> 01:10:33,162 WOMAN TO HOLD THE POSITION. 1894 01:10:33,228 --> 01:10:35,431 NOMINATED BY PRESIDENT BIDEN ON 1895 01:10:35,497 --> 01:10:40,469 MAY 15 OF 2023, CONFIRMED ON 1896 01:10:40,536 --> 01:10:43,739 NOVEMBER 7, TOOK OFFICE ON 1897 01:10:43,806 --> 01:10:44,406 NOVEMBER 9. 1898 01:10:44,473 --> 01:10:46,408 AND PREVIOUSLY JUST BEFORE THAT 1899 01:10:46,475 --> 01:10:51,547 SHE SERVED AS 16th DIRECTOR OF 1900 01:10:51,614 --> 01:10:55,951 NCI, AND SHE WAS RICHARD WILSON 1901 01:10:56,018 --> 01:10:57,219 PROFESSOR OF SURGERY AT HARVARD, 1902 01:10:57,286 --> 01:11:05,060 YOU ARE SURGEON AT BRIGHAM AND 1903 01:11:05,127 --> 01:11:06,428 WOMEN'S, AND DANA-FARBER CANCER 1904 01:11:06,495 --> 01:11:06,996 INSTITUTE. 1905 01:11:07,062 --> 01:11:10,299 DR. BERTAGNOLLI HAS BEEN AT THE 1906 01:11:10,366 --> 01:11:11,867 FOREFRONT OF CLINICAL ONCOLOGY. 1907 01:11:11,934 --> 01:11:13,235 HER LAB FOCUSED ON ADVANCING 1908 01:11:13,302 --> 01:11:16,405 UNDERSTANDING OF THE GENETIC 1909 01:11:16,472 --> 01:11:17,539 DRIVERS OF GASTROINTESTINAL 1910 01:11:17,606 --> 01:11:19,742 CANCER AND ROLE OF INFLAMMATION 1911 01:11:19,808 --> 01:11:20,976 AS PROMOTER OF CANCER GROWTH. 1912 01:11:21,043 --> 01:11:23,412 AND THEN AS A PHYSICIAN AND 1913 01:11:23,479 --> 01:11:26,048 SCIENTIST SHE LED TRANSLATIONAL 1914 01:11:26,115 --> 01:11:28,651 SCIENCE INITIATIVES WITHIN THE 1915 01:11:28,717 --> 01:11:30,085 NCI-FUNDED COOPERATIVE GROUPS 1916 01:11:30,152 --> 01:11:32,955 PROGRAM, NOW KNOWN AS NCI'S 1917 01:11:33,022 --> 01:11:35,357 NATIONAL CLINICAL TRIALS 1918 01:11:35,424 --> 01:11:35,958 NETWORK. 1919 01:11:36,025 --> 01:11:38,394 AND THEN SHE ALSO WAS CHAIR OF 1920 01:11:38,460 --> 01:11:41,563 THE ALLIANCE FOR CLINICAL TRIALS 1921 01:11:41,630 --> 01:11:44,099 IN ONCOLOGY, NATIONAL CLINICAL 1922 01:11:44,166 --> 01:11:44,733 TRIALS NETWORK MEMBER 1923 01:11:44,800 --> 01:11:47,069 ORGANIZATION, SHE HAS HUGE 1924 01:11:47,136 --> 01:11:50,005 FAMILIARITY OF COURSE WITH 1925 01:11:50,072 --> 01:11:50,372 CLINICAL TRIALS. 1926 01:11:50,439 --> 01:11:53,509 SHE HAS CHAMPIONED A VARIETY OF 1927 01:11:53,575 --> 01:11:54,276 COLLABORATIVE INITIATIVES TO 1928 01:11:54,343 --> 01:11:55,344 TRANSFORM DATA INFRASTRUCTURE 1929 01:11:55,411 --> 01:11:58,180 FOR CLINICAL RESEARCH AND IS THE 1930 01:11:58,247 --> 01:12:00,616 FOUNDING CHAIR OF THE MINIMAL 1931 01:12:00,683 --> 01:12:04,853 COMMON ONCOLOGY DATA ELEMENTS, 1932 01:12:04,920 --> 01:12:06,422 N-CODE, ALSO PAST PRESIDENT AND 1933 01:12:06,488 --> 01:12:08,157 CHAIR BOARD OF DIRECTORS 1934 01:12:08,223 --> 01:12:10,926 AMERICAN SOCIETY OF CLINICAL 1935 01:12:10,993 --> 01:12:12,861 ONCOLOGY, AND JUST A LITTLE 1936 01:12:12,928 --> 01:12:16,799 TID-BIT IS THAT SHE IS THE 1937 01:12:16,865 --> 01:12:22,705 DAUGHTER OF A FIRST GENERATION 1938 01:12:22,771 --> 01:12:25,207 ITALIAN, FRENCH BASQU AS 1939 01:12:25,274 --> 01:12:27,409 IMMIGRANTS, GREW UP ON A RANCH 1940 01:12:27,476 --> 01:12:28,310 IN SOUTHWESTERN WYOMING. 1941 01:12:28,377 --> 01:12:33,415 WE SHARE A LOVE FOR WEARING 1942 01:12:33,482 --> 01:12:36,485 COWBOY BOOTS. 1943 01:12:36,552 --> 01:12:37,319 GRADUATED FROM PRINCETON, 1944 01:12:37,386 --> 01:12:43,192 MEDICAL SCHOOL UNIVERSITY OF HUE 1945 01:12:43,258 --> 01:12:47,463 THAT, TRAINED AT BRIGHAM AND 1946 01:12:47,529 --> 01:12:48,664 WOMEN'S, FELLOWSHIP AT 1947 01:12:48,731 --> 01:12:48,964 DANA-FARBER. 1948 01:12:49,031 --> 01:12:49,631 GREAT TO HAVE YOU. 1949 01:12:49,698 --> 01:12:51,700 THANK YOU FOR JOINING US. 1950 01:12:51,767 --> 01:12:53,402 >> THANK YOU, JONI. 1951 01:12:53,469 --> 01:12:55,404 I'M SO THRILLED TO BE ABLE TO BE 1952 01:12:55,471 --> 01:12:59,241 WITH YOU ALL TODAY! 1953 01:12:59,308 --> 01:13:02,377 AND I SERVED IN THE SISTER 1954 01:13:02,444 --> 01:13:04,513 ORGANIZATION TO NCATS, I'VE 1955 01:13:04,580 --> 01:13:08,183 SERVED IN THE NCTN, BUT I'M 1956 01:13:08,250 --> 01:13:09,985 REALLY ACTUALLY QUITE FAMILIAR 1957 01:13:10,052 --> 01:13:12,421 WITH YOUR WORK, HAVING BEEN, 1958 01:13:12,488 --> 01:13:13,956 LIKE I SAID, NEARBY COLLABORATOR 1959 01:13:14,022 --> 01:13:15,023 OVER MANY YEARS. 1960 01:13:15,090 --> 01:13:17,893 SO DELIGHTED TO BE HERE TODAY TO 1961 01:13:17,960 --> 01:13:18,794 MEET WITH YOU. 1962 01:13:18,861 --> 01:13:19,194 OKAY. 1963 01:13:19,261 --> 01:13:22,698 LET'S SEE IF I CAN MAKE MY 1964 01:13:22,765 --> 01:13:23,599 SLIDES WORK. 1965 01:13:23,665 --> 01:13:24,500 OH, OKAY. 1966 01:13:24,566 --> 01:13:26,001 JONI ALREADY SAID THIS IN THE 1967 01:13:26,068 --> 01:13:26,869 INTRODUCTION, HERE'S WHERE I 1968 01:13:26,935 --> 01:13:27,736 GREW UP. 1969 01:13:27,803 --> 01:13:29,671 IT REALLY IS IN THE MIDDLE OF 1970 01:13:29,738 --> 01:13:30,105 NOWHERE. 1971 01:13:30,172 --> 01:13:31,473 SO I AM A RURAL PERSON. 1972 01:13:31,540 --> 01:13:34,409 I GREW UP IN A SPOT, THIS IS 1973 01:13:34,476 --> 01:13:35,644 WHAT IT IS. 1974 01:13:35,711 --> 01:13:38,147 THE FIRST NEIGHBOR, THE NEXT 1975 01:13:38,213 --> 01:13:40,749 HOUSE, WAS ABOUT 8 MILES AWAY. 1976 01:13:40,816 --> 01:13:42,284 THE NEXT PAVED ROAD WAS 18 MILES 1977 01:13:42,351 --> 01:13:44,586 OF DIRT ROAD BEFORE YOU HIT THE 1978 01:13:44,653 --> 01:13:44,853 PAVEMENT. 1979 01:13:44,920 --> 01:13:47,122 SO WE REALLY WERE IN A VERY 1980 01:13:47,189 --> 01:13:48,090 REMOTE LOCATION. 1981 01:13:48,157 --> 01:13:50,559 BUT YOU ALSO SEE WHAT I'M 1982 01:13:50,626 --> 01:13:52,694 INCREDIBLY PROUD OF, THAT I'M 1983 01:13:52,761 --> 01:13:54,163 CURRENTLY CREDENTIALED TO BE A 1984 01:13:54,229 --> 01:13:56,632 PHYSICIAN IN THE CLINICAL CENTER 1985 01:13:56,698 --> 01:13:59,635 AT THE NIH, HERE IS ME DOWN IN 1986 01:13:59,701 --> 01:14:01,703 THE BOTTOM RIGHT. 1987 01:14:01,770 --> 01:14:04,540 SERVING AS FIRST ASSISTANT TO A 1988 01:14:04,606 --> 01:14:06,842 FORMER POSTDOC IN MY LAB, 1989 01:14:06,909 --> 01:14:08,677 SURGICAL ONCOLOGY TRAINEE NOW 1990 01:14:08,744 --> 01:14:10,546 ONE OF THE SENIOR SURGEONS AT 1991 01:14:10,612 --> 01:14:16,018 THE NIH CLINICAL CENTER IN THE 1992 01:14:16,084 --> 01:14:18,420 IMMUNOTHERAPY BRANCH, DR. 1993 01:14:18,487 --> 01:14:19,288 STEPHANIE GOFF. 1994 01:14:19,354 --> 01:14:20,589 THERE'S NOTHING MORE PRECIOUS IN 1995 01:14:20,656 --> 01:14:21,924 YOUR CAREER THAN WHEN YOU GET TO 1996 01:14:21,990 --> 01:14:24,726 COME IN AND BE THE FIRST 1997 01:14:24,793 --> 01:14:27,262 ASSISTANT OF A FORMER TRAINEE. 1998 01:14:27,329 --> 01:14:30,132 AND IT'S REALLY VERY THRILLING. 1999 01:14:30,199 --> 01:14:31,567 SO TODAY'S DISCUSSION WE'RE 2000 01:14:31,633 --> 01:14:33,502 GOING TO TALK ABOUT WHAT WE'RE 2001 01:14:33,569 --> 01:14:37,372 TRYING TO DO TO GET NIH REALLY 2002 01:14:37,439 --> 01:14:38,440 ENERGIZED, IN AN OPPORTUNITY 2003 01:14:38,507 --> 01:14:41,276 THAT A NEW DIRECTOR HAS TO DO 2004 01:14:41,343 --> 01:14:41,476 SO. 2005 01:14:41,543 --> 01:14:43,779 SOME THINGS THAT I THINK ABOUT 2006 01:14:43,846 --> 01:14:44,980 AS GUIDING PRINCIPLES A LITTLE 2007 01:14:45,047 --> 01:14:50,085 BIT ABOUT OUR BUDGET, AND A 2008 01:14:50,152 --> 01:14:51,320 LITTLE BIT ABOUT VISION. 2009 01:14:51,386 --> 01:14:53,322 SO FIRST, THIS IS SOMETHING WE 2010 01:14:53,388 --> 01:14:54,857 ALL HAVE TO DEAL WITH, THE 2011 01:14:54,923 --> 01:14:57,559 HEALTH OF THE U.S. POPULATION IS 2012 01:14:57,626 --> 01:14:58,093 DECLINING. 2013 01:14:58,160 --> 01:15:00,229 WE HAVE TO REVERSE THIS TREND. 2014 01:15:00,295 --> 01:15:03,599 WE'RE GETTING A VERY BAD REPORT 2015 01:15:03,665 --> 01:15:04,466 CARD RIGHT NOW. 2016 01:15:04,533 --> 01:15:06,768 THERE'S MUCH THAT CAN DIVIDE US 2017 01:15:06,835 --> 01:15:07,970 RIGHT NOW. 2018 01:15:08,036 --> 01:15:10,372 HOWEVER, IT'S VERY CLEAR THAT 2019 01:15:10,439 --> 01:15:12,274 THE DESIRE FOR LONG HEALTHY 2020 01:15:12,341 --> 01:15:14,209 LIVES FOR OURSELVES AND OUR 2021 01:15:14,276 --> 01:15:18,480 LOVED ONES IS A UNIFYING AND 2022 01:15:18,547 --> 01:15:19,248 GALVANIZING FORCE ACROSS ALL 2023 01:15:19,314 --> 01:15:22,618 DISCIPLINES, ALL WALKS OF LIFE, 2024 01:15:22,684 --> 01:15:23,619 ALL POLITICAL ARENAS. 2025 01:15:23,685 --> 01:15:26,221 SO WE NEED TO REALLY EMBRACE 2026 01:15:26,288 --> 01:15:26,622 THAT. 2027 01:15:26,688 --> 01:15:29,124 BASED ON MY DISCUSSIONS WITH 2028 01:15:29,191 --> 01:15:30,626 MEMBERS OF CONGRESS, I KNOW ALL 2029 01:15:30,692 --> 01:15:32,728 OF THEM CARE VERY DEEPLY ABOUT 2030 01:15:32,794 --> 01:15:34,897 THIS ISSUE FOR THEIR 2031 01:15:34,963 --> 01:15:35,430 CONSTITUENTS. 2032 01:15:35,497 --> 01:15:37,299 AND THE OTHER THING THAT'S 2033 01:15:37,366 --> 01:15:40,736 CRITICAL, WE HAVE TO APPROACH 2034 01:15:40,802 --> 01:15:42,471 OUR WORK WITH GREAT URGENCY, 2035 01:15:42,537 --> 01:15:46,108 BECAUSE WE'RE NOT WINNING RIGHT 2036 01:15:46,174 --> 01:15:46,541 NOW. 2037 01:15:46,608 --> 01:15:48,343 AS YOU MAY KNOW, U.S. LIFE 2038 01:15:48,410 --> 01:15:51,780 EXPECTANCY IS LOW COMPARED TO 2039 01:15:51,847 --> 01:15:52,714 OUR PEER NATIONS. 2040 01:15:52,781 --> 01:15:55,951 THIS IS NOT A PANDEMIC AREA 2041 01:15:56,018 --> 01:15:56,618 ISSUE. 2042 01:15:56,685 --> 01:15:58,387 LIFE EXPECTANCY WAS DECLINING IN 2043 01:15:58,453 --> 01:15:59,988 THE U.S. WELL BEFORE THE 2044 01:16:00,055 --> 01:16:00,355 PANDEMIC. 2045 01:16:00,422 --> 01:16:03,025 AND DESPITE SEEING INCREASE IN 2046 01:16:03,091 --> 01:16:04,793 2022, WE HAVE STILL NOT MADE UP 2047 01:16:04,860 --> 01:16:06,094 FOR ADDITIONAL LOSSES DURING THE 2048 01:16:06,161 --> 01:16:11,700 PANDEMIC AND WE'RE NOT ON THE 2049 01:16:11,767 --> 01:16:12,601 RIGHT TRACK. 2050 01:16:12,668 --> 01:16:13,835 THERE'S THIS UGLY FACT. 2051 01:16:13,902 --> 01:16:16,538 EVEN THOUGH WE'RE NOT DOING AS 2052 01:16:16,605 --> 01:16:17,873 WELL AS COMPARATOR COUNTRIES, 2053 01:16:17,940 --> 01:16:20,509 OUR LIFE EXPECTANCY IS VERY LOW 2054 01:16:20,575 --> 01:16:22,411 COMPARED WITH PEER COUNTRIES, 2055 01:16:22,477 --> 01:16:24,613 EVEN THOUGH WE SPEND ENORMOUSLY 2056 01:16:24,680 --> 01:16:29,051 MORE ON OUR HEALTH CARE SYSTEM. 2057 01:16:29,117 --> 01:16:31,219 AND THIS IS DRILLING DOWN TO 2058 01:16:31,286 --> 01:16:35,057 REALLY UNDERSTAND WHERE AND WHY 2059 01:16:35,123 --> 01:16:36,792 AND IS REALLY INCREDIBLY 2060 01:16:36,858 --> 01:16:38,093 SOBERING. 2061 01:16:38,160 --> 01:16:39,494 WE ACCORDING TO A 2021 REPORT 2062 01:16:39,561 --> 01:16:41,229 FROM NATIONAL ACADEMIES, THIS 2063 01:16:41,296 --> 01:16:43,231 DECLINE IN LIFE EXPECTANCY WE'RE 2064 01:16:43,298 --> 01:16:46,768 SEEING SEEMS LARGELY RELATED TO 2065 01:16:46,835 --> 01:16:50,939 AN INCREASING MORTALITY AMONG 2066 01:16:51,006 --> 01:16:52,441 WORKING-AGE ADULTS, AGE 18-64, 2067 01:16:52,507 --> 01:16:56,211 AND THE MAIN DRIVERS OF THIS, 2068 01:16:56,278 --> 01:17:00,849 ENOUGH TO DRIVE LIFE EXPECTANCY, 2069 01:17:00,916 --> 01:17:03,318 ARE DRAMATIC INCREASE IN DEATHS 2070 01:17:03,385 --> 01:17:08,256 DUE TO DRUG POISONING, ALCOHOL 2071 01:17:08,323 --> 01:17:09,591 POISONING, ALCOHOL-RELATED 2072 01:17:09,658 --> 01:17:12,728 CAUSES, AND SUICIDE. 2073 01:17:12,794 --> 01:17:15,030 ALSO IMPORTANTLY, A SLOWING OF 2074 01:17:15,097 --> 01:17:17,232 OUR PROGRESS IN REDUCING DEATHS 2075 01:17:17,299 --> 01:17:19,401 DUE TO CARDIOVASCULAR DISEASE. 2076 01:17:19,468 --> 01:17:23,138 SO THESE ARE SOME CORE ISSUES IN 2077 01:17:23,205 --> 01:17:25,207 HEALTH THAT ALL OF US CAN MAKE, 2078 01:17:25,273 --> 01:17:28,744 CAN AND HAVE TO MAKE AN 2079 01:17:28,810 --> 01:17:30,679 IMPORTANT CONTRIBUTION TO 2080 01:17:30,746 --> 01:17:31,646 REVERSING. 2081 01:17:31,713 --> 01:17:34,383 THE REPORT, THESE REPORT AUTHORS 2082 01:17:34,449 --> 01:17:35,917 DESCRIBE A NATIONAL POPULATION 2083 01:17:35,984 --> 01:17:38,020 HEALTH CRISIS, A TREND THREATENS 2084 01:17:38,086 --> 01:17:39,588 THE FUTURE OF FAMILIES, THE 2085 01:17:39,654 --> 01:17:41,089 SOCIAL FABRIC OF COMMUNITIES AS 2086 01:17:41,156 --> 01:17:44,226 WELL AS THE PRODUCTIVITY AND 2087 01:17:44,292 --> 01:17:48,430 COMPETITIVENESS OF OUR COUNTRY. 2088 01:17:48,497 --> 01:17:51,133 SO, GUIDING PRINCIPLES, WHAT CAN 2089 01:17:51,199 --> 01:17:55,003 NIH DO TO ADDRESS THIS CRISIS, 2090 01:17:55,070 --> 01:17:57,572 ESPECIALLY IN THE TIME -- IN 2091 01:17:57,639 --> 01:18:00,208 CHALLENGING TIMES, AND IN TIME 2092 01:18:00,275 --> 01:18:01,009 OF FLAT BUDGET. 2093 01:18:01,076 --> 01:18:03,512 I'M STILL SHAPING PLANS AS I 2094 01:18:03,578 --> 01:18:04,913 MEET WITH LEADERS ACROSS THE 2095 01:18:04,980 --> 01:18:06,748 AGENCY AND INSTITUTE BUT I 2096 01:18:06,815 --> 01:18:07,883 WANTED TO SHARE SOME PRINCIPLES 2097 01:18:07,949 --> 01:18:14,089 THAT ARE GUIDING OUR MISSION. 2098 01:18:14,156 --> 01:18:16,191 FIRST, AND FOREMOST, OUR WORK IS 2099 01:18:16,258 --> 01:18:17,292 NOT FINISHED WHEN WE DELIVER 2100 01:18:17,359 --> 01:18:18,627 SCIENTIFIC DISCOVERIES. 2101 01:18:18,693 --> 01:18:19,261 WE'RE NOT THE NATIONAL 2102 01:18:19,327 --> 01:18:21,096 INSTITUTES OF DISEASE. 2103 01:18:21,163 --> 01:18:23,298 OUR WORK IS FINISHED WHEN ALL 2104 01:18:23,365 --> 01:18:26,201 PEOPLE ARE LIVING LONG AND 2105 01:18:26,268 --> 01:18:27,669 HEALTHY LIVES. 2106 01:18:27,736 --> 01:18:28,570 WE CANNOT OVEREMPHASIZE THIS. 2107 01:18:28,637 --> 01:18:31,406 WE HAVE TO DO EVERYTHING IT 2108 01:18:31,473 --> 01:18:32,607 TAKES TO ACHIEVE THIS ULTIMATE 2109 01:18:32,674 --> 01:18:36,011 AIM, EVEN THOUGH WE KNOW THIS 2110 01:18:36,078 --> 01:18:40,248 ULTIMATE AIM WON'T HAPPEN 2111 01:18:40,315 --> 01:18:42,217 WITHOUT ROBUST, SUSTAINED 2112 01:18:42,284 --> 01:18:44,286 ATTENTION TO ADVANCING 2113 01:18:44,352 --> 01:18:45,220 SCIENTIFIC DISCOVERIES. 2114 01:18:45,287 --> 01:18:49,558 HERE'S THE OTHER ONE, NOT TO 2115 01:18:49,624 --> 01:18:53,929 FORGET THE NIH RESEARCH 2116 01:18:53,995 --> 01:18:56,198 ENCOMPASSES, ABSOLUTELY 2117 01:18:56,264 --> 01:18:57,132 DEPENDENT UPON, THE LABORATORY, 2118 01:18:57,199 --> 01:18:59,468 THE CLINIC, AND THE COMMUNITY. 2119 01:18:59,534 --> 01:19:00,969 I THINK WE'VE KNOWN ABOUT THE 2120 01:19:01,036 --> 01:19:02,003 LABORATORY AND CLINIC AND TALKED 2121 01:19:02,070 --> 01:19:05,540 ABOUT THAT FOR A LONG TIME, BUT 2122 01:19:05,607 --> 01:19:08,210 INCREASINGLY WE KNOW THAT WE 2123 01:19:08,276 --> 01:19:10,112 CAN'T ACHIEVE OUR AIMS WITHOUT 2124 01:19:10,178 --> 01:19:11,580 ALSO CONSIDERING THE COMMUNITY 2125 01:19:11,646 --> 01:19:16,952 TO BE OUR ARENA FOR RESEARCH. 2126 01:19:17,018 --> 01:19:19,421 WE HAVE AN UNPRECEDENTED 2127 01:19:19,488 --> 01:19:20,922 OPPORTUNITY TO EMBRACE AND 2128 01:19:20,989 --> 01:19:22,057 INCREASE ACCESS TO INNOVATION. 2129 01:19:22,124 --> 01:19:24,893 I REALLY WANT TO FOCUS ON WHAT 2130 01:19:24,960 --> 01:19:27,429 NIH CAN DO AS A BIOMEDICAL 2131 01:19:27,496 --> 01:19:28,964 RESEARCH INSTITUTION TO ENSURE 2132 01:19:29,030 --> 01:19:30,599 OUR ADVANCES REACH THE PEOPLE 2133 01:19:30,665 --> 01:19:32,267 WHO NEED THEM, AND FOR ME THIS 2134 01:19:32,334 --> 01:19:33,802 IS PERSONAL BECAUSE AS I SHOWED 2135 01:19:33,869 --> 01:19:36,271 YOU, I GREW UP IN A VERY RURAL 2136 01:19:36,338 --> 01:19:42,177 AREA, ONE OF THE SEGMENTS OF OUR 2137 01:19:42,244 --> 01:19:43,111 SOCIETY WHICH HAS 2138 01:19:43,178 --> 01:19:45,180 DISPROPORTIONATELY BAD HEALTH 2139 01:19:45,247 --> 01:19:51,753 OUTCOMES. 2140 01:19:51,820 --> 01:19:53,288 SO, PROGRESS IS ACCELERATED WHEN 2141 01:19:53,355 --> 01:19:54,990 ADVANCED SCIENTIFIC METHODS SUCH 2142 01:19:55,056 --> 01:19:56,725 AS NEW DATA ANALYTICS ARE 2143 01:19:56,791 --> 01:19:59,294 APPLIED TO DATA THAT INCLUDE 2144 01:19:59,361 --> 01:19:59,561 EVERYONE. 2145 01:19:59,628 --> 01:20:03,098 WHEN NEW DISCOVERIES ARE RAPIDLY 2146 01:20:03,165 --> 01:20:08,203 AND EQUITABLE ADOPTED IN 2147 01:20:08,270 --> 01:20:09,471 CLINICAL CARE. 2148 01:20:09,538 --> 01:20:10,672 I CAN'T IMAGINE THIS SPEAKS TO 2149 01:20:10,739 --> 01:20:12,674 ANY PART OF NIH MORE THAN IT 2150 01:20:12,741 --> 01:20:15,944 DOES TO YOU ALL AT NCATS. 2151 01:20:16,011 --> 01:20:17,879 NEW ADVANCES IN INFORMATION AND 2152 01:20:17,946 --> 01:20:20,749 TECHNOLOGY AND DATA SCIENCE, 2153 01:20:20,815 --> 01:20:23,451 WHILE FAMILIAR TO RESEARCHERS, 2154 01:20:23,518 --> 01:20:24,085 HAVE CAPTURED VERY SIGNIFICANT 2155 01:20:24,152 --> 01:20:26,188 PUBLIC ATTENTION NOW THAT, YOU 2156 01:20:26,254 --> 01:20:32,460 KNOW, WE HAVE THE ARRIVAL OF 2157 01:20:32,527 --> 01:20:34,629 LARGE LANGUAGE MODELS, ANYONE 2158 01:20:34,696 --> 01:20:36,498 CAN USE CHATGPT, THE WORLD IS 2159 01:20:36,565 --> 01:20:37,666 TALKING BUT WE'VE BEEN THE 2160 01:20:37,732 --> 01:20:39,968 DEVELOPERS OF THESE NEW METHODS, 2161 01:20:40,035 --> 01:20:40,402 OBVIOUSLY. 2162 01:20:40,468 --> 01:20:43,371 BUT NOW IT'S GOT EVERYBODY'S 2163 01:20:43,438 --> 01:20:43,638 ATTENTION. 2164 01:20:43,705 --> 01:20:45,273 SO THIS PROVIDES A GREAT 2165 01:20:45,340 --> 01:20:47,742 OPPORTUNITY FOR US ACTUALLY. 2166 01:20:47,809 --> 01:20:48,710 OUR KNOWLEDGE AND TECHNOLOGY 2167 01:20:48,777 --> 01:20:50,178 HAVE DEVELOPED TO THE POINT 2168 01:20:50,245 --> 01:20:55,717 WHERE WE SHOULD BE ABLE TO 2169 01:20:55,784 --> 01:20:56,851 DELIVER EVIDENCE-BASED 2170 01:20:56,918 --> 01:20:58,720 DATA-DRIVEN HEALTH CARE TO EVERY 2171 01:20:58,787 --> 01:20:59,054 PATIENT. 2172 01:20:59,120 --> 01:21:02,557 YOU ALL KNOW WE ARE NOT DOING 2173 01:21:02,624 --> 01:21:03,858 THAT TODAY. 2174 01:21:03,925 --> 01:21:05,927 BUT THE TECHNOLOGY IS THERE TO 2175 01:21:05,994 --> 01:21:07,062 DO IT. 2176 01:21:07,128 --> 01:21:11,466 SO, THIS IS NOT A TECHNOLOGY 2177 01:21:11,533 --> 01:21:11,733 PROBLEM. 2178 01:21:11,800 --> 01:21:14,569 THIS IS A SOCIAL ENGINEERING 2179 01:21:14,636 --> 01:21:14,970 PROBLEM. 2180 01:21:15,036 --> 01:21:16,404 AND, AGAIN, I AM SO DELIGHTED TO 2181 01:21:16,471 --> 01:21:18,306 BE ABLE TO TALK TO THIS GROUP 2182 01:21:18,373 --> 01:21:20,275 BECAUSE YOU ARE ALL ON THE 2183 01:21:20,342 --> 01:21:23,345 FOREFRONT OF BEING ABLE TO SOLVE 2184 01:21:23,411 --> 01:21:24,746 THIS. 2185 01:21:24,813 --> 01:21:25,714 ARTIFICIAL INTELLIGENCE IS 2186 01:21:25,780 --> 01:21:27,082 ALREADY REVOLUTIONIZING WHAT IS 2187 01:21:27,148 --> 01:21:29,351 POSSIBLE IN MEDICAL RESEARCH AND 2188 01:21:29,417 --> 01:21:31,820 CARE, BUT TO REALIZE ITS 2189 01:21:31,886 --> 01:21:33,121 POTENTIAL FOR IMPROVING HEALTH, 2190 01:21:33,188 --> 01:21:36,358 WE ABSOLUTELY HAVE TO INVEST IN 2191 01:21:36,424 --> 01:21:40,228 A SECURE AND SUSTAINABLE DATA 2192 01:21:40,295 --> 01:21:41,296 SHARING INFRASTRUCTURE THAT 2193 01:21:41,363 --> 01:21:43,732 REACHES EVERYONE. 2194 01:21:43,798 --> 01:21:49,004 SO, THE BUDGET CLIMATE, ALL OF 2195 01:21:49,070 --> 01:21:49,938 THESE REALLY CRITICAL IMPORTANT 2196 01:21:50,005 --> 01:21:52,040 NEEDS REACHING BEYOND WHERE WE 2197 01:21:52,107 --> 01:21:56,745 ARE TODAY ARE SET IN A TIME OF 2198 01:21:56,811 --> 01:21:59,247 ALSO VERY CHALLENGING FISCAL 2199 01:21:59,314 --> 01:21:59,814 RESTRAINTS. 2200 01:21:59,881 --> 01:22:01,916 AS I NOTED EARLIER I WANT TO 2201 01:22:01,983 --> 01:22:04,853 FOCUS ON WHAT NIH CAN DO AS A 2202 01:22:04,919 --> 01:22:06,488 BIOMEDICAL RESEARCH INSTITUTE TO 2203 01:22:06,554 --> 01:22:07,889 ENSURE THAT OUR ADVANCES REACH 2204 01:22:07,956 --> 01:22:09,691 THE PEOPLE WHO NEED THEM. 2205 01:22:09,758 --> 01:22:12,093 BUT RIGHT NOW WE'RE ALL VERY 2206 01:22:12,160 --> 01:22:13,862 CONCERNED ABOUT THE BUDGETARY 2207 01:22:13,928 --> 01:22:16,798 PRESSURES WE WILL FACE AND 2208 01:22:16,865 --> 01:22:17,666 DIFFICULT DECISIONS WE WILL NEED 2209 01:22:17,732 --> 01:22:22,370 TO MAKE IN THE NEAR TERM. 2210 01:22:22,437 --> 01:22:23,371 I'M HOPEFUL CONDITIONING WILL 2211 01:22:23,438 --> 01:22:29,778 AVOID DRASTIC CUTS TO NIH AND 2212 01:22:29,844 --> 01:22:32,113 SIBLING AGENCIES ACROSS HHS BUT 2213 01:22:32,180 --> 01:22:33,882 A FLAT BUDGET WHICH WE'RE 2214 01:22:33,948 --> 01:22:35,517 EXPECTING WILL HAVE A 2215 01:22:35,583 --> 01:22:36,084 SIGNIFICANT NEGATIVE IMPACT. 2216 01:22:36,151 --> 01:22:38,620 WE ALWAYS SEEK OUT THE BEST NEW 2217 01:22:38,687 --> 01:22:41,189 IDEAS, AND BEST NEW SCIENCE, AND 2218 01:22:41,256 --> 01:22:42,657 EVEN WITH FUNDING WE CURRENTLY 2219 01:22:42,724 --> 01:22:43,525 RECEIVE WE'RE LEAVING GREAT 2220 01:22:43,591 --> 01:22:45,927 IDEAS AND POTENTIAL FOR NEW 2221 01:22:45,994 --> 01:22:47,462 DISCOVERIES ON THE TABLE. 2222 01:22:47,529 --> 01:22:50,065 IN TIMES OF STRESS, SUCH AS 2223 01:22:50,131 --> 01:22:51,633 THIS, IT IS THE YOUNGER 2224 01:22:51,700 --> 01:22:53,735 GENERATION OF RESEARCHERS THAT 2225 01:22:53,802 --> 01:22:57,105 ARE ALWAYS THE MOST ADVERSELY 2226 01:22:57,172 --> 01:22:57,372 AFFECTED. 2227 01:22:57,439 --> 01:23:01,209 WE COULD LOSE A GENERATION OF 2228 01:23:01,276 --> 01:23:02,844 RESEARCHERS IF WE DON'T DO 2229 01:23:02,911 --> 01:23:04,546 EVERYTHING WE CAN TO SUPPORT 2230 01:23:04,612 --> 01:23:05,547 THEM DURING THIS TIME. 2231 01:23:05,613 --> 01:23:07,749 WE NEED TO DO EVERYTHING WE CAN 2232 01:23:07,816 --> 01:23:10,919 TO CONTINUE TO FUND THE BEST 2233 01:23:10,985 --> 01:23:12,420 SCIENCE, AND TO SUPPORT THOSE 2234 01:23:12,487 --> 01:23:15,390 WHO WILL TAKE OVER WHEN WE ARE 2235 01:23:15,457 --> 01:23:15,657 DONE. 2236 01:23:15,724 --> 01:23:18,360 SO, WHAT SHOULD NIH DO? 2237 01:23:18,426 --> 01:23:20,328 ONE OF THE THINGS I LOVE ABOUT 2238 01:23:20,395 --> 01:23:23,298 BEING AT NIH IS BEING AMONG SO 2239 01:23:23,365 --> 01:23:24,699 MANY THOUGHTFUL AND DEDICATED 2240 01:23:24,766 --> 01:23:26,134 PEOPLE WHO ARE FOCUSED ON WHAT 2241 01:23:26,201 --> 01:23:29,537 NIH CAN DO TO IMPROVE HEALTH FOR 2242 01:23:29,604 --> 01:23:30,472 EVERYONE. 2243 01:23:30,538 --> 01:23:32,173 AND I'M ENJOYING DISCUSSING 2244 01:23:32,240 --> 01:23:34,042 IDEAS FOR WHAT NIH SHOULD DO TO 2245 01:23:34,109 --> 01:23:36,745 HAVE THE MOST IMPACT FOR HEALTH. 2246 01:23:36,811 --> 01:23:42,917 THIS IS A TIME OF VERY SERIOUS 2247 01:23:42,984 --> 01:23:46,388 PRIORITY SETTING EVERYTHING 2248 01:23:46,454 --> 01:23:47,021 STILL FLESHING OUT DETAILS WHAT 2249 01:23:47,088 --> 01:23:49,758 I HOPE TO PROMOTE IN MY TIME IN 2250 01:23:49,824 --> 01:23:51,393 LEADERSHIP AT NIH. 2251 01:23:51,459 --> 01:23:52,394 I HAVE TWO PRIMARY PRIORITIES 2252 01:23:52,460 --> 01:23:58,299 THAT I HOPE TO PUT IN PLACE AS 2253 01:23:58,366 --> 01:23:59,367 NIH DIRECTOR. 2254 01:23:59,434 --> 01:24:01,469 FIRST IS TO CORRECT RESEARCH TO 2255 01:24:01,536 --> 01:24:02,137 PRIMARY CARE. 2256 01:24:02,203 --> 01:24:04,873 MY HOPE IS WE CAN BETTER MEET 2257 01:24:04,939 --> 01:24:07,041 PEOPLE WHERE THEY ALREADY 2258 01:24:07,108 --> 01:24:10,678 RECEIVE CARE, TO BETTER ENGAGE 2259 01:24:10,745 --> 01:24:11,212 ALL COMMUNITIES INCLUDING 2260 01:24:11,279 --> 01:24:12,113 UNDERREPRESENTED ONES. 2261 01:24:12,180 --> 01:24:17,685 I'LL GO BACK TO MY OWN PERSONAL 2262 01:24:17,752 --> 01:24:18,353 EXPERIENCE. 2263 01:24:18,420 --> 01:24:19,454 PEOPLE IN WYOMING, EVEN AS 2264 01:24:19,521 --> 01:24:22,223 REMOTE AS THE PLACE WE LIVED, 2265 01:24:22,290 --> 01:24:24,159 COULD HAVE ACCESS TO A PRIMARY 2266 01:24:24,225 --> 01:24:24,726 CARE DOCTOR. 2267 01:24:24,793 --> 01:24:26,761 WASN'T ALWAYS EASY BUT THE FIRST 2268 01:24:26,828 --> 01:24:30,665 LINE OF DEFENSE WAS ALWAYS THE 2269 01:24:30,732 --> 01:24:32,200 PRIMARY CARE DOCTOR, SPECIALLY 2270 01:24:32,267 --> 01:24:34,302 CARE WAS EVEN HARDER. 2271 01:24:34,369 --> 01:24:37,238 WE REALLY HAVE TO FOCUS ON THIS 2272 01:24:37,305 --> 01:24:40,141 AT, YOU KNOW, THE FIRST LINE OF 2273 01:24:40,208 --> 01:24:43,745 DEFENSE, THE PRIMARY CARE 2274 01:24:43,812 --> 01:24:44,045 ENVIRONMENT. 2275 01:24:44,112 --> 01:24:45,580 WE NEED TO USE ELECTRONIC HEALTH 2276 01:24:45,647 --> 01:24:47,348 RECORD TO ENGAGE PEOPLE IN 2277 01:24:47,415 --> 01:24:48,416 RESEARCH. 2278 01:24:48,483 --> 01:24:51,352 WE NOW HAVE A TECHNOLOGY THAT IF 2279 01:24:51,419 --> 01:24:56,191 WE USE IT PROPERLY CAN TRULY 2280 01:24:56,257 --> 01:24:57,058 UNITE EVERYONE. 2281 01:24:57,125 --> 01:25:00,728 THE U.S. UTILIZATION NOW OF 2282 01:25:00,795 --> 01:25:03,731 EHRs IS IN EXCESS OF 98%. 2283 01:25:03,798 --> 01:25:06,034 AND SO WE HAVE A TOOL THAT CAN 2284 01:25:06,100 --> 01:25:11,606 BE A POWERFUL FORCE FOR DRIVING 2285 01:25:11,673 --> 01:25:12,907 EVIDENCE-BASED RESEARCH AND 2286 01:25:12,974 --> 01:25:13,374 KNOWLEDGE. 2287 01:25:13,441 --> 01:25:15,743 UNFORTUNATELY WE ARE NOT USING 2288 01:25:15,810 --> 01:25:18,713 IT THE WAY WE NEED TO AT ALL. 2289 01:25:18,780 --> 01:25:20,014 WHO IS GOING TO FIX THIS? 2290 01:25:20,081 --> 01:25:22,317 WELL, IT'S GOING TO BE NIH, IN 2291 01:25:22,383 --> 01:25:23,985 PARTNERSHIP WITH OUR SISTER 2292 01:25:24,052 --> 01:25:25,086 AGENCIES ACROSS HHS, AND THIS IS 2293 01:25:25,153 --> 01:25:28,756 ONE OF THE THINGS I AM 2294 01:25:28,823 --> 01:25:29,958 PARTICULARLY PASSIONATE ABOUT. 2295 01:25:30,024 --> 01:25:32,193 WE WANT TO INCREASE RESEARCH 2296 01:25:32,260 --> 01:25:34,262 CAPABILITIES AND EFFICIENCY WITH 2297 01:25:34,329 --> 01:25:35,930 INNOVATIVE STUDY DESIGNS THAT 2298 01:25:35,997 --> 01:25:38,666 ADDRESS COMMON HEALTH ISSUES, 2299 01:25:38,733 --> 01:25:41,503 CAN REALLY ADDRESS PREVENTION, 2300 01:25:41,569 --> 01:25:42,504 AND IMPLEMENTATION. 2301 01:25:42,570 --> 01:25:46,574 AND YOU ALL KNOW THAT THIS LAST 2302 01:25:46,641 --> 01:25:48,209 MILE RESEARCH CAN BE AMONG THE 2303 01:25:48,276 --> 01:25:51,246 MOST DIFFICULT TO DO, ESPECIALLY 2304 01:25:51,312 --> 01:25:52,714 THE MOST DIFFICULT TO 2305 01:25:52,780 --> 01:25:54,115 DISSEMINATE COMMUNITIES OF NEED. 2306 01:25:54,182 --> 01:25:56,718 FINALLY WE NEED TO RAPIDLY 2307 01:25:56,784 --> 01:25:58,286 DISSEMINATE EVIDENCE TO GUIDE 2308 01:25:58,353 --> 01:26:00,722 PATIENT AND PROVIDER DECISIONS. 2309 01:26:00,788 --> 01:26:01,656 AGAIN, WE HAVE TECHNOLOGY TOOLS 2310 01:26:01,723 --> 01:26:03,791 THAT CAN HELP DO THIS. 2311 01:26:03,858 --> 01:26:06,928 WE'RE NOT YET HARNESSING THEM AS 2312 01:26:06,995 --> 01:26:07,595 WE SHOULD. 2313 01:26:07,662 --> 01:26:09,097 AS I SAID EARLIER WE'RE IN A 2314 01:26:09,163 --> 01:26:12,734 PERIOD OF TIME WE HAVE ENORMOUS 2315 01:26:12,800 --> 01:26:14,769 ABUNDANCE OF DATA. 2316 01:26:14,836 --> 01:26:16,638 AND FEDERAL REGULATIONS NOW 2317 01:26:16,704 --> 01:26:19,073 REQUIRE NIH-FUNDED RESEARCHERS 2318 01:26:19,140 --> 01:26:20,408 TO SHARE THEIR DATA PUBLICLY. 2319 01:26:20,475 --> 01:26:24,078 IN ORDER TO MAKE THE BEST USE OF 2320 01:26:24,145 --> 01:26:28,516 THIS INFLUX OF DATA, I HOPE TO 2321 01:26:28,583 --> 01:26:30,552 MAKE THE NATIONAL LIBRARY OF 2322 01:26:30,618 --> 01:26:33,821 MEDICINE A REVITALIZED HUB FOR 2323 01:26:33,888 --> 01:26:36,591 EXPANDED BIOMEDICAL DATA, 2324 01:26:36,658 --> 01:26:39,961 RESEARCH DATA USE, NOT JUST DATA 2325 01:26:40,028 --> 01:26:43,565 SHARING, NOT JUST DATA STORAGE, 2326 01:26:43,631 --> 01:26:46,868 BUT FOCUS ON DATA USE THAT IS 2327 01:26:46,935 --> 01:26:48,503 ABLE TO INFORM NEW RESEARCH AND 2328 01:26:48,570 --> 01:26:50,271 IMPROVE HEALTH OUTCOMES. 2329 01:26:50,338 --> 01:26:53,007 MANY PEOPLE ASKED ME HOW ARE WE 2330 01:26:53,074 --> 01:26:55,977 GOING TO DEAL WITH THIS DATA 2331 01:26:56,044 --> 01:26:59,047 THAT COMES FROM EVERYWHERE, 2332 01:26:59,113 --> 01:27:00,148 EVERY DIFFERENT DIRECTION. 2333 01:27:00,214 --> 01:27:02,517 OUR FOCUS IS GOING TO BE ON THE 2334 01:27:02,584 --> 01:27:06,354 DATA WE NEED, THE DATA WE ARE 2335 01:27:06,421 --> 01:27:08,222 ACTUALLY USING TO IMPROVE 2336 01:27:08,289 --> 01:27:08,456 HEALTH. 2337 01:27:08,523 --> 01:27:10,291 AND TO GET THE RIGHT DATA IN THE 2338 01:27:10,358 --> 01:27:13,361 HANDS OF THE PEOPLE WHO ARE 2339 01:27:13,428 --> 01:27:14,195 ASKING IMPORTANT QUESTIONS. 2340 01:27:14,262 --> 01:27:15,897 SO MY VISION IS TO INTEGRATE 2341 01:27:15,964 --> 01:27:18,499 DATA FROM BASIC AND SOCIAL 2342 01:27:18,566 --> 01:27:19,767 SCIENCE RESEARCH, PUBLIC HEALTH 2343 01:27:19,834 --> 01:27:23,004 AND CLINICAL CARE, FOCUSED ON 2344 01:27:23,071 --> 01:27:24,305 USERS, NOT JUST MERELY STORAGE, 2345 01:27:24,372 --> 01:27:26,541 INCREASE CAPACITY FOR DATA 2346 01:27:26,608 --> 01:27:28,309 HOSTING, ENABLE LOW COST ACCESS 2347 01:27:28,376 --> 01:27:31,846 TO DATA USING OPEN INDUSTRY DATA 2348 01:27:31,913 --> 01:27:34,048 STANDARDS, SUPPORT BROAD ACCESS 2349 01:27:34,115 --> 01:27:35,717 TO ADVANCED ANALYTICS AND 2350 01:27:35,783 --> 01:27:36,618 COMPUTATIONAL POWER. 2351 01:27:36,684 --> 01:27:39,554 THE STORAGE ISSUE IS A 2352 01:27:39,621 --> 01:27:40,421 CONSIDERABLE ONE. 2353 01:27:40,488 --> 01:27:42,757 THE ONLY WAY TO DO IT, THE MOST 2354 01:27:42,824 --> 01:27:47,195 EFFECTIVE WAY TO DO IT, YET 2355 01:27:47,261 --> 01:27:48,129 PRESERVE THE CREATIVITY AND 2356 01:27:48,196 --> 01:27:49,864 AUTONOMY AND RESPONSIBILITY OF 2357 01:27:49,931 --> 01:27:51,399 INDIVIDUAL RESEARCH TEAMS IS TO 2358 01:27:51,466 --> 01:27:55,236 EMPLOY A FEDERATED ARCHITECTURE 2359 01:27:55,303 --> 01:27:57,805 FOR DATA USE, OUR PLAN. 2360 01:27:57,872 --> 01:27:59,674 FINALLY, WE REALLY NEED TO 2361 01:27:59,741 --> 01:28:01,743 IMPROVE, TO INCREASE OUR 2362 01:28:01,809 --> 01:28:02,276 EDUCATION AND WORKFORCE 2363 01:28:02,343 --> 01:28:05,380 DEVELOPMENT AS A PART OF THIS 2364 01:28:05,446 --> 01:28:05,580 ISSUE. 2365 01:28:05,647 --> 01:28:08,983 DO WE HAVE THE RIGHT PEOPLE WITH 2366 01:28:09,050 --> 01:28:11,953 THE RIGHT KNOWLEDGE WHO KNOW HOW 2367 01:28:12,020 --> 01:28:16,157 TO ENTER AND USE THIS NEW DATA 2368 01:28:16,224 --> 01:28:16,758 ENVIRONMENT? 2369 01:28:16,824 --> 01:28:18,292 SO, I THINK WE'RE GETTING TO THE 2370 01:28:18,359 --> 01:28:20,895 END HERE. 2371 01:28:20,962 --> 01:28:23,898 WHAT I'M PROPOSING ISN'T 2372 01:28:23,965 --> 01:28:24,265 NECESSARILY NEW. 2373 01:28:24,332 --> 01:28:25,933 IN FACT, FOR MORE THAN TEN YEARS 2374 01:28:26,000 --> 01:28:27,135 THE NATIONAL ACADEMY OF SCIENCE 2375 01:28:27,201 --> 01:28:29,570 PUT OUT A REPORT ON THE U.S. 2376 01:28:29,637 --> 01:28:31,105 HEALTH DISADVANTAGE, AND THERE 2377 01:28:31,172 --> 01:28:33,808 ARE TWO PRIMARY RECOMMENDATIONS. 2378 01:28:33,875 --> 01:28:36,744 FOCUSED ON DATA AND IMPROVED 2379 01:28:36,811 --> 01:28:37,278 ANALYTICS. 2380 01:28:37,345 --> 01:28:39,213 THE U.S. HEALTH DISADVANTAGE IS 2381 01:28:39,280 --> 01:28:43,985 ONLY INCREASED IN THE PAST 2382 01:28:44,052 --> 01:28:45,319 DECADE SINCE THIS REPORT CAME 2383 01:28:45,386 --> 01:28:46,387 OUT. 2384 01:28:46,454 --> 01:28:46,654 IT'S TIME. 2385 01:28:46,721 --> 01:28:47,388 NO MORE EXCUSES. 2386 01:28:47,455 --> 01:28:49,457 WE NEED TO PRESS FORWARD TRYING 2387 01:28:49,524 --> 01:28:51,859 TO FIND REAL SOLUTIONS TO THIS 2388 01:28:51,926 --> 01:28:54,462 MASSIVE ISSUE. 2389 01:28:54,529 --> 01:28:56,464 I THINK WITH THAT, I'D LIKE TO 2390 01:28:56,531 --> 01:28:57,565 SAY THANK YOU SO MUCH FOR 2391 01:28:57,632 --> 01:28:59,367 ALLOWING ME TO BE HERE. 2392 01:28:59,434 --> 01:29:02,003 JONI, DO WE HAVE TIME FOR A FEW 2393 01:29:02,070 --> 01:29:02,970 QUESTIONS, I HOPE? 2394 01:29:03,037 --> 01:29:04,238 >> WE SURE DO, ESPECIALLY IF YOU 2395 01:29:04,305 --> 01:29:08,176 HAVE TIME FOR A FEW QUESTIONS. 2396 01:29:08,242 --> 01:29:10,645 >> I'M ALL YOURS. 2397 01:29:10,712 --> 01:29:10,912 >> GREAT. 2398 01:29:10,978 --> 01:29:11,746 MARSHALL, OVER TO YOU. 2399 01:29:11,813 --> 01:29:13,815 >> LOVE THE VISION, FIRST UP. 2400 01:29:13,881 --> 01:29:16,117 I HATE THAT I'M ROTATING OFF 2401 01:29:16,184 --> 01:29:18,853 COUNCIL KNOW BECAUSE IT'S 2402 01:29:18,920 --> 01:29:20,154 GETTING REALLY INTERESTING. 2403 01:29:20,221 --> 01:29:22,123 I'VE WORKED IN MEDICINE FOR 2404 01:29:22,190 --> 01:29:25,893 AROUND 40 YEARS, THAT WORK IN 2405 01:29:25,960 --> 01:29:26,728 THE ELECTRONIC HEALTH RECORD 2406 01:29:26,794 --> 01:29:29,464 SYSTEM, I REALLY WOULD LOVE TO 2407 01:29:29,530 --> 01:29:31,766 SEE THAT FOCUS CHANGE BECAUSE 2408 01:29:31,833 --> 01:29:34,569 IT'S EVOLVED MORE AS A BILLING 2409 01:29:34,635 --> 01:29:36,104 SYSTEM THAN INFORMATION 2410 01:29:36,170 --> 01:29:37,071 COLLECTION SYSTEM WITH ELEMENTS 2411 01:29:37,138 --> 01:29:39,240 THERE, PAUL HARRIS AND I WORKED 2412 01:29:39,307 --> 01:29:42,610 TOGETHER FOR YEARS, THESE ARE 2413 01:29:42,677 --> 01:29:43,478 DISCUSSIONS WE'VE HAD. 2414 01:29:43,544 --> 01:29:44,412 PLEASE TACKLE THIS. 2415 01:29:44,479 --> 01:29:45,813 IF YOU CAN FIND THIS WAYS TO 2416 01:29:45,880 --> 01:29:47,315 TURN THIS INTO A TRUE HEALTH 2417 01:29:47,381 --> 01:29:48,082 DRIVER, IT'S THERE. 2418 01:29:48,149 --> 01:29:53,154 IT'S JUST WE'VE GOT TO USE IT 2419 01:29:53,221 --> 01:29:54,122 PROPERLY. 2420 01:29:54,188 --> 01:29:58,893 AND BASICALLY I'M SAYING GO GET 2421 01:29:58,960 --> 01:29:59,060 IT! 2422 01:29:59,127 --> 01:29:59,527 >> WE WILL. 2423 01:29:59,594 --> 01:30:01,395 >> THANK YOU, MARSHALL. 2424 01:30:01,462 --> 01:30:02,597 >> I'LL SAY, MARSHALL, IF YOU'VE 2425 01:30:02,663 --> 01:30:04,932 BEEN IN THIS SPACE YOU KNOW IT. 2426 01:30:04,999 --> 01:30:06,334 YOU KNOW WHAT'S HOLDING US BACK. 2427 01:30:06,400 --> 01:30:08,002 >> I KNOW EXACTLY WHAT'S HOLDING 2428 01:30:08,069 --> 01:30:08,536 US BACK. 2429 01:30:08,603 --> 01:30:09,971 >> TECHNOLOGY IS NOT THE DATA 2430 01:30:10,037 --> 01:30:10,838 STANDARD. 2431 01:30:10,905 --> 01:30:12,774 IT'S NOT ANYTHING. 2432 01:30:12,840 --> 01:30:15,443 IT'S THE WILLINGNESS TO WORK 2433 01:30:15,510 --> 01:30:16,010 TOGETHER. 2434 01:30:16,077 --> 01:30:18,813 >> MIGHT HAVE WAS WORKING IN 2435 01:30:18,880 --> 01:30:20,148 SENATE, THAT'S WHAT SHE WAS 2436 01:30:20,214 --> 01:30:22,116 DOING, THE RULES, SAYING IT HAS 2437 01:30:22,183 --> 01:30:23,684 TO BE TRANSPORTABLE AND OF 2438 01:30:23,751 --> 01:30:25,453 COURSE IMMEDIATELY LAWSUITS WERE 2439 01:30:25,520 --> 01:30:27,922 FILED TO BLOCK THAT. 2440 01:30:27,989 --> 01:30:29,423 AND IT WILL PROBABLY REQUIRE 2441 01:30:29,490 --> 01:30:31,292 LEGISLATIVE ACTION TO GET IT 2442 01:30:31,359 --> 01:30:31,659 DONE. 2443 01:30:31,726 --> 01:30:32,627 >> WELL, WE'RE WORKING OUT. 2444 01:30:32,693 --> 01:30:35,463 THE OTHER THING I WANT TO SAY 2445 01:30:35,530 --> 01:30:37,665 SINCE I HAVE THE PODIUM, AGAIN, 2446 01:30:37,732 --> 01:30:39,233 IS THAT WE HAVE A TRUST PROBLEM 2447 01:30:39,300 --> 01:30:40,735 IN THE UNITED STATES TOO THAT 2448 01:30:40,802 --> 01:30:42,737 WE'RE VERY, VERY AWARE OF AND 2449 01:30:42,804 --> 01:30:43,070 INTERESTED IN. 2450 01:30:43,137 --> 01:30:47,074 THE LAST THING WE WANT TO BE 2451 01:30:47,141 --> 01:30:48,509 DOING IS -- 2452 01:30:48,576 --> 01:30:58,820 [ NO AUDIO ] 2453 01:31:10,097 --> 01:31:11,365 NO, YOU CAN'T. 2454 01:31:11,432 --> 01:31:15,303 ALSO BE AGE TO SAY YES, YOU CAN 2455 01:31:15,369 --> 01:31:16,737 RECONTACT ME IF THERE'S 2456 01:31:16,804 --> 01:31:18,606 SOMETHING RELEVANT TO ME, HOW 2457 01:31:18,673 --> 01:31:20,675 CRITICAL THAT WOULD BE FOR 2458 01:31:20,741 --> 01:31:22,743 PEOPLE WITH RARE DISORDERS, OH 2459 01:31:22,810 --> 01:31:25,446 MY GOODNESS, IF I WAS A MOM OF A 2460 01:31:25,513 --> 01:31:26,147 LITTLE BOY WITH MUSCULAR 2461 01:31:26,214 --> 01:31:28,449 DYSTROPHY WOULDN'T I WANT TO SAY 2462 01:31:28,516 --> 01:31:29,217 YES, PLEASE, CONTACT ME, IF YOU 2463 01:31:29,283 --> 01:31:29,617 KNOW SOMETHING? 2464 01:31:29,684 --> 01:31:32,620 THERE'S GOING TO BE SO MANY 2465 01:31:32,687 --> 01:31:33,888 PEOPLE OUT THERE JUST REALLY 2466 01:31:33,955 --> 01:31:35,089 DESPERATE FOR US TO BE ABLE TO 2467 01:31:35,156 --> 01:31:38,593 DO THIS FOR THEM. 2468 01:31:38,659 --> 01:31:39,861 WE'RE ALSO GOING TO DO THAT. 2469 01:31:39,927 --> 01:31:42,630 >> I'M OUT OF THE RARE DISEASE 2470 01:31:42,697 --> 01:31:42,830 FIELD. 2471 01:31:42,897 --> 01:31:44,165 WITH REGISTRIES WE SET UP WHEN 2472 01:31:44,232 --> 01:31:50,504 WE PUT IN THAT QUESTION, ARE 2473 01:31:50,571 --> 01:31:56,444 YOU OKAY WITH SHARING DATA, 2474 01:31:56,510 --> 01:31:58,045 WE'RE NORTH OF 90%. 2475 01:31:58,112 --> 01:31:59,914 AS LONG AS PEOPLE CAN OPT OUT IT 2476 01:31:59,981 --> 01:32:01,549 MAKES FOR A GREAT SYSTEM. 2477 01:32:01,616 --> 01:32:03,985 >> THE LAST MILE WE NEED TO GO, 2478 01:32:04,051 --> 01:32:05,820 TRULY AMBITIOUS, BUT WE NEED TO 2479 01:32:05,887 --> 01:32:08,823 DO IT, IS THAT LET'S SAY YOU ARE 2480 01:32:08,890 --> 01:32:11,292 A RARE -- YOU KNOW, ARE YOU 2481 01:32:11,359 --> 01:32:12,760 SOMEBODY WHO SAYS YES, PLEASE, 2482 01:32:12,827 --> 01:32:15,796 I'M GIVING YOU MY DATA, BOY, WE 2483 01:32:15,863 --> 01:32:20,234 HAVE THE ABILITY TO THEN GO BACK 2484 01:32:20,301 --> 01:32:22,103 TO THEM AND SAY, HEY, HERE IS A 2485 01:32:22,169 --> 01:32:23,137 PAPER PUBLISHED THAT INCLUDED 2486 01:32:23,204 --> 01:32:24,005 YOUR DATA. 2487 01:32:24,071 --> 01:32:25,339 THERE'S NO REASON WHY WE CAN'T 2488 01:32:25,406 --> 01:32:26,507 DO THIS. 2489 01:32:26,574 --> 01:32:28,743 WE'RE ALSO WORKING THAT IN SO 2490 01:32:28,809 --> 01:32:30,578 THAT PEOPLE DON'T JUST BLINDLY 2491 01:32:30,645 --> 01:32:31,946 GIVE IT BUT THEY CAN ACTUALLY 2492 01:32:32,013 --> 01:32:34,115 SEE WHAT WE'VE DONE WITH IT. 2493 01:32:34,181 --> 01:32:36,517 I'M EXCITED THAT THE TEAM'S 2494 01:32:36,584 --> 01:32:37,818 BUILDING THAT IN. 2495 01:32:37,885 --> 01:32:39,287 >> YEAH, THAT DASHBOARDING IS 2496 01:32:39,353 --> 01:32:40,021 ALWAYS IMPORTANT. 2497 01:32:40,087 --> 01:32:42,523 >> YEAH. 2498 01:32:42,590 --> 01:32:42,957 OKAY, SORRY. 2499 01:32:43,024 --> 01:32:43,190 THANKS. 2500 01:32:43,257 --> 01:32:44,692 >> THANK YOU. 2501 01:32:44,759 --> 01:32:45,693 >> PAUL SHIREMAN? 2502 01:32:45,760 --> 01:32:47,261 >> LOVED YOUR TALK. 2503 01:32:47,328 --> 01:32:50,231 AS A FELLOW SURGEON, I CAN'T 2504 01:32:50,298 --> 01:32:54,902 AGREE MORE. 2505 01:32:54,969 --> 01:32:56,771 I PRACTICE CLINICALLY, HAVE A 2506 01:32:56,837 --> 01:32:58,706 LOVE AND MOSTLY HATE 2507 01:32:58,773 --> 01:32:59,607 RELATIONSHIP WITH THE ELECTRONIC 2508 01:32:59,674 --> 01:33:01,442 HEALTH RECORD, HOW UNFRIENDLY IT 2509 01:33:01,509 --> 01:33:03,411 IS TO CLINICIANS, WE'VE TAKEN 2510 01:33:03,477 --> 01:33:04,745 THE HIGHEST PAID CLINICIANS AND 2511 01:33:04,812 --> 01:33:07,048 MADE THEM SECRETARIES AND DATA 2512 01:33:07,114 --> 01:33:08,649 ENTRY PEOPLE RATHER THAN HAVING 2513 01:33:08,716 --> 01:33:11,452 THEM FOCUS ON THE PATIENT. 2514 01:33:11,519 --> 01:33:12,386 THE DATA SHARING, THE IMPORTING, 2515 01:33:12,453 --> 01:33:14,956 SO I THINK ONE OF THE CHALLENGES 2516 01:33:15,022 --> 01:33:16,757 ESPECIALLY INTEGRATING AS A 2517 01:33:16,824 --> 01:33:18,726 SURGEON THE PRIMARY CARE AND 2518 01:33:18,793 --> 01:33:20,761 TRYING TO GET THAT WHOLE 2519 01:33:20,828 --> 01:33:23,464 ECOSYSTEM TO WORK IS SOME OF THE 2520 01:33:23,531 --> 01:33:24,732 SIMPLEST THINGS ARE ACTUALLY 2521 01:33:24,799 --> 01:33:26,667 GOING TO BE THE MOST EFFECTIVE. 2522 01:33:26,734 --> 01:33:31,038 I LOVE NIH BUT OF COURSE YOU 2523 01:33:31,105 --> 01:33:32,640 WANT SOMETHING SEXY, COOL, STUDY 2524 01:33:32,707 --> 01:33:37,845 SECTION, THAT'S WHAT THEY WANT. 2525 01:33:37,912 --> 01:33:39,847 HAVING THE SIMPLE THINGS WE 2526 01:33:39,914 --> 01:33:41,849 AREN'T DOING, MEDICATION 2527 01:33:41,916 --> 01:33:42,483 ADHERENCE, MORE EFFECTIVE 2528 01:33:42,550 --> 01:33:44,552 BILLING CODES SO PRIMARY CARE 2529 01:33:44,618 --> 01:33:47,288 DOCS WITH CALL AND MAKE SURE 2530 01:33:47,355 --> 01:33:47,955 PATIENTS ARE TAKING MEDICATIONS, 2531 01:33:48,022 --> 01:33:50,858 USING A.I., THAT'S JUST ONE 2532 01:33:50,925 --> 01:33:51,726 EXAMPLE. 2533 01:33:51,792 --> 01:33:53,027 SO, I REALLY WOULD BE FASCINATED 2534 01:33:53,094 --> 01:33:54,962 ON YOUR THOUGHTS ABOUT HOW WE 2535 01:33:55,029 --> 01:33:58,799 TURN THIS SHIP AND IMPROVE OUR 2536 01:33:58,866 --> 01:33:59,467 DISSEMINATION AND IMPLEMENTATION 2537 01:33:59,533 --> 01:34:02,036 RESEARCH SO WE GET THINGS OUT 2538 01:34:02,103 --> 01:34:03,938 MORE AND AS A GIRL WHO GREW UP 2539 01:34:04,005 --> 01:34:07,141 ON A FARM TOTALLY GET THE WHOLE 2540 01:34:07,208 --> 01:34:09,110 RURAL THING, HAVING TO BE 2541 01:34:09,176 --> 01:34:10,311 PATIENT NAVIGATOR FOR MY RURAL 2542 01:34:10,378 --> 01:34:12,980 FAMILY THAT STILL LIVES IN 2543 01:34:13,047 --> 01:34:14,415 INDIANA. 2544 01:34:14,482 --> 01:34:17,018 >> YEAH, WELL, THAT'S GREAT. 2545 01:34:17,084 --> 01:34:19,220 YEAH, OKAY. 2546 01:34:19,286 --> 01:34:20,955 SO, WE HAVE TWO -- THERE'S TWO 2547 01:34:21,022 --> 01:34:23,824 GROUPS WE'RE HERE TO SERVE. 2548 01:34:23,891 --> 01:34:27,228 WE ARE HERE TO SERVE THE 2549 01:34:27,294 --> 01:34:28,262 PATIENTS IDEALLY, PEOPLE EVEN 2550 01:34:28,329 --> 01:34:29,997 BEFORE THEY ARE PATIENTS, AND 2551 01:34:30,064 --> 01:34:31,665 THE CLINICIANS. 2552 01:34:31,732 --> 01:34:32,767 THE CLINICIANS AND CAREGIVERS. 2553 01:34:32,833 --> 01:34:35,302 AND, YOU KNOW, SOMETIMES 2554 01:34:35,369 --> 01:34:36,470 CAREGIVER IS EVEN FAMILY. 2555 01:34:36,537 --> 01:34:37,905 THOSE ARE THE FRONT LINE PEOPLE 2556 01:34:37,972 --> 01:34:40,307 WE'RE HERE TO SERVE. 2557 01:34:40,374 --> 01:34:42,309 AND ANYTHING WE PRODUCE HAS 2558 01:34:42,376 --> 01:34:43,611 TO -- THAT'S WHERE IT ALL 2559 01:34:43,677 --> 01:34:43,978 HAPPENS. 2560 01:34:44,045 --> 01:34:49,183 IT DOES NOT HAPPEN ANYWHERE ELSE 2561 01:34:49,250 --> 01:34:50,918 BUT AT THAT CLINICIAN/PATIENT 2562 01:34:50,985 --> 01:34:51,552 RELATIONSHIP, WHERE EVERYTHING 2563 01:34:51,619 --> 01:34:52,353 COMES DOWN TO. 2564 01:34:52,420 --> 01:34:56,223 SO EVERYTHING WE DO HAS TO 2565 01:34:56,290 --> 01:34:57,758 ENHANCE THAT AND FACILITATE 2566 01:34:57,825 --> 01:34:57,958 THAT. 2567 01:34:58,025 --> 01:35:00,061 THE OTHER THING I WILL SAY THAT 2568 01:35:00,127 --> 01:35:02,430 NIH IS THE RESEARCH ARM. 2569 01:35:02,496 --> 01:35:03,864 WE TEST WHAT WORKS, FIGURE OUT 2570 01:35:03,931 --> 01:35:07,668 WHAT WORKS AND DOESN'T WORK. 2571 01:35:07,735 --> 01:35:09,537 I'M ALSO THRILLED AT THE 2572 01:35:09,603 --> 01:35:12,573 ENVIRONMENT WE HAVE RIGHT NOW 2573 01:35:12,640 --> 01:35:15,009 ACROSS HHS, I MEET EVERY SINGLE 2574 01:35:15,076 --> 01:35:17,178 WEEK WITH LEADERS IN CMS, CDC, 2575 01:35:17,244 --> 01:35:18,846 FDA, IN FACT I'M TALKING TO TWO 2576 01:35:18,913 --> 01:35:21,449 FDA PEOPLE THIS WEEKEND. 2577 01:35:21,515 --> 01:35:24,318 YOU KNOW, ABOUT HOW DO THESE 2578 01:35:24,385 --> 01:35:26,220 AGENCIES ALSO WORK TOGETHER TO 2579 01:35:26,287 --> 01:35:28,055 DEVELOP DECISION BECAUSE WE CAN 2580 01:35:28,122 --> 01:35:29,457 DO THE RESEARCH BUT WE'RE NOT 2581 01:35:29,523 --> 01:35:29,790 CARE DELIVERY. 2582 01:35:29,857 --> 01:35:31,525 WE'RE NOT THE CARE DELIVERY 2583 01:35:31,592 --> 01:35:31,892 INSTITUTE. 2584 01:35:31,959 --> 01:35:33,494 HOW THAT ALL WORKS TOGETHER IS 2585 01:35:33,561 --> 01:35:35,262 REALLY CRITICAL AND THE 2586 01:35:35,329 --> 01:35:36,931 ENVIRONMENT RIGHT NOW IS VERY 2587 01:35:36,997 --> 01:35:38,199 FAVORABLE FOR THAT. 2588 01:35:38,265 --> 01:35:39,633 IT'S, YOU KNOW, IT COMES AND 2589 01:35:39,700 --> 01:35:40,968 GOES WITH ADMINISTRATIONS. 2590 01:35:41,035 --> 01:35:41,802 THIS IS ANOTHER REASON WHY I 2591 01:35:41,869 --> 01:35:44,138 CONSIDER WHAT WE'RE DOING RIGHT 2592 01:35:44,205 --> 01:35:45,439 NOW TO BE INCREDIBLY URGENT. 2593 01:35:45,506 --> 01:35:46,874 BECAUSE WE'VE GOT THE TEAM RIGHT 2594 01:35:46,941 --> 01:35:48,709 NOW THAT REALLY WANTS TO DO 2595 01:35:48,776 --> 01:35:48,909 THIS. 2596 01:35:48,976 --> 01:35:53,881 SO WE BETTER RUN AS FAST AS WE 2597 01:35:53,948 --> 01:35:54,615 CAN. 2598 01:35:54,682 --> 01:35:56,217 >> GREAT. 2599 01:35:56,283 --> 01:35:57,184 THANK YOU. 2600 01:35:57,251 --> 01:35:59,053 SERGIO? 2601 01:35:59,120 --> 01:36:00,754 >> YES, THANK YOU, JONI. 2602 01:36:00,821 --> 01:36:03,858 I WILL ADD MY WARM WELCOME TO 2603 01:36:03,924 --> 01:36:05,726 YOU, DR. BERTAGNOLLI. 2604 01:36:05,793 --> 01:36:08,362 AND THANK YOU, JONI, FOR MAKING 2605 01:36:08,429 --> 01:36:10,331 THIS HAPPEN. 2606 01:36:10,397 --> 01:36:12,933 MANY THINGS THAT YOU MENTIONED 2607 01:36:13,000 --> 01:36:15,803 ARE MUSIC TO MY EARS. 2608 01:36:15,870 --> 01:36:20,241 AND BECAUSE WHAT IS BEHIND OR 2609 01:36:20,307 --> 01:36:24,111 UNDERLYING THE DATA THAT YOU 2610 01:36:24,178 --> 01:36:28,282 PRESENTED ON -- THAT WE'RE NOT 2611 01:36:28,349 --> 01:36:31,819 DOING WELL IN TERMS OF, YOU 2612 01:36:31,886 --> 01:36:34,555 KNOW, LIFE EXPECTANCY, ARE 2613 01:36:34,622 --> 01:36:37,691 HEALTH INEQUITIES. 2614 01:36:37,758 --> 01:36:40,494 AND I HAVE READ THAT IS ONE OF 2615 01:36:40,561 --> 01:36:42,329 YOUR AREAS OF -- THAT YOU'RE A 2616 01:36:42,396 --> 01:36:44,765 CHAMPION IN THAT, YOU'RE A 2617 01:36:44,832 --> 01:36:47,601 CHAMPION IN ALSO, THE WORK WITH 2618 01:36:47,668 --> 01:36:50,137 UNDERSERVED COMMUNITIES. 2619 01:36:50,204 --> 01:36:51,372 AND I WAS PARTICULARLY DELIGHTED 2620 01:36:51,438 --> 01:36:54,508 IN ONE OF YOUR SLIDES THAT YOU 2621 01:36:54,575 --> 01:36:56,677 PRESENTED ABOUT WHAT NIH COULD 2622 01:36:56,744 --> 01:37:00,748 DO, OR SHOULD DO, THAT YOU 2623 01:37:00,814 --> 01:37:02,850 MENTIONED MEET PEOPLE WHERE THEY 2624 01:37:02,917 --> 01:37:06,854 ALREADY RECEIVE CARE THROUGH 2625 01:37:06,921 --> 01:37:08,589 BETTER ENGAGEMENT, 2626 01:37:08,656 --> 01:37:10,224 UNDERREPRESENTED COMMUNITIES, 2627 01:37:10,291 --> 01:37:11,325 THAT'S ABSOLUTELY MUSIC TO OUR 2628 01:37:11,392 --> 01:37:11,992 EARS. 2629 01:37:12,059 --> 01:37:16,063 YOU KNOW, THAT'S WHERE THINGS 2630 01:37:16,130 --> 01:37:16,897 ARE HAPPENING. 2631 01:37:16,964 --> 01:37:24,138 AND IF YOU ALLOW ME TO PUSH A 2632 01:37:24,205 --> 01:37:25,472 LITTLE BIT FURTHER, THAT 2633 01:37:25,539 --> 01:37:29,810 FOCUSING ON THOSE WHO ARE COMING 2634 01:37:29,877 --> 01:37:32,680 TO RECEIVE SERVICES, IT'S 2635 01:37:32,746 --> 01:37:34,648 IMPORTANT, BUT FOR DECADES WE 2636 01:37:34,715 --> 01:37:37,384 KNOW WHAT ARE THE BARRIERS OF 2637 01:37:37,451 --> 01:37:41,322 ACCESS TO CARE, OF MANY 2638 01:37:41,388 --> 01:37:46,060 POPULATIONS, AND ALSO RELATIVELY 2639 01:37:46,126 --> 01:37:47,962 LACK OF STABILIZATION, I WOULD 2640 01:37:48,028 --> 01:37:49,496 LOVE FOR YOU TO COMMENT, YOU 2641 01:37:49,563 --> 01:37:52,233 KNOW, IF WE CAN PUSH A LITTLE 2642 01:37:52,299 --> 01:37:53,934 BIT FURTHER THAT INSTEAD OF 2643 01:37:54,001 --> 01:37:56,103 BEING ON THE WAITING MODE, YOU 2644 01:37:56,170 --> 01:37:59,673 KNOW, COME TO US, SO WE CAN TAKE 2645 01:37:59,740 --> 01:38:02,209 CARE OF YOU, THAT WE WORK WITH 2646 01:38:02,276 --> 01:38:05,246 SYSTEMS THAT WE GO WHERE PEOPLE 2647 01:38:05,312 --> 01:38:08,082 ARE AT AND OVERCOME THOSE 2648 01:38:08,148 --> 01:38:11,719 BARRIERS OF ACCESS TO CARE, IT 2649 01:38:11,785 --> 01:38:14,021 WOULD BE FANTASTIC AND I THINK 2650 01:38:14,088 --> 01:38:18,325 IT WOULD GET I ANTICIPATE TO 2651 01:38:18,392 --> 01:38:21,562 THOSE TRUNCATED LIFE 2652 01:38:21,629 --> 01:38:24,965 EXPECTANCIES THAT WE SAW SO, YOU 2653 01:38:25,032 --> 01:38:28,469 KNOW, THIS IMPACT DURING THE 2654 01:38:28,535 --> 01:38:28,936 PANDEMIC ESPECIALLY. 2655 01:38:29,003 --> 01:38:31,438 AND ONE LAST COMMENT, I WAS 2656 01:38:31,505 --> 01:38:37,444 DELIGHTED THAT JONI TALKED ABOUT 2657 01:38:37,511 --> 01:38:43,917 YOUR BACKGROUND, ABOUT BEING 2658 01:38:43,984 --> 01:38:47,988 ITALIAN BASQUE. 2659 01:38:48,055 --> 01:38:48,389 I'M DELIGHTED, MY 2660 01:38:48,455 --> 01:38:50,591 [SPEAKING IN A FOREIGN LANGUAGE] 2661 01:38:50,658 --> 01:38:51,692 IS BASQUE IS WELL. 2662 01:38:51,759 --> 01:39:01,068 >> MY MOTHER'S LAST NAME IS 2663 01:39:01,135 --> 01:39:02,469 KATAKOBURO. 2664 01:39:02,536 --> 01:39:07,341 >> CANNOT BE MORE BASQUE. 2665 01:39:07,408 --> 01:39:08,442 >> A QUICK STORY. 2666 01:39:08,509 --> 01:39:10,511 I'VE BEEN SO FORTUNATE TO HAVE 2667 01:39:10,577 --> 01:39:12,012 WORKED WITH SOME AMAZING PEOPLE. 2668 01:39:12,079 --> 01:39:16,216 SO, I HAVE A VERY GOOD FRIEND, 2669 01:39:16,283 --> 01:39:18,185 ONE FRIEND WHO HER NAME IS 2670 01:39:18,252 --> 01:39:19,953 PEGGY, SHE'S A SURGEON, WORKS IN 2671 01:39:20,020 --> 01:39:21,889 QUEENS, NEW YORK. 2672 01:39:21,955 --> 01:39:24,425 SHE'S THE DIRECTOR OF THE QUEENS 2673 01:39:24,491 --> 01:39:24,758 CANCER CENTER. 2674 01:39:24,825 --> 01:39:29,330 DO YOU KNOW WHAT PEGGY DID? 2675 01:39:29,396 --> 01:39:30,764 PEGGY-- QUEENS IS CRAZY, YOU 2676 01:39:30,831 --> 01:39:33,200 KNOW, THREE-QUARTERS OF PATIENTS 2677 01:39:33,267 --> 01:39:37,638 ARE ON MEDICAID, IT'S NEW YORK. 2678 01:39:37,705 --> 01:39:39,740 SO GET MEDICAID OR SIGNED UP, 2679 01:39:39,807 --> 01:39:43,477 THEY DON'T HAVE INSURANCE, MANY 2680 01:39:43,544 --> 01:39:44,845 ARE BRAND-NEW IMMIGRANTS, MANY, 2681 01:39:44,912 --> 01:39:48,749 YOU KNOW, WHAT DID PEGGY DO? 2682 01:39:48,816 --> 01:39:51,518 IN HER CLINIC THERE'S A FOOD 2683 01:39:51,585 --> 01:39:51,752 PANTRY. 2684 01:39:51,819 --> 01:39:54,521 IN HER CLINIC THERE'S ALSO A DAY 2685 01:39:54,588 --> 01:39:54,888 CARE. 2686 01:39:54,955 --> 01:39:56,323 BECAUSE THE MOTHER WHO NEEDS TO 2687 01:39:56,390 --> 01:39:58,025 COME IN TO HAVE HER CHEMOTHERAPY 2688 01:39:58,092 --> 01:40:00,327 DOESN'T HAVE ANYONE TO WATCH THE 2689 01:40:00,394 --> 01:40:01,962 CHILDREN. 2690 01:40:02,029 --> 01:40:04,264 YOU KNOW, SO PEGGY HAS ALWAYS 2691 01:40:04,331 --> 01:40:05,699 TAKEN THE APPROACH, AND SHE USED 2692 01:40:05,766 --> 01:40:08,202 TO TELL ME, IT'S A BEAUTIFUL 2693 01:40:08,268 --> 01:40:10,571 EXPRESSION, WHAT IF YOUR BIGGEST 2694 01:40:10,637 --> 01:40:12,773 PROBLEM IS NOT THAT YOU HAVE 2695 01:40:12,840 --> 01:40:15,442 CANCER, YOU HAVE BIGGER PROBLEMS 2696 01:40:15,509 --> 01:40:15,876 THAN THAT? 2697 01:40:15,943 --> 01:40:17,644 YOU KNOW. 2698 01:40:17,711 --> 01:40:19,146 IT'S JUST -- THESE KINDS OF 2699 01:40:19,213 --> 01:40:20,714 SOLUTIONS, THESE KINDS OF 2700 01:40:20,781 --> 01:40:23,083 THINKING ABOUT WHAT YOUR 2701 01:40:23,150 --> 01:40:23,584 COMMUNITY NEEDS, ARE SO 2702 01:40:23,650 --> 01:40:26,253 BEAUTIFUL AND, YOU KNOW, YOU 2703 01:40:26,320 --> 01:40:27,688 CAN'T MAKE ONE SIZE THAT'S GOING 2704 01:40:27,755 --> 01:40:29,356 TO FIT EVERYTHING EITHER. 2705 01:40:29,423 --> 01:40:31,325 THEY HAVE TO BE DONE CLINIC BY 2706 01:40:31,392 --> 01:40:32,426 CLINIC BY CLINIC. 2707 01:40:32,493 --> 01:40:34,027 WE CAN GIVE A LOT OF GREAT 2708 01:40:34,094 --> 01:40:34,428 EXAMPLES. 2709 01:40:34,495 --> 01:40:37,531 THANK YOU SO MUCH FOR YOUR 2710 01:40:37,598 --> 01:40:37,798 COMMENTS. 2711 01:40:37,865 --> 01:40:38,132 >> THANK YOU. 2712 01:40:38,198 --> 01:40:39,433 >> THANK YOU. 2713 01:40:39,500 --> 01:40:41,435 WE HAVE MATTIAS AND PAUL AND 2714 01:40:41,502 --> 01:40:43,937 WE'LL PAUSE FOR A MOMENT. 2715 01:40:44,004 --> 01:40:44,304 MATTIAS, PLEASE. 2716 01:40:44,371 --> 01:40:45,739 >> THANKS, MONICA, FOR MAKING 2717 01:40:45,806 --> 01:40:46,940 TIME TODAY. 2718 01:40:47,007 --> 01:40:50,244 YES, VERY EXCITING TO SEE YOU. 2719 01:40:50,310 --> 01:40:53,080 I CANNOT SHARE MORE, I'M SIGNING 2720 01:40:53,147 --> 01:40:57,918 OFF COUNCIL AS WELL, THE LAST 2721 01:40:57,985 --> 01:41:00,087 COUPLE YEARS, THIS IS BREAKING 2722 01:41:00,154 --> 01:41:02,222 OUR SYSTEM AND WE HAVE 2723 01:41:02,289 --> 01:41:05,492 INFLUENCED MANY PEOPLE, 2724 01:41:05,559 --> 01:41:07,661 INCLUDING MY OWN CLINIC. 2725 01:41:07,728 --> 01:41:10,097 ALSO FASCINATING, MARSHALL 2726 01:41:10,164 --> 01:41:11,498 ALREADY INDICATED THAT IN THE 2727 01:41:11,565 --> 01:41:14,668 RARE DISEASE SPACE WHERE WE TURN 2728 01:41:14,735 --> 01:41:17,070 THINGS UPSIDE DOWN IN NCATS FOR 2729 01:41:17,137 --> 01:41:23,644 THE LAST 25 YEARS, WE LET 2730 01:41:23,710 --> 01:41:25,946 PATIENTS TRY WHAT WE DO, YOU'LL 2731 01:41:26,013 --> 01:41:26,980 TURN THINGS AROUND IMMEDIATELY. 2732 01:41:27,047 --> 01:41:28,282 IF PATIENTS CAN TELL US WHAT WE 2733 01:41:28,348 --> 01:41:32,953 DO, HOW WE DO IT, AND ARE PART 2734 01:41:33,020 --> 01:41:35,289 OF OUR LEADERSHIP TEAM 2735 01:41:35,355 --> 01:41:36,023 THROUGHOUT THE PROCESS, THE 2736 01:41:36,089 --> 01:41:38,492 ISSUE GOES AWAY AND INVERSES, 2737 01:41:38,559 --> 01:41:40,327 OUR PATIENTS ARE TALKING TO THE 2738 01:41:40,394 --> 01:41:41,695 STAKEHOLDERS AND MAKE SURE THAT 2739 01:41:41,762 --> 01:41:44,231 WHAT WE DO IS UNDERSTOOD AND 2740 01:41:44,298 --> 01:41:46,667 TAKEN UP. 2741 01:41:46,733 --> 01:41:48,836 AND THE CHALLENGE WILL BE TO 2742 01:41:48,902 --> 01:41:50,237 BRING THAT SOCIETY SEGMENTS 2743 01:41:50,304 --> 01:41:52,606 WE'RE NOT REACHING WELL BUT AS 2744 01:41:52,673 --> 01:41:53,640 STATED, IT'S EXCITING TO SEE IN 2745 01:41:53,707 --> 01:41:57,578 ALL OF US WE'RE DOING IT ALREADY 2746 01:41:57,644 --> 01:42:00,447 HERE, THIS LITTLE THING, TAKE 2747 01:42:00,514 --> 01:42:05,853 THE PATIENTS IN CHARGE, YES, OUR 2748 01:42:05,919 --> 01:42:06,587 HEALTHCARE SYSTEMS CMOs MAY 2749 01:42:06,653 --> 01:42:08,355 NOT LIKE IT BUT I'LL SEND MY 2750 01:42:08,422 --> 01:42:11,625 DATA WHERE I WANT MY DATA SEEN 2751 01:42:11,692 --> 01:42:12,626 AND VICE VERSA, SCIENTISTS CAN 2752 01:42:12,693 --> 01:42:16,463 REACH PATIENTS WHERE THEY ARE. 2753 01:42:16,530 --> 01:42:18,999 SO BUILD THAT IN, AND I'M A 2754 01:42:19,066 --> 01:42:21,268 NEPHROLOGIST AT MICHIGAN, THE 2755 01:42:21,335 --> 01:42:26,673 KIDNEY POSITION, RARE TO COMMON 2756 01:42:26,740 --> 01:42:28,408 DISEASE, OUR PATIENTS DONATING 2757 01:42:28,475 --> 01:42:29,309 RISKS TO RESEARCH UNPRECEDENTED. 2758 01:42:29,376 --> 01:42:30,911 WE HAVE GOOD PEOPLE IN THIS 2759 01:42:30,978 --> 01:42:32,546 COUNTRY IF WE MEET THEM WHERE 2760 01:42:32,613 --> 01:42:34,548 THEY ARE AND BUILD A COMMUNITY 2761 01:42:34,615 --> 01:42:36,617 CONSENSUS THAT WE CAN MAKE A 2762 01:42:36,683 --> 01:42:36,984 DIFFERENCE. 2763 01:42:37,050 --> 01:42:39,119 SO YES, FOCUS ON THE TRUST 2764 01:42:39,186 --> 01:42:42,222 ISSUE, LET'S EMPOWER OUR 2765 01:42:42,289 --> 01:42:44,224 PATIENTS IN SCIENCE TOGETHER AND 2766 01:42:44,291 --> 01:42:45,926 HOPEFULLY GET ACROSS A HURDLE 2767 01:42:45,993 --> 01:42:47,928 WHICH IS A HUGE CHALLENGE AND 2768 01:42:47,995 --> 01:42:52,599 ONLY OUR PATIENTS CAN SOLVE THAT 2769 01:42:52,666 --> 01:42:52,833 WITH US. 2770 01:42:52,900 --> 01:42:55,102 >> WELL, I'M SURE BASED ON THIS 2771 01:42:55,168 --> 01:42:57,037 APPROACH YOUR PATIENTS ARE VERY 2772 01:42:57,104 --> 01:42:58,305 FORTUNATE, THEIR OUTCOMES ARE 2773 01:42:58,372 --> 01:42:59,072 VERY MUCH MORE SUCCESSFUL 2774 01:42:59,139 --> 01:43:00,741 BECAUSE OF THE WAY YOU HAVE 2775 01:43:00,807 --> 01:43:02,142 APPROACHED THEM. 2776 01:43:02,209 --> 01:43:04,411 SO CONGRATULATIONS. 2777 01:43:04,478 --> 01:43:07,080 THAT REALLY IS WHAT PAYS OFF FOR 2778 01:43:07,147 --> 01:43:07,848 THEM. 2779 01:43:07,915 --> 01:43:10,784 >> THANK YOU VERY MUCH FOR YOUR 2780 01:43:10,851 --> 01:43:11,351 COMMENTS, PAUL? 2781 01:43:11,418 --> 01:43:12,686 >> YES, THANK YOU SO MUCH FOR 2782 01:43:12,753 --> 01:43:15,088 SHARING YOUR VISION. 2783 01:43:15,155 --> 01:43:16,757 IT'S VERY EXCITING. 2784 01:43:16,823 --> 01:43:18,492 ECHO THE PRAISE FROM EVERYONE 2785 01:43:18,559 --> 01:43:18,692 ELSE. 2786 01:43:18,759 --> 01:43:20,694 I LOVED THE FOCUS ON TRUST. 2787 01:43:20,761 --> 01:43:22,529 THAT'S SUCH A PROBLEM THAT WE 2788 01:43:22,596 --> 01:43:24,698 HAVE IN OUR SOCIETY RIGHT NOW. 2789 01:43:24,765 --> 01:43:26,233 REALLY APPRECIATE THAT YOU'RE 2790 01:43:26,300 --> 01:43:26,867 FOCUSING THERE. 2791 01:43:26,934 --> 01:43:29,870 ONE OF THE AREAS THAT YOU 2792 01:43:29,937 --> 01:43:31,939 MENTIONED, YOU KNOW, FOCUSED ON 2793 01:43:32,005 --> 01:43:34,007 RETURN OF VALUE TO THE 2794 01:43:34,074 --> 01:43:35,108 POPULATION RESEARCH 2795 01:43:35,175 --> 01:43:36,310 PARTICIPANTS, THAT'S A HUGE 2796 01:43:36,376 --> 01:43:36,677 DEAL. 2797 01:43:36,743 --> 01:43:38,145 PARTICULARLY IF WE START 2798 01:43:38,211 --> 01:43:39,813 THINKING ABOUT THE FACT THAT 2799 01:43:39,880 --> 01:43:41,014 DIVERSE COMMUNITIES HAVE DIVERSE 2800 01:43:41,081 --> 01:43:42,349 OPINIONS ON WHAT'S VALUABLE TO 2801 01:43:42,416 --> 01:43:42,583 THEM. 2802 01:43:42,649 --> 01:43:44,751 SO I THINK THAT'S A GREAT AREA 2803 01:43:44,818 --> 01:43:46,520 TO FOCUS ON. 2804 01:43:46,587 --> 01:43:49,222 AND ANOTHER THING THAT I'M 2805 01:43:49,289 --> 01:43:51,625 CURIOUS, YOUR THOUGHTS ON, WOULD 2806 01:43:51,692 --> 01:43:53,994 BE BUILDING TRUST IN THESE -- 2807 01:43:54,061 --> 01:43:55,228 TRUST THROUGH MAKING ACCESSIBLE 2808 01:43:55,295 --> 01:43:56,797 SOME OF THESE DATA SOURCES THAT 2809 01:43:56,863 --> 01:43:57,764 YOU'RE MENTIONING, AND THAT YOU 2810 01:43:57,831 --> 01:43:59,333 WANT TO BUILD. 2811 01:43:59,399 --> 01:44:01,935 MAKING THAT DATA AVAILABLE IN A 2812 01:44:02,002 --> 01:44:04,338 VERY SAFE WAY, TO EDUCATORS, AND 2813 01:44:04,404 --> 01:44:04,605 STUDENTS. 2814 01:44:04,671 --> 01:44:08,308 YOU KNOW, AT ALL LEVELS OF 2815 01:44:08,375 --> 01:44:11,211 EDUCATION, USING SORT OF REAL 2816 01:44:11,278 --> 01:44:12,546 WORLD INFORMATION AROUND 2817 01:44:12,613 --> 01:44:13,313 REAL-WORLD PROBLEMS, HEALTH 2818 01:44:13,380 --> 01:44:15,315 PROBLEMS THAT PEOPLE HAVE TO 2819 01:44:15,382 --> 01:44:17,317 SORT OF TEACH AT THAT LEVEL AND 2820 01:44:17,384 --> 01:44:19,019 GAIN AN APPRECIATION FOR DATA 2821 01:44:19,086 --> 01:44:19,886 AND DATA METHODS. 2822 01:44:19,953 --> 01:44:22,289 CAN YOU SAY A LITTLE BIT MORE 2823 01:44:22,356 --> 01:44:27,661 ABOUT YOUR THOUGHTS ON USING 2824 01:44:27,728 --> 01:44:28,295 THIS FOR EDUCATION PURPOSES? 2825 01:44:28,362 --> 01:44:30,397 >> OH, CERTAINLY. 2826 01:44:30,464 --> 01:44:31,198 WELL, SO NATIONAL LIBRARY OF 2827 01:44:31,264 --> 01:44:32,733 MEDICINE, YOU KNOW, WE HAVE THIS 2828 01:44:32,799 --> 01:44:35,302 ENTITY THAT WE CAN USE AS A REAL 2829 01:44:35,369 --> 01:44:37,938 HOME FOR MANY OF THESE 2830 01:44:38,005 --> 01:44:38,238 INITIATIVES. 2831 01:44:38,305 --> 01:44:41,642 ONE OF ITS MAIN FOCUSES IS GOING 2832 01:44:41,708 --> 01:44:43,010 TO BE EDUCATION, ACCESS, BEING 2833 01:44:43,076 --> 01:44:44,745 ABLE TO PUT THE TOOLS IN THE 2834 01:44:44,811 --> 01:44:47,147 HANDS OF PEOPLE WHO CAN ACTUALLY 2835 01:44:47,214 --> 01:44:47,414 USE THEM. 2836 01:44:47,481 --> 01:44:50,117 LET ME GO THE OTHER MILE AND 2837 01:44:50,183 --> 01:44:53,587 TALK ABOUT THE EDUCATION AND THE 2838 01:44:53,654 --> 01:44:54,488 DOCTOR/PATIENT RELATIONSHIP AND 2839 01:44:54,554 --> 01:44:56,390 HOW THAT CAN BE INCREDIBLY 2840 01:44:56,456 --> 01:44:57,891 HELPFUL SINCE WE'RE TALKING 2841 01:44:57,958 --> 01:44:59,693 ABOUT TRUST. 2842 01:44:59,760 --> 01:45:00,627 WOULDN'T IT BE AMAZING AND THIS 2843 01:45:00,694 --> 01:45:02,462 IS PART OF WHAT WE'RE TRYING TO 2844 01:45:02,529 --> 01:45:03,163 BUILD. 2845 01:45:03,230 --> 01:45:05,098 WOULDN'T IT BE AMAZING IF YOU 2846 01:45:05,165 --> 01:45:10,570 HAD YOUR PATIENTS COME IN AND 2847 01:45:10,637 --> 01:45:13,206 SAY, HERE'S MY DATA, AND THEN 2848 01:45:13,273 --> 01:45:15,075 YOU, AT YOUR COMPUTER, THE NEXT 2849 01:45:15,142 --> 01:45:18,578 TIME YOU SIT DOWN WITH YOUR 2850 01:45:18,645 --> 01:45:20,013 PATIENT, CAN SAY, HERE'S THE 2851 01:45:20,080 --> 01:45:23,450 DATA COLLECTION WHERE YOUR DATA 2852 01:45:23,517 --> 01:45:25,686 IS LIVING, AND HERE IS THE 2853 01:45:25,752 --> 01:45:27,120 RESULTS THAT WE'RE SEEING OUT OF 2854 01:45:27,187 --> 01:45:27,354 IT. 2855 01:45:27,421 --> 01:45:30,691 YOU KNOW, YOU CAN DO THAT ONE ON 2856 01:45:30,757 --> 01:45:32,826 ONE WITH THEM, AND THIS IS A 2857 01:45:32,893 --> 01:45:34,561 LEARNING THAT WE'RE GETTING, YOU 2858 01:45:34,628 --> 01:45:35,696 KNOW, AT THE TIME AND 2859 01:45:35,762 --> 01:45:36,663 CONVERSATIONS ABOUT WHAT THE 2860 01:45:36,730 --> 01:45:37,464 DISEASE MEANS, WHAT'S THE 2861 01:45:37,531 --> 01:45:41,368 QUESTION, WHAT ARE WE TRYING TO 2862 01:45:41,435 --> 01:45:43,870 CONQUER, YOU KNOW, THIS -- NOT 2863 01:45:43,937 --> 01:45:44,971 ONLY -- WE THINK ABOUT THIS NOT 2864 01:45:45,038 --> 01:45:46,406 ONLY IN TRYING TO DEVELOP A 2865 01:45:46,473 --> 01:45:48,842 RELATIONSHIP WITH THE PATIENTS 2866 01:45:48,909 --> 01:45:52,279 BUT ALSO TRYING TO ENABLE AND 2867 01:45:52,345 --> 01:45:53,280 PROMOTE THE RELATIONSHIP BETWEEN 2868 01:45:53,346 --> 01:45:55,382 THE CLINICIAN AND THE PATIENT 2869 01:45:55,449 --> 01:45:57,684 THEMSELVES AS BEING ABLE TO 2870 01:45:57,751 --> 01:46:00,754 LEARN TOGETHER FROM THIS. 2871 01:46:00,821 --> 01:46:01,722 >> RIGHT. 2872 01:46:01,788 --> 01:46:02,622 THANK YOU. 2873 01:46:02,689 --> 01:46:04,591 >> IF I MIGHT ADD TOO, PAUL, 2874 01:46:04,658 --> 01:46:07,761 WHILE WE'RE ON THIS TOPIC I'M 2875 01:46:07,828 --> 01:46:10,063 REALLY GLAD YOU BROUGHT UP THIS 2876 01:46:10,130 --> 01:46:11,698 IDEA OF EDUCATION BECAUSE WHEN 2877 01:46:11,765 --> 01:46:12,466 WE'RE TALKING ABOUT THE 2878 01:46:12,532 --> 01:46:14,868 COMPLEXITY OF THE DATA THAT 2879 01:46:14,935 --> 01:46:17,571 WE'RE TALKING ABOUT, IT'S HUGE. 2880 01:46:17,637 --> 01:46:19,940 AND I THINK WE'RE STILL LEARNING 2881 01:46:20,006 --> 01:46:25,278 HOW TO HANDLE IT, HOW TO COLLECT 2882 01:46:25,345 --> 01:46:25,579 IT. 2883 01:46:25,645 --> 01:46:27,981 AND FOR -- IN MY PRESENTATION I 2884 01:46:28,048 --> 01:46:31,918 TALKED ABOUT THE NEW TENANT 2885 01:46:31,985 --> 01:46:33,954 MODELS THAT WE'RE PROPOSING, AND 2886 01:46:34,020 --> 01:46:35,222 DOING FEASIBILITY STUDIES, 2887 01:46:35,288 --> 01:46:35,889 PILOTING THEM. 2888 01:46:35,956 --> 01:46:39,493 ONE OF THOSE IS EXACTLY ON AN 2889 01:46:39,559 --> 01:46:41,895 EDUCATION TENANT. 2890 01:46:41,962 --> 01:46:46,166 AND IT'S PARTICULARLY TO TRY TO 2891 01:46:46,233 --> 01:46:49,002 ENCOURAGE, YOU KNOW, NEW TO DATA 2892 01:46:49,069 --> 01:46:50,637 SCIENCE PEOPLE, ALSO PEOPLE WHO 2893 01:46:50,704 --> 01:46:53,507 HAVE BEEN IN MEDICAL SCIENCE 2894 01:46:53,573 --> 01:46:54,808 THEIR ENTIRE LIVES BUT HAVEN'T 2895 01:46:54,875 --> 01:46:57,444 DONE A LOT IN DATA SCIENCE, AND 2896 01:46:57,511 --> 01:46:58,845 ALSO THE POWER USERS. 2897 01:46:58,912 --> 01:47:01,214 WE WANT TO REALLY CROSS THE 2898 01:47:01,281 --> 01:47:01,615 GAMUT THERE. 2899 01:47:01,681 --> 01:47:02,983 BUT THAT'S REALLY THE ONLY WAY 2900 01:47:03,049 --> 01:47:05,786 WE'RE GOING TO LEARN ABOUT 2901 01:47:05,852 --> 01:47:07,721 WHAT'S NEEDED FOR THEN MAKING 2902 01:47:07,788 --> 01:47:11,224 THOSE DATA AS USABLE AS POSSIBLE 2903 01:47:11,291 --> 01:47:12,793 FOR THE PEOPLE WHO WANT TO USE 2904 01:47:12,859 --> 01:47:13,193 THOSE QUESTIONS. 2905 01:47:13,260 --> 01:47:17,330 >> THIS IS REALLY GOOD. 2906 01:47:17,397 --> 01:47:20,500 WE'VE SEEN A MICROCOSM WITH THE 2907 01:47:20,567 --> 01:47:24,204 CCDI, IT'S IN ITS FIFTH YEAR OF 2908 01:47:24,271 --> 01:47:25,505 OPERATIONS, CONGRESSIONALLY 2909 01:47:25,572 --> 01:47:25,772 MANDATED. 2910 01:47:25,839 --> 01:47:27,174 EVERY CHILD WITH CANCER IN THE 2911 01:47:27,240 --> 01:47:30,877 UNITED STATES, THE DATA ARE 2912 01:47:30,944 --> 01:47:33,180 SHARED, SHARED AND THERE'S A 2913 01:47:33,246 --> 01:47:34,381 USER COMMUNITY BUILT AROUND IT. 2914 01:47:34,447 --> 01:47:36,283 AND, YOU KNOW, ALL OF THESE DATA 2915 01:47:36,349 --> 01:47:37,317 ARE AVAILABLE. 2916 01:47:37,384 --> 01:47:38,218 THERE'S LEARNING. 2917 01:47:38,285 --> 01:47:39,386 WHAT THEY FOUND IN THE FIRST 2918 01:47:39,452 --> 01:47:42,389 FOUR YEARS, FIRST OF ALL IT'S 2919 01:47:42,455 --> 01:47:44,124 BEEN PHENOMENALLY SUCCESSFUL. 2920 01:47:44,191 --> 01:47:45,458 EVERYBODY IS CONTRIBUTING. 2921 01:47:45,525 --> 01:47:48,195 IT'S NOT JUST DATA SHARING 2922 01:47:48,261 --> 01:47:48,762 EXERCISE. 2923 01:47:48,829 --> 01:47:50,831 IT'S NOW AN ENTIRE RESEARCH 2924 01:47:50,897 --> 01:47:51,898 DEVELOPMENT TEAM, ALL WORKING 2925 01:47:51,965 --> 01:47:52,265 TOGETHER. 2926 01:47:52,332 --> 01:47:57,637 IT'S NOW LINKED TO A MOLECULAR 2927 01:47:57,704 --> 01:47:59,172 CHARACTERIZATION PROTOCOL, BENCH 2928 01:47:59,239 --> 01:48:00,740 WORK COMING IN INCLUDED IN 2929 01:48:00,807 --> 01:48:05,045 CLINICAL WORK BUT ONE OF THE 2930 01:48:05,111 --> 01:48:05,645 FIRST THINGS WE REALIZED LAST 2931 01:48:05,712 --> 01:48:10,884 YEAR AT THIS TIME IT'S ONLY 2932 01:48:10,951 --> 01:48:13,820 BEING ACCESSED BY POWER USERS. 2933 01:48:13,887 --> 01:48:19,626 THAT'S NOT GOOD. 2934 01:48:19,693 --> 01:48:21,394 CCDI SPAWNED A PROGRAM TO 2935 01:48:21,461 --> 01:48:22,929 FACILITATE, DONE WITHIN THIS 2936 01:48:22,996 --> 01:48:24,764 COMMUNITY THAT WAS ALREADY USING 2937 01:48:24,831 --> 01:48:26,733 THE DATA SO INSTEAD OF JUST, YOU 2938 01:48:26,800 --> 01:48:29,669 KNOW, KIND OF ARTIFICIALLY 2939 01:48:29,736 --> 01:48:31,204 GIVING PEOPLE ACCESS IT WAS 2940 01:48:31,271 --> 01:48:32,339 SAYING WHAT'S YOUR QUESTION AND 2941 01:48:32,405 --> 01:48:35,942 ACTUALLY HELPING THEM GET INTO 2942 01:48:36,009 --> 01:48:39,246 THE QUESTION AND ANSWER -- YOU 2943 01:48:39,312 --> 01:48:39,980 KNOW, START ENGAGING THEIR 2944 01:48:40,046 --> 01:48:41,648 RESEARCH SO WE COULD SEE MUCH 2945 01:48:41,715 --> 01:48:43,383 MORE OF THIS HAPPENING. 2946 01:48:43,450 --> 01:48:44,251 >> RIGHT. 2947 01:48:44,317 --> 01:48:44,751 THAT SOUNDS WONDERFUL. 2948 01:48:44,818 --> 01:48:47,320 I THINK THE MORE WE CAN GET SOME 2949 01:48:47,387 --> 01:48:49,623 OF THE DATA, THE DATA METHODS 2950 01:48:49,689 --> 01:48:54,461 INTO DIDACTIC COURSES THE 2951 01:48:54,527 --> 01:48:56,263 EARLIER IN THE EDUCATION 2952 01:48:56,329 --> 01:48:58,865 PROCESS, THE BETTER. 2953 01:48:58,932 --> 01:48:59,199 >> THANK YOU. 2954 01:48:59,266 --> 01:49:01,101 >> JONI, THANK YOU SO MUCH FOR 2955 01:49:01,167 --> 01:49:01,534 INVITING ME. 2956 01:49:01,601 --> 01:49:02,669 THIS HAS BEEN WONDERFUL. 2957 01:49:02,736 --> 01:49:05,305 AND LET ME JUST ALSO THANK YOU 2958 01:49:05,372 --> 01:49:08,041 AGAIN SO SINCERELY FOR YOUR 2959 01:49:08,108 --> 01:49:10,977 SERVICE ON THIS COUNCIL. 2960 01:49:11,044 --> 01:49:13,046 THESE ARE ABSOLUTELY CRITICAL TO 2961 01:49:13,113 --> 01:49:16,750 WHAT WE DO, AND BELIEVE ME, ALL 2962 01:49:16,816 --> 01:49:18,285 OF THESE RESULTS OF THESE 2963 01:49:18,351 --> 01:49:19,486 COUNCIL MEETINGS CRAFT WHAT WE 2964 01:49:19,552 --> 01:49:24,224 DO EVERYWHERE AT NIH SO WE'RE 2965 01:49:24,291 --> 01:49:24,891 GRATEFUL FOR YOUR INPUT. 2966 01:49:24,958 --> 01:49:28,762 >> THANK YOU SO MUCH, MONICA. 2967 01:49:28,828 --> 01:49:29,796 WE'LL SEE YOU LATER. 2968 01:49:29,863 --> 01:49:37,003 >> BYE-BYE. 2969 01:49:37,070 --> 01:49:40,974 >> ALL RIGHT. 2970 01:49:41,041 --> 01:49:41,741 LET'S SEE. 2971 01:49:41,808 --> 01:49:43,710 SOUNDS LIKE A GREAT WAY TO SORT 2972 01:49:43,777 --> 01:49:47,814 OF END THE FIRST PART OF OUR 2973 01:49:47,881 --> 01:49:48,214 COUNCIL AFTERNOON. 2974 01:49:48,281 --> 01:49:50,283 I'D LIKE TO OPEN FOR ANY 2975 01:49:50,350 --> 01:49:52,719 QUESTIONS PERHAPS THAT WE DIDN'T 2976 01:49:52,786 --> 01:49:55,188 GET TO BEFORE, SO WE CAN 2977 01:49:55,255 --> 01:49:56,156 ACCOMMODATE MONICA. 2978 01:49:56,222 --> 01:49:57,757 OR IF YOU'D LIKE TO TAKE A BREAK 2979 01:49:57,824 --> 01:49:58,692 AND COME BACK WITH QUESTIONS 2980 01:49:58,758 --> 01:50:00,160 BEFORE WE GET STARTED ON THE 2981 01:50:00,226 --> 01:50:01,995 NEXT PART THAT'S FINE TOO. 2982 01:50:02,062 --> 01:50:03,463 THAT'S YOUR -- SHALL WE TAKE A 2983 01:50:03,530 --> 01:50:05,065 FEW QUESTIONS IF THERE ARE ANY 2984 01:50:05,131 --> 01:50:07,434 NOW AND MAYBE TAKE A BREAK AT 2985 01:50:07,500 --> 01:50:07,867 2:30? 2986 01:50:07,934 --> 01:50:10,904 OR ARE YOU READY FOR A BREAK? 2987 01:50:10,971 --> 01:50:12,539 I DON'T SEE ANY HANDS UP. 2988 01:50:12,605 --> 01:50:13,506 >> LET'S HAVE A BREAK. 2989 01:50:13,573 --> 01:50:15,542 >> LET'S HAVE A BREAK, ALL 2990 01:50:15,608 --> 01:50:15,742 RIGHT. 2991 01:50:15,809 --> 01:50:17,610 THANK YOU, SERGIO. 2992 01:50:17,677 --> 01:50:21,014 I LIKE THE DECISIVENESS. 2993 01:50:21,081 --> 01:50:23,049 LET'S HAVE A BREAK ANDS WE'LL 2994 01:50:23,116 --> 01:50:29,522 COME BACK AT, GOSH, REMIND ME, 2995 01:50:29,589 --> 01:50:32,759 GREG, WHEN ARE WE COMING BACK? 2996 01:50:32,826 --> 01:50:33,026 >> 2:35. 2997 01:50:33,093 --> 01:50:35,996 >> WE'LL SEE YOU SOON. 2998 01:50:36,062 --> 01:50:34,094 THANK YOU, EVERYONE. 2999 01:50:34,094 --> 01:50:34,661 WELCOME BACK. 3000 01:50:34,728 --> 01:50:36,396 AND WE HAVE TWO MORE 3001 01:50:36,463 --> 01:50:37,964 PRESENTATIONS TODAY, AND I HOPE 3002 01:50:38,031 --> 01:50:40,533 A GOOD DISCUSSION AFTER THESE 3003 01:50:40,600 --> 01:50:41,935 PRESENTATIONS AS WELL. 3004 01:50:42,002 --> 01:50:45,538 THE FIRST UP WILL BE DAN TAGLE, 3005 01:50:45,605 --> 01:50:48,074 DIRECTOR OF OFFICE OF SPECIAL 3006 01:50:48,141 --> 01:50:50,010 INITIATIVES, TO GIVE AN UPDATE 3007 01:50:50,076 --> 01:50:52,512 ON WHAT'S GOING ON IN HIS AREA. 3008 01:50:52,579 --> 01:50:59,753 SO, DAN, I'LL TURN IT OVER TO 3009 01:50:59,819 --> 01:51:00,153 YOU. 3010 01:51:00,220 --> 01:51:04,024 >> THANK YOU, JONI. 3011 01:51:04,090 --> 01:51:05,025 GOOD AFTERNOON, EVERYONE. 3012 01:51:05,091 --> 01:51:07,227 SPECIALLY TO ADVISORY COUNCIL 3013 01:51:07,293 --> 01:51:07,560 MEMBERS. 3014 01:51:07,627 --> 01:51:09,829 I'LL BE GIVING AN UPDATE ON 3015 01:51:09,896 --> 01:51:11,398 OFFICE OF SPECIAL INITIATIVES 3016 01:51:11,464 --> 01:51:13,333 AND THE PROGRAMS AND ACTIVITIES 3017 01:51:13,400 --> 01:51:16,603 THAT WE'RE DOING WITHIN THE 3018 01:51:16,669 --> 01:51:16,836 OFFICE. 3019 01:51:16,903 --> 01:51:20,707 JUST TO GIVE YOU SORT OF A BRIEF 3020 01:51:20,774 --> 01:51:24,711 OVERVIEW, WHO WE ARE, WE'RE A 3021 01:51:24,778 --> 01:51:26,813 VERY DIVERSE AND 3022 01:51:26,880 --> 01:51:27,580 MULTI-DISCIPLINARY TEAM OF 3023 01:51:27,647 --> 01:51:38,124 SCIENTISTS , ALL SEEKING TO 3024 01:51:38,425 --> 01:51:39,292 ADDRESS TRANSLATIONAL PROBLEMS 3025 01:51:39,359 --> 01:51:44,731 WITHIN NCATS THROUGH INNOVATIVE 3026 01:51:44,798 --> 01:51:47,901 SOLUTIONS BY DEVELOPING AND 3027 01:51:47,967 --> 01:51:48,902 IMPLEMENTATION DISRUPTIVE 3028 01:51:48,968 --> 01:51:49,803 TECHNOLOGIES TO RESULT IN A 3029 01:51:49,869 --> 01:51:54,841 PARADIGM SHIFT IN THE FIELD. 3030 01:51:54,908 --> 01:51:56,709 TO GIVE YOU A SENSE OF WHAT 3031 01:51:56,776 --> 01:52:01,147 WE'RE DOING, ACTIVITIES SPAN 3032 01:52:01,214 --> 01:52:03,550 RANGE OF FUNDAMENTAL RESEARCH TO 3033 01:52:03,616 --> 01:52:05,518 DEVELOPMENT, CLINICAL 3034 01:52:05,585 --> 01:52:06,186 DEVELOPMENT, LEADING TO 3035 01:52:06,252 --> 01:52:07,220 REGULATORY ACCEPTANCE. 3036 01:52:07,287 --> 01:52:08,588 ALL THE PROGRAMS WITHIN THE 3037 01:52:08,655 --> 01:52:13,593 OFFICE ADHERES TO THE NCATS 3038 01:52:13,660 --> 01:52:15,895 PRINCIPLES OF DEVELOPING 3039 01:52:15,962 --> 01:52:17,597 TECHNOLOGY, DEMONSTRATING 3040 01:52:17,664 --> 01:52:19,632 UTILITY, AND THEN ULTIMATELY 3041 01:52:19,699 --> 01:52:20,867 DISSEMINATING THE TECHNOLOGY FOR 3042 01:52:20,934 --> 01:52:22,836 USE BY THE COMMUNITY. 3043 01:52:22,902 --> 01:52:26,573 SO WE HAVE A NUMBER OF DIFFERENT 3044 01:52:26,639 --> 01:52:29,409 PROGRAMS, VARIOUS STAGES, ALONG 3045 01:52:29,476 --> 01:52:35,348 THE 3D PRINCIPLES, FROM 3046 01:52:35,415 --> 01:52:35,782 DEVELOPMENT THROUGH 3047 01:52:35,849 --> 01:52:36,783 DISSEMINATION. 3048 01:52:36,850 --> 01:52:38,818 COLOR CODED IN THE SENSE LIGHT 3049 01:52:38,885 --> 01:52:42,021 BROWN WOULD BE A.I. DRIVEN 3050 01:52:42,088 --> 01:52:44,124 MANUFACTURING TECHNOLOGIES BY 3051 01:52:44,190 --> 01:52:47,293 START AND ASPIRE. 3052 01:52:47,360 --> 01:52:49,996 SCENT PROGRAM AND RADx RAD, 3053 01:52:50,063 --> 01:52:50,930 DIAGNOSTIC TECHNOLOGIES. 3054 01:52:50,997 --> 01:52:52,532 WE HAVE A NEW PROGRAM, JUST IN 3055 01:52:52,599 --> 01:52:55,902 THE EARLY STAGES OF BEING 3056 01:52:55,969 --> 01:52:57,003 DEVELOPED, QUANTUM INFORMATION 3057 01:52:57,070 --> 01:53:00,406 SCIENCES, SHOWN IN PINK. 3058 01:53:00,473 --> 01:53:11,017 AND THEN IN YELLOW A PROGRAM ON 3059 01:53:12,152 --> 01:53:14,087 EXTREME, EXOSOME THERAPY FOR 3060 01:53:14,154 --> 01:53:16,322 REGENERATIVE MEDICINE, TWO IN 3061 01:53:16,389 --> 01:53:18,158 BLUE ARE COLLABORATIVE EFFORTS, 3062 01:53:18,224 --> 01:53:22,862 LIGHT BLUE IS COMMON FUND 3063 01:53:22,929 --> 01:53:24,063 PROGRAMS, COMMON-FUND-SUPPORTED, 3064 01:53:24,130 --> 01:53:28,001 DARK BLUE IS NSF COLLABORATIONS 3065 01:53:28,067 --> 01:53:30,703 ON CYBERPHYSICAL SYSTEMS, 3066 01:53:30,770 --> 01:53:31,104 NATIONAL ROBOTICS. 3067 01:53:31,171 --> 01:53:34,340 IN GREEN IN VITRO MODELING 3068 01:53:34,407 --> 01:53:38,845 TECHNOLOGIES, 3D BIOPRINTING AND 3069 01:53:38,912 --> 01:53:39,479 TISSUE CHIPS, MICROPHYSIOLOGIC 3070 01:53:39,546 --> 01:53:39,946 SYSTEMS. 3071 01:53:40,013 --> 01:53:42,982 IT WILL BE A FOCUS OF MY 3072 01:53:43,049 --> 01:53:44,184 DISCUSSION ON TISSUE CHIPS, DRUG 3073 01:53:44,250 --> 01:53:45,618 SCREENING, TO GIVE A SENSE OF 3074 01:53:45,685 --> 01:53:49,355 WHERE THINGS ARE AT IN VARIOUS 3075 01:53:49,422 --> 01:53:52,292 PROGRAMS, START, THE PROGRAM 3076 01:53:52,358 --> 01:53:54,294 LEAD IS DR. REDNIKE, USING 3077 01:53:54,360 --> 01:53:55,628 SYNTHETIC BIOLOGY APPROACHES FOR 3078 01:53:55,695 --> 01:54:00,233 PRODUCTION OF COMPOUNDS OR 3079 01:54:00,300 --> 01:54:05,538 DELIVERY OF THERAPEUTICS. 3080 01:54:05,605 --> 01:54:06,940 ASPIRE INVOLVES COLLABORATION 3081 01:54:07,006 --> 01:54:10,109 WITH NCATS INTRAMURAL SCIENTISTS 3082 01:54:10,176 --> 01:54:11,244 AND EXTRAMURAL SCIENTISTS, 3083 01:54:11,311 --> 01:54:14,514 PRIMARILY TO ESTABLISH PHYSICAL 3084 01:54:14,581 --> 01:54:16,182 AND VIRTUAL MODULES FOR 3085 01:54:16,249 --> 01:54:18,418 AUTOMATED SYNTHETIC CHEMISTRY, 3086 01:54:18,484 --> 01:54:19,319 ARTIFICIAL INTELLIGENCE, MACHINE 3087 01:54:19,385 --> 01:54:27,227 LEARNING, ENGINEERING, 3088 01:54:27,293 --> 01:54:30,830 INFORMATICS, BIOLOGICAL TESTING 3089 01:54:30,897 --> 01:54:31,064 TESTING. 3090 01:54:31,130 --> 01:54:35,768 A PROGRAM IN DIAGNOSIS, ASCENT, 3091 01:54:35,835 --> 01:54:39,505 STANDS FOR SENSING CONDITIONS 3092 01:54:39,572 --> 01:54:45,278 WITH TRONIC TECHNOLOGY, USING 3093 01:54:45,345 --> 01:54:45,945 VOLATILE ORGANIC COMPOUND 3094 01:54:46,012 --> 01:54:48,681 DETECTION, THIS IS LED BY DR. 3095 01:54:48,748 --> 01:54:50,149 CROUCHER AND DR. JOHNSTONE, AND 3096 01:54:50,216 --> 01:54:54,821 WE HAVE TWO RADx RAD PROGRAMS, 3097 01:54:54,887 --> 01:54:55,989 AGAIN ONE USING ELECTRONIC NOSE 3098 01:54:56,055 --> 01:54:58,091 TECHNOLOGY FROM SKIN AND BREATH 3099 01:54:58,157 --> 01:54:59,926 TO DETECT SIGNATURES FOR 3100 01:54:59,993 --> 01:55:02,228 SARS-COV-2 AND LONG COVID, AGAIN 3101 01:55:02,295 --> 01:55:04,998 LED BY DR. CROUCHER AND DR. 3102 01:55:05,064 --> 01:55:08,635 JOHNSTONE, AND THEN ONE ON 3103 01:55:08,701 --> 01:55:10,570 EXOSOME-BASED ISOLATION 3104 01:55:10,637 --> 01:55:11,971 TECHNOLOGIES, PRIMARILY TO 3105 01:55:12,038 --> 01:55:12,939 DETECT SARS-COV-2 AND HOST 3106 01:55:13,006 --> 01:55:16,142 IMMUNE RESPONSE, AND THIS IS LED 3107 01:55:16,209 --> 01:55:22,248 BY DR. HAPPEL AND DR. JOHNSTONE. 3108 01:55:22,315 --> 01:55:24,250 WE HAVE THE QUANTUM INFORMATION 3109 01:55:24,317 --> 01:55:26,853 SCIENCES, WHICH IS TAKING 3110 01:55:26,919 --> 01:55:29,722 ADVANTAGE OF LATEST DEVELOPMENTS 3111 01:55:29,789 --> 01:55:31,024 IN QUANTUM TECHNOLOGIES, 3112 01:55:31,090 --> 01:55:32,659 PRIMARILY TOWARDS EARLY 3113 01:55:32,725 --> 01:55:36,329 DETECTION DIAGNOSTICS AND DEVICE 3114 01:55:36,396 --> 01:55:39,599 DEVELOPMENT AND DRUG DEVELOPMENT 3115 01:55:39,666 --> 01:55:41,534 LED BY DR. SENTEEL. 3116 01:55:41,601 --> 01:55:46,372 THEN THE LAST GROUP WOULD BE ON 3117 01:55:46,439 --> 01:55:47,807 EXOSOME-BASED TECHNOLOGY, 3118 01:55:47,874 --> 01:55:49,075 INDUSTRIALIZATION AND 3119 01:55:49,142 --> 01:55:50,209 TRANSLATION OF EXTRACELLULAR 3120 01:55:50,276 --> 01:55:53,513 VESICLES FOR USE IN REGENERATIVE 3121 01:55:53,579 --> 01:55:58,785 MEDICINE LED BY DR. HAPPEL, AND 3122 01:55:58,851 --> 01:55:59,786 3D BIOPRINTING PROGRAM IS 3123 01:55:59,852 --> 01:56:02,922 ANOTHER ONE OF THOSE THAT 3124 01:56:02,989 --> 01:56:04,290 INVOLVES NCATS INTRAMURAL 3125 01:56:04,357 --> 01:56:05,825 INVESTIGATORS AND EXTRAMURAL 3126 01:56:05,892 --> 01:56:08,061 SCIENTISTS, PRIMARILY TO DEVELOP 3127 01:56:08,127 --> 01:56:10,029 AND DEMONSTRATE USE OF 3D 3128 01:56:10,096 --> 01:56:12,332 BIOPRINTED MATERIALS FOR DISEASE 3129 01:56:12,398 --> 01:56:13,599 MODELING AND DRUG SCREENING, 3130 01:56:13,666 --> 01:56:23,009 THIS PROGRAM IS LED BY DR. 3131 01:56:23,076 --> 01:56:23,843 RUDNICKI. 3132 01:56:23,910 --> 01:56:26,946 I'LL BE FOCUSING ON THE ONE 3133 01:56:27,013 --> 01:56:30,750 CLOSEST IN TERMS OF MATURITY AS 3134 01:56:30,817 --> 01:56:33,286 A PROGRAM, SO THE BIG PROBLEM 3135 01:56:33,353 --> 01:56:35,888 THAT WE'RE TRYING TO ADDRESS 3136 01:56:35,955 --> 01:56:41,294 HERE WITH TISSUE CHIPS, 3137 01:56:41,361 --> 01:56:42,261 MICROPHYSIOLOGICAL SYSTEMS, 3138 01:56:42,328 --> 01:56:45,665 DEVELOPMENT OF BETTER PREDICTIVE 3139 01:56:45,732 --> 01:56:48,134 TOOLS AND DRUG DEVELOPMENT. 3140 01:56:48,201 --> 01:56:49,168 PERCENTAGE OF DRUGS ENTERING 3141 01:56:49,235 --> 01:56:51,304 CLINICAL TRIALS IS QUITE ABYSMAL 3142 01:56:51,371 --> 01:56:56,142 IN THE SENSE ONLY 10% ARE 3143 01:56:56,209 --> 01:56:58,845 SUCCESSFUL, 55% ATTRITION DUE TO 3144 01:56:58,911 --> 01:57:01,180 LACK OF EFFICACY, 28% DUE TO 3145 01:57:01,247 --> 01:57:02,615 TOXIC EFFECTS IN HUMANS. 3146 01:57:02,682 --> 01:57:05,852 ON THE WHOLE IT TAKES AN AVERAGE 3147 01:57:05,918 --> 01:57:07,887 TIME OF 10-15 YEARS TO BRING A 3148 01:57:07,954 --> 01:57:11,991 DRUG TO MARKET AT A COST OF 3149 01:57:12,058 --> 01:57:12,658 $2.6 BILLION. 3150 01:57:12,725 --> 01:57:16,562 AND AS SHOWN IN THE CHART WOULD 3151 01:57:16,629 --> 01:57:21,334 BE THE AVERAGE IN BLUE, THE TOP 3152 01:57:21,401 --> 01:57:22,068 CHART, 9.6%, ACROSS ALL 3153 01:57:22,135 --> 01:57:24,670 INDICATIONS WHICH IS THE AVERAGE 3154 01:57:24,737 --> 01:57:26,205 OF 10% SUCCESS RATE, WE DO WELL 3155 01:57:26,272 --> 01:57:29,075 IN SOME INDICATIONS AND NOT TOO 3156 01:57:29,142 --> 01:57:31,511 WELL IN MOST OF THEM. 3157 01:57:31,577 --> 01:57:33,379 AND IT'S LARGELY CONSIDERED THAT 3158 01:57:33,446 --> 01:57:36,082 THE CURRENT MODELS THAT WE USE 3159 01:57:36,149 --> 01:57:38,084 SUCH AS 2D CELL CULTURE SYSTEMS 3160 01:57:38,151 --> 01:57:41,687 AND IN SOME CASES IN VIVO ANIMAL 3161 01:57:41,754 --> 01:57:43,289 MODELS DO NOT ALWAYS PREDICT 3162 01:57:43,356 --> 01:57:43,956 HUMAN RESPONSE. 3163 01:57:44,023 --> 01:57:45,158 THAT'S BECAUSE AS SHOWN HERE 3164 01:57:45,224 --> 01:57:48,895 THERE'S A LACK OF CONCORDANCE 3165 01:57:48,961 --> 01:57:53,733 WITHIN TOXICITIES THAT TENDS TO 3166 01:57:53,800 --> 01:57:55,101 BE VERY TISSUE SPECIFIC. 3167 01:57:55,168 --> 01:57:57,236 TO GIVE A SENSE OF WHERE THINGS 3168 01:57:57,303 --> 01:57:59,372 ARE AT, IN THE TISSUE CHIPS 3169 01:57:59,439 --> 01:58:01,607 PROGRAM, THIS IS THE PROGRAM 3170 01:58:01,674 --> 01:58:03,709 THAT STARTED BACK IN 2012, JUST 3171 01:58:03,776 --> 01:58:06,245 WHEN NCATS WAS BEING STARTED. 3172 01:58:06,312 --> 01:58:09,582 AND SO CERTAINLY OVER THE COURSE 3173 01:58:09,649 --> 01:58:12,251 OF SEVERAL COUNCILS HAVE GIVEN 3174 01:58:12,318 --> 01:58:17,990 UPDATES HOW WE'RE DEVELOPING 3175 01:58:18,057 --> 01:58:19,559 TECHNOLOGY, SO I WON'T BELABOR 3176 01:58:19,625 --> 01:58:21,994 AND GO OVER THE PROGRESS WE'VE 3177 01:58:22,061 --> 01:58:23,496 MADE IN THOSE AREAS. 3178 01:58:23,563 --> 01:58:26,032 INSTEAD THIS UPDATE WILL FOCUS 3179 01:58:26,098 --> 01:58:27,366 ON LATTER HALF, LATTER 3180 01:58:27,433 --> 01:58:31,103 TWO-THIRDS OF THE 3D IN TERMS OF 3181 01:58:31,170 --> 01:58:34,574 DEMONSTRATING UTILITY AND 3182 01:58:34,640 --> 01:58:35,808 DISSEMINATING THE TECHNOLOGIES 3183 01:58:35,875 --> 01:58:37,109 FOCUSED MORE ON HOW WE'RE 3184 01:58:37,176 --> 01:58:39,712 DEPLOYING TECHNOLOGY FOR USE IN 3185 01:58:39,779 --> 01:58:42,315 PERSONALIZED MEDICINE, HOW WE'RE 3186 01:58:42,381 --> 01:58:44,150 BUILDING CONFIDENCE IN THE 3187 01:58:44,217 --> 01:58:46,219 TECHNOLOGY, AS SHOWN HERE, AND 3188 01:58:46,285 --> 01:58:48,120 HOW WE'RE WORKING TOWARDS 3189 01:58:48,187 --> 01:58:50,756 REGULATORY ACCEPTANCE AS WELL AS 3190 01:58:50,823 --> 01:58:54,160 BUILDING COMMUNITY AND THEN JUST 3191 01:58:54,227 --> 01:58:55,461 AS INDICATION OF THE 3192 01:58:55,528 --> 01:58:56,996 PARTNERSHIPS THAT WE HAD, NCATS 3193 01:58:57,063 --> 01:58:58,965 IS ALL ABOUT PARTNERSHIPS AS 3194 01:58:59,031 --> 01:58:59,765 WELL SO WE HAVE 18 INSTITUTES 3195 01:58:59,832 --> 01:59:01,901 AND CENTERS AT THE NIH WHO ARE 3196 01:59:01,968 --> 01:59:04,103 PARTNERS IN THIS AS WELL AS 3197 01:59:04,170 --> 01:59:09,041 OTHER FEDERAL AGENCIES SUCH AS 3198 01:59:09,108 --> 01:59:13,145 FDA, NASA, DARPA, BARDA, EPA, AS 3199 01:59:13,212 --> 01:59:15,748 WELL AS PRIVATE PARTNERSHIPS 3200 01:59:15,815 --> 01:59:18,150 WITH IQ MPS AFFILIATE, WHICH IS 3201 01:59:18,217 --> 01:59:21,354 AN ORGANIZATION MADE OF 26 3202 01:59:21,420 --> 01:59:22,522 PHARMA COMPANIES. 3203 01:59:22,588 --> 01:59:27,727 NOW IN TERMS OF DEMONSTRATING 3204 01:59:27,793 --> 01:59:29,929 UTILITY ARE TISSUE CHIPS A 3205 01:59:29,996 --> 01:59:31,297 BETTER PREDICTOR OF HUMAN 3206 01:59:31,364 --> 01:59:33,799 PHYSIOLOGIC RESPONSE, SO IN THIS 3207 01:59:33,866 --> 01:59:35,101 ILLUSTRATION I'LL FOCUS ON THE 3208 01:59:35,167 --> 01:59:35,301 LIVER. 3209 01:59:35,368 --> 01:59:38,938 YOU MAY KNOW THE LIVER IS 3210 01:59:39,005 --> 01:59:40,006 RESPONSIBLE FOR CONCENTRATING 3211 01:59:40,072 --> 01:59:40,840 METABOLIZING MAJORITY OF 3212 01:59:40,907 --> 01:59:42,542 MEDICATIONS, AND BECAUSE OF THAT 3213 01:59:42,608 --> 01:59:44,310 DRUG INDUCED LIVER INJURY IS THE 3214 01:59:44,377 --> 01:59:47,680 MOST COMMON CAUSE OF ACUTE LIVER 3215 01:59:47,747 --> 01:59:52,919 FAILURE, 15 TO 20 PER 100 3216 01:59:52,985 --> 01:59:57,557 100,000, ADVERSE DRUG REACTION 3217 01:59:57,623 --> 01:59:58,424 RESULTING IN LIVER INJURY 3218 01:59:58,491 --> 02:00:00,159 REQUIRES DISCONTINUATION OF THE 3219 02:00:00,226 --> 02:00:01,394 DRUG, HOSPITALIZATION, LIVER 3220 02:00:01,460 --> 02:00:02,695 TRANSPLANT OR EVEN DEATH. 3221 02:00:02,762 --> 02:00:04,597 SO HERE'S AN EXAMPLE OF WHAT 3222 02:00:04,664 --> 02:00:08,568 LIVER ON A CHIP LOOKS LIKE. 3223 02:00:08,634 --> 02:00:19,011 HUMAN HEPATOCYTES AND 3224 02:00:21,213 --> 02:00:25,551 NON-PARENCHYMAL CELLS, SO IN 3225 02:00:25,618 --> 02:00:30,823 THIS EXAMPLE WE'RE LOOKING AT 3226 02:00:30,890 --> 02:00:34,727 PARTICULAR DRUG, WHEN DEVELOPED 3227 02:00:34,794 --> 02:00:35,227 ANTI-VIRAL AGENT AGAINST 3228 02:00:35,294 --> 02:00:38,431 HEPATITIS B, RAN THROUGH RAT AND 3229 02:00:38,497 --> 02:00:44,003 DOG IN VIVO MODELS, AND SHOWED 3230 02:00:44,070 --> 02:00:46,772 CLEAR SAFETY, SO WAS APPROVED BY 3231 02:00:46,839 --> 02:00:49,508 THE FDA TOWARDS HUMAN CLINICAL 3232 02:00:49,575 --> 02:00:51,344 TRIAL USE, BUT UNFORTUNATELY 3233 02:00:51,410 --> 02:00:53,546 FIVE OUT OF THE 15 PATIENTS 3234 02:00:53,613 --> 02:00:58,084 ENROLLED IN PHASE 1 STUDIES 3235 02:00:58,150 --> 02:01:00,686 DIED, DUE TO FORMATION OF -- 3236 02:01:00,753 --> 02:01:01,787 ACCUMULATION OF FATTY DEPOSITS 3237 02:01:01,854 --> 02:01:02,421 IN THE LIVER. 3238 02:01:02,488 --> 02:01:05,358 THE QUESTION WE'RE ASKING NOW 3239 02:01:05,424 --> 02:01:09,795 COULD HUMAN LIVER ON A CHIP HAVE 3240 02:01:09,862 --> 02:01:11,297 PREDICTED TOXICITY RAT AND DOG 3241 02:01:11,364 --> 02:01:14,233 MODEL DID NOT. 3242 02:01:14,300 --> 02:01:18,838 HERE IS ON THE CHART ON A SHOWS 3243 02:01:18,904 --> 02:01:21,440 A RAT HEPATOCYTE, RAT LIVER ON A 3244 02:01:21,507 --> 02:01:22,341 CHIP, TESTED ALONGSIDE HUMAN 3245 02:01:22,408 --> 02:01:26,145 LIVER ON A CHIP, AND THOSE WITH 3246 02:01:26,212 --> 02:01:29,782 ZERO, 1, 10, 30 MICROMOLARS OF 3247 02:01:29,849 --> 02:01:31,751 FIALURIDINE, STAINED WITH NILE 3248 02:01:31,817 --> 02:01:34,420 RED TO SHOW ACCUMULATION OF 3249 02:01:34,487 --> 02:01:35,621 FATTY DEPOSITS SHOWN IN YELLOW. 3250 02:01:35,688 --> 02:01:37,657 AS YOU CAN SEE IN THE 3251 02:01:37,723 --> 02:01:39,425 QUANTITATION ON THE RIGHT-HAND 3252 02:01:39,492 --> 02:01:43,162 SIDE, THE RAT DELIVER HEPATOCYTE 3253 02:01:43,229 --> 02:01:44,997 DID NOT SHOW ANY SIGNIFICANT 3254 02:01:45,064 --> 02:01:49,835 STAINING WITH NILE RED, WHEREAS 3255 02:01:49,902 --> 02:01:58,711 IN HUMAN HEPATOCYTE CHIP, 3256 02:01:58,778 --> 02:02:02,882 INDICATES INCREASE IN FATTY 3257 02:02:02,948 --> 02:02:04,617 DEPOSIT WHICH TRANSLATES. 3258 02:02:04,684 --> 02:02:07,186 ONE CAN LOOK AT FUNCTIONAL 3259 02:02:07,253 --> 02:02:13,292 MARKERS SUCH AS ALBUMIN 3260 02:02:13,359 --> 02:02:16,028 SECRETION, SHOWING AT HIGH DOSE 3261 02:02:16,095 --> 02:02:19,965 OF FIALURIDINE ALBUMIN 3262 02:02:20,032 --> 02:02:23,369 SECRETION, HUMAN HEPATOCYTE 3263 02:02:23,436 --> 02:02:24,370 SHOWED DECREASE DEPENDENT, 3264 02:02:24,437 --> 02:02:29,909 LOOKING AT LIVER INJURY MARKERS, 3265 02:02:29,975 --> 02:02:31,677 THERE'S ALSO A DOSE-DEPENDENT 3266 02:02:31,744 --> 02:02:36,916 INCREASE IN EXPRESSION OF THOSE 3267 02:02:36,982 --> 02:02:38,684 LIVER INJURY MARKERS. 3268 02:02:38,751 --> 02:02:41,921 THIS STUDY WAS ALSO EXPANDED TO 3269 02:02:41,987 --> 02:02:45,791 A GROUP OF 22 OTHER COMPOUNDS, 3270 02:02:45,858 --> 02:02:49,962 JUST LIKE FIALURIDINE, THAT WERE 3271 02:02:50,029 --> 02:02:55,334 TESTED IN ANIMAL MODELS, 2D CELL 3272 02:02:55,401 --> 02:02:57,369 CULTURE MODELS, AND PASSED 3273 02:02:57,436 --> 02:02:59,839 THROUGH THE INITIAL PRE-IND 3274 02:02:59,905 --> 02:03:03,576 SUBMISSION AND THEN WENT INTO 3275 02:03:03,642 --> 02:03:04,643 CLINICAL TRIALS, BUT 3276 02:03:04,710 --> 02:03:05,778 UNFORTUNATELY OUT OF THE 22 3277 02:03:05,845 --> 02:03:08,414 COMPOUNDS THAT WERE TESTED JUST 3278 02:03:08,481 --> 02:03:10,683 LIKE FIALURIDINE THEY ALL FAILED 3279 02:03:10,750 --> 02:03:14,653 IN HUMAN TRIALS AND SUBSEQUENTLY 3280 02:03:14,720 --> 02:03:16,455 WITHDRAWN DUE TO TOXICITIES 3281 02:03:16,522 --> 02:03:18,824 RESULTING IN MORE THAN 200 3282 02:03:18,891 --> 02:03:20,960 PATIENT DEATHS, TEN LIVER 3283 02:03:21,026 --> 02:03:23,295 TRANSPLANTS, WHEN TESTED. 3284 02:03:23,362 --> 02:03:26,232 WHEN HUMAN LIVER ON A CHIP WAS 3285 02:03:26,298 --> 02:03:27,633 LOOKED AT, WITH THIS COMPOUND, 3286 02:03:27,700 --> 02:03:30,603 THE HUMAN LIVER ON A CHIP SHOWED 3287 02:03:30,669 --> 02:03:33,506 87% SENSITIVITY, AS WELL AS 100% 3288 02:03:33,572 --> 02:03:35,207 SPECIFICITY, BEING ABLE TO 3289 02:03:35,274 --> 02:03:37,610 PREDICT THE DRUG TOXICITIES THAT 3290 02:03:37,676 --> 02:03:41,213 THE OTHER MODELS WERE NOT ABLE 3291 02:03:41,280 --> 02:03:42,114 TO PREDICT. 3292 02:03:42,181 --> 02:03:42,982 NOW SHIFTING GEARS A LITTLE BIT 3293 02:03:43,048 --> 02:03:46,585 IN TERMS OF HOW WE CAN 3294 02:03:46,652 --> 02:03:48,220 DEMONSTRATE USE OF TISSUE CHIPS 3295 02:03:48,287 --> 02:03:51,824 FOR DISEASE MODELING AND 3296 02:03:51,891 --> 02:03:53,692 EFFICACY STUDIES, HERE IS AN 3297 02:03:53,759 --> 02:03:58,597 EXAMPLE A GROUP OF RARE DISEASES 3298 02:03:58,664 --> 02:03:59,799 WHICH ARE AUTOIMMUNE 3299 02:03:59,865 --> 02:04:06,038 DEMYELINATING NEUROPATHIES 3300 02:04:06,105 --> 02:04:10,009 SUCHY POLY NEUROPATHY AND MOTOR 3301 02:04:10,075 --> 02:04:12,378 NEUROPATHY HAVE NO PARTICULAR 3302 02:04:12,444 --> 02:04:14,914 MOD TOLLS RELY ON, BUT IT'S AN 3303 02:04:14,980 --> 02:04:18,083 AUTOIMMUNE DISEASE, SO THE 3304 02:04:18,150 --> 02:04:22,488 PATIENTS DO DEVELOP ANTI-SERA, 3305 02:04:22,555 --> 02:04:24,156 AGAINST THEIR OWN NEUROMUSCULAR 3306 02:04:24,223 --> 02:04:26,225 JUNCTION, SO THE TISSUE CHIP 3307 02:04:26,292 --> 02:04:30,162 MODEL HERE CONSISTS OF A 3308 02:04:30,229 --> 02:04:33,799 CO-CULTURE OF HUMAN PRIMARY 3309 02:04:33,866 --> 02:04:40,005 SCHWANN CELLS, AND INDUCED 3310 02:04:40,072 --> 02:04:42,174 PLURIPOTENT STEM CELL-DERIVED 3311 02:04:42,241 --> 02:04:42,474 MOTONEURONS. 3312 02:04:42,541 --> 02:04:44,376 WHEN TREATED WITH ANTI-SERA THAT 3313 02:04:44,443 --> 02:04:46,445 WAS ISOLATED FROM 15 PATIENTS, 3314 02:04:46,512 --> 02:04:54,820 EACH OF THESE BOXES ON THE 3315 02:04:54,887 --> 02:04:56,088 HISTOGRAM RECOMMENDS ANTI-SERA 3316 02:04:56,155 --> 02:04:57,957 FROM EACH, EACH JUNCTION ON A 3317 02:04:58,023 --> 02:05:07,466 CHIP WHEN STAINED WITH, AGAIN, 3318 02:05:07,533 --> 02:05:11,503 SHOWED YOU CAN GRASP EACH OF THE 3319 02:05:11,570 --> 02:05:13,239 ANTI-SERA ON JUNCTION SHOWED 3320 02:05:13,305 --> 02:05:15,975 STAINING FOR THIS COMPLEMENT 3321 02:05:16,041 --> 02:05:18,177 ACTIVATION PATHWAY. 3322 02:05:18,244 --> 02:05:28,153 NOW, TO TEST FOR EFFICACY OF 3323 02:05:28,220 --> 02:05:30,823 CANDIDATE DRUG TNT005, A 3324 02:05:30,890 --> 02:05:36,629 MONOCLONAL ANTIBODY, WHEN 3325 02:05:36,695 --> 02:05:42,902 TREATED SHOWED THAT THEY DID NOT 3326 02:05:42,968 --> 02:05:44,436 GET ACTIVATED OR ACCUMULATE IN 3327 02:05:44,503 --> 02:05:45,371 THE PATIENT'S SERA. 3328 02:05:45,437 --> 02:05:48,107 EFFICACY DATA WAS INCORPORATED 3329 02:05:48,173 --> 02:05:51,243 WITH OTHER DATASETS, AND WAS 3330 02:05:51,310 --> 02:06:00,953 THEN SUBMITTED TO THE FDA IND, 3331 02:06:01,020 --> 02:06:04,456 NOW IN PHASE 2 SPONSORED BY 3332 02:06:04,523 --> 02:06:04,690 SANOFI. 3333 02:06:04,757 --> 02:06:05,224 ANOTHER AREA DEMONSTRATING 3334 02:06:05,291 --> 02:06:06,959 UTILITY OF TISSUE CHIPS IS 3335 02:06:07,026 --> 02:06:08,794 MODELING DISEASES THAT ARE HARD 3336 02:06:08,861 --> 02:06:12,531 OR DIFFICULT TO MODEL HERE ON 3337 02:06:12,598 --> 02:06:13,799 EARTH, ESPECIALLY TAKES LONG 3338 02:06:13,866 --> 02:06:17,736 TIME SO ONE AREA OF COURSE IS IN 3339 02:06:17,803 --> 02:06:17,937 AGING. 3340 02:06:18,003 --> 02:06:21,407 AS IT TURNS OUT, UNDER THE 3341 02:06:21,473 --> 02:06:23,342 INFLUENCE OF A MICROGRAVITY 3342 02:06:23,409 --> 02:06:24,710 ENVIRONMENT ONE CAN ACCELERATE 3343 02:06:24,777 --> 02:06:27,046 EFFECTS OF AGING AT LEAST 3344 02:06:27,112 --> 02:06:27,680 OBSERVE THE CLINICALLY WITH 3345 02:06:27,746 --> 02:06:30,950 ASTRONAUTS, THE QUESTION IS CAN 3346 02:06:31,016 --> 02:06:32,952 WE CAPTURE THOSE PHYSIOLOGICAL 3347 02:06:33,018 --> 02:06:35,020 CHANGES THE ASTRONAUTS' CELLS 3348 02:06:35,087 --> 02:06:36,822 AND TISSUES EXPERIENCE UNDER 3349 02:06:36,889 --> 02:06:39,525 MICROGRAVITY AND BE ABLE TO TAKE 3350 02:06:39,591 --> 02:06:41,327 ADVANTAGE OF THE MICROGRAVITY 3351 02:06:41,393 --> 02:06:46,098 ENVIRONMENT AND BE ABLE TO 3352 02:06:46,165 --> 02:06:46,832 DEVELOP MODELS OF ACCELERATED 3353 02:06:46,899 --> 02:06:48,667 AGING AND BE ABLE TO ACHIEVE 3354 02:06:48,734 --> 02:06:51,303 THAT, SO WE HAVE PROJECTS THAT 3355 02:06:51,370 --> 02:06:54,039 LOOK AT IMMUNOSENESCENCE, 3356 02:06:54,106 --> 02:06:56,909 CHANGES IN BLOOD-BRAIN BARRIER 3357 02:06:56,976 --> 02:06:58,677 PERMEABILITY, RESULT OF EXPOSURE 3358 02:06:58,744 --> 02:06:59,945 TO MICROGRAVITY, THE 3359 02:07:00,012 --> 02:07:01,280 MOBILIZATION OF IMMUNE SYSTEM 3360 02:07:01,347 --> 02:07:03,349 FROM BONE MARROW AS A 3361 02:07:03,415 --> 02:07:06,986 CONSEQUENCE OF LUNG INFECTION, 3362 02:07:07,052 --> 02:07:08,320 LOOKING AT OSTEOARTHRITIS, 3363 02:07:08,387 --> 02:07:10,923 PROTEINURIA AND KIDNEY STONE 3364 02:07:10,990 --> 02:07:12,157 FORMATION, ALSO CARDIAC 3365 02:07:12,224 --> 02:07:15,160 DYSFUNCTION, ALSO LOOKING AT 3366 02:07:15,227 --> 02:07:16,395 MUSCLE WASTING OR SARCOPENIA, 3367 02:07:16,462 --> 02:07:21,767 AND CHANGES IN THE GUT 3368 02:07:21,834 --> 02:07:24,269 MICROBIOME, RESULTING IN GUT 3369 02:07:24,336 --> 02:07:25,070 INFLAMMATION. 3370 02:07:25,137 --> 02:07:27,139 SO HERE'S AN EXAMPLE OF AN 3371 02:07:27,206 --> 02:07:28,173 ENDORSEMENT I GUESS FROM THE 3372 02:07:28,240 --> 02:07:33,946 ASTRONAUTS WHO WORKED WITH 3373 02:07:34,013 --> 02:07:35,080 TISSUE CHIPS. 3374 02:07:35,147 --> 02:07:38,250 >> GREETINGS FROM THE 3375 02:07:38,317 --> 02:07:38,951 INTERNATIONAL SPACE SPACE 3376 02:07:39,018 --> 02:07:42,021 STATION, I'M HERE WITH MY CREW 3377 02:07:42,087 --> 02:07:44,423 MATE OF THE JAPAN AGENCY, MY 3378 02:07:44,490 --> 02:07:45,724 CREWMATES AND I HAVE BEEN HARD 3379 02:07:45,791 --> 02:07:48,360 AT WORK SUPPORTING AN ARRAY OF 3380 02:07:48,427 --> 02:07:49,795 RESEARCH EXPERIMENTS AND 3381 02:07:49,862 --> 02:07:51,864 TECHNOLOGY DEMONSTRATIONS IN 3382 02:07:51,930 --> 02:07:52,664 THIS MICROGRAVITY ENVIRONMENT, 3383 02:07:52,731 --> 02:07:54,700 SPACE STATION IS UNIQUE 3384 02:07:54,767 --> 02:07:55,934 LABORATORY UNLIKE ANY OTHER 3385 02:07:56,001 --> 02:07:57,002 WHERE THERE'S NO GRAVITY. 3386 02:07:57,069 --> 02:07:58,771 AND BECAUSE OF THAT WE CAN LOOK 3387 02:07:58,837 --> 02:08:03,308 AT SCIENCE IN A NEW WAY TO 3388 02:08:03,375 --> 02:08:04,877 BENEFIT HUMANITY. 3389 02:08:04,943 --> 02:08:06,845 >> ONE OF THE AREAS OF INTEREST 3390 02:08:06,912 --> 02:08:08,847 IS RESEARCH IN HUMAN CELLS AND 3391 02:08:08,914 --> 02:08:10,249 TISSUES, THROUGH A LAB ON A 3392 02:08:10,315 --> 02:08:12,851 CHIP, WHAT WE LIKE TO CALL 3393 02:08:12,918 --> 02:08:14,253 TISSUE CHIPS. 3394 02:08:14,319 --> 02:08:16,255 WE KNOW THAT THE SPACE 3395 02:08:16,321 --> 02:08:18,023 ENVIRONMENT HAS PROFOUND IMPACT 3396 02:08:18,090 --> 02:08:20,125 ON HUMAN PHYSIOLOGY, AND THROUGH 3397 02:08:20,192 --> 02:08:23,262 TISSUE CHIPS WE CAN SEEK NEW 3398 02:08:23,328 --> 02:08:25,664 AVENUES FOR DRUG DISCOVERY, 3399 02:08:25,731 --> 02:08:26,231 POTENTIAL THERAPEUTIC 3400 02:08:26,298 --> 02:08:28,867 DEVELOPMENT IN THE SPACE 3401 02:08:28,934 --> 02:08:29,168 ENVIRONMENT. 3402 02:08:29,234 --> 02:08:30,069 MANY OF THESE TISSUE CHIP 3403 02:08:30,135 --> 02:08:31,770 INVESTIGATIONS ARE NEAR AND DEAR 3404 02:08:31,837 --> 02:08:35,441 TO THE AMERICAN HEART 3405 02:08:35,507 --> 02:08:37,376 ASSOCIATION. 3406 02:08:37,443 --> 02:08:38,610 >> I ENCOURAGE THOSE IN 3407 02:08:38,677 --> 02:08:41,747 ATTENDANCE TO THINK ABOUT TAKING 3408 02:08:41,814 --> 02:08:43,115 YOUR RESEARCH BEYOND EARTH'S 3409 02:08:43,182 --> 02:08:43,816 HORIZON, THROUGH SPACE-BASED 3410 02:08:43,882 --> 02:08:45,584 RESEARCH WE CAN HOPEFULLY FIND 3411 02:08:45,651 --> 02:08:50,255 WAYS TO TREAT MANY MITIGATING 3412 02:08:50,322 --> 02:08:51,790 AILMENTS HUMANS DEVELOP ON OUR 3413 02:08:51,857 --> 02:08:53,692 PLANET. 3414 02:08:53,759 --> 02:08:56,128 THANK YOU FOR ALL YOU DO TO 3415 02:08:56,195 --> 02:09:06,738 TREAT PATIENTS ON EARTH E EARTH. 3416 02:09:07,439 --> 02:09:08,907 >> THAT'S RAISING IT TO A WHOLE 3417 02:09:08,974 --> 02:09:09,274 NEW BAR. 3418 02:09:09,341 --> 02:09:10,809 IF YOU'RE GOING TO START DOING 3419 02:09:10,876 --> 02:09:14,513 MESSAGES FROM SPACE NOW, COME 3420 02:09:14,580 --> 02:09:14,680 ON! 3421 02:09:14,746 --> 02:09:18,817 >> WELL, WHAT CAN WE SAY? 3422 02:09:18,884 --> 02:09:20,853 WE'RE INNOVATIVE, OUTSIDE OF THE 3423 02:09:20,919 --> 02:09:24,990 BOX, OUTSIDE OF EARTH THINKERS, 3424 02:09:25,057 --> 02:09:25,457 YES. 3425 02:09:25,524 --> 02:09:30,028 JUST TO GIVE A SENSE OF HOW THE 3426 02:09:30,095 --> 02:09:33,098 EXPERIMENTS IN LOW EARTH ORBIT, 3427 02:09:33,165 --> 02:09:35,267 LEO, IS BENEFITING RESEARCH, SO 3428 02:09:35,334 --> 02:09:38,470 WE HAVE HAD CERTAINLY ABOUT NINE 3429 02:09:38,537 --> 02:09:40,572 PAYLOADS SENT OUT INTO 3430 02:09:40,639 --> 02:09:41,240 INTERNATIONAL SPACE STATION, AND 3431 02:09:41,306 --> 02:09:43,075 SO FAR, YOU KNOW, SO FAR WE'VE 3432 02:09:43,142 --> 02:09:45,477 BEEN ABLE TO CAPTURE 3433 02:09:45,544 --> 02:09:48,447 AGING-RELATED MARKERS. 3434 02:09:48,514 --> 02:09:49,014 FOR EXAMPLE, CARDIOVASCULAR 3435 02:09:49,081 --> 02:09:51,483 DECONDITIONING, SIX MONTHS OF 3436 02:09:51,550 --> 02:09:52,784 EXPOSURE UNDER MICROGRAVITY IS 3437 02:09:52,851 --> 02:09:54,853 EQUIVALENT TO ROUGHLY TEN YEARS 3438 02:09:54,920 --> 02:09:57,823 OF BIOLOGICAL AGING, BUT WHEN WE 3439 02:09:57,890 --> 02:10:00,826 SENT TISSUE CHIPS INTO THE SPACE 3440 02:10:00,893 --> 02:10:01,460 STATION WITHIN SIX WEEKS, 3441 02:10:01,527 --> 02:10:04,363 CERTAINLY FOUR WEEKS TO SIX 3442 02:10:04,429 --> 02:10:10,102 WEEKS, THERE IS ALREADY 3443 02:10:10,169 --> 02:10:13,472 DECREASED CONTRACTILITY, TWITCH 3444 02:10:13,539 --> 02:10:15,841 FORCE, SIMILAR TO THOSE IN AGING 3445 02:10:15,908 --> 02:10:19,077 ON MUSCLE CELLS, BUT ALSO IMMUNE 3446 02:10:19,144 --> 02:10:23,982 CELLS, BONE AND SKELETAL 3447 02:10:24,049 --> 02:10:24,216 MUSCLES. 3448 02:10:24,283 --> 02:10:27,152 ONE OF THE MAIN BENEFITS WE'VE 3449 02:10:27,219 --> 02:10:29,354 LEARNED WORKING WITH NASA 3450 02:10:29,421 --> 02:10:30,856 ENGINEERS AND PAYLOAD DEVELOPERS 3451 02:10:30,923 --> 02:10:32,491 WE CAN TAKE ADVANTAGE OF 3452 02:10:32,558 --> 02:10:34,393 DEVELOPMENT IN PARTNERSHIP WITH 3453 02:10:34,459 --> 02:10:36,862 THOSE PAYLOAD DEVELOPERS IN 3454 02:10:36,929 --> 02:10:39,097 IMPROVING TECHNOLOGIES FOR MPS, 3455 02:10:39,164 --> 02:10:41,400 BECAUSE IT TAKES A VERY SMALL 3456 02:10:41,466 --> 02:10:42,801 FOOTPRINT TO SEND CARGO TO 3457 02:10:42,868 --> 02:10:46,939 SPACE, AND SO BECAUSE OF THAT WE 3458 02:10:47,005 --> 02:10:49,942 HAVE TO MINIATURIZE AND AUTOMATE 3459 02:10:50,008 --> 02:10:52,778 OUR PLATFORM SENDING THEM TO 3460 02:10:52,844 --> 02:10:52,978 SPACE. 3461 02:10:53,045 --> 02:10:54,713 THE BENEFIT OF MINIATURIZATION 3462 02:10:54,780 --> 02:10:56,481 AND AUTOMATION CAN CERTAINLY 3463 02:10:56,548 --> 02:10:57,883 BENEFIT USE OF TISSUE CHIP 3464 02:10:57,950 --> 02:11:01,620 TECHNOLOGY ON EARTH, SO WE HAVE 3465 02:11:01,687 --> 02:11:02,654 RELEASED TWO RFAs CURRENT 3466 02:11:02,721 --> 02:11:07,025 RIGHT NOW SO THAT WE CAN MAKE 3467 02:11:07,092 --> 02:11:08,627 TISSUE CHIP TECHNOLOGY TO BE 3468 02:11:08,694 --> 02:11:10,662 COST EFFECTIVE AS WELL AS 3469 02:11:10,729 --> 02:11:13,932 AVAILABLE TO MANY RESEARCHERS 3470 02:11:13,999 --> 02:11:17,069 HERE ON EARTH. 3471 02:11:17,135 --> 02:11:19,404 CERTAINLY IN MY PRESENTATION FOR 3472 02:11:19,471 --> 02:11:20,372 CONCEPT CLEARANCE AT COUNCIL 3473 02:11:20,439 --> 02:11:23,542 BACK IN SEPTEMBER I MENTIONED 3474 02:11:23,609 --> 02:11:25,611 THAT MODERN DISEASES, HUMAN 3475 02:11:25,677 --> 02:11:34,052 CONDITIONS ON EARTH -- MODELING 3476 02:11:34,119 --> 02:11:40,425 CAN BE DIFFICULT, LEO, LOW EARTH 3477 02:11:40,492 --> 02:11:41,059 ORBIT, MICROGRAVITY, DEVELOPING 3478 02:11:41,126 --> 02:11:43,161 COUNTERMEASURES FOR USE ON EARTH 3479 02:11:43,228 --> 02:11:45,564 AND LOOK AT BIOMANUFACTURING 3480 02:11:45,631 --> 02:11:48,900 CAPABILITIES SUCH AS PROTEIN 3481 02:11:48,967 --> 02:11:49,735 CRYSTALLIZATION, PROTEIN CRYSTAL 3482 02:11:49,801 --> 02:11:52,938 TENDS TO FORM PERFECT CRYSTALS 3483 02:11:53,005 --> 02:11:56,742 UNDER MICROGRAVITY, WE CAN LOOK 3484 02:11:56,808 --> 02:11:58,343 AT 3D BIOMETRIC BIOPRINTING TO 3485 02:11:58,410 --> 02:11:59,311 BIOPRINT PERHAPS ENTIRE ORGAN 3486 02:11:59,378 --> 02:12:02,414 SYSTEMS THAT CAN BE USED FOR 3487 02:12:02,481 --> 02:12:03,282 TRANSPLANTATION AND REGENERATIVE 3488 02:12:03,348 --> 02:12:08,420 MEDICINE BEING ABLE TO DEVELOP 3489 02:12:08,487 --> 02:12:11,290 THE TELEMETRY OR ROBOTICS, 3490 02:12:11,356 --> 02:12:12,457 MEDICAL CAPABILITIES, BECAUSE 3491 02:12:12,524 --> 02:12:14,626 MOST OF THE READOUTS WE DO WHEN 3492 02:12:14,693 --> 02:12:16,628 WE SEND TISSUE CHIPS TO SPACE 3493 02:12:16,695 --> 02:12:19,298 ARE SENT BACK TO US THROUGH 3494 02:12:19,364 --> 02:12:20,666 TELEMETRY, ONE AREA OF INTEREST 3495 02:12:20,732 --> 02:12:23,835 WOULD BE IN THE DEVELOPMENT OF 3496 02:12:23,902 --> 02:12:26,038 LONG SHELF LIFE PHARMACEUTICALS, 3497 02:12:26,104 --> 02:12:28,106 EVEN PHARMACOLOGY AND DEMAND 3498 02:12:28,173 --> 02:12:28,440 CAPABILITIES. 3499 02:12:28,507 --> 02:12:31,376 SO IN THAT REGARD, AS PRESENTED 3500 02:12:31,443 --> 02:12:33,245 AS A CONCEPT CLEARANCE LAST 3501 02:12:33,312 --> 02:12:35,881 SEPTEMBER WE HAVE RENEWED TISSUE 3502 02:12:35,947 --> 02:12:37,749 CHIPS IN SPACE PROGRAM, AND 3503 02:12:37,816 --> 02:12:39,718 WE'RE IN THE PROCESS OF WRITING 3504 02:12:39,785 --> 02:12:45,824 NOTICE OF FUNDING OPPORTUNITY 3505 02:12:45,891 --> 02:12:47,926 ANNOUNCEMENTS FOR THAT. 3506 02:12:47,993 --> 02:12:49,127 ONE AREA DEMONSTRATING 3507 02:12:49,194 --> 02:12:52,197 USEFULNESS IS PRECISION 3508 02:12:52,264 --> 02:12:53,365 MEDICINE, PERSONALIZED MEDICINE. 3509 02:12:53,432 --> 02:12:55,600 EXAMPLE IN TERMS OF PROSTATE 3510 02:12:55,667 --> 02:12:59,304 CANCER METASTASIS TO BONE 3511 02:12:59,371 --> 02:13:05,677 MARROW, METASTATIC RESISTANT 3512 02:13:05,744 --> 02:13:11,249 RESISTANT PROSTATE CANCER IS 3513 02:13:11,316 --> 02:13:13,085 LETHAL, NO CURES, WE'RE RUNNING 3514 02:13:13,151 --> 02:13:20,025 PHASE 2 CLINICAL ARM TRIAL, IMMU 3515 02:13:20,092 --> 02:13:22,160 32, ANTIBODY DRUG CONJUGATE 3516 02:13:22,227 --> 02:13:25,564 WHICH MARKS MOST RAPIDLY 3517 02:13:25,630 --> 02:13:27,366 PROLIFERATING CELLS, AND THIS 3518 02:13:27,432 --> 02:13:35,707 ADC IS CONJUGATED TO DRUG SN-38 3519 02:13:35,774 --> 02:13:37,909 TOPOISOMERASE INHIBITOR, WHICH 3520 02:13:37,976 --> 02:13:38,443 CAUSES APOPTOSIS, RAPIDLY 3521 02:13:38,510 --> 02:13:39,811 PROLIFERATING CELLS. 3522 02:13:39,878 --> 02:13:44,015 SO THIS IS A STUDY SPONSORED BY 3523 02:13:44,082 --> 02:13:44,616 GILEAD. 3524 02:13:44,683 --> 02:13:47,185 WE TAKE TUMOR BIOPSIES FROM 50 3525 02:13:47,252 --> 02:13:49,855 PATIENTS ENROLLED IN PHASE 1 3526 02:13:49,921 --> 02:13:54,559 STUDY, AND PUT IN TISSUE CHIP, 3527 02:13:54,626 --> 02:13:55,594 RECREATE TUMOR MICROENVIRONMENT 3528 02:13:55,660 --> 02:14:00,932 FOR THE PATIENTS SUMP AS 3529 02:14:00,999 --> 02:14:02,234 INCORPORATION OF M2 MACROPHAGES, 3530 02:14:02,300 --> 02:14:03,368 OSTEOBLASTS TO IDENTIFY WHICH OF 3531 02:14:03,435 --> 02:14:05,604 THE PATIENT POPULATION WILL BE 3532 02:14:05,670 --> 02:14:06,805 RESPONDERS AND NON-RESPONDERS 3533 02:14:06,872 --> 02:14:08,774 AND THAT'S BEING ABLE TO 3534 02:14:08,840 --> 02:14:10,308 EFFICIENTLY STRATIFY THE PATIENT 3535 02:14:10,375 --> 02:14:14,146 GROUP FOR MORE EFFICIENT 3536 02:14:14,212 --> 02:14:17,215 CLINICAL TRIALS. 3537 02:14:17,282 --> 02:14:18,450 ONE AREA THAT WE'RE 3538 02:14:18,517 --> 02:14:19,851 DEMONSTRATING UTILITY IN 3539 02:14:19,918 --> 02:14:21,052 BUILDING CONFIDENCE IN THIS 3540 02:14:21,119 --> 02:14:27,559 TECHNOLOGY SO WHAT WE'VE DONE IS 3541 02:14:27,626 --> 02:14:28,493 CREATE VALIDATION FRAMEWORK, 3542 02:14:28,560 --> 02:14:30,362 VALIDATION WOULD BE BY 3543 02:14:30,429 --> 02:14:32,431 DEVELOPERS OF THE TECHNOLOGY 3544 02:14:32,497 --> 02:14:36,067 THROUGH PUBLICATIONS, AND THEN 3545 02:14:36,134 --> 02:14:38,470 NCATS FUNDED ESTABLISHMENT OF 3546 02:14:38,537 --> 02:14:40,105 TISSUE CHIP TESTING CENTERS FOR 3547 02:14:40,172 --> 02:14:43,008 MIT, TEXAS A & M, A FEDERATED 3548 02:14:43,074 --> 02:14:44,943 MPS DATABASE THROUGH UNIVERSITY 3549 02:14:45,010 --> 02:14:47,312 OF PITTSBURGH, PRIMARILY TO 3550 02:14:47,379 --> 02:14:49,915 INDEPENDENTLY TEST RESULTS OF 3551 02:14:49,981 --> 02:14:50,615 THE PHYSIOLOGICAL VALIDATION BY 3552 02:14:50,682 --> 02:14:54,152 DEVELOPERS IN TERMS OF 3553 02:14:54,219 --> 02:14:55,120 DEMONSTRATING ROBUSTNESS, 3554 02:14:55,187 --> 02:14:55,921 REPRODUCIBILITY, RELIABILITY AND 3555 02:14:55,987 --> 02:14:59,124 RELEVANCE OF THE DATA THAT WAS 3556 02:14:59,191 --> 02:15:00,058 GENERATED DURING THE 3557 02:15:00,125 --> 02:15:01,426 PHYSIOLOGICAL VALIDATION. 3558 02:15:01,493 --> 02:15:04,529 AND NOW WE'RE IN THE LAST STAGE 3559 02:15:04,596 --> 02:15:05,630 OF THE VALIDATION FRAMEWORK, 3560 02:15:05,697 --> 02:15:09,000 INDUSTRIAL, WHERE WE HAVE 3561 02:15:09,067 --> 02:15:11,336 ENCOURAGED TESTING CENTERS IN 3562 02:15:11,403 --> 02:15:12,471 THE DATABASE TO FORM 3563 02:15:12,537 --> 02:15:13,538 SELF-SUSTAINING BUSINESS MODELS 3564 02:15:13,605 --> 02:15:17,108 TO BE ABLE TO CONTINUE EFFORTS 3565 02:15:17,175 --> 02:15:20,245 ON THIS PARTICULAR CASE, M.I.T. 3566 02:15:20,312 --> 02:15:28,386 BECAME CRO, NOW JAVELIN BIOTECH, 3567 02:15:28,453 --> 02:15:30,789 AND TEXASA BECAME MODEL 3568 02:15:30,856 --> 02:15:35,026 PARTICIPATING BY ACADEMIA, 3569 02:15:35,093 --> 02:15:40,499 INDUSTRY, MPS IS NOW BIOSYSTICS 3570 02:15:40,565 --> 02:15:41,132 PLATFORM. 3571 02:15:41,199 --> 02:15:42,901 DEMONSTRATING UTILITY WE'VE SEEN 3572 02:15:42,968 --> 02:15:44,870 INCREASED USE OF MPS, TISSUE 3573 02:15:44,936 --> 02:15:46,605 CHIPS BY PHARMA. 3574 02:15:46,671 --> 02:15:49,007 WE PARTNERED WITH THE MPS 3575 02:15:49,074 --> 02:15:51,109 AFFILIATE, MADE UP OF 26 PHARMA 3576 02:15:51,176 --> 02:15:53,645 COMPANIES, AND THROUGH OUR 3577 02:15:53,712 --> 02:15:54,179 PARTNERSHIPS THEY HAVE 3578 02:15:54,246 --> 02:15:56,581 CO-AUTHORED A NUMBER OF 3579 02:15:56,648 --> 02:15:58,316 PUBLICATIONS INDICATING WHAT ARE 3580 02:15:58,383 --> 02:15:59,851 FIT FOR PURPOSE FOR INDUSTRY 3581 02:15:59,918 --> 02:16:03,455 USE, IN TERMS OF VARIOUS ORGAN 3582 02:16:03,522 --> 02:16:05,891 SYSTEMS, WHAT TYPES OF 3583 02:16:05,957 --> 02:16:07,192 BIOMARKERS AND ASSAYS ARE 3584 02:16:07,259 --> 02:16:09,294 NEEDED, PARTICULARLY IN THE 3585 02:16:09,361 --> 02:16:11,296 AREAS OF HIGH NEEDS WITHIN 3586 02:16:11,363 --> 02:16:15,333 PHARMA AND OF COURSE IN DRUG 3587 02:16:15,400 --> 02:16:17,669 DEVELOPMENT AS WELL. 3588 02:16:17,736 --> 02:16:21,540 HERE IS A SNAPSHOT OF THINGS, 3589 02:16:21,606 --> 02:16:22,541 ACTIVITIES DONE BY PHARMA. 3590 02:16:22,607 --> 02:16:26,411 HERE ARE THE END USERS, 3591 02:16:26,478 --> 02:16:28,079 PRIMARILY THE LARGE 3592 02:16:28,146 --> 02:16:29,714 PHARMACEUTICAL COMPANIES, AND 3593 02:16:29,781 --> 02:16:30,916 THEN COMMERCIAL COMPANIES THAT 3594 02:16:30,982 --> 02:16:32,183 SUPPLY TISSUE CHIPS, AND 3595 02:16:32,250 --> 02:16:34,886 DIFFERENT TISSUE CHIPS SHOWN IN 3596 02:16:34,953 --> 02:16:37,589 THE COLUMN BY DIFFERENT -- USED 3597 02:16:37,656 --> 02:16:38,456 BY DIFFERENT PHARMA COMPANIES, 3598 02:16:38,523 --> 02:16:42,093 AND WHAT THEY ARE USED FOR IN 3599 02:16:42,160 --> 02:16:42,928 DRUG DEVELOPMENT. 3600 02:16:42,994 --> 02:16:47,832 SO PRIMARILY CENTERED WITHIN 3601 02:16:47,899 --> 02:16:48,934 TARGET IDENTIFICATION, 3602 02:16:49,000 --> 02:16:53,705 PRE-CLINICAL SAFETY, 3603 02:16:53,772 --> 02:17:00,812 PRE-CLINICAL EVE CASE, FARM COVE 3604 02:17:00,879 --> 02:17:02,113 KINNETT-- PHARMACOKINETICS. 3605 02:17:02,180 --> 02:17:04,449 THIS IS IN ADDITION TO BUILDING 3606 02:17:04,516 --> 02:17:05,850 CONFIDENCE BY ALLOWING ACCESS TO 3607 02:17:05,917 --> 02:17:06,117 THE DATA. 3608 02:17:06,184 --> 02:17:10,021 THIS IS ALSO ONE WAY THAT WE'RE 3609 02:17:10,088 --> 02:17:10,622 DISSEMINATING THE INFORMATION 3610 02:17:10,689 --> 02:17:13,892 WHERE WE CERTAINLY TAKE 3611 02:17:13,959 --> 02:17:18,330 EXPERIMENTAL DATA FROM TISSUE 3612 02:17:18,396 --> 02:17:20,231 CHIP OR MICROPHYSIOLOGICAL 3613 02:17:20,298 --> 02:17:21,399 SYSTEMS, INCORPORATE WITH META 3614 02:17:21,466 --> 02:17:23,602 DATA COMING FROM CLINICAL 3615 02:17:23,668 --> 02:17:25,737 DATASETS, PRE-CLINICAL DATA, AS 3616 02:17:25,804 --> 02:17:27,672 WELL AS COMPOUNDS THAT HAVE 3617 02:17:27,739 --> 02:17:28,773 ALL -- UNIVERSAL COMPOUNDS HAVE 3618 02:17:28,840 --> 02:17:30,108 BEEN TESTED IN HUMANS. 3619 02:17:30,175 --> 02:17:35,981 MOREOVER ON TOP OF THAT, 3620 02:17:36,047 --> 02:17:37,749 ANALYTICAL TOOLS HAVE BEEN 3621 02:17:37,816 --> 02:17:39,050 DEVELOPED BY THE DATABASE TO BE 3622 02:17:39,117 --> 02:17:41,820 ABLE TO BE USED IN TERMS OF 3623 02:17:41,886 --> 02:17:43,488 DETERMINING EXPERIMENTAL MODEL 3624 02:17:43,555 --> 02:17:44,789 AND REPRODUCIBILITY, COMPOUND 3625 02:17:44,856 --> 02:17:47,692 SAFETY AND EFFICACY, AS WELL AS 3626 02:17:47,759 --> 02:17:49,928 MECHANISM OF DISEASE, MECHANISM 3627 02:17:49,995 --> 02:17:51,229 OF COMPOUND ACTION, BEING ABLE 3628 02:17:51,296 --> 02:17:59,304 TO DEVELOP COMPUTATIONAL MODELS 3629 02:17:59,371 --> 02:18:02,807 FOR ADME AND TOXICITY AND 3630 02:18:02,874 --> 02:18:03,708 DISEASE PATHOLOGY. 3631 02:18:03,775 --> 02:18:05,377 ONE WAY WE'RE DISSEMINATING 3632 02:18:05,443 --> 02:18:13,752 TECHNOLOGY BY PARTNERSHIP WITH 3633 02:18:13,818 --> 02:18:14,719 OFFICE OF STRATEGIC ALLIANCE 3634 02:18:14,786 --> 02:18:17,055 ENCOURAGING FORMATION OF 3635 02:18:17,122 --> 02:18:19,958 START-UP AND SPINOFF COMPANIES, 3636 02:18:20,025 --> 02:18:23,328 IN THIS AREA OF 3D TISSUE 3637 02:18:23,395 --> 02:18:26,031 MODELS, AND LARGELY HAVE BEEN 3638 02:18:26,097 --> 02:18:27,332 SUPPORTED THROUGH SMALL BUSINESS 3639 02:18:27,399 --> 02:18:28,833 FUNDS, NOT ONLY BY NCATS BUT 3640 02:18:28,900 --> 02:18:33,338 CERTAINLY BY THE NIH AS WELL. 3641 02:18:33,405 --> 02:18:34,839 LASTLY, ONE AREA OF 3642 02:18:34,906 --> 02:18:37,909 DISSEMINATION WE'RE TRYING TO DO 3643 02:18:37,976 --> 02:18:42,247 IS IN GOING TOWARDS REGULATORY 3644 02:18:42,313 --> 02:18:43,348 ACCEPTANCE, SO IN THIS 3645 02:18:43,415 --> 02:18:46,051 PARTICULAR ACTIVITY WE HAVE 3646 02:18:46,117 --> 02:18:48,720 ESTABLISHED TRANSLATIONAL 3647 02:18:48,787 --> 02:18:49,354 CENTERS FOR MICROPHYSIOLOGICAL 3648 02:18:49,421 --> 02:18:51,790 SYSTEMS, THIS IS A LETTER OF 3649 02:18:51,856 --> 02:18:53,858 AGREEMENT WITH NCATS AND FDA 3650 02:18:53,925 --> 02:18:56,394 WITH NOTION THAT WE WOULD FUND 3651 02:18:56,461 --> 02:18:58,530 ABOUT THREE TO FOUR CENTERS, ALL 3652 02:18:58,596 --> 02:19:01,499 OVER THE UNITED STATES, AND EACH 3653 02:19:01,566 --> 02:19:04,335 CENTER WOULD TAKE FOUR TO FIVE 3654 02:19:04,402 --> 02:19:05,770 VALIDATED MPS WITH SPECIFIC 3655 02:19:05,837 --> 02:19:07,739 CONTEXT OF USE, AND WORK 3656 02:19:07,806 --> 02:19:11,443 ALONGSIDE THE FDA IN BEING ABLE 3657 02:19:11,509 --> 02:19:13,745 TO DEVELOP QUALIFICATION 3658 02:19:13,812 --> 02:19:14,713 SUBMISSION PACKAGE THAT FDA 3659 02:19:14,779 --> 02:19:19,117 WOULD REQUIRE TO BE ABLE TO 3660 02:19:19,184 --> 02:19:20,318 QUALIFY THESE TISSUE CHIPS AS 3661 02:19:20,385 --> 02:19:22,020 DRUG DEVELOPMENT TOOLS. 3662 02:19:22,087 --> 02:19:23,221 WHAT WE HAVE ULTIMATELY WOULD BE 3663 02:19:23,288 --> 02:19:25,223 TISSUE CHIPS FIT FOR PURPOSE, 3664 02:19:25,290 --> 02:19:27,392 FOR INDUSTRY NEEDS, WITH 3665 02:19:27,459 --> 02:19:29,861 SPECIFIC CONTEXT OF USE, THAT 3666 02:19:29,928 --> 02:19:30,929 MEETS REGULATORY QUALIFICATION, 3667 02:19:30,995 --> 02:19:33,064 AND THEN BE ABLE TO RAPIDLY 3668 02:19:33,131 --> 02:19:34,699 COMMERCIALIZE THAT SO IT CAN BE 3669 02:19:34,766 --> 02:19:40,605 USED BY THE GENERAL RESEARCH 3670 02:19:40,672 --> 02:19:40,872 COMMUNITY. 3671 02:19:40,939 --> 02:19:45,643 THE LAST YEAR IN TERMS OF 3672 02:19:45,710 --> 02:19:51,316 DISSEMINATION IS THROUGH 3673 02:19:51,382 --> 02:19:52,851 ESTABLISHMENT OF INTERNATIONAL 3674 02:19:52,917 --> 02:19:54,819 USERS THROUGH MPS WORLD SUMMIT, 3675 02:19:54,886 --> 02:19:58,123 PRIMARILY WORKING WITH ALL THE 3676 02:19:58,189 --> 02:20:00,625 MAJOR STAKEHOLDERS, PHARMA, 3677 02:20:00,692 --> 02:20:02,894 REGULATORY AGENCIES, ACADEMICS, 3678 02:20:02,961 --> 02:20:04,863 INDUSTRY, TO BE ABLE TO CONNECT, 3679 02:20:04,929 --> 02:20:06,564 EXCHANGE, EDUCATE EACH OTHER IN 3680 02:20:06,631 --> 02:20:11,169 THE USE OF TISSUE CHIPS, SO 3681 02:20:11,236 --> 02:20:14,539 NCATS FUNDED THROUGH SEED 3682 02:20:14,606 --> 02:20:15,673 FUNDING CONFERENCE IN NEW 3683 02:20:15,740 --> 02:20:17,742 ORLEANS, 2022, AND JUST LAST 3684 02:20:17,809 --> 02:20:19,310 YEAR IN BERLIN, GERMANY. 3685 02:20:19,377 --> 02:20:21,079 JUST TO SHOW THE INTEREST, BY 3686 02:20:21,146 --> 02:20:24,916 THE COMMUNITY, NEW ORLEANS WE 3687 02:20:24,983 --> 02:20:27,552 HAD 450 IN-PERSON ATTENDEES, 3688 02:20:27,619 --> 02:20:29,988 ALMOST 1300 IN BERLIN, A NUMBER 3689 02:20:30,054 --> 02:20:31,523 OF ABSTRACTS THAT HAVE MORE THAN 3690 02:20:31,589 --> 02:20:34,793 DOUBLED IN BERLIN COMPARED TO 3691 02:20:34,859 --> 02:20:36,528 NEW ORLEANS, SPEAKERS REMAIN 3692 02:20:36,594 --> 02:20:37,428 CONSTANT, IT'S A FOUR-DAY 3693 02:20:37,495 --> 02:20:39,030 SYMPOSIUM, WE HAVE TO KEEP THE 3694 02:20:39,097 --> 02:20:41,533 NUMBER OF SPEAKERS AT THE 3695 02:20:41,599 --> 02:20:45,436 OPTIMAL LEVEL, BUT THE NUMBER OF 3696 02:20:45,503 --> 02:20:47,539 POSTERS AS WELL WELL AS EARLY 3697 02:20:47,605 --> 02:20:48,306 STAGE INVESTIGATORS HAVE GROWN 3698 02:20:48,373 --> 02:20:50,375 IN NUMBER AS WELL AS 3699 02:20:50,441 --> 02:20:52,877 PARTICIPATING COUNTRIES AND 3700 02:20:52,944 --> 02:20:57,682 NUMBER OF SPONSORS. 3701 02:20:57,749 --> 02:20:59,017 THE LAST AREA WE'RE DOING TO 3702 02:20:59,083 --> 02:21:05,123 TRAIN THE NEXT GENERATION IN 3703 02:21:05,190 --> 02:21:05,590 SCIENTISTS, ESTABLISH 3704 02:21:05,657 --> 02:21:11,196 INTERNATIONAL MPS SOCIETY WITH A 3705 02:21:11,262 --> 02:21:12,263 VISION TO ACCELERATE MPS, 3706 02:21:12,330 --> 02:21:13,364 IMPROVE HEALTH AND ENVIRONMENT, 3707 02:21:13,431 --> 02:21:15,200 TRAIN THE NEXT GENERATION OF 3708 02:21:15,266 --> 02:21:16,334 SCIENTISTS IN THE NEW 3709 02:21:16,401 --> 02:21:18,403 TECHNOLOGY, JUST TO BRING TO 3710 02:21:18,469 --> 02:21:19,838 YOUR ATTENTION THAT THIS YEAR 3711 02:21:19,904 --> 02:21:22,841 WE'RE HAVING OUR THIRD ANNUAL 3712 02:21:22,907 --> 02:21:29,514 MEETING IN SEATTLE, JUNE 10-14. 3713 02:21:29,581 --> 02:21:30,615 AND THEN BECAUSE OF THE NCATS 3714 02:21:30,682 --> 02:21:32,050 INVESTMENT AND ACTIVITIES IN 3715 02:21:32,116 --> 02:21:33,785 LEADING THE EFFORTS IN TERMS OF 3716 02:21:33,852 --> 02:21:35,253 IN VITRO MODEL, CERTAINLY 3717 02:21:35,320 --> 02:21:36,788 THERE'S BEEN A SURGE IN 3718 02:21:36,855 --> 02:21:40,658 INTEREST, NOT ONLY WITHIN NIH 3719 02:21:40,725 --> 02:21:43,862 BUT ACROSS FEDERAL AGENCIES, AND 3720 02:21:43,928 --> 02:21:44,529 ACROSS THE BIOMEDICAL RESEARCH 3721 02:21:44,596 --> 02:21:47,599 COMMUNITY IN USE OF NEW 3722 02:21:47,665 --> 02:21:48,700 APPROACHES METHODOLOGIES, 3723 02:21:48,766 --> 02:21:49,234 NAMs. 3724 02:21:49,300 --> 02:21:54,272 AS JONI MENTIONED IN HER 3725 02:21:54,339 --> 02:21:56,908 DIRECTOR'S REPORT, THERE'S A NEW 3726 02:21:56,975 --> 02:21:57,709 EFFORT CONCEPT WITHIN NIH COMMON 3727 02:21:57,775 --> 02:22:04,349 FUND TO LOOK AT THE VARIOUS NAM 3728 02:22:04,415 --> 02:22:06,217 APPROACHES, IN SILICO, SUCH AS 3729 02:22:06,284 --> 02:22:08,720 IN SILICO MODELING, COMPLEX IN 3730 02:22:08,786 --> 02:22:11,322 VITRO, CHEMICAL SENSING, BE ABLE 3731 02:22:11,389 --> 02:22:13,558 TO INTEGRATE THAT TOGETHER, TO 3732 02:22:13,625 --> 02:22:15,326 FORM LIKE A COMMON DATA 3733 02:22:15,393 --> 02:22:18,663 ECOSYSTEM WHERE ALL THE DATASETS 3734 02:22:18,730 --> 02:22:20,632 ARE BEING INTEGRATED AND AS JONI 3735 02:22:20,698 --> 02:22:24,936 MENTIONED BEING ABLE TO LOOK AT 3736 02:22:25,003 --> 02:22:27,872 THE WHOLE BEING BETTER THAN THE 3737 02:22:27,939 --> 02:22:30,541 SUM OF ITS PARTS. 3738 02:22:30,608 --> 02:22:33,011 AND THEN I'D LIKE TO THANK THE 3739 02:22:33,077 --> 02:22:34,545 PROGRAM STAFF THAT ARE VERY 3740 02:22:34,612 --> 02:22:42,420 INVOLVED IN THE TISSUE CHIP 3741 02:22:42,487 --> 02:22:43,855 PROGRAM. 3742 02:22:43,922 --> 02:22:45,690 AND ACKNOWLEDGE ALL THE OTHER 3743 02:22:45,757 --> 02:22:48,126 PARTNERS IN THE DIFFERENT 3744 02:22:48,192 --> 02:22:49,527 INSTITUTES AND CENTERS AT THE 3745 02:22:49,594 --> 02:22:51,629 NIH, PARTNERSHIP WAS THE FOOD 3746 02:22:51,696 --> 02:22:55,533 AND DRUG ADMINISTRATION, IQ MPS 3747 02:22:55,600 --> 02:22:56,768 AFFILIATE, NASA, BARDA, 3748 02:22:56,834 --> 02:22:57,735 INTERNATIONAL SPACE STATION, 3749 02:22:57,802 --> 02:22:59,938 NATIONAL LABORATORY. 3750 02:23:00,004 --> 02:23:06,277 WITH THAT I'LL END WITH CALL FOR 3751 02:23:06,344 --> 02:23:07,578 QUESTIONS, PRIMARILY CERTAINLY 3752 02:23:07,645 --> 02:23:09,647 WOULD APPRECIATE COMMENTS FROM 3753 02:23:09,714 --> 02:23:11,983 COUNCIL MEMBERS IN TERMS OF FOUR 3754 02:23:12,050 --> 02:23:13,618 AREAS THAT I'VE IDENTIFIED IN 3755 02:23:13,685 --> 02:23:16,454 TERMS OF WHAT OTHER AREAS OF 3756 02:23:16,521 --> 02:23:17,755 BIOMEDICAL RESEARCH APPLICATIONS 3757 02:23:17,822 --> 02:23:21,192 CAN NCATS LEVERAGE, TISSUE CHIP 3758 02:23:21,259 --> 02:23:23,661 TECHNOLOGIES, ARE THERE 3759 02:23:23,728 --> 02:23:24,862 ADDITIONAL STAKEHOLDERS NCATS 3760 02:23:24,929 --> 02:23:29,033 SHOULD ENGAGE FOR DISSEMINATION, 3761 02:23:29,100 --> 02:23:30,601 AND THIRDLY BEYOND TRADITIONAL 3762 02:23:30,668 --> 02:23:31,436 CENTERS FOR MPS DOES COUNCIL 3763 02:23:31,502 --> 02:23:34,706 ENVISION OTHER ACTIVITIES TO GET 3764 02:23:34,772 --> 02:23:36,007 TO PROMOTE WIDESPREAD ADOPTION, 3765 02:23:36,074 --> 02:23:37,475 AND THEN THE LAST BULLET WOULD 3766 02:23:37,542 --> 02:23:40,411 BE HOW CAN NIH BUILD UPON NCATS' 3767 02:23:40,478 --> 02:23:43,514 INVESTMENT IN TISSUE CHIPS TO 3768 02:23:43,581 --> 02:23:54,058 ENHANCE GOAL OFP NIH COMMON 3769 02:23:55,059 --> 02:23:58,029 GUNNED COMPLEMENT-ARIE PROGRAM 3770 02:23:58,096 --> 02:24:00,331 AND HOW DO WE COORDINATE WITH 3771 02:24:00,398 --> 02:24:01,866 INTERNATIONAL FUNDING AND 3772 02:24:01,933 --> 02:24:09,741 REGULATORY AGENCIES AND I'LL 3773 02:24:09,807 --> 02:24:12,577 ENTERTAIN QUESTIONS FROM 3774 02:24:12,643 --> 02:24:13,144 COUNCIL. 3775 02:24:13,211 --> 02:24:14,445 >> I SEE MATTIAS AND MARSHALL TO 3776 02:24:14,512 --> 02:24:16,581 GET US STARTED. 3777 02:24:16,647 --> 02:24:19,317 AS OTHERS THINGS WE'LL START 3778 02:24:19,384 --> 02:24:19,984 WITH MATTIAS. 3779 02:24:20,051 --> 02:24:23,321 >> CONGRATULATIONS. 3780 02:24:23,388 --> 02:24:24,822 YOU HAVE BUILT A FULCRUM, ONE OF 3781 02:24:24,889 --> 02:24:28,092 THE DIAMONDS IN THE NCATS 3782 02:24:28,159 --> 02:24:28,693 PORTFOLIO. 3783 02:24:28,760 --> 02:24:31,295 IT IS REALLY, REALLY IMPRESSIVE. 3784 02:24:31,362 --> 02:24:32,096 SO MANY LEVELS. 3785 02:24:32,163 --> 02:24:34,198 TO AN EXTENT I HAVE TO SAY WHEN 3786 02:24:34,265 --> 02:24:38,002 YOU BUILD OUT YOUR TRIAD WHERE 3787 02:24:38,069 --> 02:24:40,171 MPSs ARE KEY SOURCE OF 3788 02:24:40,238 --> 02:24:42,840 INFORMATION, ONE ASPECT WHICH I 3789 02:24:42,907 --> 02:24:45,443 WOULD RECOMMEND TO CONSIDER IS 3790 02:24:45,510 --> 02:24:46,677 ALSO FOR VALIDATION, 3791 02:24:46,744 --> 02:24:48,846 REGISTRATION, CONTEXT OF USE 3792 02:24:48,913 --> 02:24:50,581 DEFINITION IS LET'S GO BACK TO 3793 02:24:50,648 --> 02:24:53,651 OUR PATIENTS, AND PATIENTS AS WE 3794 02:24:53,718 --> 02:24:55,319 DISCUSSED EARLIER IF WE ENGAGE 3795 02:24:55,386 --> 02:24:58,656 THEM PROPERLY THEY ARE WILLING 3796 02:24:58,723 --> 02:25:00,825 TO DO THAT, IN THE SENSE ONE OF 3797 02:25:00,892 --> 02:25:05,029 THE MAIN CHALLENGES RIGHT NOW IS 3798 02:25:05,096 --> 02:25:06,831 TO BENCHMARK THE CLINICAL TRIALS 3799 02:25:06,898 --> 02:25:10,334 ON THE CHIP AGAINST OUR CLINICAL 3800 02:25:10,401 --> 02:25:13,638 TRIALS IN HUMANS. 3801 02:25:13,704 --> 02:25:15,840 AND THE CHIP FORMS ARE 3802 02:25:15,907 --> 02:25:16,941 OUTPERFORMING OUR KNOWLEDGE 3803 02:25:17,008 --> 02:25:18,709 ACQUISITION FROM HUMANS BY 3804 02:25:18,776 --> 02:25:21,612 ORDERS OF MAGNITUDE, MAYBE 3805 02:25:21,679 --> 02:25:23,247 EXCEPT IN THE NEOPLASTIC FIELD. 3806 02:25:23,314 --> 02:25:25,016 WITH THE TECHNOLOGIES WHICH WE 3807 02:25:25,083 --> 02:25:26,651 SEE RAPIDLY EXPLODING IN EVEN 3808 02:25:26,717 --> 02:25:29,253 OUT OF SMALL AMOUNTS OF TISSUE 3809 02:25:29,320 --> 02:25:31,322 TO GENERATE MASSIVE AMOUNTS OF 3810 02:25:31,389 --> 02:25:34,092 DATA, WHICH WILL ALLOW YOUR 3811 02:25:34,158 --> 02:25:39,330 A.I.-DRIVEN DISEASE MODELING TO 3812 02:25:39,397 --> 02:25:40,431 USE PATIENT-DERIVED MATERIALS, 3813 02:25:40,498 --> 02:25:43,301 IT WILL BE FOR MY FIELD AND 3814 02:25:43,367 --> 02:25:45,236 PRECISION MEDICINE CONCEPTS WE 3815 02:25:45,303 --> 02:25:48,473 HAVE NOW 18 DIFFERENT HIGHLY 3816 02:25:48,539 --> 02:25:49,207 COMPLEX PROFILING TECHNOLOGIES 3817 02:25:49,273 --> 02:25:54,946 RUN AGAINST TWO FINE NEEDLE 3818 02:25:55,012 --> 02:25:56,881 BIOPSIES FROM PATIENT VOLUNTEERS 3819 02:25:56,948 --> 02:25:59,317 WHO DONATE TISSUE RESEARCH IN 3820 02:25:59,383 --> 02:26:01,686 CLINICAL CARE AND CLINICAL 3821 02:26:01,752 --> 02:26:01,919 TRIALS. 3822 02:26:01,986 --> 02:26:04,422 SO, JONI, WHAT MIGHT BE ONE 3823 02:26:04,489 --> 02:26:08,726 UNIQUE SPOT FOR NCATS IS THAT IF 3824 02:26:08,793 --> 02:26:09,727 YOU COUPLE OPERATIONAL WITH 3825 02:26:09,794 --> 02:26:11,462 EFFORT IN THE RARE DISEASE 3826 02:26:11,529 --> 02:26:15,166 NETWORKS THAT YOU HAVE ACCESS TO 3827 02:26:15,233 --> 02:26:15,733 HIGHLY DEDICATED PATIENT 3828 02:26:15,800 --> 02:26:19,570 POPULATIONS, WHO ARE WILLING TO 3829 02:26:19,637 --> 02:26:21,172 DONATE THESE TO RESEARCH, THEY 3830 02:26:21,239 --> 02:26:25,776 ARE REALLY DOING THIS, EVEN 3831 02:26:25,843 --> 02:26:27,345 DONATING BIOPSIES, IN TISSUE 3832 02:26:27,411 --> 02:26:29,714 RISKY TO BIOPSY KIDNEY 3833 02:26:29,780 --> 02:26:30,948 SUCCESSFULLY AND SAFELY, YOU CAN 3834 02:26:31,015 --> 02:26:32,817 DO THE SAME FOR MANY OTHER 3835 02:26:32,884 --> 02:26:34,418 CHRONIC DISEASES WITH ORGANS ARE 3836 02:26:34,485 --> 02:26:36,787 ACCESSIBLE AND THEY ARE 3837 02:26:36,854 --> 02:26:38,823 INNOVATIVE WAYS IF YOU START 3838 02:26:38,890 --> 02:26:40,024 WITH SMALL COHORT OF A FEW 3839 02:26:40,091 --> 02:26:42,326 HUNDRED PEOPLE WHERE HAVE YOU 3840 02:26:42,393 --> 02:26:44,162 THAT KNOWLEDGE, THEN PROJECT OUT 3841 02:26:44,228 --> 02:26:48,933 INTO THE EX VIVO SYSTEMS WHERE 3842 02:26:49,000 --> 02:26:55,306 CLINICALLY TISSUE ON A CHIP CAN 3843 02:26:55,373 --> 02:26:56,240 BE TUNED SO WE KNOW WHERE IT 3844 02:26:56,307 --> 02:26:57,475 WORKS AND DOESN'T. 3845 02:26:57,542 --> 02:26:59,076 NO OTHER PLACE TO DO THAT THAN 3846 02:26:59,143 --> 02:27:06,083 NCATS BECAUSE YOU HAVE THE 3847 02:27:06,150 --> 02:27:07,185 PLATFORM AVAILABLE, RDCRN AND 3848 02:27:07,251 --> 02:27:08,853 CTSA FOR RARE AND COMMON 3849 02:27:08,920 --> 02:27:10,588 DISEASE, BLOOD FORM, IF WE 3850 02:27:10,655 --> 02:27:12,423 ENGAGE PATIENTS EARLY THAT THEY 3851 02:27:12,490 --> 02:27:15,193 ARE THE STAKEHOLDERS IN OUR RARE 3852 02:27:15,259 --> 02:27:16,394 DISEASE NETWORK, MARSHALL, WE 3853 02:27:16,460 --> 02:27:17,795 WILL SUPPORT IT, THEY ARE 3854 02:27:17,862 --> 02:27:21,632 DRIVING US TOWARDS THESE TYPE OF 3855 02:27:21,699 --> 02:27:24,402 APPROACHES, SO PATIENT ADOPTION 3856 02:27:24,468 --> 02:27:25,069 IS SIGNIFICANTLY LESS A 3857 02:27:25,136 --> 02:27:31,309 CHALLENGE THAN IN THE PAST. 3858 02:27:31,375 --> 02:27:33,177 STAY IN TOUCH, PARTICULARLY 3859 02:27:33,244 --> 02:27:34,145 ASTHMA, TECHNOLOGY DEVELOPMENT 3860 02:27:34,212 --> 02:27:40,418 WHICH ALLOWS US TO FEED INTO 3861 02:27:40,484 --> 02:27:41,953 A.I. DRIVEN, IF YOU WOULD HAVE 3862 02:27:42,019 --> 02:27:47,825 ASKED ME THREE OR FOUR YEARS AGO 3863 02:27:47,892 --> 02:27:51,329 WOULD HAVE BEEN UNIMAGINABLE, 3864 02:27:51,395 --> 02:27:55,299 MONITOR STATES OUT OF 3865 02:27:55,366 --> 02:27:58,035 CROSS-SECTIONAL ASSESSMENT, AS 3866 02:27:58,102 --> 02:27:58,669 WAS BEAUTIFULLY PUBLISHED BUILD 3867 02:27:58,736 --> 02:28:03,541 EX VIVO ORGAN ON A BLOOD MODEL 3868 02:28:03,608 --> 02:28:06,210 SYSTEMS TO PREDICT TOXICITY OF 3869 02:28:06,277 --> 02:28:07,545 ORGAN CROSSTALK, NOT ABLE TO 3870 02:28:07,612 --> 02:28:08,246 CAPTURE EARLY. 3871 02:28:08,312 --> 02:28:12,416 RAW MATERIALS ARE IN PLACE, 3872 02:28:12,483 --> 02:28:13,985 CLEARLY CLINICAL COLLEAGUES 3873 02:28:14,051 --> 02:28:16,754 OUTPERFORMED US WITH DATA AND 3874 02:28:16,821 --> 02:28:17,521 INFORMATION CAPTURE, BUT 3875 02:28:17,588 --> 02:28:19,323 CLINICAL FRAMEWORK IF NCATS IS 3876 02:28:19,390 --> 02:28:26,897 WILLING TO DRIVE THAT FRAMEWORK. 3877 02:28:26,964 --> 02:28:29,100 >> THANK YOU FOR YOUR COMMENTS 3878 02:28:29,166 --> 02:28:30,034 AND SUGGESTIONS. 3879 02:28:30,101 --> 02:28:31,269 CERTAINLY THAT'S IN OUR MIND IN 3880 02:28:31,335 --> 02:28:34,672 TERMS OF HOW WE ARE MOVING 3881 02:28:34,739 --> 02:28:35,673 FORWARD WITH TISSUE CHIPS, 3882 02:28:35,740 --> 02:28:37,441 ESPECIALLY WITH POWERED BY THE 3883 02:28:37,508 --> 02:28:40,011 NIH COMMON FUND WHERE WE'RE 3884 02:28:40,077 --> 02:28:41,679 ACTUALLY LOOKING TO CREATE 3885 02:28:41,746 --> 02:28:42,747 DIGITAL TWINS WITH ELECTRONIC 3886 02:28:42,813 --> 02:28:43,981 HEALTH RECORDS OF PATIENTS, AND 3887 02:28:44,048 --> 02:28:47,151 THEN BEING ABLE TO PAIR THAT 3888 02:28:47,218 --> 02:28:48,853 WITH BIOMEMETIC TWINS OR TISSUE 3889 02:28:48,919 --> 02:28:51,322 CHIPS SO WE CAN IN SOME WAYS 3890 02:28:51,389 --> 02:28:52,189 CROSS-VALIDATE EACH OTHER BOTH 3891 02:28:52,256 --> 02:29:00,865 IN TERMS OF THE DIGITAL OR COME 3892 02:29:00,931 --> 02:29:03,301 COMPUTATIONAL PREDICTIONS, 3893 02:29:03,367 --> 02:29:04,802 LOOKING AT HOW CLOSE 3894 02:29:04,869 --> 02:29:07,538 APPROXIMATION WE GET WITH 3895 02:29:07,605 --> 02:29:10,808 COMPUTATIONAL OR IN VITRO 3896 02:29:10,875 --> 02:29:11,108 VALIDATION. 3897 02:29:11,175 --> 02:29:14,245 >> ONE THING I WOULD ADD TOO, 3898 02:29:14,312 --> 02:29:15,846 MATTIAS, I THINK YOU'RE 3899 02:29:15,913 --> 02:29:17,548 ABSOLUTELY RIGHT. 3900 02:29:17,615 --> 02:29:18,249 THAT'S THE DIRECTION, AT LEAST 3901 02:29:18,316 --> 02:29:19,817 ONE OF THE DIRECTIONS WE'RE 3902 02:29:19,884 --> 02:29:23,321 INTERESTED IN GOING INTO, AND I 3903 02:29:23,387 --> 02:29:24,655 MENTIONED THE I3D WORKSHOP, PART 3904 02:29:24,722 --> 02:29:26,257 OF THAT IS ALSO TRYING TO ENSURE 3905 02:29:26,324 --> 02:29:29,093 WE HAVE SOME SORT OF FRAMEWORK 3906 02:29:29,160 --> 02:29:32,596 TO DO THAT, IN ADDITION YOU TALK 3907 02:29:32,663 --> 02:29:34,632 ABOUT THE ACCESSIBLE ORGANS, I 3908 02:29:34,699 --> 02:29:36,600 THINK THAT'S SUPER IMPORTANT. 3909 02:29:36,667 --> 02:29:41,272 WE'VE BEEN USING iPS CELLS, 3910 02:29:41,339 --> 02:29:43,374 GENERATING, YOU KNOW, REDERIVED 3911 02:29:43,441 --> 02:29:45,076 SPECIFIC CELL TYPES, SO THAT'S 3912 02:29:45,142 --> 02:29:47,645 AN IMPORTANT TECHNOLOGY BUT 3913 02:29:47,712 --> 02:29:49,680 GETTING PRIMARY CELLS IS ALSO 3914 02:29:49,747 --> 02:29:51,315 IMPORTANT IF WE CAN, AND THE 3915 02:29:51,382 --> 02:29:52,683 THIRD APPROACH THAT WE'VE BEEN 3916 02:29:52,750 --> 02:29:58,322 LOOKING AT IS USING CRISPR TO 3917 02:29:58,389 --> 02:29:59,323 THEN CREATE THE MUTATION WE 3918 02:29:59,390 --> 02:30:00,091 MIGHT SEE IN A PARTICULAR 3919 02:30:00,157 --> 02:30:03,327 DISEASE AREA. 3920 02:30:03,394 --> 02:30:04,695 SO THOSE THREE APPROACHES I 3921 02:30:04,762 --> 02:30:06,997 THINK, LOOKING AT THEM IN 3922 02:30:07,064 --> 02:30:10,234 PARALLEL, DOING THE DEEP SORT OF 3923 02:30:10,301 --> 02:30:13,704 TECHNICAL WORK TO EVALUATE ANY 3924 02:30:13,771 --> 02:30:16,374 DIFFERENCES WILL TELL US, YOU 3925 02:30:16,440 --> 02:30:18,876 KNOW, WHETHER WE LOSE THE 3926 02:30:18,943 --> 02:30:20,010 GRANULARITY OR IF THAT 3927 02:30:20,077 --> 02:30:21,746 GRANULARITY IS EVEN IMPORTANT. 3928 02:30:21,812 --> 02:30:23,614 SO I THINK, YOU KNOW, BEING ABLE 3929 02:30:23,681 --> 02:30:25,916 TO DO THOSE KINDS OF STUDIES IS 3930 02:30:25,983 --> 02:30:27,752 SOMETHING WE WANT TO ALSO 3931 02:30:27,818 --> 02:30:30,721 ESTABLISH AS WELL, ON THAT 3932 02:30:30,788 --> 02:30:33,157 COURSE, TO MORE CLINICAL 3933 02:30:33,224 --> 02:30:33,457 ENGAGEMENT. 3934 02:30:33,524 --> 02:30:37,962 >> JONI, BUILD IN THE CLOSING, 3935 02:30:38,028 --> 02:30:40,164 BUILD IN A COHORT WHERE YOU 3936 02:30:40,231 --> 02:30:41,198 ACTUALLY TEST YOUR MODELS, AND 3937 02:30:41,265 --> 02:30:43,667 YOU WILL SEE WHERE YOUR MODELS 3938 02:30:43,734 --> 02:30:46,070 FAIL AND THEN WITH POWER OF THE 3939 02:30:46,137 --> 02:30:48,038 MODEL BUILDS YOU HAVE RIGHT NOW, 3940 02:30:48,105 --> 02:30:54,512 A FEW ITERATIONS, YOU WILL MAKE 3941 02:30:54,578 --> 02:30:56,847 LEAPS FORWARD WITHOUT BENCH 3942 02:30:56,914 --> 02:30:57,915 MARKING AGAINST IN VIVO STATE, 3943 02:30:57,982 --> 02:31:00,751 IN CLINICAL TRIALS YOU WILL DO 3944 02:31:00,818 --> 02:31:01,218 THE DO THAT. 3945 02:31:01,285 --> 02:31:02,286 THE TECHNOLOGY IS THERE. 3946 02:31:02,353 --> 02:31:05,456 PATIENT INTEREST IS THERE. 3947 02:31:05,523 --> 02:31:06,991 YOU HAVE TO PUSH CLINICIAN 3948 02:31:07,057 --> 02:31:08,893 SCIENTISTS TO SWITCH INTO 3949 02:31:08,959 --> 02:31:10,928 INVASIVE MODE BUT IT CAN AND IS 3950 02:31:10,995 --> 02:31:12,696 DONE SAFELY IN MULTIPLE ORGAN 3951 02:31:12,763 --> 02:31:16,100 SYSTEMS, MOST OF THE ORGANS ARE 3952 02:31:16,167 --> 02:31:18,302 ACCESSIBLE, MAKES A FUNDAMENTAL 3953 02:31:18,369 --> 02:31:20,371 DIFFERENCE FOR MODELING TEAMS. 3954 02:31:20,438 --> 02:31:20,738 >> AGREED, YES. 3955 02:31:20,805 --> 02:31:24,975 >> A PAPER FROM US FROM A COUPLE 3956 02:31:25,042 --> 02:31:28,879 DAYS AGO WE BUILD OUT. 3957 02:31:28,946 --> 02:31:30,147 >> THAT'S TERRIFIC. 3958 02:31:30,214 --> 02:31:35,319 I WOULD LOVE TO SEE THAT. 3959 02:31:35,386 --> 02:31:36,987 AGAIN, YOU MIGHT BE ROTATING OFF 3960 02:31:37,054 --> 02:31:39,323 BUT WE'LL BE IN TOUCH ON THESE 3961 02:31:39,390 --> 02:31:42,827 IDEAS TOO AS THEY GO FORWARD. 3962 02:31:42,893 --> 02:31:45,162 I APPRECIATE THOSE COMMENTS. 3963 02:31:45,229 --> 02:31:45,429 MARSHALL? 3964 02:31:45,496 --> 02:31:46,697 >> TWO COMMENTS AND OBSERVATION. 3965 02:31:46,764 --> 02:31:48,966 THE REST OF THE COUNCIL, WHEN WE 3966 02:31:49,033 --> 02:31:50,968 ROTATE OFF, YOU HAVE TO STEP UP 3967 02:31:51,035 --> 02:31:54,538 AND START RAISING YOUR HANDS, 3968 02:31:54,605 --> 02:31:56,974 OTHERWISE IT'S GOING TO GET 3969 02:31:57,041 --> 02:31:57,274 QUIET HERE. 3970 02:31:57,341 --> 02:31:58,742 AFTER RARE DISEASE WHICH IS 3971 02:31:58,809 --> 02:32:00,211 WHERE MY HEART WILL ALWAYS DWELL 3972 02:32:00,277 --> 02:32:02,446 THIS IS MY FAVORITE PROGRAM, 3973 02:32:02,513 --> 02:32:05,716 BECAUSE IT'S THE BLUE SKY 3974 02:32:05,783 --> 02:32:08,786 SECTION OF NCATS, ONE 3975 02:32:08,853 --> 02:32:10,754 OBSERVATION IS YOU REALLY NEED 3976 02:32:10,821 --> 02:32:14,725 TO START ENGAGING THE FDA 3977 02:32:14,792 --> 02:32:17,461 HEAVILY IN THIS, PARTICULARLY 3978 02:32:17,528 --> 02:32:18,329 BIOMEDICAL QUALIFICATION 3979 02:32:18,395 --> 02:32:18,562 PROGRAM. 3980 02:32:18,629 --> 02:32:20,064 BECAUSE WHAT I THINK HAPPENS IS 3981 02:32:20,130 --> 02:32:23,300 YOU DO THIS ADVANCED WORK WITH 3982 02:32:23,367 --> 02:32:24,235 THESE INCREDIBLY POWERFUL 3983 02:32:24,301 --> 02:32:25,669 MODELS, AND THEN WHEN IT COMES 3984 02:32:25,736 --> 02:32:27,104 TO FOLKS TAKING THESE THINGS TO 3985 02:32:27,171 --> 02:32:30,474 THE FDA, YOU GO BACK TO THE 3986 02:32:30,541 --> 02:32:31,475 MIDDLE AGES. 3987 02:32:31,542 --> 02:32:34,512 AND IF THESE THINGS CAN BE PUT 3988 02:32:34,578 --> 02:32:36,580 TO THE FDA, GET THEM HEAVILY 3989 02:32:36,647 --> 02:32:39,383 INVOLVED, HOW YOU'RE GOING TO 3990 02:32:39,450 --> 02:32:40,885 USE THIS, TO ACCELERATE CLINICAL 3991 02:32:40,951 --> 02:32:43,854 TRIALS, I THINK THAT WILL BE 3992 02:32:43,921 --> 02:32:46,891 TREMENDOUSLY POWERFUL. 3993 02:32:46,957 --> 02:32:48,325 BUT RIGHT NOW IT'S NOT, BECAUSE 3994 02:32:48,392 --> 02:32:50,828 IT'S DOING ALL THIS STUFF BUT 3995 02:32:50,895 --> 02:32:53,264 THAT NEXT STEP TAKING IT TO THE 3996 02:32:53,330 --> 02:32:55,299 HUMAN TRIALS IS REALLY MISSING 3997 02:32:55,366 --> 02:32:55,900 FROM THERE. 3998 02:32:55,966 --> 02:32:57,902 THE NEXT ONE IS, YOU MAY ALREADY 3999 02:32:57,968 --> 02:33:00,804 BE VERY WELL AWARE OF THIS, THIS 4000 02:33:00,871 --> 02:33:03,073 MAY BE REDUNDANT COMMENT, BUT I 4001 02:33:03,140 --> 02:33:06,243 KNOW FROM RARE DISEASE CLINICAL 4002 02:33:06,310 --> 02:33:10,481 RESEARCH AND OTHER GROUPS, ATCC, 4003 02:33:10,548 --> 02:33:12,216 CORIELL, HAVE VAST REPOSITORIES 4004 02:33:12,283 --> 02:33:15,953 OF RARE DISEASE CELL LINES THAT 4005 02:33:16,020 --> 02:33:17,721 REFLECT AN INSANE LEVEL OF 4006 02:33:17,788 --> 02:33:19,356 DIFFERENT TYPES OF PHYSIOLOGY. 4007 02:33:19,423 --> 02:33:21,892 THAT LEADS TO MY COMMENT, WHICH 4008 02:33:21,959 --> 02:33:23,827 IS IN THESE TISSUE MODELS, 4009 02:33:23,894 --> 02:33:25,796 SIGNALS ARE OFTEN BLUNTED WHEN 4010 02:33:25,863 --> 02:33:28,666 YOU'RE USING WHAT I WOULD SAY 4011 02:33:28,732 --> 02:33:30,601 TISSUE FROM THE MAINSTREAM 4012 02:33:30,668 --> 02:33:32,503 POPULATION, WHEREAS IF YOU CAN 4013 02:33:32,570 --> 02:33:36,507 FIND A RELEVANT RARE DISEASE 4014 02:33:36,574 --> 02:33:38,943 MODEL, THOSE EXTREME SYSTEMS 4015 02:33:39,009 --> 02:33:40,578 WILL OFTEN GIVE A SIGNAL THAT 4016 02:33:40,644 --> 02:33:42,546 YOU CAN THEN VALIDATE INTO MORE 4017 02:33:42,613 --> 02:33:44,782 GENERAL POPULATION BUT YOU MIGHT 4018 02:33:44,848 --> 02:33:46,383 OTHERWISE MISS, SO I WOULD 4019 02:33:46,450 --> 02:33:48,218 STRONGLY ENCOURAGE YOU AS MUCH 4020 02:33:48,285 --> 02:33:50,020 AS POSSIBLE TO DEVELOP A LOT OF 4021 02:33:50,087 --> 02:33:51,322 THOSE RARE DISEASE MODELS, FOR 4022 02:33:51,388 --> 02:33:53,324 THE BENEFIT OF RARE DISEASE BUT 4023 02:33:53,390 --> 02:33:55,793 FROM THE STANDPOINT OF WHAT THEY 4024 02:33:55,859 --> 02:33:58,963 CAN TEACH YOU AND HOW THEY MAY 4025 02:33:59,029 --> 02:34:01,198 REACT IN NORMAL PHYSIOLOGY 4026 02:34:01,265 --> 02:34:06,837 RESPONSES. 4027 02:34:06,904 --> 02:34:09,373 BUT KEEP IT UP. 4028 02:34:09,440 --> 02:34:10,240 >> POINTS WELL TAKEN. 4029 02:34:10,307 --> 02:34:15,613 TISSUE CHIPS ARE PART OF THE I3D 4030 02:34:15,679 --> 02:34:20,417 RARE, AS I'VE MENTIONED IN MY 4031 02:34:20,484 --> 02:34:22,753 TALK, CLOSE TO OVER, THE EASE OF 4032 02:34:22,820 --> 02:34:28,425 USING TISSUE CHIPS IN TERMS OF 4033 02:34:28,492 --> 02:34:30,260 PATIENT DERIVED MATERIALS ARE 4034 02:34:30,327 --> 02:34:31,595 THE BIG ADVANTAGE ESPECIALLY THE 4035 02:34:31,662 --> 02:34:33,597 RARE DISEASE POPULATION. 4036 02:34:33,664 --> 02:34:37,201 THAT'S WHY I GAVE THE EXAMPLE OF 4037 02:34:37,267 --> 02:34:37,768 RARE NEUROPATHIES, 4038 02:34:37,835 --> 02:34:40,904 STRAIGHTFORWARD, ALL IT TOOK WAS 4039 02:34:40,971 --> 02:34:42,973 SIX MONTHS OF WORK, IT WENT 4040 02:34:43,040 --> 02:34:44,408 RIGHT INTO CLINICAL TRIALS. 4041 02:34:44,475 --> 02:34:44,642 >> YEAH. 4042 02:34:44,708 --> 02:34:47,177 I'VE GOT TO TELL YOU THE FDA IS 4043 02:34:47,244 --> 02:34:51,949 NOT AS AWARE AS THEY NEED TO BE. 4044 02:34:52,016 --> 02:34:54,084 THEY CAN BE -- ARE THERE ANY FDA 4045 02:34:54,151 --> 02:34:58,455 PLEBS MEMBERS ON THE CALL? 4046 02:34:58,522 --> 02:35:03,260 I DON'T THINK SO. 4047 02:35:03,327 --> 02:35:04,128 THEY CAN BE REACTIONARY. 4048 02:35:04,194 --> 02:35:06,030 >> FDA HAS BEEN A PARTNER IN THE 4049 02:35:06,096 --> 02:35:09,133 DEVELOPMENT OF THIS PROGRAM. 4050 02:35:09,199 --> 02:35:09,833 THEY HAVE PROVIDED REGULATORY 4051 02:35:09,900 --> 02:35:13,203 ADVICE, AND AS I MENTIONED IN 4052 02:35:13,270 --> 02:35:14,405 THE TRANSLATIONAL CENTERS FOR 4053 02:35:14,471 --> 02:35:16,173 MPS WHERE WE'RE ACTUALLY 4054 02:35:16,240 --> 02:35:20,644 KNOCKING AT THE DOOR IN TERMS OF 4055 02:35:20,711 --> 02:35:21,578 REGULATORY QUALIFICATION THEY 4056 02:35:21,645 --> 02:35:23,380 WILL BE INTIMATELY INVOLVED, AND 4057 02:35:23,447 --> 02:35:26,884 WE'RE WORKING ALSO WITH C-PATH, 4058 02:35:26,950 --> 02:35:29,086 NON-PROFIT ARM OF FDA. 4059 02:35:29,153 --> 02:35:33,123 >> I KNOW C-PATH WELL, YES. 4060 02:35:33,190 --> 02:35:34,124 DEFINITELY AROUND THE 4061 02:35:34,191 --> 02:35:35,759 QUALIFICATION PROGRAM BECAUSE 4062 02:35:35,826 --> 02:35:38,028 THAT WAS THE WAY WE GOT DRUG 4063 02:35:38,095 --> 02:35:39,296 DEVELOPMENT COMPANIES TO LOOK AT 4064 02:35:39,363 --> 02:35:41,765 THIS TOO. 4065 02:35:41,832 --> 02:35:43,300 IT'S GOT AN OFFICIAL "THIS IS 4066 02:35:43,367 --> 02:35:45,836 OKAY TO USE" KIND OF THING. 4067 02:35:45,903 --> 02:35:46,136 >> CORRECT. 4068 02:35:46,203 --> 02:35:49,006 >> GREAT. 4069 02:35:49,073 --> 02:35:50,340 THANK YOU. 4070 02:35:50,407 --> 02:35:50,674 KELLY? 4071 02:35:50,741 --> 02:35:53,477 >> I'M OFF MUTE. 4072 02:35:53,544 --> 02:35:54,445 THAT WAS AWESOME. 4073 02:35:54,511 --> 02:35:57,181 SECOND, AT SOME POINT IT MIGHT 4074 02:35:57,247 --> 02:36:02,019 BE USEFUL TO SHARE WITH YOU AN 4075 02:36:02,086 --> 02:36:03,320 OPEN SOURCE BIOLOGICAL DIGITAL 4076 02:36:03,387 --> 02:36:04,354 TWIN PROGRAM WE'VE BEEN HELPING 4077 02:36:04,421 --> 02:36:06,123 A COUPLE RARE DISEASE 4078 02:36:06,190 --> 02:36:08,392 ORGANIZATIONS START THAT ARE 4079 02:36:08,459 --> 02:36:09,226 FOCUSED ON AUTOIMMUNE 4080 02:36:09,293 --> 02:36:12,429 POPULATIONS, AND SOME RARE 4081 02:36:12,496 --> 02:36:13,597 AUTOIMMUNE POPULATIONS, WITH A 4082 02:36:13,664 --> 02:36:14,732 LOT OF TISSUE COLLECTION, SO 4083 02:36:14,798 --> 02:36:18,569 THAT MAY BE USEFUL AT SOME 4084 02:36:18,635 --> 02:36:18,902 POINT. 4085 02:36:18,969 --> 02:36:24,908 AS A BRASS TACKS MATTER I WANT 4086 02:36:24,975 --> 02:36:27,311 TO MAKE SURE YOU HAVE WHAT YOU 4087 02:36:27,377 --> 02:36:33,250 NEED AT AEROSPACE COMPANIES, IN 4088 02:36:33,317 --> 02:36:39,356 YOU NEED HELP NORTHROP GRUMMAN 4089 02:36:39,423 --> 02:36:42,760 OR LOCKHEED, LET ME KNOW. 4090 02:36:42,826 --> 02:36:44,428 >> THANK YOU. 4091 02:36:44,495 --> 02:36:46,630 >> WE'D APPRECIATE THAT. 4092 02:36:46,697 --> 02:36:54,905 ANY OTHER QUESTIONS FOR DAN? 4093 02:36:54,972 --> 02:36:55,105 OKAY. 4094 02:36:55,172 --> 02:36:57,141 DAN, THANK YOU SO MUCH AS ALWAYS 4095 02:36:57,207 --> 02:36:58,308 FOR YOUR GREAT PRESENTATION. 4096 02:36:58,375 --> 02:37:06,750 AND WE HAVE ONE MORE TO GO, I'M 4097 02:37:06,817 --> 02:37:08,819 DELIGHTED TO INTRODUCE OUR NEW 4098 02:37:08,886 --> 02:37:10,687 DIRECTOR FOR OFFICE OF STRATEGIC 4099 02:37:10,754 --> 02:37:15,058 ALLIANCES, I HAVE ASKED HIM TO 4100 02:37:15,125 --> 02:37:17,795 FOCUS ON HIS VISION FOR OSA, AND 4101 02:37:17,861 --> 02:37:19,763 LET YOU KNOW MORE ABOUT WHAT 4102 02:37:19,830 --> 02:37:26,270 HE'S BEEN DOING ABOUT AND UP TO 4103 02:37:26,336 --> 02:37:28,672 AND GET YOUR INPUT. 4104 02:37:28,739 --> 02:37:29,540 BALKI, OVER TO YOU. 4105 02:37:29,606 --> 02:37:30,107 >> GOOD AFTERNOON. 4106 02:37:30,174 --> 02:37:33,010 THIS HAS BEEN A WONDERFUL DAY SO 4107 02:37:33,076 --> 02:37:33,277 FAR. 4108 02:37:33,343 --> 02:37:34,745 WE'VE HEARD GREAT SCIENTIFIC 4109 02:37:34,812 --> 02:37:41,218 TALKS, AS WELL AS VISIONARY 4110 02:37:41,285 --> 02:37:41,418 TALKS. 4111 02:37:41,485 --> 02:37:45,389 I'LL ADD SPIN BY POSITING THAT 4112 02:37:45,455 --> 02:37:46,623 TRANSLATION IS NOT JUST 4113 02:37:46,690 --> 02:37:48,992 SCIENTIFIC SCIENCE BUT ALSO A 4114 02:37:49,059 --> 02:37:51,295 LEGAL CHALLENGE AND, YOU KNOW, 4115 02:37:51,361 --> 02:37:53,931 BUSINESS CHALLENGE. 4116 02:37:53,997 --> 02:37:56,900 SO I'M THE DIRECTOR OF OFFICE OF 4117 02:37:56,967 --> 02:37:58,535 STRATEGIC ALLIANCES, LIKE JONI 4118 02:37:58,602 --> 02:37:59,303 MENTIONED. 4119 02:37:59,369 --> 02:38:01,772 WHAT I'LL DO TODAY IS PROVIDE A 4120 02:38:01,839 --> 02:38:04,241 PROGRAM UPDATE AND ALSO SHARE MY 4121 02:38:04,308 --> 02:38:07,277 VISION FOR THE OFFICE. 4122 02:38:07,344 --> 02:38:14,384 A LITTLE BIT OFF FREE-WHEELING 4123 02:38:14,451 --> 02:38:17,487 THINKING, VISUALIZING IZING KIND 4124 02:38:17,554 --> 02:38:18,455 OF SESSION. 4125 02:38:18,522 --> 02:38:19,890 NEXT SLIDE PLEASE. 4126 02:38:19,957 --> 02:38:24,795 I WANT TO START WITH THIS 4127 02:38:24,862 --> 02:38:27,130 PARTICULAR GRAPHIC THAT IS 4128 02:38:27,197 --> 02:38:28,065 POPULAR. 4129 02:38:28,131 --> 02:38:33,670 THIS SHOWS THAT NCATS FIRST USED 4130 02:38:33,737 --> 02:38:34,838 MISSION BY REENGINEERING 4131 02:38:34,905 --> 02:38:35,405 TRANSLATIONAL PIPELINE FOR 4132 02:38:35,472 --> 02:38:37,407 EFFICIENCY AND SEED. 4133 02:38:37,474 --> 02:38:39,543 THE OFFICE OF STRATEGIC ALLIANCE 4134 02:38:39,610 --> 02:38:40,644 WE SUPPORT ALL NCATS EFFORTS 4135 02:38:40,711 --> 02:38:44,147 EACH STEP OF THE WAY IN EACH OF 4136 02:38:44,214 --> 02:38:44,948 THE 3-Ds. 4137 02:38:45,015 --> 02:38:47,117 BY WAY OF EXAMPLES AND 4138 02:38:47,184 --> 02:38:49,553 DESCRIBING SOME OF THE TOOLS WE 4139 02:38:49,620 --> 02:38:51,388 USE, I'LL TELL YOU HOW OSA'S 4140 02:38:51,455 --> 02:38:56,193 WORK IS CENTRAL AND CRITICAL FOR 4141 02:38:56,260 --> 02:39:00,497 NCATS SUCCESS.. 4142 02:39:00,564 --> 02:39:08,505 IT SUPPORTS TRANSLATIONAL 4143 02:39:08,572 --> 02:39:09,773 MISSION BY COMBINING SCIENCE, 4144 02:39:09,840 --> 02:39:12,643 LAW, BUSINESS INTO ONE USABLE 4145 02:39:12,709 --> 02:39:13,410 PRODUCT. 4146 02:39:13,477 --> 02:39:17,047 ON A PRACTICAL LEVEL, IN ORDER 4147 02:39:17,114 --> 02:39:19,917 TO REALLY DO TRANSLATIONAL 4148 02:39:19,983 --> 02:39:21,652 SCIENCE, ON TOP OF GREAT SCIENCE 4149 02:39:21,718 --> 02:39:25,088 WE NEED TO INFUSE BEST ELEMENTS 4150 02:39:25,155 --> 02:39:28,325 OF BUSINESS AND LAW TO MAKE 4151 02:39:28,392 --> 02:39:29,793 TRANSLATION TRULY SUCCESSFUL. 4152 02:39:29,860 --> 02:39:32,462 AND IN TERMS OF OUR OFFICE, 4153 02:39:32,529 --> 02:39:33,897 THERE ARE THREE DIFFERENT 4154 02:39:33,964 --> 02:39:36,533 FUNCTIONS THAT WE SUPPORT, 4155 02:39:36,600 --> 02:39:41,038 INTELLECTUAL PROPERTY 4156 02:39:41,104 --> 02:39:41,471 MANAGEMENT, ALLIANCE 4157 02:39:41,538 --> 02:39:43,206 MANAGEMENTS, SMALL BUSINESS 4158 02:39:43,273 --> 02:39:44,174 PROGRAMS. 4159 02:39:44,241 --> 02:39:46,543 I'M FOCUS TODAY ON INTELLECTUAL 4160 02:39:46,610 --> 02:39:48,979 PROPERTY MANAGEMENTS AND 4161 02:39:49,046 --> 02:39:50,147 ALLIANCE MANAGEMENT, I'LL TALK 4162 02:39:50,213 --> 02:39:51,148 ABOUT SMALL BUSINESS PROGRAMS 4163 02:39:51,214 --> 02:39:53,417 NEXT YEAR. 4164 02:39:53,483 --> 02:39:55,485 NEXT SLIDE PLEASE. 4165 02:39:55,552 --> 02:39:58,021 SO THROUGH THIS SLIDE, THE NEXT 4166 02:39:58,088 --> 02:40:00,991 FEW SLIDES, I WANT TO FOCUS MORE 4167 02:40:01,058 --> 02:40:03,293 ON WHAT I CALL OSA VISION. 4168 02:40:03,360 --> 02:40:06,196 JUST LIKE THE NCATS VISION, THE 4169 02:40:06,263 --> 02:40:08,498 OSA VISION IS FAIRLY SIMPLE, A 4170 02:40:08,565 --> 02:40:09,900 SIMPLE SENTENCE. 4171 02:40:09,967 --> 02:40:14,137 TO MAKE NCATS THE PREFERRED 4172 02:40:14,204 --> 02:40:17,507 PARTNER, AIMS TO MAKE NCATS THE 4173 02:40:17,574 --> 02:40:18,875 PREFERRED PARTNER FOR 4174 02:40:18,942 --> 02:40:21,411 COLLABORATING ON TRANSLATIONAL 4175 02:40:21,478 --> 02:40:22,379 PROJECTS BY INCREASING 4176 02:40:22,446 --> 02:40:24,815 EFFICIENCIES AND BY REDUCING 4177 02:40:24,881 --> 02:40:25,182 BARRIERS. 4178 02:40:25,248 --> 02:40:27,884 SO LET ME SORT OF GIVE YOU A 4179 02:40:27,951 --> 02:40:29,553 LITTLE BIT OF A SCIENTIFIC 4180 02:40:29,619 --> 02:40:30,854 ANALOGY, IN TERMS OF WHAT A 4181 02:40:30,921 --> 02:40:31,788 PREFERRED PARTNER WOULD BE. 4182 02:40:31,855 --> 02:40:37,027 WHEN YOU THINK OF CHEMISTRY 4183 02:40:37,094 --> 02:40:40,397 WORLD, THINK OF THE CARBON ATOM, 4184 02:40:40,464 --> 02:40:42,966 IT HAS UNIQUE PROPERTY OF BEING 4185 02:40:43,033 --> 02:40:45,402 ABLE TO BOND WITH ATOMS MUCH 4186 02:40:45,469 --> 02:40:48,572 SMALLER THAN IT IS, LIKE 4187 02:40:48,638 --> 02:40:50,207 HYDROGEN, MUCH LARGER LIKE 4188 02:40:50,273 --> 02:40:52,709 SULPHUR AND CHLORINE, AND ATOMS 4189 02:40:52,776 --> 02:40:54,678 JUST LIKE ITSELF, CARBON, 4190 02:40:54,745 --> 02:40:55,579 NITROGEN, OXYGEN. 4191 02:40:55,645 --> 02:40:59,349 JUST LIKE CARBON IS ABLE TO BOND 4192 02:40:59,416 --> 02:41:01,818 WITH ALL SIZES AND SHAPES AND 4193 02:41:01,885 --> 02:41:04,054 KINDS OF OTHER ATOMS TO MAKE 4194 02:41:04,121 --> 02:41:05,122 WONDERFUL MOLECULES, WE WOULD 4195 02:41:05,188 --> 02:41:09,426 LIKE NCATS TO BE THE PREFERRED 4196 02:41:09,493 --> 02:41:11,862 PARTNER THAT OTHER 4197 02:41:11,928 --> 02:41:12,496 ORGANIZATIONS, SMALL, LARGE, 4198 02:41:12,562 --> 02:41:13,697 MEDIUM, WHEREVER THEY ARE, TO BE 4199 02:41:13,764 --> 02:41:15,465 ABLE TO BOND WITH US, TO BE ABLE 4200 02:41:15,532 --> 02:41:20,137 TO PARTNER WITH US AND TAKE 4201 02:41:20,203 --> 02:41:21,805 TRANSLATIONAL PROGRESS FORWARD. 4202 02:41:21,872 --> 02:41:25,475 NOW, THE NCATS VISION IF IT 4203 02:41:25,542 --> 02:41:28,812 IS -- OSA VISION, ONCE IT IS 4204 02:41:28,879 --> 02:41:30,981 COMPLETELY PUT INTO PRACTICE, 4205 02:41:31,048 --> 02:41:33,450 WILL SUPPORT EACH ELEMENT OF 4206 02:41:33,517 --> 02:41:35,619 NCATS' VISION. 4207 02:41:35,685 --> 02:41:36,420 MORE TREATMENTS BY INNOVATING, 4208 02:41:36,486 --> 02:41:41,825 BY HAVING A VOLUME AND SPEED OF 4209 02:41:41,892 --> 02:41:44,661 NEGOTIATIONS FAIRLY SUPERIOR, 4210 02:41:44,728 --> 02:41:46,296 PROVIDE MORE SLOTS ON GOAL, 4211 02:41:46,363 --> 02:41:47,631 LEADING TO MORE TREATMENTS. 4212 02:41:47,697 --> 02:41:50,467 BY DOING AGREEMENTS WITH SPEED 4213 02:41:50,534 --> 02:41:53,336 AND EFFICIENCY, BY USING 4214 02:41:53,403 --> 02:41:54,671 TEMPLATES, I'LL GIVE EXAMPLES, 4215 02:41:54,738 --> 02:41:59,309 BUILDING NETWORKS AND 4216 02:41:59,376 --> 02:42:01,545 RELATIONSHIPS WILL HAVE 4217 02:42:01,611 --> 02:42:03,080 RELATIONSHIPS AND THE DISCOVERY 4218 02:42:03,146 --> 02:42:08,318 EVER DRUGS GO MORE QUICKLY, BY 4219 02:42:08,385 --> 02:42:11,221 USING PLATFORM TECHNOLOGIES, 4220 02:42:11,288 --> 02:42:11,955 REDUCING BARRIERS TO 4221 02:42:12,022 --> 02:42:13,757 COLLABORATIONS WE CAN INCLUDE 4222 02:42:13,824 --> 02:42:14,891 ALL PEOPLE IN THE PICTURE. 4223 02:42:14,958 --> 02:42:18,195 WHAT DOES IT TAKE TO BE A 4224 02:42:18,261 --> 02:42:18,595 PREFERRED PARTNER? 4225 02:42:18,662 --> 02:42:20,831 THERE ARE AT LEAST SIX ELEMENTS, 4226 02:42:20,897 --> 02:42:24,835 MAYBE MORE, THAT ARE SHOWN IN 4227 02:42:24,901 --> 02:42:25,535 THIS SCHEMATIC PLANETARY 4228 02:42:25,602 --> 02:42:26,002 DIAGRAM. 4229 02:42:26,069 --> 02:42:28,171 THE FIRST ONE THAT COMES TO MIND 4230 02:42:28,238 --> 02:42:29,739 IS TRUST. 4231 02:42:29,806 --> 02:42:32,676 TRUST IS SOMETHING THAT EVERY 4232 02:42:32,742 --> 02:42:34,344 SPEAKER IN THIS PANEL TODAY AS 4233 02:42:34,411 --> 02:42:36,980 WELL AS OTHERS HAVE SPOKEN ABOUT 4234 02:42:37,047 --> 02:42:40,717 TRUST IS SO IMPORTANT IN 4235 02:42:40,784 --> 02:42:41,485 COLLABORATIONS, IN SCIENCE, IN 4236 02:42:41,551 --> 02:42:42,319 PRETTY MUCH ANYTHING YOU DO 4237 02:42:42,385 --> 02:42:44,321 WHERE YOU WANT TO MAKE PROGRESS. 4238 02:42:44,387 --> 02:42:48,425 TRUST IS SOMETHING THAT'S 4239 02:42:48,492 --> 02:42:50,193 EARNED, DEPENDS ON SOME SORT OF 4240 02:42:50,260 --> 02:42:54,231 TRACK RECORD, SO BY HAVING A 4241 02:42:54,297 --> 02:42:55,332 LARGE VOLUME OF COLLABORATIONS 4242 02:42:55,398 --> 02:42:57,434 DONE IN VERY SMALL MANNER, YOU 4243 02:42:57,501 --> 02:42:59,603 CAN EARN TRUST. 4244 02:42:59,669 --> 02:43:01,872 SPEED IS ALSO IMPORTANT WHEN YOU 4245 02:43:01,938 --> 02:43:02,772 HAVE PARTNERS, PREFERENTIALLY 4246 02:43:02,839 --> 02:43:03,240 WORKING WITH YOU. 4247 02:43:03,306 --> 02:43:06,977 THEY WANT TO BE ABLE TO GET 4248 02:43:07,043 --> 02:43:08,178 THINGS DONE QUICKLY. 4249 02:43:08,245 --> 02:43:11,681 INNOVATION IS ANOTHER THING THAT 4250 02:43:11,748 --> 02:43:13,416 PARTNERS LOOK FOR IN A PARTNER. 4251 02:43:13,483 --> 02:43:15,352 I'M GOING TO GO THROUGH SOME OF 4252 02:43:15,418 --> 02:43:17,354 THE CASE STUDIES AND EXAMPLES 4253 02:43:17,420 --> 02:43:18,855 AND WE'LL COME BACK TO THIS AT 4254 02:43:18,922 --> 02:43:21,958 THE VERY END SO WE CAN TALK 4255 02:43:22,025 --> 02:43:25,395 ABOUT HOW WE CAN MAKE OURSELVES 4256 02:43:25,462 --> 02:43:31,001 EVEN STRONGER, TO MAKE OSA THE 4257 02:43:31,067 --> 02:43:31,868 PREFERRED PARTNER. 4258 02:43:31,935 --> 02:43:33,336 IN THE NEXT SLIDE, NEXT SLIDE 4259 02:43:33,403 --> 02:43:36,840 PLEASE, SO THIS IS THE OFFICE OF 4260 02:43:36,907 --> 02:43:38,341 STRATEGIC ALLIANCES, I'M VERY 4261 02:43:38,408 --> 02:43:41,211 FORTUNATE TO HAVE A GREAT TEAM 4262 02:43:41,278 --> 02:43:42,712 OF VERY DIVERSE, CREATIVE, AND 4263 02:43:42,779 --> 02:43:44,614 DEDICATED INDIVIDUALS. 4264 02:43:44,681 --> 02:43:46,316 THESE ARE INDIVIDUALS WHO USE 4265 02:43:46,383 --> 02:43:49,452 DIFFERENT ASPECTS OF SCIENCE OR 4266 02:43:49,519 --> 02:43:52,255 BUSINESS OR LAW, DIFFERENT 4267 02:43:52,322 --> 02:43:53,223 COMBINATIONS, JUST LIKE THE 4268 02:43:53,290 --> 02:43:58,195 CARBON ATOM. 4269 02:43:58,261 --> 02:44:00,830 IT USEST ORBITAL TO BOND WITH 4270 02:44:00,897 --> 02:44:02,132 DIFFERENT ATOMS, DEPENDING ON 4271 02:44:02,199 --> 02:44:03,433 THE ATOM MIGHT USE DIFFERENT 4272 02:44:03,500 --> 02:44:04,334 PROPERTIES, JUST LIKE THAT MANY 4273 02:44:04,401 --> 02:44:09,139 OF THE PEOPLE IN MY STAFF, THEY 4274 02:44:09,206 --> 02:44:11,007 USE DIFFERENT SKILLS AS WELL AS 4275 02:44:11,074 --> 02:44:14,744 PERSONALITY TYPES, AS WELL AS 4276 02:44:14,811 --> 02:44:16,213 BACKGROUNDS TO FORM THE RIGHT 4277 02:44:16,279 --> 02:44:16,546 PARTNERSHIPS. 4278 02:44:16,613 --> 02:44:18,949 I'LL TALK ABOUT SOME OF THE WORK 4279 02:44:19,015 --> 02:44:20,984 TODAY BUT WHAT I WANT YOU TO 4280 02:44:21,051 --> 02:44:22,385 TAKE AWAY FROM THIS CONVERSATION 4281 02:44:22,452 --> 02:44:27,190 IS THE FACT THAT IN ORDER TO 4282 02:44:27,257 --> 02:44:28,658 REALLY FORGE PARTNERSHIPS YOU 4283 02:44:28,725 --> 02:44:31,728 HAVE MULTIPLE ELEMENTS COMING 4284 02:44:31,795 --> 02:44:33,797 INTO PLAY. 4285 02:44:33,863 --> 02:44:35,632 TRUST, FLEXIBILITY, SPEED, 4286 02:44:35,699 --> 02:44:38,602 EFFICIENCY, ET CETERA. 4287 02:44:38,668 --> 02:44:38,902 NEXT SLIDE. 4288 02:44:38,969 --> 02:44:41,404 I WANT TO SHOW YOU IN THIS SLIDE 4289 02:44:41,471 --> 02:44:43,673 AND A COUPLE OTHER SLIDES SOME 4290 02:44:43,740 --> 02:44:45,742 OF THE STATISTICS OF OUR OFFICE. 4291 02:44:45,809 --> 02:44:49,179 SO IN THIS PARTICULAR SLIDE I'M 4292 02:44:49,246 --> 02:44:51,014 GIVEN YOU A SNAPSHOT OF THE 4293 02:44:51,081 --> 02:44:54,050 NUMBER OF AGREEMENTS THAT NCATS 4294 02:44:54,117 --> 02:44:58,088 HAS DONE OVER THE LAST TWO 4295 02:44:58,154 --> 02:45:02,192 YEARS, FY 22 AND FY 23. 4296 02:45:02,259 --> 02:45:04,194 I'LL GO QUICKLY, BUT ALSO DWELL 4297 02:45:04,261 --> 02:45:05,795 MORE ON OTHERS. 4298 02:45:05,862 --> 02:45:09,499 RIGHT ON TOP IS COOPERATIVE 4299 02:45:09,566 --> 02:45:10,000 RESEARCH AND DEVELOPMENT 4300 02:45:10,066 --> 02:45:10,600 AGREEMENT, CRADA, SOME OF YOU 4301 02:45:10,667 --> 02:45:12,769 ARE FAMILIAR WITH. 4302 02:45:12,836 --> 02:45:14,404 THESE ARE FAIRLY COMPLICATED 4303 02:45:14,471 --> 02:45:16,806 AGREEMENTS THAT TAKE SEVERAL 4304 02:45:16,873 --> 02:45:19,042 MONTHS, SOMETIMES EVEN YEARS TO 4305 02:45:19,109 --> 02:45:21,845 NEGOTIATE, IT HAS A LOT OF BELLS 4306 02:45:21,911 --> 02:45:23,913 AND WHISTLES, IT CAN BRING MONEY 4307 02:45:23,980 --> 02:45:26,549 IN, BRING RESOURCES IN, IT HAS A 4308 02:45:26,616 --> 02:45:31,254 LOT OF CLAUSES THAT DEAL WITH 4309 02:45:31,321 --> 02:45:31,888 INTELLECTUAL PROPERTY, SOMEWHAT 4310 02:45:31,955 --> 02:45:32,922 COMPLICATED TO NEGOTIATE. 4311 02:45:32,989 --> 02:45:34,291 WE DID ABOUT FOUR IN THE LAST 4312 02:45:34,357 --> 02:45:36,393 TWO YEARS. 4313 02:45:36,459 --> 02:45:37,594 NIH TYPICALLY DOES ABOUT 40 OR 4314 02:45:37,661 --> 02:45:41,431 50 A YEAR, SO IN THAT SENSE IT'S 4315 02:45:41,498 --> 02:45:43,633 IS A FAIRLY DIFFICULT AGREEMENT 4316 02:45:43,700 --> 02:45:49,005 NEGOTIATE, ALSO VERY FAR 4317 02:45:49,072 --> 02:45:51,308 REACHING. 4318 02:45:51,374 --> 02:45:54,811 MATERIAL TRANSFER AGREEMENTS ARE 4319 02:45:54,878 --> 02:45:58,181 STRAIGHTFORWARD, FOUR TO FIVE 4320 02:45:58,248 --> 02:46:00,884 PAGES LONG IN MTAs, 200 A 4321 02:46:00,950 --> 02:46:02,319 YEAR, RESEARCH COLLABORATION 4322 02:46:02,385 --> 02:46:05,622 AGREEMENT IS PROBABLY THE MOST 4323 02:46:05,689 --> 02:46:07,223 ROBUST, MOST EFFICIENT 4324 02:46:07,290 --> 02:46:07,490 AGREEMENT. 4325 02:46:07,557 --> 02:46:10,860 I CALL IT THE WORKHORSE 4326 02:46:10,927 --> 02:46:12,062 AGREEMENT WITH HIGHEST 4327 02:46:12,128 --> 02:46:12,495 EFFICIENCY. 4328 02:46:12,562 --> 02:46:14,464 IT'S AN AGREEMENT THAT CAN 4329 02:46:14,531 --> 02:46:15,899 ACTUALLY BE PUT INTO PLACE 4330 02:46:15,965 --> 02:46:19,636 WITHIN DAYS OR WEEKS, ABOUT FIVE 4331 02:46:19,703 --> 02:46:22,472 TO EIGHT PAGES LONG, 4332 02:46:22,539 --> 02:46:23,773 INCORPORATION THE RESEARCH PLAN, 4333 02:46:23,840 --> 02:46:27,243 LOTS OF CONDITIONS IN TERMS OF 4334 02:46:27,310 --> 02:46:32,782 PUBLICATION RIGHTS, I.T. RIGHTS, 4335 02:46:32,849 --> 02:46:33,550 CONFIDENTIAL CLAUSES, INCLUDES A 4336 02:46:33,616 --> 02:46:35,418 LOT OF IMPORTANT CLAUSES IN AN 4337 02:46:35,485 --> 02:46:37,954 EFFICIENT WAY. 4338 02:46:38,021 --> 02:46:41,124 I WALL THIS ONE AGREEMENT, IF 4339 02:46:41,191 --> 02:46:42,992 SOMEBODY WERE TO TELL ME THERE'S 4340 02:46:43,059 --> 02:46:44,527 ONLY ONE YOU COULD USE, I WOULD 4341 02:46:44,594 --> 02:46:45,261 CHOOSE THIS ONE. 4342 02:46:45,328 --> 02:46:47,931 IT DOES A LOT AND IS ALSO VERY 4343 02:46:47,997 --> 02:46:48,198 EFFICIENT. 4344 02:46:48,264 --> 02:46:50,533 WE DO A NUMBER OF OTHER KINDS OF 4345 02:46:50,600 --> 02:46:51,968 AGREEMENTS, THE REASON WE HAVE 4346 02:46:52,035 --> 02:46:53,903 SO MANY DIFFERENT AGREEMENTS IN 4347 02:46:53,970 --> 02:46:57,207 PLACE THAT WE USE IS BECAUSE 4348 02:46:57,273 --> 02:46:58,942 EACH COLLABORATION IS VERY 4349 02:46:59,008 --> 02:46:59,376 DIFFERENT. 4350 02:46:59,442 --> 02:47:01,578 SOME MAY LAST A FEW DAYS OR 4351 02:47:01,644 --> 02:47:03,313 WEEKS, OR MONTHS, OTHERS MAY 4352 02:47:03,380 --> 02:47:08,118 LAST FOR YEARS, MAYBE A DECADE. 4353 02:47:08,184 --> 02:47:09,486 , DEPENDING ON THE AGREEMENT, 4354 02:47:09,552 --> 02:47:11,287 THE PARTNER, WHAT YOU WANT TO 4355 02:47:11,354 --> 02:47:13,990 ACHIEVE YOU USE DIFFERENT KINDS 4356 02:47:14,057 --> 02:47:19,662 OF AGREEMENTS TO BEAR ON THE 4357 02:47:19,729 --> 02:47:20,130 PROBLEM. 4358 02:47:20,196 --> 02:47:22,866 THE NEXT SLIDE, I WANT TO TALK 4359 02:47:22,932 --> 02:47:25,368 ABOUT THE INTELLECTUAL PROPERTY 4360 02:47:25,435 --> 02:47:27,771 MANAGEMENT ASPECT OF NCATS. 4361 02:47:27,837 --> 02:47:29,973 SO WHAT I'VE SHOWN █HERE, GOING 4362 02:47:30,039 --> 02:47:34,377 FROM LEFT TO RIGHT, ARE EIGHT 4363 02:47:34,444 --> 02:47:36,012 DIFFERENT INSTITUTES WITHIN NIH, 4364 02:47:36,079 --> 02:47:40,617 TWO SMALL INCLUDING NCATS, FOUR 4365 02:47:40,683 --> 02:47:43,987 MEDIUM, AND TWO LARGE 4366 02:47:44,053 --> 02:47:44,287 INSTITUTES. 4367 02:47:44,354 --> 02:47:48,057 WHAT YOU CAN SEE ON THE TOP OF 4368 02:47:48,124 --> 02:47:50,894 THE TABLE IS THE NUMBER OF 4369 02:47:50,960 --> 02:47:51,494 INTELLECTUAL PROPERTY FILINGS 4370 02:47:51,561 --> 02:47:55,832 DONE OVER THE LAST TWO YEARS BY 4371 02:47:55,899 --> 02:47:58,768 THESE INSTITUTES. 4372 02:47:58,835 --> 02:48:02,672 NCATS 62 IN THE LAST TWO YEARS, 4373 02:48:02,739 --> 02:48:03,306 INTELLECTUAL PROPERTY FILINGS. 4374 02:48:03,373 --> 02:48:06,209 WHAT I'VE SHOWN IN THE LINE 4375 02:48:06,276 --> 02:48:10,146 BELOW THAT IS THE BUDGET, THE 4376 02:48:10,213 --> 02:48:11,714 INTRAMURAL RESEARCH BUDGET FOR 4377 02:48:11,781 --> 02:48:15,318 EACH OF THE INSTITUTES. 4378 02:48:15,385 --> 02:48:17,687 GOING FROM $261 MILLION TO $2 4379 02:48:17,754 --> 02:48:18,354 BILLION ON THE RIGHT. 4380 02:48:18,421 --> 02:48:21,825 WHAT I THEN DO IS I DIVIDE FIRST 4381 02:48:21,891 --> 02:48:24,928 NUMBER BY SECOND NUMBER IN ORDER 4382 02:48:24,994 --> 02:48:28,531 TO NORMALIZE AMOUNT OF 4383 02:48:28,598 --> 02:48:32,535 INTELLECTUAL PROPERTY GENERATED 4384 02:48:32,602 --> 02:48:33,770 PER UNIT OF CURRENCY, LAST LINE. 4385 02:48:33,837 --> 02:48:37,273 WHAT YOU SEE IN THE LAST LINE IS 4386 02:48:37,340 --> 02:48:41,044 WHAT I WOULD CALL INTELLECTUAL 4387 02:48:41,110 --> 02:48:41,644 PROPERTY ACTIVITY FOR $100 4388 02:48:41,711 --> 02:48:42,412 MILLION. 4389 02:48:42,479 --> 02:48:46,549 THE LARGER THE NUMBER, THE MORE 4390 02:48:46,616 --> 02:48:49,018 I.P. IS GENERATED FOR A GIVEN 4391 02:48:49,085 --> 02:48:51,120 DOLLAR. 4392 02:48:51,187 --> 02:48:53,656 BOTTOM LINE, NCATS GENERATES 4393 02:48:53,723 --> 02:48:55,291 MORE INTELLECTUAL PROPERTY WITH 4394 02:48:55,358 --> 02:48:58,628 FEWER DOLLARS, WE COMPARE WELL 4395 02:48:58,695 --> 02:48:59,529 WITH EVEN SOME LARGER 4396 02:48:59,596 --> 02:48:59,929 INSTITUTES. 4397 02:48:59,996 --> 02:49:02,532 NOW, THIS IS SOMETHING TO BE 4398 02:49:02,599 --> 02:49:04,000 PROUD OF, AND VERY NOTABLE. 4399 02:49:04,067 --> 02:49:05,802 WHAT COULD BE THE REASON FOR 4400 02:49:05,869 --> 02:49:06,302 SOME OF THIS? 4401 02:49:06,369 --> 02:49:09,539 THERE ARE A NUMBER OF REASONS 4402 02:49:09,606 --> 02:49:11,608 LIKE THE FACT THAT NCATS, LIKE 4403 02:49:11,674 --> 02:49:14,744 MANY THAT HAVE SPOKEN BEFORE ME, 4404 02:49:14,811 --> 02:49:17,013 USES COLLABORATIONS TO EXPAND 4405 02:49:17,080 --> 02:49:18,081 ITS SCIENTIFIC REACH. 4406 02:49:18,147 --> 02:49:23,553 WE ALSO FOCUS ON PLATFORM 4407 02:49:23,620 --> 02:49:24,487 TECHNOLOGIES. 4408 02:49:24,554 --> 02:49:26,523 WE EMPLOY TEAM SCIENCE TO DERIVE 4409 02:49:26,589 --> 02:49:28,591 GREATER SYNERGY AND IDEATION. 4410 02:49:28,658 --> 02:49:29,492 SO ALL THESE THINGS PROBABLY 4411 02:49:29,559 --> 02:49:32,862 HELP A LOT IN MAKING SURE THAT 4412 02:49:32,929 --> 02:49:34,831 WE USE THE BEST -- MAKE BEST USE 4413 02:49:34,898 --> 02:49:38,134 OF RESEARCH DOLLARS GIVEN TO US. 4414 02:49:38,201 --> 02:49:39,302 FINALLY, THE CLOSE WORKING 4415 02:49:39,369 --> 02:49:41,938 RELATIONSHIP BETWEEN THE OFFICE 4416 02:49:42,005 --> 02:49:43,306 OF STRATEGIC ALLIANCES AND 4417 02:49:43,373 --> 02:49:45,775 SCIENTISTS PLAY A HUGE ROLE IN 4418 02:49:45,842 --> 02:49:46,910 THE SUCCESS. 4419 02:49:46,976 --> 02:49:52,448 WE CAN USE THE BEST COMBINATION 4420 02:49:52,515 --> 02:49:53,883 OF BUSINESS, SCIENCE, LAW, TO 4421 02:49:53,950 --> 02:49:55,518 FORM THE RIGHT PARTNERSHIPS, 4422 02:49:55,585 --> 02:49:56,519 ACHIEVE THE RIGHT TRANSLATIONAL 4423 02:49:56,586 --> 02:49:58,154 RESULTS. 4424 02:49:58,221 --> 02:50:03,293 I THINK ALL OF THAT COMES 4425 02:50:03,359 --> 02:50:05,995 TOGETHER IN WHAT IS NCATS. 4426 02:50:06,062 --> 02:50:07,897 SO, WHEN YOU LOOK AT A TABLE 4427 02:50:07,964 --> 02:50:12,869 LIKE THIS IT GIVES YOU AN IDEA 4428 02:50:12,936 --> 02:50:14,938 THAT NCATS IS HAS HIT ON UNIQUE 4429 02:50:15,004 --> 02:50:16,739 WAYS TO INCREASE PACE OF 4430 02:50:16,806 --> 02:50:17,640 TRANSLATION, SOMETHING WE CAN 4431 02:50:17,707 --> 02:50:22,278 ALL BE VERY PROUD OF. 4432 02:50:22,345 --> 02:50:25,014 THE NEXT SLIDE, I SHOW A LITTLE 4433 02:50:25,081 --> 02:50:26,683 BIT ABOUT THE LICENSES THAT 4434 02:50:26,749 --> 02:50:29,552 NCATS HAS DONE OVER THE LAST 15 4435 02:50:29,619 --> 02:50:29,752 YEARS. 4436 02:50:29,819 --> 02:50:32,689 LET ME PAUSE FOR A MINUTE AND 4437 02:50:32,755 --> 02:50:34,691 SAY THAT NCATS, PART OF NIH, 4438 02:50:34,757 --> 02:50:37,961 PART OF THE FEDERAL GOVERNMENT, 4439 02:50:38,027 --> 02:50:42,532 WE CANNOT COMMERCIALIZE 4440 02:50:42,599 --> 02:50:42,799 PRODUCTS. 4441 02:50:42,865 --> 02:50:45,068 SO LICENSING IS A CONVENTIONAL 4442 02:50:45,134 --> 02:50:47,303 OUTCOME OF INVENTIONS WE CREATE. 4443 02:50:47,370 --> 02:50:49,973 WE LOOK FOR PARTNERS ON THE 4444 02:50:50,039 --> 02:50:50,607 OUTSIDE, COMMERCIAL SECTOR, TO 4445 02:50:50,673 --> 02:50:52,308 TAKE THEM AND BUILD THEM INTO 4446 02:50:52,375 --> 02:50:52,842 PRODUCTS. 4447 02:50:52,909 --> 02:50:55,411 I'LL GIVE SOME EXAMPLES OF HOW 4448 02:50:55,478 --> 02:50:58,848 WE'VE DONE THAT. 4449 02:50:58,915 --> 02:51:00,049 SO, COMMERCIAL LICENSES, PATENT 4450 02:51:00,116 --> 02:51:01,918 COMMERCIAL LICENSES, WE'VE DONE 4451 02:51:01,985 --> 02:51:05,855 EIGHT, SOME HAVE BEEN VERY FAR 4452 02:51:05,922 --> 02:51:06,122 REACHING. 4453 02:51:06,189 --> 02:51:11,227 IN THE MIDDLE OF THE TABLE I 4454 02:51:11,294 --> 02:51:15,298 SHOW IIA, THESE ARE AGREEMENTS 4455 02:51:15,365 --> 02:51:16,265 BETWEEN TWO INSTITUTIONS THAT 4456 02:51:16,332 --> 02:51:18,267 CO-OWN A PIECE OF INTELLECTUAL 4457 02:51:18,334 --> 02:51:18,868 PROPERTY. 4458 02:51:18,935 --> 02:51:20,703 WHEN YOU COLLABORATE WITH 4459 02:51:20,770 --> 02:51:24,540 ANOTHER INSURE INSTITUTION, 4460 02:51:24,607 --> 02:51:25,608 JOINT INVENTION, IT'S PREFERABLE 4461 02:51:25,675 --> 02:51:28,211 TO GET AN AGREEMENT THAT SAYS 4462 02:51:28,277 --> 02:51:30,613 ONE OR THE OTHER ORGANIZATION 4463 02:51:30,680 --> 02:51:33,783 WOULD TAKE THE LEAD ON THE IP, 4464 02:51:33,850 --> 02:51:36,653 MANAGING IP, MARKETING IP, 4465 02:51:36,719 --> 02:51:38,621 PERHAPS FINDING LICENSES PARTNER 4466 02:51:38,688 --> 02:51:39,055 DURING NEGOTIATIONS. 4467 02:51:39,122 --> 02:51:42,558 IN THE CASE OF NCATS, BECAUSE OF 4468 02:51:42,625 --> 02:51:47,363 COLLABORATIVE NATURE, MANY MORE 4469 02:51:47,430 --> 02:51:48,998 OF OUR IIAs, INSTITUTIONAL 4470 02:51:49,065 --> 02:51:50,500 AGREEMENTS, HAVE THE OUTSIDE 4471 02:51:50,566 --> 02:51:52,101 INSTITUTION TAKING THE LEAD AND 4472 02:51:52,168 --> 02:51:54,170 NIH TAKES THE LEAD ON A SMALLER 4473 02:51:54,237 --> 02:51:56,139 PROPORTION OF THOSE. 4474 02:51:56,205 --> 02:51:59,409 I'LL GIVE EXAMPLES OF EACH OF 4475 02:51:59,475 --> 02:52:03,579 THOSE CATEGORIES OF IIAs. 4476 02:52:03,646 --> 02:52:05,348 NEXT SLIDE PLEASE. 4477 02:52:05,415 --> 02:52:08,484 SO I'M GOING TO SWITCH GEARS AND 4478 02:52:08,551 --> 02:52:12,088 PRESENT SOME CASE STUDIES TO 4479 02:52:12,155 --> 02:52:14,657 EXEMPLIFY HOW OSA HAS BEEN DOING 4480 02:52:14,724 --> 02:52:16,292 ITS WORK IN COLLABORATION WITH 4481 02:52:16,359 --> 02:52:18,561 THE SCIENTISTS, IN COLLABORATION 4482 02:52:18,628 --> 02:52:24,367 WITH OUTSIDE PARTNERS. 4483 02:52:24,434 --> 02:52:27,370 NEXT SLIDE PLEASE. 4484 02:52:27,437 --> 02:52:29,305 AS YOU REMEMBER, THE VISION 4485 02:52:29,372 --> 02:52:30,907 CIRCLE WITH THE PLANETARY 4486 02:52:30,973 --> 02:52:32,075 DIAGRAM OF THE DIFFERENT 4487 02:52:32,141 --> 02:52:35,178 ELEMENTS, ONE OF THE ELEMENTS I 4488 02:52:35,244 --> 02:52:35,978 MENTIONED WAS INNOVATION. 4489 02:52:36,045 --> 02:52:37,947 SO THIS IS A STORY I WANT TO 4490 02:52:38,014 --> 02:52:39,615 TELL YOU IN A LITTLE BIT OF 4491 02:52:39,682 --> 02:52:41,718 DETAIL BECAUSE I WANT TO TELL 4492 02:52:41,784 --> 02:52:42,752 YOU ABOUT THE INNOVATION THAT 4493 02:52:42,819 --> 02:52:46,155 OUR OFFICE HAS DONE IN THE 4494 02:52:46,222 --> 02:52:48,658 COLLABORATION PROCESS ITSELF. 4495 02:52:48,725 --> 02:52:49,759 NOW, INNOVATION IS EASY TO SEE 4496 02:52:49,826 --> 02:52:52,161 IN SCIENCE, EASY TO SEE IN 4497 02:52:52,228 --> 02:52:53,463 ENGINEERING, IN FACT YOU CAN 4498 02:52:53,529 --> 02:52:55,298 ACTUALLY LOOK AT A PIECE OF 4499 02:52:55,364 --> 02:52:56,866 INNOVATION AND YOU CAN TOUCH IT, 4500 02:52:56,933 --> 02:52:59,168 FEEL IT, EVEN TASTE IT. 4501 02:52:59,235 --> 02:53:03,306 IN THE FIELD OF BUSINESS AND 4502 02:53:03,372 --> 02:53:04,440 LAW, WHEN THERE ARE INNOVATIONS 4503 02:53:04,507 --> 02:53:06,809 THEY ARE FEW AND FAR IN BETWEEN. 4504 02:53:06,876 --> 02:53:09,112 THEY ARE VERY HARD TO REALLY 4505 02:53:09,178 --> 02:53:10,213 UNDERSTAND AND EVEN EXPLAIN. 4506 02:53:10,279 --> 02:53:11,748 SO I'M GOING TO TAKE A FEW 4507 02:53:11,814 --> 02:53:14,417 MINUTES TO EXPLAIN WHAT THIS 4508 02:53:14,484 --> 02:53:15,685 INNOVATION REALLY IS. 4509 02:53:15,752 --> 02:53:17,754 REMEMBER I TALKED ABOUT THE 4510 02:53:17,820 --> 02:53:19,856 CRADA, THE CRADA AGREEMENT IS 4511 02:53:19,922 --> 02:53:22,024 SOMETHING THAT WAS WRITTEN IN 4512 02:53:22,091 --> 02:53:23,760 THE 1980s, ALONG WITH 4513 02:53:23,826 --> 02:53:24,761 TECHNOLOGY TRANSFER LAWS, AND 4514 02:53:24,827 --> 02:53:26,729 HAS BEEN IN EXISTENCE FOR OVER 4515 02:53:26,796 --> 02:53:28,197 40 YEARS. 4516 02:53:28,264 --> 02:53:29,899 TALK ABOUT INNOVATION, THERE WAS 4517 02:53:29,966 --> 02:53:31,868 ONE INNOVATION IN THE CRADA 4518 02:53:31,934 --> 02:53:33,202 AGREEMENT WHICH WAS THE 4519 02:53:33,269 --> 02:53:37,039 MATERIALS CRADA IN THE EARLY 4520 02:53:37,106 --> 02:53:41,110 2000s, WHEN COMPANY WANTED TO 4521 02:53:41,177 --> 02:53:46,682 PROVIDE MATERIALS TO NIH, WANTED 4522 02:53:46,749 --> 02:53:48,217 INTELLECTUAL PRODUCT RIGHTS, THE 4523 02:53:48,284 --> 02:53:49,285 MATERIALS CRADA. 4524 02:53:49,352 --> 02:53:52,155 IN 2020, NCATS DEVELOPED A NEW 4525 02:53:52,221 --> 02:53:57,360 KIND OF CRADA CALLED C-RCA, WHAT 4526 02:53:57,426 --> 02:54:00,029 IS THE IMPETUS AND MOTIVATION 4527 02:54:00,096 --> 02:54:00,696 FOR THIS? 4528 02:54:00,763 --> 02:54:02,565 THE RCA LIKE I MENTIONED IS 4529 02:54:02,632 --> 02:54:05,434 PROBABLY THE MOST EFFICIENT OF 4530 02:54:05,501 --> 02:54:07,470 THE COLLABORATION AGREEMENTS. 4531 02:54:07,537 --> 02:54:09,205 THE CRADA IS SOMEWHAT 4532 02:54:09,272 --> 02:54:10,673 COMPLICATED. 4533 02:54:10,740 --> 02:54:14,577 IT'S GOT A LOT OF LEGAL 4534 02:54:14,644 --> 02:54:14,877 PROTECTIONS. 4535 02:54:14,944 --> 02:54:17,146 AND LIKE GOLDILOCKS, OSA WAS 4536 02:54:17,213 --> 02:54:21,083 LOOKING FOR SOMETHING JUST 4537 02:54:21,150 --> 02:54:29,258 RIGHT, WHICH WOULD COMBINE THE 4538 02:54:29,325 --> 02:54:34,197 LEGAL CRADA, WITH SPEED AND 4539 02:54:34,263 --> 02:54:37,066 EFFICIENCY. 4540 02:54:37,133 --> 02:54:41,637 WE CREATED C-RCA, COMBINING THE 4541 02:54:41,704 --> 02:54:42,538 BEST ELEMENTS. 4542 02:54:42,605 --> 02:54:46,909 WE'RE USED IT 25 TIMES, OTHER 4543 02:54:46,976 --> 02:54:50,179 INSTITUTES STARTED USING IT. 4544 02:54:50,246 --> 02:54:51,581 BENEFITS OF C-RCA, IT TAKES 4545 02:54:51,647 --> 02:54:54,016 WEEKS TO MAYBE DAYS TO COMPLETE 4546 02:54:54,083 --> 02:54:56,152 VERSUS MONTHS FOR A CRADA TO 4547 02:54:56,219 --> 02:54:59,055 COMPLETE BUT HAS THE SAME LEGAL 4548 02:54:59,121 --> 02:55:00,189 COVERAGE. 4549 02:55:00,256 --> 02:55:03,125 LIKE I SAID, PRESERVES LEGAL 4550 02:55:03,192 --> 02:55:04,427 SAFEGUARD FOR BACKGROUND IP, 4551 02:55:04,493 --> 02:55:07,563 IT'S BEEN USED OVER 25 TIMES AT 4552 02:55:07,630 --> 02:55:11,400 NCATS, WE'VE PUBLISHED ON IT SO 4553 02:55:11,467 --> 02:55:15,204 WE CAN DISSEMINATE TO LARGER 4554 02:55:15,271 --> 02:55:16,973 COMMUNITY. 4555 02:55:17,039 --> 02:55:18,274 NEXT SLIDE PLEASE. 4556 02:55:18,341 --> 02:55:20,309 SO ANOTHER EXAMPLE I WANT TO 4557 02:55:20,376 --> 02:55:23,846 SHOW YOU IS IN THE AREA OF 4558 02:55:23,913 --> 02:55:24,180 EFFICIENCIES. 4559 02:55:24,247 --> 02:55:29,452 WHEN YOU HAVE A SITUATION LIKE 4560 02:55:29,518 --> 02:55:31,954 THE N3C WHEN THE N3C PROJECT 4561 02:55:32,021 --> 02:55:35,291 FISHES STARTED WE WANTED TO 4562 02:55:35,358 --> 02:55:37,193 INGEST DATA FROM MANY, MANY 4563 02:55:37,260 --> 02:55:39,862 DIFFERENT INSTITUTIONS. 4564 02:55:39,929 --> 02:55:41,697 WE WANTED LITERALLY TO HAVE A 4565 02:55:41,764 --> 02:55:44,800 SITUATION WHERE THINGS COULD BE 4566 02:55:44,867 --> 02:55:46,636 DONE IN A VERY STREAMLINED 4567 02:55:46,702 --> 02:55:49,071 FASHION, AND WE ALSO ARE ABLE TO 4568 02:55:49,138 --> 02:55:51,274 SCALE THINGS UP. 4569 02:55:51,340 --> 02:55:52,375 IMAGINE IF 20 TO 30 PARTNERS 4570 02:55:52,441 --> 02:55:55,177 COME TO YOU AND SAY WE WANT TO 4571 02:55:55,244 --> 02:55:56,979 FILE AN AGREEMENT TO DO THIS. 4572 02:55:57,046 --> 02:55:59,282 THERE'S NO EASY SOLUTION. 4573 02:55:59,348 --> 02:56:01,751 WHAT WE DECIDED TO DO, CHRIS 4574 02:56:01,817 --> 02:56:03,119 DILLON TOOK ON THIS CHALLENGE, 4575 02:56:03,185 --> 02:56:05,454 SAID WE NEED TO COME UP WITH 4576 02:56:05,521 --> 02:56:09,292 SOME TEMPLATE AGREEMENT THAT 4577 02:56:09,358 --> 02:56:12,695 WILL BE USABLE, ROBUST, AND 4578 02:56:12,762 --> 02:56:14,897 PALATABLE TO A LOT OF PEOPLE AND 4579 02:56:14,964 --> 02:56:24,874 DEVELOPED WITH LILLY PORTILLO, 4580 02:56:24,941 --> 02:56:26,375 THREE AGREEMENTS, DTA, DUA, 4581 02:56:26,442 --> 02:56:29,545 PPRL, FOUR MONTHS TO GENERATE IN 4582 02:56:29,612 --> 02:56:31,647 TERMS OF ROBUST STRONG TEMPLATE. 4583 02:56:31,714 --> 02:56:33,916 IN DEVELOPING THESE TEMPLATES, 4584 02:56:33,983 --> 02:56:35,284 MULTIPLE PERSPECTIVES WERE 4585 02:56:35,351 --> 02:56:38,054 TAKEN, IN ADDITION TO THE 4586 02:56:38,120 --> 02:56:40,823 POTENTIAL DATA USERS, AND DATA 4587 02:56:40,890 --> 02:56:42,124 PROVIDERS. 4588 02:56:42,191 --> 02:56:44,393 SO, BY USING THIS PARTICULAR 4589 02:56:44,460 --> 02:56:45,294 TEMPLATE AND POWER OF 4590 02:56:45,361 --> 02:56:47,830 FLEXIBILITY OF TEMPLATE WE WERE 4591 02:56:47,897 --> 02:56:49,999 ABLE TO EXECUTE THE NC 3 DATA 4592 02:56:50,066 --> 02:56:54,203 USE AND DATA TRANSFER AGREEMENTS 4593 02:56:54,270 --> 02:56:57,873 OVER 500 TIMES, AND HAD TO MAKE 4594 02:56:57,940 --> 02:57:00,276 ADJUSTMENTS ONCE OR TWICE, 4595 02:57:00,343 --> 02:57:02,111 FAIRLY MINOR CHANGES. 4596 02:57:02,178 --> 02:57:03,245 SO SPEED AND EFFICIENCY IS 4597 02:57:03,312 --> 02:57:04,480 SOMETHING WE ARE VERY PROUD OF 4598 02:57:04,547 --> 02:57:09,719 IN TERMS OF WHAT WE DO AT NCATS, 4599 02:57:09,785 --> 02:57:12,922 OFFICE OF STRATEGIC ALLIANCES. 4600 02:57:12,989 --> 02:57:15,291 THE NEXT SLIDE PLEASE. 4601 02:57:15,358 --> 02:57:18,227 SO, THIS SLIDE I WANT TO GIVE AN 4602 02:57:18,294 --> 02:57:19,895 EXAMPLE OF HOW WHEN YOU DEVELOP 4603 02:57:19,962 --> 02:57:21,297 A PLATFORM TECHNOLOGY, WHAT'S 4604 02:57:21,364 --> 02:57:23,299 THE BEST WAY TO DISSEMINATE IT? 4605 02:57:23,366 --> 02:57:27,636 SO THIS IS A STORY THAT WAS -- 4606 02:57:27,703 --> 02:57:30,039 DESCRIBES THE WORK DONE AT THE 4607 02:57:30,106 --> 02:57:35,277 STEM CELL RESEARCH LAB LED BY 4608 02:57:35,344 --> 02:57:42,418 CARLOS AND HIS COLLEAGUES 4609 02:57:42,485 --> 02:57:43,719 VERY CHALLENGING MOST PEOPLE WHO 4610 02:57:43,786 --> 02:57:46,655 WORK WITH STEM CELLS KNOW THIS. 4611 02:57:46,722 --> 02:57:48,024 GROWING, CARING FOR, EXPANDING 4612 02:57:48,090 --> 02:57:51,861 STEM CELLS IS NOT A JOKE. 4613 02:57:51,927 --> 02:57:52,528 THE PROCESSES ARE DIFFICULT, 4614 02:57:52,595 --> 02:57:55,064 PEOPLE USE ALL KINDS OF GROWTH 4615 02:57:55,131 --> 02:57:56,766 FACTORS, BUT IN THIS PARTICULAR 4616 02:57:56,832 --> 02:57:59,268 CASE THE STEM CELL RESEARCH 4617 02:57:59,335 --> 02:58:00,469 LABORATORY REVOLUTIONIZED THE 4618 02:58:00,536 --> 02:58:04,173 FIELD BY COMING UP WITH THE 4619 02:58:04,240 --> 02:58:05,408 FOUR-PART COCKTAIL OF SMALL 4620 02:58:05,474 --> 02:58:07,810 MOLECULES, WELL DEFINED, FOUR 4621 02:58:07,877 --> 02:58:10,112 MOLECULES, WHICH PUT TOGETHER 4622 02:58:10,179 --> 02:58:12,748 CAN MAKE STEM CELL PROCESS MUCH, 4623 02:58:12,815 --> 02:58:18,521 MUCH MORE EASY AND STREAMLINED. 4624 02:58:18,587 --> 02:58:22,992 BY USING THE CEPT FOUR-PART 4625 02:58:23,059 --> 02:58:27,129 COCKTAIL OF WELL-DEFINED 4626 02:58:27,196 --> 02:58:28,297 MOLECULES, BY THE WAY TOOK 4627 02:58:28,364 --> 02:58:31,300 SEVERAL MONTHS TO DEVELOP THIS 4628 02:58:31,367 --> 02:58:32,134 BY HIGH-THROUGHPUT SCREENING AND 4629 02:58:32,201 --> 02:58:35,371 ASSAYS, I WON'T GO INTO THAT, 4630 02:58:35,438 --> 02:58:38,340 BUT THE PARTICULAR COCKTAIL WAS 4631 02:58:38,407 --> 02:58:42,978 ABLE TO INCREASE CELL VIABILITY, 4632 02:58:43,045 --> 02:58:45,781 REDUCE DNA DAMAGE, CREATE 4633 02:58:45,848 --> 02:58:48,417 PHENOTYPIC ACCURACY IN TERMS OF 4634 02:58:48,484 --> 02:58:54,857 CELL LINES GROWING, AND SUPPORTS 4635 02:58:54,924 --> 02:58:57,927 FUNCTION OF MATURE CELLS. 4636 02:58:57,993 --> 02:58:59,095 NEXT SLIDE. 4637 02:58:59,161 --> 02:59:05,234 SO, ONCE THIS INVENTION CAME TO 4638 02:59:05,301 --> 02:59:07,770 OUR OFFICE, LOOKED AT SAID MY 4639 02:59:07,837 --> 02:59:08,904 GOD, THIS IS REVOLUTIONARY 4640 02:59:08,971 --> 02:59:10,639 PLATFORM, NIGHT TO GET IT TO THE 4641 02:59:10,706 --> 02:59:12,808 MOST NUMBER OF USERS AS QUICKLY 4642 02:59:12,875 --> 02:59:14,110 AS POSSIBLE. 4643 02:59:14,176 --> 02:59:16,078 SO HE TOOK AN APPROACH THAT 4644 02:59:16,145 --> 02:59:25,187 WOULD BE CALLED NON-EXCLUSIVE 4645 02:59:25,254 --> 02:59:26,822 LICENSING, ON NON-EXCLUSIVE 4646 02:59:26,889 --> 02:59:29,692 BASIS, TRY TO COMMERCIALIZE IT. 4647 02:59:29,758 --> 02:59:32,828 WHILE DOING THIS, TOOK FOUR 4648 02:59:32,895 --> 02:59:33,562 APPROACHES. 4649 02:59:33,629 --> 02:59:35,397 FIRST WAS INTERNAL ALLS 4650 02:59:35,464 --> 02:59:36,999 NON-EXCLUSIVE LICENSE WHERE HE 4651 02:59:37,066 --> 02:59:39,335 WOULD LICENSE IT TO COMPANIES 4652 02:59:39,401 --> 02:59:43,072 FOR INTERNAL USE, EVEN OTHER 4653 02:59:43,139 --> 02:59:45,441 NON-PROFIT AGENCIES. 4654 02:59:45,508 --> 02:59:47,343 THERE WERE FIELD SPECIFIC 4655 02:59:47,409 --> 02:59:48,410 COMMERCIAL NON-EXCLUSIVE LICENSE 4656 02:59:48,477 --> 02:59:51,580 WHERE PATENT WAS LICENSED ON 4657 02:59:51,647 --> 02:59:53,149 NON-EXCLUSIVE BASIS FOR CERTAIN 4658 02:59:53,215 --> 02:59:53,582 FIELDS. 4659 02:59:53,649 --> 02:59:55,384 THERE WAS ALSO COMMERCIAL 4660 02:59:55,451 --> 02:59:57,186 EVALUATION LICENSES SO A COMPANY 4661 02:59:57,253 --> 02:59:58,521 THAT WANTS TO COMMERCIALIZE IT 4662 02:59:58,587 --> 03:00:01,991 COULD TAKE IT FOR A SMALL PERIOD 4663 03:00:02,057 --> 03:00:03,325 OF TIME, EVALUATE US, TELL US 4664 03:00:03,392 --> 03:00:08,898 WHAT THEY WANT TO DO AFTER THAT. 4665 03:00:08,964 --> 03:00:11,634 FOR THE ACADEMIC, WE'LL GIVE A 4666 03:00:11,700 --> 03:00:15,204 MATERIAL TRANSFER AGREEMENT THAT 4667 03:00:15,271 --> 03:00:19,074 WILL ALLOW YOU ACCESS TO THE 4668 03:00:19,141 --> 03:00:22,311 METHODOLOGY AND MATERIALS ON A 4669 03:00:22,378 --> 03:00:23,779 SHORT-TERM BASIS. 4670 03:00:23,846 --> 03:00:25,014 SO BOTTOM LINE NON-EXCLUSIVELY 4671 03:00:25,080 --> 03:00:27,183 LICENSING TO A NUMBER OF 4672 03:00:27,249 --> 03:00:28,617 DIFFERENT COMPANIES, THE 4673 03:00:28,684 --> 03:00:31,487 COMPANIES LISTED HERE, HE WAS 4674 03:00:31,554 --> 03:00:35,691 ABLE TO REACH THE -- PROVIDE 4675 03:00:35,758 --> 03:00:37,593 STEM CELL COCKTAIL PLATFORM THAT 4676 03:00:37,660 --> 03:00:41,197 HAS MANY DIFFERENT USERS WITH AS 4677 03:00:41,263 --> 03:00:45,601 MUCH REACH AND AS LITTLE PAIN AS 4678 03:00:45,668 --> 03:00:51,507 POSSIBLE. 4679 03:00:51,574 --> 03:00:52,141 NEXT SLIDE PLEASE. 4680 03:00:52,208 --> 03:00:59,048 SO THIS IS AN EXAMPLE OF A 4681 03:00:59,114 --> 03:01:00,282 LICENSE NEGOTIATION WHICH WAS 4682 03:01:00,349 --> 03:01:02,017 EXCLUSIVELY LICENSE WHERE THE 4683 03:01:02,084 --> 03:01:06,789 COLLABORATOR TOOK THE LEAD. 4684 03:01:06,855 --> 03:01:09,458 IN THIS CASE PRESENTED WITH 4685 03:01:09,525 --> 03:01:11,227 INVENTION, TREATMENT FOR RARE 4686 03:01:11,293 --> 03:01:13,095 CANCERS WITH SMALL MOLECULES. 4687 03:01:13,162 --> 03:01:16,232 ONE OF THE LABS LED BY CRAIG 4688 03:01:16,298 --> 03:01:20,603 THOMAS AND OTHERS AT NCATS WITH 4689 03:01:20,669 --> 03:01:21,904 THE CINCINNATI GROUP DEVELOPED 4690 03:01:21,971 --> 03:01:23,872 SMALL MOLECULES VERY PROMISING. 4691 03:01:23,939 --> 03:01:25,507 IN THOSE EARLY STAGES, AMY TOOK 4692 03:01:25,574 --> 03:01:27,843 A LOOK AND SAID, WHAT'S THE BEST 4693 03:01:27,910 --> 03:01:30,346 WAY TO GO FORWARD? 4694 03:01:30,412 --> 03:01:32,314 SHOULD NCATS OR NIH TAKE THE 4695 03:01:32,381 --> 03:01:34,516 LEAD OR CINCINNATI TAKE THE 4696 03:01:34,583 --> 03:01:34,850 LEAD? 4697 03:01:34,917 --> 03:01:37,152 BASED ON THE DATA AND ALL THE 4698 03:01:37,219 --> 03:01:38,454 ANALYSIS SHE CONCLUDED THAT THE 4699 03:01:38,520 --> 03:01:40,522 BEST THING WOULD BE FOR THE 4700 03:01:40,589 --> 03:01:44,994 CINCINNATI GROUP TO TAKE THE 4701 03:01:45,060 --> 03:01:47,529 LEAD, SO NEGOTIATED 4702 03:01:47,596 --> 03:01:49,098 INTERINSTITUTE AGREEMENT WITH 4703 03:01:49,164 --> 03:01:51,267 CINCINNATI CHILDREN'S HEALTH 4704 03:01:51,333 --> 03:01:55,871 MEDICAL CENTER, AND IIA 4705 03:01:55,938 --> 03:01:56,739 TYPICALLY AN EXCLUSIVE LICENSE 4706 03:01:56,805 --> 03:01:59,275 WHICH GIVERS THE OTHER PART FULL 4707 03:01:59,341 --> 03:02:01,076 RIGHTS TO FILE THE PATENTS AS 4708 03:02:01,143 --> 03:02:04,613 WELL AS MARKET THE PATENT AND 4709 03:02:04,680 --> 03:02:05,147 FINE LICENSEES. 4710 03:02:05,214 --> 03:02:08,317 NOW, AT THE END OF THE DAY THERE 4711 03:02:08,384 --> 03:02:09,585 WERE 86 PATENT APPLICATIONS, 4712 03:02:09,652 --> 03:02:13,789 WITH LOTS OF COMPLEXITY. 4713 03:02:13,856 --> 03:02:15,024 AMY MADE THE RIGHT CHOICE 4714 03:02:15,090 --> 03:02:17,426 BECAUSE MANAGING ALL THOSE 4715 03:02:17,493 --> 03:02:18,460 APPLICATIONS, FOOTING THE BILL, 4716 03:02:18,527 --> 03:02:21,897 TAKING ALL THE EXPENSES UP 4717 03:02:21,964 --> 03:02:23,966 FRONT WOULD HAVE BEEN A HUGE 4718 03:02:24,033 --> 03:02:24,266 UNDERTAKING. 4719 03:02:24,333 --> 03:02:27,303 SOME RISK AND BURDEN WAS SHIFTED 4720 03:02:27,369 --> 03:02:29,571 TO CINCINNATI. 4721 03:02:29,638 --> 03:02:31,307 SHE ALSO NEGOTIATED A THREE-WAY 4722 03:02:31,373 --> 03:02:35,244 CRADA WITH A START-UP COMPANY, 4723 03:02:35,311 --> 03:02:36,545 KURON, LICENSED THE TECHNOLOGY 4724 03:02:36,612 --> 03:02:40,215 FROM CINCINNATI. 4725 03:02:40,282 --> 03:02:42,718 NEXT SLIDE PLEASE. 4726 03:02:42,785 --> 03:02:47,189 IN TERMS OF COLLABORATION WITH 4727 03:02:47,256 --> 03:02:48,324 THE 3-WAY COLLABORATION 4728 03:02:48,390 --> 03:02:52,961 CINCINNATI SET ALL START-UP 4729 03:02:53,028 --> 03:02:54,663 COMPANY, KUROME, THAT GOT 4730 03:02:54,730 --> 03:02:57,499 FUNDING AND THEY ALSO WERE ABLE 4731 03:02:57,566 --> 03:03:03,272 TO PUT TOGETHER A BOARD AND A 4732 03:03:03,339 --> 03:03:05,574 NUMBER OF SCIENTISTS, SO THEY 4733 03:03:05,641 --> 03:03:10,312 COULD MANUFACTURE THE DRUG, DO 4734 03:03:10,379 --> 03:03:11,814 IND-ENABLING STUDIES, IND WILL 4735 03:03:11,880 --> 03:03:14,683 BE FILED PRETTY SOON. 4736 03:03:14,750 --> 03:03:16,752 THE NEXT SLIDE SHOWS JUST THE 4737 03:03:16,819 --> 03:03:17,953 OPPOSITE. 4738 03:03:18,020 --> 03:03:20,589 IN THIS PARTICULAR CASE, SORI 4739 03:03:20,656 --> 03:03:22,558 WAS GIVEN THE TECHNOLOGY WHICH 4740 03:03:22,624 --> 03:03:24,893 MANY OF YOU HEARD ABOUT, I WON'T 4741 03:03:24,960 --> 03:03:27,296 TALK ABOUT THE SCIENCE, BUT 4742 03:03:27,363 --> 03:03:37,473 BASICALLY FIRST IN CLASS 4743 03:03:37,539 --> 03:03:38,540 MOLECULE, METARRESTIN, ARRESTING 4744 03:03:38,607 --> 03:03:40,709 METASTASIS, FIRST IN CLASS 4745 03:03:40,776 --> 03:03:43,045 CANCER DRUG. 4746 03:03:43,112 --> 03:03:45,414 IN THIS CASE, HE DECIDED THE 4747 03:03:45,481 --> 03:03:46,949 BEST COURSE OF ACTION WOULD BE 4748 03:03:47,015 --> 03:03:50,252 FOR NCATS TO TAKE THE LEAD, WE 4749 03:03:50,319 --> 03:03:54,056 TOOK THE LEAD, FILED PATENT 4750 03:03:54,123 --> 03:03:55,090 APPLICATION IN COLLABORATION 4751 03:03:55,157 --> 03:03:55,824 WITH OTHER PARTNERS. 4752 03:03:55,891 --> 03:03:58,527 ALONG THE WAY THERE WAS SOME 4753 03:03:58,594 --> 03:03:59,228 FUNDING FROM THE THERAPEUTIC 4754 03:03:59,294 --> 03:04:03,265 DEVELOPMENT BRANCH TO DO 4755 03:04:03,332 --> 03:04:04,700 PRE-CLINICAL EVALUATION, SOME 4756 03:04:04,767 --> 03:04:05,634 IND-ENABLING WORK, AND SOME 4757 03:04:05,701 --> 03:04:09,371 PHASE 1 WORK WAS DONE IN NCI. 4758 03:04:09,438 --> 03:04:13,108 AND THEN BASED ON THAT, WE HAVE 4759 03:04:13,175 --> 03:04:15,077 A LICENSING PARTNER NOW, WHICH 4760 03:04:15,144 --> 03:04:17,379 CAN TAKE A PHASE 1 ASSET AND 4761 03:04:17,446 --> 03:04:20,549 DEVELOP IT EVEN FURTHER. 4762 03:04:20,616 --> 03:04:22,050 SO, I'VE SHOWN TWO DIFFERENT 4763 03:04:22,117 --> 03:04:23,419 WAYS OF APPROACHING THE SAME 4764 03:04:23,485 --> 03:04:24,253 PROBLEM. 4765 03:04:24,319 --> 03:04:25,053 WHEN YOU HAVE A JOINT INVENTION 4766 03:04:25,120 --> 03:04:27,890 YOU CAN TAKE THE LEAD YOURSELF, 4767 03:04:27,956 --> 03:04:28,657 ALLOW THE COLLABORATING PARTNER 4768 03:04:28,724 --> 03:04:30,726 TO TAKE THE LEAD. 4769 03:04:30,793 --> 03:04:32,795 EACH ONE HAS GOT PROS AND CONS, 4770 03:04:32,861 --> 03:04:34,663 YOU HAVE TO MAKE THE RIGHT 4771 03:04:34,730 --> 03:04:40,235 JUDGMENT AT THE RIGHT TIME. 4772 03:04:40,302 --> 03:04:41,537 NEXT SLIDE PLEASE. 4773 03:04:41,603 --> 03:04:43,105 SO THE LAST EXAMPLE OF THE LAST 4774 03:04:43,172 --> 03:04:47,910 CASE STUDY I WANT TO TALK ABOUT 4775 03:04:47,976 --> 03:04:52,047 IS SOMETHING THAT CHRIS DILLON 4776 03:04:52,114 --> 03:04:52,548 LED. 4777 03:04:52,614 --> 03:04:54,283 TRANSLATION IS BOTH SCIENTIFIC 4778 03:04:54,349 --> 03:04:55,484 AND BUSINESS CHALLENGE. 4779 03:04:55,551 --> 03:04:59,421 AND IN ORDER FOR A GOOD 4780 03:04:59,488 --> 03:05:00,622 TRANSLATIONAL SCIENTIST THEY 4781 03:05:00,689 --> 03:05:01,924 NEED THE RIGHT TOOLS OF SCIENCE 4782 03:05:01,990 --> 03:05:06,495 AND RIGHT BUSINESS TOOLS TO BE 4783 03:05:06,562 --> 03:05:13,068 ABLE TO BE A TRANSLATIONAL 4784 03:05:13,135 --> 03:05:15,270 SCIENTIST. 4785 03:05:15,337 --> 03:05:17,873 WE DEVELOPED A PROGRAM, 4786 03:05:17,940 --> 03:05:25,848 ADVANCING INNOVATION THROUGH 4787 03:05:25,914 --> 03:05:26,381 MENTORSHIP, PATENTED AFTER 4788 03:05:26,448 --> 03:05:30,752 I-CORPS HOW TO FIND OUT WHAT 4789 03:05:30,819 --> 03:05:31,286 POTENTIALS ARE, BASICALLY 4790 03:05:31,353 --> 03:05:36,358 EXPERIENTIAL LEARNING PROCESS 4791 03:05:36,425 --> 03:05:37,226 THROUGH CUSTOMER DISCOVERY 4792 03:05:37,292 --> 03:05:37,793 METHODOLOGY. 4793 03:05:37,860 --> 03:05:40,462 YOU USE THE WORD CUSTOMER IN A 4794 03:05:40,529 --> 03:05:40,863 BROAD WAY. 4795 03:05:40,929 --> 03:05:45,067 A CUSTOMER COULD BE POTENTIAL 4796 03:05:45,133 --> 03:05:45,834 COLLABORATOR, POTENTIAL USER, 4797 03:05:45,901 --> 03:05:48,203 COULD BE THOUGHT LEADER, COULD 4798 03:05:48,270 --> 03:05:51,039 BE A COMPETITOR, COULD BE 4799 03:05:51,106 --> 03:05:51,473 ANYBODY. 4800 03:05:51,540 --> 03:05:53,208 GROUPS ARE FORMED WHERE A GROUP 4801 03:05:53,275 --> 03:05:56,111 OF THREE OR FOUR PEOPLE WOULD 4802 03:05:56,178 --> 03:05:58,947 GET TOGETHER AND START DOING 4803 03:05:59,014 --> 03:06:01,884 INTERVIEWS OF MULTIPLE PEOPLE ON 4804 03:06:01,950 --> 03:06:04,286 THE OUTSIDE, PEOPLE WHO EITHER 4805 03:06:04,353 --> 03:06:07,623 KNOW ABOUT THE SUBJECT, ARE 4806 03:06:07,689 --> 03:06:10,559 EXPERTS, POTENTIAL USERS. 4807 03:06:10,626 --> 03:06:12,528 SO 14 TEAMS STRAINED OVER THE 4808 03:06:12,594 --> 03:06:14,062 LAST FOUR YEARS, 39 STAFF 4809 03:06:14,129 --> 03:06:15,931 TRAINED, SOME PROJECTS HAVE BEEN 4810 03:06:15,998 --> 03:06:16,565 VERY FASCINATING. 4811 03:06:16,632 --> 03:06:21,970 SO AT THE BOTTOM I LISTED THREE. 4812 03:06:22,037 --> 03:06:27,609 ONE LED BY BILL SANDERS, WORKING 4813 03:06:27,676 --> 03:06:28,377 ON THE BUNYAVIRUS RESEARCH, 4814 03:06:28,443 --> 03:06:32,114 DECIDED THEY WANTED TO FIND OUT 4815 03:06:32,180 --> 03:06:33,782 WHAT IS KEEPING THE FIELD 4816 03:06:33,849 --> 03:06:36,118 DORMANT, WHAT ARE SOME 4817 03:06:36,184 --> 03:06:36,952 CHALLENGES. 4818 03:06:37,019 --> 03:06:39,288 SO THEY STARTED TALKING TO 4819 03:06:39,354 --> 03:06:46,328 COLLABORATORS AND FOUND OUT 4820 03:06:46,395 --> 03:06:51,300 MERCK COULD BE POTENTIAL 4821 03:06:51,366 --> 03:06:51,633 COLLABORATOR. 4822 03:06:51,700 --> 03:06:55,103 THE OTHER TEAM WORKING ON A 4823 03:06:55,170 --> 03:06:59,274 METHODOLOGY, ENDED UP FILING 4824 03:06:59,341 --> 03:07:01,443 PATENTS, DEVELOPED PROTOTYPE 4825 03:07:01,510 --> 03:07:06,048 INSTRUMENT. 4826 03:07:06,114 --> 03:07:07,115 NEXT SLIDE PLEASE. 4827 03:07:07,182 --> 03:07:09,885 I WANT TO STOP ON THIS SLIDE AND 4828 03:07:09,952 --> 03:07:12,754 TALK ABOUT DIFFERENT ELEMENTS 4829 03:07:12,821 --> 03:07:21,797 INVOLVED, HOPEFULLY I'VE SHOWN 4830 03:07:21,863 --> 03:07:23,565 ALONG WITH CASE STUDIES, TRUST 4831 03:07:23,632 --> 03:07:24,866 IS MOST IMPORTANT, EARNED WITH 4832 03:07:24,933 --> 03:07:29,705 COLLABORATION AND PARTNERSHIPS. 4833 03:07:29,771 --> 03:07:30,572 WITH SPEED AND EFFICIENCILY THEY 4834 03:07:30,639 --> 03:07:32,240 WILL COME BACK. 4835 03:07:32,307 --> 03:07:37,579 IF YOU HAVE INNOVATIVE METHODS 4836 03:07:37,646 --> 03:07:39,948 TO REDUCE VISCOSITY, PARTNERS 4837 03:07:40,015 --> 03:07:40,282 COME. 4838 03:07:40,349 --> 03:07:41,717 SHOW FLEXIBILITY, THEY WILL 4839 03:07:41,783 --> 03:07:42,117 COME. 4840 03:07:42,184 --> 03:07:43,919 IF YOU ARE A BRIDGE BUILDER, 4841 03:07:43,986 --> 03:07:46,989 THEY WILL ALSO COME TO YOU. 4842 03:07:47,055 --> 03:07:52,327 ONE BIG CHALLENGE WHICH ANY 4843 03:07:52,394 --> 03:07:53,261 ORGANIZATION HAS IN DEVELOPING 4844 03:07:53,328 --> 03:07:55,964 PARTNERSHIPS IS TO DEVELOP 4845 03:07:56,031 --> 03:07:56,398 NETWORKS. 4846 03:07:56,465 --> 03:07:58,500 IN ORDER TO HAVE LOTS AND LOTS 4847 03:07:58,567 --> 03:08:00,836 OF PARTNERS AND TO BE THE 4848 03:08:00,902 --> 03:08:02,204 PREFERRED PARTNER YOU NEED TO 4849 03:08:02,270 --> 03:08:05,107 HAVE A BROAD AND DEEP NETWORK. 4850 03:08:05,173 --> 03:08:06,375 AND THAT'S ONE AREA WHERE I 4851 03:08:06,441 --> 03:08:09,511 THINK WE REALLY COULD DO A LOT 4852 03:08:09,578 --> 03:08:09,878 MORE. 4853 03:08:09,945 --> 03:08:12,814 I'M GOING TO STOP THERE AND ASK 4854 03:08:12,881 --> 03:08:15,550 THE COUNCIL FOR SUGGESTIONS, 4855 03:08:15,617 --> 03:08:17,319 QUESTIONS, FEEDBACK, ON ANY OF 4856 03:08:17,386 --> 03:08:20,455 THESE ELEMENTS OR ANYTHING THAT 4857 03:08:20,522 --> 03:08:27,796 I'VE TALKED ABOUT. 4858 03:08:27,863 --> 03:08:29,765 >> THANK YOU, BARKI. 4859 03:08:29,831 --> 03:08:33,368 I LIKE THE METAPHOR WITH 4860 03:08:33,435 --> 03:08:34,569 CHEMICAL ENTITY, THE MOLECULES, 4861 03:08:34,636 --> 03:08:45,013 TO HOW WE THINK ABOUT 4862 03:08:54,122 --> 03:08:55,290 COLLABORATIONS. 4863 03:08:55,357 --> 03:08:55,824 >> SERGIO, YOU'RE FIRST. 4864 03:08:55,891 --> 03:08:56,792 >> THANK YOU, BALKI. 4865 03:08:56,858 --> 03:09:00,829 ONE COMMENT I WANT TO MAKE IS 4866 03:09:00,896 --> 03:09:04,199 THAT IT'S JUST GREAT THAT YOU 4867 03:09:04,266 --> 03:09:06,501 SHARED WITH US THE VISION 4868 03:09:06,568 --> 03:09:11,273 ELEMENTS, AND YOU SPOKE ABOUT 4869 03:09:11,339 --> 03:09:14,076 EACH OF THEM, ESPECIALLY TRUST, 4870 03:09:14,142 --> 03:09:21,516 IN PARTICULAR TRUST. 4871 03:09:21,583 --> 03:09:24,786 TRUST IS FRONT AND CENTER IN ANY 4872 03:09:24,853 --> 03:09:29,624 OF THE ACTIVITIES, IT SEEMS TO 4873 03:09:29,691 --> 03:09:35,297 ME THAT YOU DO WITHIN OSA, AND I 4874 03:09:35,363 --> 03:09:39,801 HAVE BEEN THINKING, I WAS 4875 03:09:39,868 --> 03:09:41,570 THINKING THROUGHOUT YOUR 4876 03:09:41,636 --> 03:09:43,405 PRESENTATION, HOW CRITICAL IT 4877 03:09:43,472 --> 03:09:51,480 IS, I MEAN TRUST, IT IS FOR 4878 03:09:51,546 --> 03:09:52,781 DEVELOPING, DEMONSTRATING, 4879 03:09:52,848 --> 03:09:53,615 DISSEMINATING WHATEVER IS BEING 4880 03:09:53,682 --> 03:09:54,182 DONE. 4881 03:09:54,249 --> 03:09:57,152 THIS CUTS ACROSS ALL THE 4882 03:09:57,219 --> 03:09:57,519 PROGRAMS. 4883 03:09:57,586 --> 03:10:02,791 AND I WOULD ENCOURAGE YOU TO -- 4884 03:10:02,858 --> 03:10:04,426 MAYBE YOU'RE ALREADY DOING IT. 4885 03:10:04,493 --> 03:10:06,795 YOU KNOW, YOU DEVELOP YOUR 4886 03:10:06,862 --> 03:10:08,930 PARTNERSHIPS. 4887 03:10:08,997 --> 03:10:10,766 AND DEVELOP THE PLANS. 4888 03:10:10,832 --> 03:10:11,967 THAT YOU REALLY THINK ABOUT 4889 03:10:12,033 --> 03:10:15,837 THOSE WHO STAND TO BENEFIT THE 4890 03:10:15,904 --> 03:10:20,175 MOST, FOR THIS PROGRAM, AND GET 4891 03:10:20,242 --> 03:10:22,811 THEM SYSTEMATICALLY INVOLVED IN 4892 03:10:22,878 --> 03:10:26,615 THOSE THREE CRITICAL PHASES. 4893 03:10:26,681 --> 03:10:28,550 THE THREE Ds. 4894 03:10:28,617 --> 03:10:30,986 I'M THINKING ABOUT IN PARTICULAR 4895 03:10:31,052 --> 03:10:31,386 DISSEMINATION. 4896 03:10:31,453 --> 03:10:39,528 IF YOU DO THAT, YOU WILL HAVE A 4897 03:10:39,594 --> 03:10:41,229 CADRE OR AUDIENCE THAT WILL 4898 03:10:41,296 --> 03:10:46,468 BECOME CHAMPIONS FOR WHAT YOU'RE 4899 03:10:46,535 --> 03:10:51,373 TRYING TO DISSEMINATE, I THINK. 4900 03:10:51,439 --> 03:10:54,676 JONI, I'M DELIGHTED, TRULY, 4901 03:10:54,743 --> 03:10:59,314 ACROSS THE VARIOUS PROGRAMS 4902 03:10:59,381 --> 03:11:03,218 TRUST HAS EMERGED AS A KEY 4903 03:11:03,285 --> 03:11:13,428 ELEMENT, YOU KNOW, AND I WOULD 4904 03:11:13,495 --> 03:11:16,464 ENCOURAGE ALSO NCATS TO MAKE IT 4905 03:11:16,531 --> 03:11:19,201 MORE KIND OF FRONT AND CENTER. 4906 03:11:19,267 --> 03:11:21,636 TRUST AND TRUSTWORTHINESS. 4907 03:11:21,703 --> 03:11:23,171 WE SPOKE ALREADY ABOUT 4908 03:11:23,238 --> 03:11:23,572 TRUSTWORTHINESS. 4909 03:11:23,638 --> 03:11:27,342 BECAUSE I THINK, YOU KNOW, ONE 4910 03:11:27,409 --> 03:11:31,112 OF THE KEY EXPERIENCES THAT WE 4911 03:11:31,179 --> 03:11:35,283 KEEP HAVING AS WE GO ABOUT DOING 4912 03:11:35,350 --> 03:11:39,154 TRANSLATIONAL RESEARCH, FOR 4913 03:11:39,221 --> 03:11:39,921 EXAMPLE, WITH ESPECIALLY 4914 03:11:39,988 --> 03:11:41,990 UNDERSERVED COMMUNITIES, A 4915 03:11:42,057 --> 03:11:45,527 TREMENDOUS DISTRUST THAT EXISTS 4916 03:11:45,594 --> 03:11:54,169 IN THOSE COMMUNITIES. 4917 03:11:54,236 --> 03:11:58,840 AND I WAS REALLY ELATED WHEN YOU 4918 03:11:58,907 --> 03:12:01,142 HOSTED THE BRIEF BIO BY MONICA 4919 03:12:01,209 --> 03:12:05,113 BERTAGNOLLI THAT SHE'S ALSO 4920 03:12:05,180 --> 03:12:11,086 FOCUSING ON RESTORING TRUST IN 4921 03:12:11,152 --> 03:12:12,354 SCIENCE, SOMETHING SO DAMAGED 4922 03:12:12,420 --> 03:12:15,290 YOU WE NEED TO ACTIVELY AND 4923 03:12:15,357 --> 03:12:18,126 COLLECTIVELY DO SOMETHING ABOUT 4924 03:12:18,193 --> 03:12:18,293 IT. 4925 03:12:18,360 --> 03:12:18,593 THANK YOU. 4926 03:12:18,660 --> 03:12:20,528 >> TRUST IS SOMETHING YOU HAVE 4927 03:12:20,595 --> 03:12:23,498 TO EARN, AND, YOU KNOW, IN MY 4928 03:12:23,565 --> 03:12:24,132 SIMPLE PHILOSOPHY TRUST IS 4929 03:12:24,199 --> 03:12:27,335 SOMETHING YOU CAN BUILD WITH A 4930 03:12:27,402 --> 03:12:28,036 GOOD TRACK RECORD. 4931 03:12:28,103 --> 03:12:30,138 ONE OF THE THINGS WE'VE SEEN AT 4932 03:12:30,205 --> 03:12:31,806 NCATS, THE MORE AGREEMENTS THAT 4933 03:12:31,873 --> 03:12:34,109 WE DO, THE MORE VOLUME THAT WE 4934 03:12:34,175 --> 03:12:38,346 DO, THE MORE TRUST WE BUILD. 4935 03:12:38,413 --> 03:12:41,750 AS WE WORK WITH PEOPLE, I TRY TO 4936 03:12:41,816 --> 03:12:44,619 TELL THE PEOPLE ON BOTH SIDES 4937 03:12:44,686 --> 03:12:48,490 THAT THE AGREEMENT ITSELF IS A 4938 03:12:48,556 --> 03:12:50,058 STARTING POINT. 4939 03:12:50,125 --> 03:12:53,561 AS YOU INTERACT WITH EACH OTHER 4940 03:12:53,628 --> 03:12:55,130 PLEASE BUILD AND MORE TRUST TO 4941 03:12:55,196 --> 03:12:56,531 CONTINUE TO HAVE MORE 4942 03:12:56,598 --> 03:13:03,738 COLLABORATION AND RELATIONSHIPS. 4943 03:13:03,805 --> 03:13:05,840 I AGREE, SERGIO, YOU HAVE TO 4944 03:13:05,907 --> 03:13:06,942 EARN AND KEEP EARNING. 4945 03:13:07,008 --> 03:13:07,242 >> RIGHT. 4946 03:13:07,309 --> 03:13:16,651 ONE LAST COMMENT. 4947 03:13:16,718 --> 03:13:19,321 I WAS AT THIS MEETING YESTERDAY 4948 03:13:19,387 --> 03:13:26,628 IN D.C., THE NATIONAL ACADEMY OF 4949 03:13:26,695 --> 03:13:30,665 MEDICINE, AND IT WAS A MEETING 4950 03:13:30,732 --> 03:13:39,207 ON POWER OF ENGAGEMENT, 4951 03:13:39,274 --> 03:13:39,741 SPECIFICALLY WITH 4952 03:13:39,808 --> 03:13:40,408 REPRESENTATIVES ACROSS THE 4953 03:13:40,475 --> 03:13:48,717 NATION, CDC AND MANY OTHER 4954 03:13:48,783 --> 03:13:50,485 ORGANIZATIONS, IT WAS SO 4955 03:13:50,552 --> 03:13:53,088 INSPIRING TO SEE THE ROLE COMING 4956 03:13:53,154 --> 03:13:58,393 FROM VARIOUS ANGLES, ONCE AGAIN 4957 03:13:58,460 --> 03:13:59,427 TRUST AND TRUSTWORTHINESS. 4958 03:13:59,494 --> 03:14:00,895 JONI, I'LL REACH OUT TO YOU AND 4959 03:14:00,962 --> 03:14:02,297 SHARE SOME OF THAT WORK BECAUSE 4960 03:14:02,364 --> 03:14:02,964 IT WAS INSPIRING. 4961 03:14:03,031 --> 03:14:05,700 >> I WOULD APPRECIATE THAT. 4962 03:14:05,767 --> 03:14:08,536 I'M SO GLAD, SERGIO, YOU'RE AT 4963 03:14:08,603 --> 03:14:10,205 THESE CONFERENCES AN MEETINGS TO 4964 03:14:10,271 --> 03:14:12,407 ALSO LEND YOUR VOICE AND TALK 4965 03:14:12,474 --> 03:14:15,110 ABOUT HOW IMPORTANT THIS IS TO 4966 03:14:15,176 --> 03:14:17,278 THE RESEARCH COMMUNITY, LET 4967 03:14:17,345 --> 03:14:19,147 ALONE THE ENGAGEMENT COMMUNITY 4968 03:14:19,214 --> 03:14:20,448 AND THE PATIENT COMMUNITY. 4969 03:14:20,515 --> 03:14:26,388 BUT I THINK WE ALL NEED TO HEAR 4970 03:14:26,454 --> 03:14:28,123 HOW IMPACTFUL THESE IDEAS OF 4971 03:14:28,189 --> 03:14:29,758 BUILDING TRUST ARE AND THEN AS 4972 03:14:29,824 --> 03:14:32,961 WE TALK ABOUT THEM MORE, THEY 4973 03:14:33,028 --> 03:14:37,132 WILL BECOME MORE IN OUR 4974 03:14:37,198 --> 03:14:38,266 INTEGRATED, INTO OUR EVERYDAY 4975 03:14:38,333 --> 03:14:38,600 APPROACHES. 4976 03:14:38,666 --> 03:14:39,834 THANK YOU FOR DOING THAT WORK. 4977 03:14:39,901 --> 03:14:41,369 PLEASE SEND ME THE MATERIALS. 4978 03:14:41,436 --> 03:14:44,105 I'D LOVE TO SEE THEM. 4979 03:14:44,172 --> 03:14:45,640 >> THANK YOU. 4980 03:14:45,707 --> 03:14:46,107 >> PAUL? 4981 03:14:46,174 --> 03:14:47,375 >> BALKI, GREAT PRESENTATION, I 4982 03:14:47,442 --> 03:14:53,715 APPRECIATED THE USE CASES, VERY 4983 03:14:53,782 --> 03:14:53,948 HELPFUL. 4984 03:14:54,015 --> 03:14:56,384 A COMMENT AND QUESTIONS. 4985 03:14:56,451 --> 03:15:00,889 I THINK WE ALL SEE OSA AS VITAL 4986 03:15:00,955 --> 03:15:02,424 FOR DISSEMINATION ESPECIALLY FOR 4987 03:15:02,490 --> 03:15:02,957 INTRAMURAL PROGRAM BUT 4988 03:15:03,024 --> 03:15:05,393 APPRECIATE USE CASE YOU GAVE 4989 03:15:05,460 --> 03:15:07,896 AROUND THE N3C PLATFORM AND 4990 03:15:07,962 --> 03:15:11,699 POWER AND ABSOLUTE NECESSITY FOR 4991 03:15:11,766 --> 03:15:13,068 STANDARD AGREEMENTS, TO DO THOSE 4992 03:15:13,134 --> 03:15:13,902 PROJECTS AT SCALE. 4993 03:15:13,968 --> 03:15:19,441 MY QUESTION REALLY IS AROUND THE 4994 03:15:19,507 --> 03:15:20,575 LICENSING NCATS AS A GOVERNMENT 4995 03:15:20,642 --> 03:15:24,612 ENTITY IS ALLOWED TO DO. 4996 03:15:24,679 --> 03:15:27,816 YOU MENTIONED SEVERAL USE CASES. 4997 03:15:27,882 --> 03:15:29,484 IS LICENSING FROM NCATS, IS IT 4998 03:15:29,551 --> 03:15:33,922 ALWAYS DONE AT NO COST TO THE 4999 03:15:33,988 --> 03:15:34,189 LICENSEE? 5000 03:15:34,255 --> 03:15:37,125 OR ARE THERE MODELS WHERE THERE 5001 03:15:37,192 --> 03:15:39,160 IS INFUSION OF INVESTMENT BACK 5002 03:15:39,227 --> 03:15:41,096 IN FOR FURTHER SHARING, ET 5003 03:15:41,162 --> 03:15:41,329 CETERA? 5004 03:15:41,396 --> 03:15:43,131 THIS IS JUST A NAIVE QUESTION 5005 03:15:43,198 --> 03:15:48,203 BUT I'VE ALWAYS BEEN CURIOUS. 5006 03:15:48,269 --> 03:15:53,108 >> IN BROAD TERMS SOME RULES AND 5007 03:15:53,174 --> 03:15:54,309 REGULATIONS GOVERN LICENSING, 5008 03:15:54,375 --> 03:15:56,678 LICENSING PRINCIPLES. 5009 03:15:56,744 --> 03:15:59,214 NIH CAN TAKE ROYALTY MONEY, 5010 03:15:59,280 --> 03:16:02,450 INTELLECTUAL PROPERTY THAT YOU 5011 03:16:02,517 --> 03:16:03,751 OUT-LICENSE, YOU CAN ESSENTIALLY 5012 03:16:03,818 --> 03:16:07,889 ASK FOR A COMMERCIAL DEVELOPMENT 5013 03:16:07,956 --> 03:16:10,058 PLAN, THE GROUP THAT WANTS TO 5014 03:16:10,125 --> 03:16:11,326 LICENSE THE TECHNOLOGY. 5015 03:16:11,392 --> 03:16:16,498 IF YOU LICENSE SOMETHING 5016 03:16:16,564 --> 03:16:17,132 NON-EXCLUSIVELY ROYALTIES AND 5017 03:16:17,198 --> 03:16:18,066 PAYMENTS ARE LOWER. 5018 03:16:18,133 --> 03:16:19,701 IF YOU LICENSE EXCLUSIVELY YOU 5019 03:16:19,767 --> 03:16:23,304 CAN PRETTY MUCH ASK FOR A FAIRLY 5020 03:16:23,371 --> 03:16:23,938 DETAILED COMMERCIAL DEVELOPMENT 5021 03:16:24,005 --> 03:16:34,082 PLAN AND BASED ON THAT, YOU CAN 5022 03:16:34,149 --> 03:16:35,884 BUILD IN MODELS OF PAYMENTS, 5023 03:16:35,950 --> 03:16:38,887 MILESTONE PAYMENTS, ROYALTY 5024 03:16:38,953 --> 03:16:40,488 PAYMENTS, UP.FRONT PAYMENTS. 5025 03:16:40,555 --> 03:16:41,856 EVERYTHING STARTS WITH 5026 03:16:41,923 --> 03:16:43,091 COMMERCIAL DEVELOPMENT PLAN 5027 03:16:43,158 --> 03:16:48,129 POTENTIAL LICENSEE SUBMITS TO 5028 03:16:48,196 --> 03:16:48,296 YOU. 5029 03:16:48,363 --> 03:16:49,164 YOU NEGOTIATE FROM THERE. 5030 03:16:49,230 --> 03:16:51,132 >> YOU'RE ALLOWED TO SET UP 5031 03:16:51,199 --> 03:16:53,835 ROYALTY PLANS, THAT CAN SEED THE 5032 03:16:53,902 --> 03:16:55,336 PROGRAM FOR OTHER DEVELOPMENT, 5033 03:16:55,403 --> 03:16:56,104 FURTHER DISSEMINATION? 5034 03:16:56,171 --> 03:16:57,338 >> YES, THE ROYALTY -- SOME 5035 03:16:57,405 --> 03:17:00,742 RULES IN TERMS OF HOW ROYALTIES 5036 03:17:00,808 --> 03:17:01,109 ARE DISTRIBUTED. 5037 03:17:01,176 --> 03:17:02,744 SOME PORTION OF THE ROYALTY GOES 5038 03:17:02,810 --> 03:17:04,412 TO INVENTORS, FROM THE PATENT, 5039 03:17:04,479 --> 03:17:06,848 THE REST GOES TO THE INSTITUTE. 5040 03:17:06,915 --> 03:17:07,282 >> THANK YOU. 5041 03:17:07,348 --> 03:17:10,852 >> THERE'S TYPICALLY A CAP TO 5042 03:17:10,919 --> 03:17:12,020 THAT AS WELL. 5043 03:17:12,086 --> 03:17:13,988 >> JUST ONE LAST QUESTION, 5044 03:17:14,055 --> 03:17:14,455 RESEARCH COLLABORATIVE 5045 03:17:14,522 --> 03:17:18,560 AGREEMENT, THE THE WORKHORSE, 5046 03:17:18,626 --> 03:17:19,861 HOW STANDARDIZED IS THAT 5047 03:17:19,928 --> 03:17:20,128 AGREEMENT? 5048 03:17:20,195 --> 03:17:21,196 SOUNDS LIKE YOU'RE DOING A TON 5049 03:17:21,262 --> 03:17:22,530 OF THOSE. 5050 03:17:22,597 --> 03:17:23,798 >> YES. 5051 03:17:23,865 --> 03:17:24,499 THOSE ARE FAIRLY STANDARDIZED 5052 03:17:24,566 --> 03:17:28,903 BUT THEY ARE A LOT MORE FLEXIBLE 5053 03:17:28,970 --> 03:17:31,472 SO SOMETIMES WHAT HAPPENS IS 5054 03:17:31,539 --> 03:17:33,875 DEPENDING ON THE RELATIVE VALUE 5055 03:17:33,942 --> 03:17:37,445 OF EACH PARTNER, EACH ONE GETS 5056 03:17:37,512 --> 03:17:38,913 TO NEGOTIATE, YOU KNOW, A LITTLE 5057 03:17:38,980 --> 03:17:40,848 BIT MORE OR LESS DEPENDING ON 5058 03:17:40,915 --> 03:17:42,550 WHO HAS THE UPPER HAND. 5059 03:17:42,617 --> 03:17:45,153 SO THERE'S SOME NEGOTIATION 5060 03:17:45,220 --> 03:17:46,621 INVOLVED BUT DEFINITELY THERE 5061 03:17:46,688 --> 03:17:48,556 ARE SOME LANGUAGE OR CLAUSES 5062 03:17:48,623 --> 03:17:50,124 FAIRLY STANDARD WHICH WE DON'T 5063 03:17:50,191 --> 03:17:51,292 CHANGE, BUT THERE ARE OTHERS 5064 03:17:51,359 --> 03:17:53,661 WHICH WE HAVE SOME FLEXIBILITY. 5065 03:17:53,728 --> 03:17:56,331 >> THANK YOU SO MUCH. 5066 03:17:56,397 --> 03:17:57,765 >> UH-HUH, SURE. 5067 03:17:57,832 --> 03:17:59,300 >> GREAT. 5068 03:17:59,367 --> 03:17:59,500 PAULA? 5069 03:17:59,567 --> 03:18:03,204 >> THAT WAS VERY IMPRESSIVE, 5070 03:18:03,271 --> 03:18:03,438 BALKI. 5071 03:18:03,504 --> 03:18:05,406 LET'S FACE IT, ALL OF US WHO DO 5072 03:18:05,473 --> 03:18:08,009 RESEARCH HAVE HAD TO SIT 5073 03:18:08,076 --> 03:18:09,244 TWIDDLING OUR THUMBS WHILE 5074 03:18:09,310 --> 03:18:10,878 CONTRACTS AND USE CASES AND ALL 5075 03:18:10,945 --> 03:18:12,947 OF THAT ARE BEING NEGOTIATED. 5076 03:18:13,014 --> 03:18:15,917 WE'VE ALSO TALKED EARLIER IN 5077 03:18:15,984 --> 03:18:17,118 THIS MEETING ABOUT HOW VALUABLE 5078 03:18:17,185 --> 03:18:24,659 PATIENT DATA IS AND ELECTRONIC 5079 03:18:24,726 --> 03:18:27,829 HEALTH RECORD DATA, SO N3C HAS 5080 03:18:27,895 --> 03:18:29,631 BEEN A GREAT EXAMPLE HOW HOW DO 5081 03:18:29,697 --> 03:18:31,332 YOU TAKE IT TO THE NEXT LEVEL, 5082 03:18:31,399 --> 03:18:34,702 HOW DO YOU WORK YOUR MAGIC TO 5083 03:18:34,769 --> 03:18:35,603 HAVE GREATER ACCESSIBILITY, EVEN 5084 03:18:35,670 --> 03:18:38,039 MEDICAL RECORDS TO A CLINICIAN, 5085 03:18:38,106 --> 03:18:39,707 WHO HAS PATIENTS GOING MULTIPLE 5086 03:18:39,774 --> 03:18:43,111 PLACES, BUT ALSO FOR THE 5087 03:18:43,177 --> 03:18:45,913 RESEARCH, THE MACHINE LEARNING, 5088 03:18:45,980 --> 03:18:47,048 THE LARGE LANGUAGE MODELS, ALL 5089 03:18:47,115 --> 03:18:49,751 THE THINGS THAT NEED THIS BIG 5090 03:18:49,817 --> 03:18:51,152 DATA, WHAT'S THE NEXT STEP IN 5091 03:18:51,219 --> 03:18:54,322 DATA SHARING THAT YOU AND NCATS 5092 03:18:54,389 --> 03:18:56,291 CAN KIND OF INNOVATE SO THAT 5093 03:18:56,357 --> 03:18:59,894 WE'RE NOT AT A STAND STILL SO 5094 03:18:59,961 --> 03:19:00,094 OFTEN? 5095 03:19:00,161 --> 03:19:01,896 >> YEAH, I THINK THAT'S A BIGGER 5096 03:19:01,963 --> 03:19:03,831 QUESTION THAN WHAT WE CAN 5097 03:19:03,898 --> 03:19:04,232 ANSWER. 5098 03:19:04,299 --> 03:19:06,968 BUT I THINK THERE ARE SOME WAYS 5099 03:19:07,035 --> 03:19:10,838 BY WHICH DATA CAN BE SHARED MORE 5100 03:19:10,905 --> 03:19:11,072 WIDELY. 5101 03:19:11,139 --> 03:19:12,507 IF SOMETHING DOESN'T HAVE TO BE 5102 03:19:12,573 --> 03:19:15,677 PATENTED MID A VISE IS PUBLISH 5103 03:19:15,743 --> 03:19:20,515 OF -- MY ADVICE IS PUBLISH IT, 5104 03:19:20,581 --> 03:19:21,983 SHARE IT WIDELY, SHARE THE 5105 03:19:22,050 --> 03:19:22,950 INFORMATION, SHARE THE 5106 03:19:23,017 --> 03:19:23,384 KNOW-HOUR. 5107 03:19:23,451 --> 03:19:24,585 BUT IF THERE ARE SITUATIONS 5108 03:19:24,652 --> 03:19:28,356 WHERE SOMETHING NEEDS TO BE 5109 03:19:28,423 --> 03:19:31,125 PATENTED, PATENT IT. 5110 03:19:31,192 --> 03:19:33,594 ONCE THE PATENT IS COMPLETED, 5111 03:19:33,661 --> 03:19:36,864 YOU CAN START DISSEMINATING 5112 03:19:36,931 --> 03:19:40,902 INFORMATION, A LOT OF TIMES THE 5113 03:19:40,968 --> 03:19:43,137 FEDERAL SCIENTISTS, THEY SHARE A 5114 03:19:43,204 --> 03:19:45,506 LOT OF KNOW-HOW WITH OTHER 5115 03:19:45,573 --> 03:19:46,674 PEOPLE, WITH OUTSIDE PEOPLE, 5116 03:19:46,741 --> 03:19:48,876 BECAUSE DATA BY ITSELF IS NOT 5117 03:19:48,943 --> 03:19:50,978 SUFFICIENT BECAUSE SOMETIMES 5118 03:19:51,045 --> 03:19:54,048 DATA HAS TO COME WITH 5119 03:19:54,115 --> 03:19:56,317 INTERPRETATION, WITH BACKGROUND, 5120 03:19:56,384 --> 03:19:58,653 CONTEXT, AND THAT'S WHERE I 5121 03:19:58,720 --> 03:20:01,155 THINK THE NIH SCIENTISTS REALLY 5122 03:20:01,222 --> 03:20:02,690 SHINE BECAUSE WE HAVE PROBABLY 5123 03:20:02,757 --> 03:20:08,062 ONE OF THE MOST OPEN DATA 5124 03:20:08,129 --> 03:20:08,730 SHARING PHILOSOPHIES, BUT, 5125 03:20:08,796 --> 03:20:11,232 AGAIN, IT IS SOMETHING THAT IS A 5126 03:20:11,299 --> 03:20:17,338 MUCH LARGER QUESTION AT THE NIH 5127 03:20:17,405 --> 03:20:18,239 LEVEL. 5128 03:20:18,306 --> 03:20:19,540 JONI, IF YOU WANT TO ADD 5129 03:20:19,607 --> 03:20:20,208 ANYTHING GO AHEAD. 5130 03:20:20,274 --> 03:20:21,642 >> IT'S A GREAT IDEA. 5131 03:20:21,709 --> 03:20:27,348 I THINK THAT IN MANY WAYS WE TRY 5132 03:20:27,415 --> 03:20:28,316 TO TEMPLATIZE THEM, THEN IT 5133 03:20:28,383 --> 03:20:30,752 COMES TO PERHAPS JUST MAKING 5134 03:20:30,818 --> 03:20:33,688 THOSE AVAILABLE IN A WAY. 5135 03:20:33,755 --> 03:20:37,759 AS BALKI TALKED ABOUT, N3C 5136 03:20:37,825 --> 03:20:40,361 AGREEMENTS, YOU KNOW, WE SPENT 5137 03:20:40,428 --> 03:20:41,596 THE BULK -- RATHER THAN GENERATE 5138 03:20:41,662 --> 03:20:42,964 AN AGREEMENT AND SENDING IT OUT 5139 03:20:43,030 --> 03:20:45,700 TO PEOPLE AND HAVE THEM CHANGE 5140 03:20:45,767 --> 03:20:47,902 IT WE SPENT THE BULK OF TIME 5141 03:20:47,969 --> 03:20:49,170 TALKING WITH PEOPLE FIRST, 5142 03:20:49,237 --> 03:20:50,772 UNDERSTANDING WHAT THE NEEDS 5143 03:20:50,838 --> 03:20:53,474 WERE, AND THEN BUILT THE 5144 03:20:53,541 --> 03:20:55,343 AGREEMENT THAT COULD ACCOMMODATE 5145 03:20:55,410 --> 03:20:57,645 EVERYTHING THAT WE NEEDED TO DO. 5146 03:20:57,712 --> 03:21:00,748 AND JUST PUTTING IN THAT LITTLE 5147 03:21:00,815 --> 03:21:02,717 WORK UP FRONT, YOU KNOW, SLOWING 5148 03:21:02,784 --> 03:21:06,521 DOWN UP FRONT HELPED US TO SPEED 5149 03:21:06,587 --> 03:21:07,722 THINGS UP SHORTLY THEREAFTER. 5150 03:21:07,789 --> 03:21:10,224 AND SO THAT SLOWING DOWN AND 5151 03:21:10,291 --> 03:21:12,293 SPEEDING UP REALLY HELPS, SO 5152 03:21:12,360 --> 03:21:14,495 THINKING ABOUT THESE AS MORE 5153 03:21:14,562 --> 03:21:15,163 TEMPLATES DISSEMINATED TO THE 5154 03:21:15,229 --> 03:21:16,998 COMMUNITY MIGHT ALSO BE HELPFUL. 5155 03:21:17,064 --> 03:21:18,232 BUT WE'RE REALLY LEARNING FROM 5156 03:21:18,299 --> 03:21:20,768 THE COMMUNITY ON HOW TO BUILD 5157 03:21:20,835 --> 03:21:21,068 THEM WELL. 5158 03:21:21,135 --> 03:21:23,371 AND I THINK THAT'S THE IMPORTANT 5159 03:21:23,438 --> 03:21:25,440 PIECE HERE FROM US. 5160 03:21:25,506 --> 03:21:27,742 AND I THINK AS WE'VE DONE THAT 5161 03:21:27,809 --> 03:21:30,678 WE HAVE, GOING BACK TO SERGIO'S 5162 03:21:30,745 --> 03:21:32,180 COMMENT ON TRUST, AND 5163 03:21:32,246 --> 03:21:32,847 TRUSTWORTHINESS, YOU KNOW, 5164 03:21:32,914 --> 03:21:33,781 BECAUSE WE'RE LISTENING TO THE 5165 03:21:33,848 --> 03:21:34,949 COMMUNITY AND THEY ARE SEEING 5166 03:21:35,016 --> 03:21:37,718 THAT BUILT INTO THE AGREEMENTS, 5167 03:21:37,785 --> 03:21:43,825 THAT ULTIMATELY HELPS US SO THAT 5168 03:21:43,891 --> 03:21:46,828 WE HAVE BECOME A MORE FAMILIAR 5169 03:21:46,894 --> 03:21:47,562 PARTNER AND COLLABORATIVE TO 5170 03:21:47,628 --> 03:21:48,329 WORK WITH. 5171 03:21:48,396 --> 03:21:50,932 THERE'S STILL MORE TO GO, IN 5172 03:21:50,998 --> 03:21:52,266 TERMS OF DISSEMINATION, AND 5173 03:21:52,333 --> 03:21:53,234 SOMETHING THAT WE CERTAINLY 5174 03:21:53,301 --> 03:21:54,869 THINK ABOUT QUITE A BIT ON HOW 5175 03:21:54,936 --> 03:22:04,612 WE MIGHT BE ABLE TO DO THAT. 5176 03:22:04,679 --> 03:22:04,812 ANIKA? 5177 03:22:04,879 --> 03:22:05,947 >> GREAT PRESENTATION. 5178 03:22:06,013 --> 03:22:07,181 I ECHO WHAT'S BEEN SAID. 5179 03:22:07,248 --> 03:22:10,151 IT'S JUST GREAT SEEING ALL THE 5180 03:22:10,218 --> 03:22:11,319 PRESENTATIONS, HOW THEY HAVE 5181 03:22:11,385 --> 03:22:13,721 BEEN BUILDING, YOU KNOW, ONTO 5182 03:22:13,788 --> 03:22:15,122 THINGS THAT WERE DISCUSSED 5183 03:22:15,189 --> 03:22:17,525 EARLIER IN THE YEAR AND COMING 5184 03:22:17,592 --> 03:22:19,193 TO FRUITION. 5185 03:22:19,260 --> 03:22:21,929 SAME WITH DAN'S, REALLY NICE TO 5186 03:22:21,996 --> 03:22:22,129 SEE. 5187 03:22:22,196 --> 03:22:27,802 I WAS INTRIGUED BY YOUR LAST 5188 03:22:27,869 --> 03:22:31,739 SLIDE, YOU KNOW, JUST -- HOW 5189 03:22:31,806 --> 03:22:35,176 YOU'RE USING THE I-CORPS MODEL 5190 03:22:35,243 --> 03:22:37,245 TO TRAIN ENTREPRENEURS AND SMALL 5191 03:22:37,311 --> 03:22:40,948 BUSINESSES IN HOW TO, YOU KNOW, 5192 03:22:41,015 --> 03:22:42,783 MOVE THEIR EFFORTS FORWARD. 5193 03:22:42,850 --> 03:22:44,552 AND IT REALLY -- YOU KNOW, YOU 5194 03:22:44,619 --> 03:22:46,787 OFTEN HEAR ABOUT, YOU KNOW, ONE 5195 03:22:46,854 --> 03:22:47,722 OF THE TRANSLATIONAL SCIENCE 5196 03:22:47,788 --> 03:22:50,758 ISSUES IS YOU HAVE PEOPLE WHO 5197 03:22:50,825 --> 03:22:52,727 ARE GREAT SCIENTISTS BUT THEY 5198 03:22:52,793 --> 03:22:53,961 ARE NOT GREAT BUSINESS PEOPLE. 5199 03:22:54,028 --> 03:22:55,363 AND SO IT KIND OF GETS TO THAT 5200 03:22:55,429 --> 03:22:59,467 POINT OF HOW DO YOU DO TRAINING 5201 03:22:59,534 --> 03:23:01,335 OF THESE SCIENTISTS AND 5202 03:23:01,402 --> 03:23:03,137 ENGINEERS SO THEY KNOW, YOU 5203 03:23:03,204 --> 03:23:05,039 KNOW, HOW TO MOVE FORWARD THEIR 5204 03:23:05,106 --> 03:23:05,306 BUSINESS. 5205 03:23:05,373 --> 03:23:07,108 AND, YOU KNOW, YOU SEEM LIKE YOU 5206 03:23:07,174 --> 03:23:11,479 GAVE CASE STUDIES OF THAT. 5207 03:23:11,546 --> 03:23:15,316 I GUESS I'M WONDERING IF -- LIKE 5208 03:23:15,383 --> 03:23:16,417 IT MADE ME THINK ABOUT, YOU 5209 03:23:16,484 --> 03:23:17,451 KNOW, BUSINESSES THAT CAME OUT 5210 03:23:17,518 --> 03:23:18,586 OF LIKE THE TISSUE CHIPS 5211 03:23:18,653 --> 03:23:19,220 PROJECT. 5212 03:23:19,287 --> 03:23:22,356 YOU KNOW, ARE YOU KIND OF 5213 03:23:22,423 --> 03:23:23,257 BUILDING THEIR KNOWLEDGE AND 5214 03:23:23,324 --> 03:23:25,192 UNDERSTANDING HOW TO MOVE 5215 03:23:25,259 --> 03:23:30,565 FORWARD AND HANDLE I.P. AND THEN 5216 03:23:30,631 --> 03:23:33,467 PAULA TRIGGERED THE SAME IDEA 5217 03:23:33,534 --> 03:23:35,503 TRAINING ENTREPRENEURS AS WE'RE 5218 03:23:35,570 --> 03:23:37,138 DEVELOPING THESE NEW AGREEMENTS, 5219 03:23:37,204 --> 03:23:39,173 AND THESE NEW DATA PLATFORMS 5220 03:23:39,240 --> 03:23:40,241 THAT COULD ACCELERATE THEIR 5221 03:23:40,308 --> 03:23:42,076 BUSINESSES, YOU KNOW, IS THAT 5222 03:23:42,143 --> 03:23:43,477 PART OF MAYBE YOUR SHOP IN TERMS 5223 03:23:43,544 --> 03:23:46,914 OF HOW TO DO THE TRAINING? 5224 03:23:46,981 --> 03:23:49,183 SO I GUESS IN SUMMARY, THERE WAS 5225 03:23:49,250 --> 03:23:51,319 A LOT OF PRESENTATION ON HOW 5226 03:23:51,385 --> 03:23:54,889 YOUR OFFICE HAS BEEN USED TO 5227 03:23:54,956 --> 03:23:56,490 ACCELERATE NCATS WORK AND BECOME 5228 03:23:56,557 --> 03:23:57,525 PREFERRED PARTNER BUT I GUESS 5229 03:23:57,592 --> 03:23:59,727 THE OTHER PIECE OF THAT IS HOW 5230 03:23:59,794 --> 03:24:02,463 DO YOU KIND OF BUILD THE 5231 03:24:02,530 --> 03:24:03,631 CAPACITY OF THE SMALL BUSINESSES 5232 03:24:03,698 --> 03:24:06,867 AND ENTREPRENEURS OUT THERE SO 5233 03:24:06,934 --> 03:24:08,703 THEY CAN TRAVERSE THE VALLEY OF 5234 03:24:08,769 --> 03:24:11,205 DEATH EVEN BETTER. 5235 03:24:11,272 --> 03:24:13,741 PARTICULARLY AS THESE NEW TOOLS 5236 03:24:13,808 --> 03:24:14,809 AND PLATFORMS AND YOUR SHOP 5237 03:24:14,875 --> 03:24:16,143 BUILDING ALL THESE AGREEMENTS 5238 03:24:16,210 --> 03:24:18,546 MAKING IT EASIER TO DO 5239 03:24:18,613 --> 03:24:20,047 TRANSLATIONAL SCIENCE AND DRUG 5240 03:24:20,114 --> 03:24:20,881 DEVELOPMENT JUST KIND OF 5241 03:24:20,948 --> 03:24:22,917 BUILDING CAPACITY IN THAT 5242 03:24:22,984 --> 03:24:23,150 REGARD. 5243 03:24:23,217 --> 03:24:25,086 THE FLIP SIDE, YOU KNOW, THOSE 5244 03:24:25,152 --> 03:24:26,220 ARE SMALL BUSINESSES, ALSO 5245 03:24:26,287 --> 03:24:31,158 THINKING THE FLIP SIDE OF THE 5246 03:24:31,225 --> 03:24:33,561 VENTURE CAPITALISTS, THEIR ROLE 5247 03:24:33,628 --> 03:24:35,296 BUILDING THEIR KNOWLEDGE, HOW TO 5248 03:24:35,363 --> 03:24:38,366 INTERFACE WITH SMALL BUSINESSES 5249 03:24:38,432 --> 03:24:42,069 IN BIOMEDICAL RESEARCH, AND THEN 5250 03:24:42,136 --> 03:24:43,704 WHICH MIGHT BE HARDER, I THINK 5251 03:24:43,771 --> 03:24:48,743 EVEN WITH LARGE COMPANIES 5252 03:24:48,809 --> 03:24:49,377 THERE'S INTERNAL PROCESSES THAT 5253 03:24:49,443 --> 03:24:51,379 ARE BOTTLENECKS WHEN IT COMES TO 5254 03:24:51,445 --> 03:24:53,247 BUSINESS AND LEGALITY AND SO IS 5255 03:24:53,314 --> 03:24:55,249 THERE SOMETHING THERE SO 5256 03:24:55,316 --> 03:24:57,351 BASICALLY USING LEVERAGING YOUR 5257 03:24:57,418 --> 03:24:58,185 EXPERTISE, YOU KNOW, THE 5258 03:24:58,252 --> 03:25:01,055 BUSINESS AND LEGAL SIDE IS IN 5259 03:25:01,122 --> 03:25:03,858 AND OF ITSELF THAT NEEDS TO BE 5260 03:25:03,924 --> 03:25:07,061 IMPROVED TO HELP ADVANCE 5261 03:25:07,128 --> 03:25:07,595 TRANSLATIONAL SCIENCE, SO, 5262 03:25:07,662 --> 03:25:09,897 AGAIN, THAT COULD BE THE REALM 5263 03:25:09,964 --> 03:25:11,966 OF BUILDING CAPACITY OF THE 5264 03:25:12,033 --> 03:25:13,067 ENTREPRENEURS AND SMALL 5265 03:25:13,134 --> 03:25:14,235 BUSINESSES AS YOU'RE DOING AND 5266 03:25:14,301 --> 03:25:15,703 REALLY LOOKING AT THOSE PIECES 5267 03:25:15,770 --> 03:25:19,173 AS WELL AS HOW TO GET OVER THAT 5268 03:25:19,240 --> 03:25:20,541 VALLEY OF DEATH. 5269 03:25:20,608 --> 03:25:21,942 >> YEAH, THANKS, ANIKA. 5270 03:25:22,009 --> 03:25:25,212 I'LL ANSWER IN TWO PARTS. 5271 03:25:25,279 --> 03:25:26,547 ONE IS IN TERMS OF SOME OF THE 5272 03:25:26,614 --> 03:25:29,083 THINGS WE DO IN OUR OFFICE, IF 5273 03:25:29,150 --> 03:25:31,385 WE FIND SOMETHING INTERESTING OR 5274 03:25:31,452 --> 03:25:33,888 IF WE FIND SOMETHING UNIQUE WE 5275 03:25:33,954 --> 03:25:40,861 TRY TO PUBLISH IT AND PRESENT 5276 03:25:40,928 --> 03:25:41,429 DIFFERENT TRADE CONFERENCES. 5277 03:25:41,495 --> 03:25:45,066 FOR INSTANCE CRCA WE PUBLISHED 5278 03:25:45,132 --> 03:25:46,901 AND PRESENTED. 5279 03:25:46,967 --> 03:25:50,971 SIMILARLY OTHER SITUATIONS WHERE 5280 03:25:51,038 --> 03:25:52,640 WE'VE DONE INTERESTING 5281 03:25:52,707 --> 03:25:53,774 COLLABORATIONS, LICENSED, 5282 03:25:53,841 --> 03:25:57,678 PRESENTED AT TRADE CONFERENCES 5283 03:25:57,745 --> 03:26:02,783 LIKE THE ASSOCIATION OF 5284 03:26:02,850 --> 03:26:03,417 UNIVERSITY TECHNOLOGY MANAGERS. 5285 03:26:03,484 --> 03:26:05,419 IN TERMS OF SMALL BUSINESS 5286 03:26:05,486 --> 03:26:07,354 COMMUNITY THINKING AND TRAINING 5287 03:26:07,421 --> 03:26:13,160 THEM ALREADY A LOT OF SUPPORTIVE 5288 03:26:13,227 --> 03:26:16,497 PROGRAMS THAT NIH RUNS. 5289 03:26:16,564 --> 03:26:20,301 FOR INSTANCE, THE MAIN NIH SMALL 5290 03:26:20,367 --> 03:26:20,901 BUSINESS EDUCATION OFFICE, RUN 5291 03:26:20,968 --> 03:26:24,138 BY OFFICE OF THE DIRECTOR, THEY 5292 03:26:24,205 --> 03:26:26,874 HAVE PROGRAMS WHERE 5293 03:26:26,941 --> 03:26:28,509 ENTREPRENEURS WHO HAVE NEVER 5294 03:26:28,576 --> 03:26:30,044 APPLIED OR RECEIVED SBIR 5295 03:26:30,111 --> 03:26:32,346 PROGRAM, THEY CAN GO THROUGH 5296 03:26:32,413 --> 03:26:35,149 TRAINING PROGRAM CALLED AAP, 5297 03:26:35,216 --> 03:26:37,184 APPLICANT ASSISTANCE PROGRAM. 5298 03:26:37,251 --> 03:26:40,187 DURING THE PROJECT ITSELF, THEY 5299 03:26:40,254 --> 03:26:48,195 CAN GET CONSULTATIONS FROM 5300 03:26:48,262 --> 03:26:49,930 VARIOUS GROUPS, IF SOMETHING 5301 03:26:49,997 --> 03:26:53,334 NEEDS TO BE PATTENEDDED THEY 5302 03:26:53,400 --> 03:26:55,870 CAN -- PATENTED THEY CAN GET 5303 03:26:55,936 --> 03:26:59,106 POINTERS, EVEN AFTER THEY CAN GO 5304 03:26:59,173 --> 03:27:01,375 THROUGH I-CORPS TRAINING TO SEE 5305 03:27:01,442 --> 03:27:02,276 IF COMMERCIALIZATION THINKING IS 5306 03:27:02,343 --> 03:27:03,911 ALONG THE RIGHT WAY OR NOT. 5307 03:27:03,978 --> 03:27:08,082 AND SOME COMPANIES HAVE PIVOTED 5308 03:27:08,149 --> 03:27:10,584 AND WHEN THEY COME BACK TO NCATS 5309 03:27:10,651 --> 03:27:12,219 WITH A PHASE 2 APPLICATION THEIR 5310 03:27:12,286 --> 03:27:13,220 APPLICATION IS MUCH, MUCH 5311 03:27:13,287 --> 03:27:19,660 STRONGER BECAUSE THEY HAVE GONE 5312 03:27:19,727 --> 03:27:20,461 THROUGH THE I-CORPS PROGRAM AND 5313 03:27:20,528 --> 03:27:23,497 THOUGHT ABOUT HOW TO MOVE 5314 03:27:23,564 --> 03:27:24,064 FORWARD. 5315 03:27:24,131 --> 03:27:27,234 WE ALSO HAVE INTERNAL 5316 03:27:27,301 --> 03:27:28,536 EDUCATIONAL SERIES WHERE ONCE IN 5317 03:27:28,602 --> 03:27:31,172 THREE OR FOUR MONTHS OUR OFFICE 5318 03:27:31,238 --> 03:27:35,109 WILL RUN SEMINARS ABOUT 5319 03:27:35,176 --> 03:27:38,746 PATENTING, LICENSING, DIFFERENT 5320 03:27:38,813 --> 03:27:40,114 FINANCIAL MODELS, ABOUT COMPANY 5321 03:27:40,181 --> 03:27:41,782 FORMATION, ET CETERA. 5322 03:27:41,849 --> 03:27:46,053 BUT THESE ARE MOSTLY INTERNAL 5323 03:27:46,120 --> 03:27:47,788 SEMINARS FOR NCATS STAFF. 5324 03:27:47,855 --> 03:27:49,156 WE ARE A FAIRLY SMALL OFFICE, 5325 03:27:49,223 --> 03:27:51,025 HAVE TO FOCUS ON WHAT WE DO. 5326 03:27:51,091 --> 03:27:52,159 >> YEAH, YEAH. 5327 03:27:52,226 --> 03:27:57,097 MAYBE TO YOUR POINT, LIKE IF NIH 5328 03:27:57,164 --> 03:28:01,836 IS ALREADY DOING TRAININGS FOR 5329 03:28:01,902 --> 03:28:03,137 ENTREPRENEURS, THROUGH SMALL 5330 03:28:03,204 --> 03:28:04,905 BUSINESS PROGRAMS, MAKING YOUR 5331 03:28:04,972 --> 03:28:06,240 INNOVATIVE INSTRUMENTS THAT YOU 5332 03:28:06,307 --> 03:28:07,975 CREATED HAVE BEEN INCLUDED IN 5333 03:28:08,042 --> 03:28:10,578 THOSE TRAININGS, YOU KNOW, LIKE 5334 03:28:10,644 --> 03:28:14,582 THE CRCA, AND OTHER THINGS, SO 5335 03:28:14,648 --> 03:28:16,750 THAT THESE YOUNG SCIENTISTS AND 5336 03:28:16,817 --> 03:28:18,586 BUSINESSES KNOW ABOUT THESE NEW 5337 03:28:18,652 --> 03:28:21,589 TOOLS OF HOW THEY CAN CREATE 5338 03:28:21,655 --> 03:28:23,090 AGREEMENTS AND DO BUSINESS, 5339 03:28:23,157 --> 03:28:24,625 BECAUSE YOU GUYS HAVE DONE SOME 5340 03:28:24,692 --> 03:28:25,426 GREAT WORK. 5341 03:28:25,492 --> 03:28:29,463 SO MAYBE THAT'S A WAY TO KIND OF 5342 03:28:29,530 --> 03:28:30,731 DEAL WITH SMALL CAPACITY STAFF. 5343 03:28:30,798 --> 03:28:32,299 >> THANK YOU. 5344 03:28:32,366 --> 03:28:33,968 WE TRY TO LEVERAGE AS MUCH AS WE 5345 03:28:34,034 --> 03:28:40,741 CAN ON THE OUTSIDE WHAT WE CAN. 5346 03:28:40,808 --> 03:28:41,375 >> MARSHALL? 5347 03:28:41,442 --> 03:28:42,910 >> I'LL MAKE THIS QUICK. 5348 03:28:42,977 --> 03:28:49,183 WHAT YOU'RE DOING IS REALLY 5349 03:28:49,250 --> 03:28:49,383 GOOD. 5350 03:28:49,450 --> 03:28:51,919 I'VE HAD INTERACTIONS ON SOME 5351 03:28:51,986 --> 03:28:52,152 DEVICES. 5352 03:28:52,219 --> 03:28:54,188 THE PROBLEM I RUN INTO TIME AND 5353 03:28:54,255 --> 03:28:57,024 TIME AGAIN THE TECHNOLOGY 5354 03:28:57,091 --> 03:28:58,392 TRANSFER OFFICES AT MOST 5355 03:28:58,459 --> 03:29:00,427 UNIVERSITIES ARE OFTEN STAFFED 5356 03:29:00,494 --> 03:29:02,062 BY VERY JUNIOR FOLK, THE LEGAL 5357 03:29:02,129 --> 03:29:06,533 FOLKS THEY ASSIGN TO THEM 5358 03:29:06,600 --> 03:29:08,969 TYPICALLY HAVE THE HALF-LIFE OF 5359 03:29:09,036 --> 03:29:11,472 A MAY FLY, I.E. A DAY OR TWO. 5360 03:29:11,538 --> 03:29:14,208 AND THEY DON'T REALLY HAVE MUCH 5361 03:29:14,275 --> 03:29:14,875 INSTITUTIONAL KNOWLEDGE, NOR DO 5362 03:29:14,942 --> 03:29:18,712 THEY KNOW WHERE TO GET IT FROM. 5363 03:29:18,779 --> 03:29:20,814 AND THAT ACTUALLY I FIND 5364 03:29:20,881 --> 03:29:21,882 PARTICULARLY WHEN WORKING WITH 5365 03:29:21,949 --> 03:29:23,984 NIH TRYING TO GET NIH-FUNDED 5366 03:29:24,051 --> 03:29:26,153 RESEARCH OUT THERE INTO THAT, IF 5367 03:29:26,220 --> 03:29:28,422 THERE'S A WAY TO INCREASE WITH 5368 03:29:28,489 --> 03:29:30,491 YOUR ALREADY SMALL OFFICE THE 5369 03:29:30,557 --> 03:29:32,159 AMOUNT OF SORT OF TEACHING 5370 03:29:32,226 --> 03:29:34,061 MATERIAL FOR THESE TECHNOLOGY 5371 03:29:34,128 --> 03:29:36,997 TRANSFER GROUPS OUT THERE IN THE 5372 03:29:37,064 --> 03:29:39,833 REAL WORLD, THEY NEED -- I MEAN, 5373 03:29:39,900 --> 03:29:46,307 THEY WILL CLAIM TO HAVE 5374 03:29:46,373 --> 03:29:47,007 PRESERVED A LIFE PRESERVER, SOME 5375 03:29:47,074 --> 03:29:49,143 PLACES DO IT WELL BUT THE 5376 03:29:49,209 --> 03:29:50,344 MAJORITY I'VE WORKED WITH OVER 5377 03:29:50,411 --> 03:29:52,413 THE YEARS, I WAS COUNTING THE 5378 03:29:52,479 --> 03:29:53,681 OTHER DAY 130 PATENTS THEY HAVE 5379 03:29:53,747 --> 03:29:54,748 DONE DIFFERENT THINGS WITH, I 5380 03:29:54,815 --> 03:29:57,251 HAVEN'T SEEN A ONE OF THEM GO 5381 03:29:57,318 --> 03:30:01,388 SMOOTHLY BASED ON THE 5382 03:30:01,455 --> 03:30:02,189 UNIVERSITY'S TECHNOLOGY 5383 03:30:02,256 --> 03:30:02,589 TRANSFER. 5384 03:30:02,656 --> 03:30:03,891 >> I HEAR YOU, MARSHALL. 5385 03:30:03,958 --> 03:30:06,460 ONE OF THE CHALLENGES FOR ANY 5386 03:30:06,527 --> 03:30:08,929 TECHNOLOGY TRANSFER OFFICE IN A 5387 03:30:08,996 --> 03:30:10,998 UNIVERSITY FOR INSTANCE IS THEY 5388 03:30:11,065 --> 03:30:12,866 TEND TO BE SEPARATE, ISOLATED 5389 03:30:12,933 --> 03:30:13,100 OFFICE. 5390 03:30:13,167 --> 03:30:14,068 >> YEAH, THEY ARE. 5391 03:30:14,134 --> 03:30:15,302 >> THEY ARE, RIGHT? 5392 03:30:15,369 --> 03:30:19,440 AND THEY ARE DEALING WITH 5393 03:30:19,506 --> 03:30:20,841 ENGINEERING, SCIENCE, ALL KINDS 5394 03:30:20,908 --> 03:30:23,777 OF DISCIPLINES. 5395 03:30:23,844 --> 03:30:26,880 AT NCATS, AND NIH, SPECIFICALLY 5396 03:30:26,947 --> 03:30:29,516 NCATS, WE'RE VERY LUCKY THAT 5397 03:30:29,583 --> 03:30:31,952 WE'RE EMBEDDED WITH SCIENTISTS, 5398 03:30:32,019 --> 03:30:35,756 VERY MISSION FOCUSED, MISSION 5399 03:30:35,823 --> 03:30:36,991 ORIENTED. 5400 03:30:37,057 --> 03:30:37,925 PEOPLE IN MY OFFICE HAVE BEEN 5401 03:30:37,992 --> 03:30:41,328 WITH US FOR A LONG TIME. 5402 03:30:41,395 --> 03:30:42,429 >> SHARE YOUR BEST PRACTICES 5403 03:30:42,496 --> 03:30:43,230 WITH THE COMMUNITY. 5404 03:30:43,297 --> 03:30:45,299 I KNOW THAT'S ONE MORE JOB. 5405 03:30:45,366 --> 03:30:47,801 YOU DON'T NEED ANOTHER JOB, I 5406 03:30:47,868 --> 03:30:48,168 GET IT. 5407 03:30:48,235 --> 03:30:51,305 >> I'LL BE HAPPY TO SHARE MANY 5408 03:30:51,372 --> 03:30:51,538 SECRETS. 5409 03:30:51,605 --> 03:30:54,608 ONE OF THE BIGGEST SECRET SAUCE 5410 03:30:54,675 --> 03:30:56,677 IF YOU'RE IN AN ORGANIZATION 5411 03:30:56,744 --> 03:31:00,080 LIKE NCATS, VERY TEAM ORIENTED, 5412 03:31:00,147 --> 03:31:02,716 IT MAKES THE LIFE OF TECH 5413 03:31:02,783 --> 03:31:03,917 TRANSFER OFFICE MUCH EASIER. 5414 03:31:03,984 --> 03:31:04,218 >> IT DOES. 5415 03:31:04,284 --> 03:31:05,819 >> BECAUSE YOU'RE SO SURROUNDED 5416 03:31:05,886 --> 03:31:09,289 BY PEOPLE YOU CAN GO TO, BECAUSE 5417 03:31:09,356 --> 03:31:10,457 MANY TECH TRANSFER OFFICES WHEN 5418 03:31:10,524 --> 03:31:13,160 THEY TRY TO SOLVE PROBLEMS THEY 5419 03:31:13,227 --> 03:31:14,661 ARE ON THEIR OWN. 5420 03:31:14,728 --> 03:31:14,895 >> YEAH. 5421 03:31:14,962 --> 03:31:17,364 >> A SITUATION I CANNOT SOLVE IT 5422 03:31:17,431 --> 03:31:19,833 MYSELF, I CAN GO DOWN THE ROAD 5423 03:31:19,900 --> 03:31:22,403 AND TALK TO ANTON, SAM, AND SAY 5424 03:31:22,469 --> 03:31:24,571 THIS IS SOMETHING I NEED HELP 5425 03:31:24,638 --> 03:31:24,772 WITH. 5426 03:31:24,838 --> 03:31:27,174 >> I DON'T WANT YOU TO RUN A 5427 03:31:27,241 --> 03:31:28,275 SUPPORT GROUP FOR THEM ALTHOUGH 5428 03:31:28,342 --> 03:31:29,743 THAT WOULD BE GREAT. 5429 03:31:29,810 --> 03:31:31,178 IF NOTHING ELSE, IF THERE'S A 5430 03:31:31,245 --> 03:31:34,515 WAY TO GET SOME LESSONS LEARNED 5431 03:31:34,581 --> 03:31:40,421 AND BEST PRACTICES OUT THERE IN 5432 03:31:40,487 --> 03:31:43,057 SOME USEFUL FORMAT THIS WOULD BE 5433 03:31:43,123 --> 03:31:43,323 POWERFUL. 5434 03:31:43,390 --> 03:31:48,362 >> TO THAT SUGGESTION, MARSHALL, 5435 03:31:48,429 --> 03:31:49,963 TECH TRANSFER 101 MIGHT BE 5436 03:31:50,030 --> 03:31:54,868 HELPFUL, SOMETHING TO THINK 5437 03:31:54,935 --> 03:31:55,636 ABOUT FOR SURE. 5438 03:31:55,702 --> 03:31:57,938 THANK YOU. 5439 03:31:58,005 --> 03:32:01,542 AS ALWAYS, THESE ARE GREAT 5440 03:32:01,608 --> 03:32:01,809 COMMENTS. 5441 03:32:01,875 --> 03:32:03,310 BUILDING THAT COMMUNITY, IN 5442 03:32:03,377 --> 03:32:04,845 ADDITION TO SHARING THAT 5443 03:32:04,912 --> 03:32:05,712 KNOWLEDGE, IS CERTAINLY 5444 03:32:05,779 --> 03:32:08,582 SOMETHING THAT WE WOULD WANT TO 5445 03:32:08,649 --> 03:32:08,749 DO. 5446 03:32:08,816 --> 03:32:12,719 >> IF THESE THINGS DON'T MAKE A 5447 03:32:12,786 --> 03:32:13,554 TRANSITION TO COMMERCIAL 5448 03:32:13,620 --> 03:32:15,022 APPLICATION, MOST PATIENTS WILL 5449 03:32:15,089 --> 03:32:16,356 NEVER SEE THEM. 5450 03:32:16,423 --> 03:32:17,858 >> YEAH, YEAH. 5451 03:32:17,925 --> 03:32:19,460 THAT'S ULTIMATELY WHAT WE WANT, 5452 03:32:19,526 --> 03:32:20,427 RIGHT. 5453 03:32:20,494 --> 03:32:22,129 >> ONE OF THE THINGS, MARSHALL, 5454 03:32:22,196 --> 03:32:30,104 I LEARNED ALONG THE WAY IS THAT 5455 03:32:30,170 --> 03:32:31,004 SOME THINGS, WHEN YOU TEACH HOW 5456 03:32:31,071 --> 03:32:32,739 TO BE A BETTER NEGOTIATOR YOU 5457 03:32:32,806 --> 03:32:36,910 CAN GET A GOOD AGREEMENT 5458 03:32:36,977 --> 03:32:37,377 TOGETHER. 5459 03:32:37,444 --> 03:32:37,678 >> OH, YEAH. 5460 03:32:37,744 --> 03:32:38,946 LET ME ALSO KNOW WHAT YOU CAN 5461 03:32:39,012 --> 03:32:40,981 AND CAN'T DO, ALL SORTS OF 5462 03:32:41,048 --> 03:32:42,382 THINGS LIKE THAT. 5463 03:32:42,449 --> 03:32:42,683 >> EXACTLY. 5464 03:32:42,749 --> 03:32:42,883 KELLY? 5465 03:32:42,950 --> 03:32:44,685 >> OH, I PUT MY HAND DOWN IN THE 5466 03:32:44,751 --> 03:32:46,320 INTEREST OF TIME. 5467 03:32:46,386 --> 03:32:48,755 I WAS GOING TO ASK YOU IF YOU -- 5468 03:32:48,822 --> 03:32:51,925 FIRST I WANT TO SAY HOW 5469 03:32:51,992 --> 03:32:55,095 VISIONARY AND HEROIC TO HAVE 5470 03:32:55,162 --> 03:32:55,863 INNOVATED FOR COLLABORATION 5471 03:32:55,929 --> 03:32:58,031 AGREEMENTS. 5472 03:32:58,098 --> 03:33:01,168 I FELT THAT WAS SO INTERESTING. 5473 03:33:01,235 --> 03:33:03,837 I WONDERED IF YOU HAVE BEEN 5474 03:33:03,904 --> 03:33:04,938 EXPERIMENTING OR EXPLORING THE 5475 03:33:05,005 --> 03:33:06,840 POSSIBILITY OF USING SMART 5476 03:33:06,907 --> 03:33:08,575 CONTRACTS TO AUTOMATE SOME 5477 03:33:08,642 --> 03:33:12,613 ROYALTY AGREEMENTS AND OTHER 5478 03:33:12,679 --> 03:33:13,780 KINDS OF AGREEMENTS. 5479 03:33:13,847 --> 03:33:17,518 I'LL PAUSE THERE AND ASK THAT 5480 03:33:17,584 --> 03:33:18,152 QUESTION. 5481 03:33:18,218 --> 03:33:18,852 >> CAN YOU ELABORATE? 5482 03:33:18,919 --> 03:33:22,489 DO YOU MEAN USING THIRD PARTIES? 5483 03:33:22,556 --> 03:33:24,925 >> NO, ACTUALLY -- THAT'S WHY I 5484 03:33:24,992 --> 03:33:26,894 DIDN'T -- THAT'S WHY I LOWERED 5485 03:33:26,960 --> 03:33:27,127 MY HAND. 5486 03:33:27,194 --> 03:33:31,165 WHAT I'M GOING TO DO RATHER 5487 03:33:31,231 --> 03:33:34,368 THAN -- I'M GOING TO CEDE THE 5488 03:33:34,434 --> 03:33:35,602 FLOOR AND SEND AN E-MAIL. 5489 03:33:35,669 --> 03:33:36,136 IT'S TOO LONG. 5490 03:33:36,203 --> 03:33:36,503 >> THAT WORKS. 5491 03:33:36,570 --> 03:33:37,871 THAT WOULD BE GREAT. 5492 03:33:37,938 --> 03:33:41,275 THANK YOU FOR THE FOLLOW-UP AND 5493 03:33:41,341 --> 03:33:41,909 CONNECTION. 5494 03:33:41,975 --> 03:33:42,809 SOUNDS LIKE IT WOULD BE VERY 5495 03:33:42,876 --> 03:33:45,412 INTERESTING, FROM THAT LITTLE 5496 03:33:45,479 --> 03:33:46,647 BIT I HEARD. 5497 03:33:46,713 --> 03:33:50,817 AND THEN A COUPLE COMMENTS HERE 5498 03:33:50,884 --> 03:33:53,520 IN THE CHAT, BALKI. 5499 03:33:53,587 --> 03:33:55,189 PAUL HARRIS MENTIONED YOU MIGHT 5500 03:33:55,255 --> 03:33:56,957 CONSIDER A PUBLICATION, SHARING 5501 03:33:57,024 --> 03:34:00,127 LESSONS LEARNED. 5502 03:34:00,194 --> 03:34:01,328 MARSHALL LIKED THAT IDEA AS 5503 03:34:01,395 --> 03:34:10,370 WELL, SINCE IT'S A STUMBLING 5504 03:34:10,437 --> 03:34:10,737 BLOCK. 5505 03:34:10,804 --> 03:34:12,940 YEAH, THANK YOU. 5506 03:34:13,006 --> 03:34:15,309 AND ANIKA IS PULLING UP SOME 5507 03:34:15,375 --> 03:34:16,076 TECH TRANSFER EDUCATION 5508 03:34:16,143 --> 03:34:18,445 RESOURCES WE HAVE ON OUR WEBSITE 5509 03:34:18,512 --> 03:34:19,012 TOO. 5510 03:34:19,079 --> 03:34:20,614 SO MAYBE A COMBINATION OF BOTH 5511 03:34:20,681 --> 03:34:22,449 OF THOSE THINGS, THINKING ABOUT 5512 03:34:22,516 --> 03:34:24,251 HOW TO DISSEMINATE THAT TO THE 5513 03:34:24,318 --> 03:34:25,319 COMMUNITY WOULD BE HELPFUL. 5514 03:34:25,385 --> 03:34:28,188 ALWAYS SOMETHING TO THINK ABOUT 5515 03:34:28,255 --> 03:34:31,191 AND CHEW ON HERE. 5516 03:34:31,258 --> 03:34:35,295 ANY OTHER COMMENTS FOR BALKI? 5517 03:34:35,362 --> 03:34:39,733 AND IF NOT, THANK YOU SO MUCH 5518 03:34:39,800 --> 03:34:42,202 FOR THAT OVERVIEW, BALKI. 5519 03:34:42,269 --> 03:34:49,776 WE HAD A TOUR DE FORCE TODAY. 5520 03:34:49,843 --> 03:34:52,279 IT SEEMED THE THEME HAS BEEN 5521 03:34:52,346 --> 03:34:55,882 REALLY FOCUSED AROUND TRUST AND 5522 03:34:55,949 --> 03:34:56,883 TRUSTWORTHINESS, AND HOW TO 5523 03:34:56,950 --> 03:34:58,151 INCLUDE THAT FUNDAMENTALLY IN 5524 03:34:58,218 --> 03:34:59,486 WHAT WE DO. 5525 03:34:59,553 --> 03:35:01,221 THE FACT THAT IT HAS COME UP A 5526 03:35:01,288 --> 03:35:03,290 LOT IS A GOOD SIGN. 5527 03:35:03,357 --> 03:35:06,693 AND BUT CLEARLY WE HAVE MORE TO 5528 03:35:06,760 --> 03:35:06,893 DO. 5529 03:35:06,960 --> 03:35:09,896 WE TALKED ABOUT HOW IT CAN BE 5530 03:35:09,963 --> 03:35:11,932 INFUSED IN DATA SCIENCE, 5531 03:35:11,999 --> 03:35:13,600 PRE-CLINICAL MODELS, TECH 5532 03:35:13,667 --> 03:35:14,134 TRANSFER. 5533 03:35:14,201 --> 03:35:19,039 EVERY ASPECT WE TOUCH WILL BE 5534 03:35:19,106 --> 03:35:19,306 IMPORTANT. 5535 03:35:19,373 --> 03:35:21,842 ALSO TALKING ABOUT THE -- HOW TO 5536 03:35:21,908 --> 03:35:23,910 BRING THE NAMs CAREFULLY MORE 5537 03:35:23,977 --> 03:35:27,314 INTO THE CLINIC, AND ENGAGING 5538 03:35:27,381 --> 03:35:31,351 PATIENTS IN THAT WORK TOO. 5539 03:35:31,418 --> 03:35:34,688 ALSO AN IMPORTANT THING TO THINK 5540 03:35:34,755 --> 03:35:35,355 ABOUT AND CONTRIBUTION, THINKING 5541 03:35:35,422 --> 03:35:43,530 ABOUT A.I. AND M.L. ENABLED 5542 03:35:43,597 --> 03:35:45,365 WORK, CAPTURING INSIGHTS INTO 5543 03:35:45,432 --> 03:35:47,301 THE LITERATURE WE CAN'T 5544 03:35:47,367 --> 03:35:48,201 NECESSARILY SEE OURSELVES, 5545 03:35:48,268 --> 03:35:50,937 SOUNDS LIKE THERE'S GREAT GROUND 5546 03:35:51,004 --> 03:35:51,838 BEING MADE THERE. 5547 03:35:51,905 --> 03:35:55,742 IT WAS GREAT TO HAVE MONICA 5548 03:35:55,809 --> 03:35:59,079 BERTAGNOLLI GIVE HER VISION AND 5549 03:35:59,146 --> 03:36:01,248 OVERSIGHT OF NIH NOW AT THE 5550 03:36:01,315 --> 03:36:03,850 HELM, TALKING ABOUT HER GUIDING 5551 03:36:03,917 --> 03:36:06,053 PRINCIPLES, AND DESPITE THE FACT 5552 03:36:06,119 --> 03:36:08,722 WE HAVE SOME BUDGET CONCERNS, 5553 03:36:08,789 --> 03:36:09,856 YOU KNOW, WE'RE GOING TO DO THE 5554 03:36:09,923 --> 03:36:12,592 BEST WITH WHAT WE HAVE, HOW TO 5555 03:36:12,659 --> 03:36:13,427 PRIORITIZE AND RESTORE SOME 5556 03:36:13,493 --> 03:36:15,495 TRUST AGAIN CAME UP IN THAT 5557 03:36:15,562 --> 03:36:16,029 CONVERSATION. 5558 03:36:16,096 --> 03:36:19,800 I'M EXCITED TO SEE HOW THAT 5559 03:36:19,866 --> 03:36:21,168 UNFOLDS. 5560 03:36:21,234 --> 03:36:22,069 WITH DAN AND BALKI'S 5561 03:36:22,135 --> 03:36:23,403 PRESENTATION, IT'S GOOD TO HAVE 5562 03:36:23,470 --> 03:36:25,005 THE UPDATES, I APPRECIATE YOUR 5563 03:36:25,072 --> 03:36:30,577 COMMENTS AND FEEDBACK ON THAT. 5564 03:36:30,644 --> 03:36:33,113 AND I DON'T HAVE ANYTHING MORE 5565 03:36:33,180 --> 03:36:35,215 TO SAY EXCEPT I REALLY 5566 03:36:35,282 --> 03:36:36,650 APPRECIATE AS ALWAYS THE 5567 03:36:36,717 --> 03:36:37,617 IMPORTANT CONTRIBUTIONS THAT OUR 5568 03:36:37,684 --> 03:36:40,454 COUNCIL MAKES AND JUST SAY ONCE 5569 03:36:40,520 --> 03:36:44,091 MORE, AGAIN, THANK YOU TO 5570 03:36:44,157 --> 03:36:48,962 MATTIAS AND MARSHALL FOR YOUR 5571 03:36:49,029 --> 03:36:50,731 LASTING IMPRINT ON NCATS, AND I 5572 03:36:50,797 --> 03:36:53,600 LOOK FORWARD TO SEEING THE REST 5573 03:36:53,667 --> 03:36:55,235 OF OUR COUNCIL MEMBERS AT OUR 5574 03:36:55,302 --> 03:36:56,870 NEXT MEETING IN MAY. 5575 03:36:56,937 --> 03:37:00,073 WITH THAT, I WILL GAVEL US OUT 5576 03:37:00,140 --> 03:37:01,608 OF OUR MEETING TODAY. 5577 03:37:01,675 --> 03:37:04,344 THANK YOU SO MUCH AGAIN. 5578 03:37:04,411 [END OF PROGRAM]